Cd25 antibodies

ABSTRACT

Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of International Application No. PCT/US2019/061552, filed Nov. 14, 2019, which claims the priority benefit of U.S. Provisional Application No. 62/767,405, filed on Nov. 14, 2018, the entire contents of which are hereby incorporated by reference in their entirety for all purposes.

INCORPORATION-BY-REFERENCE OF MATERIALS FILED ON COMPACT DISC

The present application includes a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 18, 2021, is named RBYC_022.01US_SeqList_ST25.txt and is 521,445 bytes in size.

BACKGROUND

The CD25 protein is the alpha chain of interleukin-2 (IL-2) receptor and is a transmembrane protein present on regulatory T cells, and activated T cells. In a normal state, regulatory T cells constitutively express CD25 and act to suppress the expansion of effector cells. Regulatory T cells maintain the healthy state and inhibit effector T cells from reacting against self antigens or over-reacting to foreign antigens. In a normal, protective immune response, effector T cells multiply after contact with foreign antigen and overcome inhibition by regulatory T cells. In case of proliferative diseases, however cancer cells disable the healthy immune response by increasing the amount of regulatory T cells and thereby limiting the generation of effector T cells against them. Additional molecular tools to alter the proliferation of CD25-expressing regulatory T cells are needed, for example to dampen the immune system for use in cancer therapies or to upregulate the immune system for use in autoimmune diseases; provided herein are such tools.

SUMMARY

Provided herein are antibodies that specifically bind to CD25 (anti-CD25 antibodies, interchangeably referred to herein as CD25 antibodies). The antibodies may be human, chimeric or humanized. Also provided herein are methods of use and methods of making the antibodies described. For example, the CD25 antibodies may be used therapeutically to treat cancer, comprising administering to a subject in need thereof an antibody or a pharmaceutical composition thereof. Also provided are methods of producing the CD25 antibodies described herein.

In one aspect, provided herein is a monoclonal CD25 antibody which binds to human CD25, and possesses at least one, at least two, at least three, at least four, at least five, or at lease six of the following characteristics:

a. the antibody does not disrupt the binding of the IL-2 ligand to the alpha chain of the IL-2 receptor (CD25), and binds to a different epitope than to which 7G7B6 binds; b. the antibody does not disrupt the binding of the IL-2 ligand to the alpha chain of the IL-2 receptor (CD25), but does disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor; c. the antibody disrupts the binding of the IL-2 ligand to the alpha, beta, and/or gamma chains of the IL-2 receptor, and binds to a different epitope than to which daclizumab or baciliximab bind; d. the antibody exhibits a higher affinity of binding to CD25 at pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4; e. the antibody comprises the amino acid sequence of any one of the variable heavy chains presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, and 5A or FIGS. 3A, 3B and 5 , humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto; f. the antibody comprises the amino acid sequence of any one of the variable light chains presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, and 5B or FIGS. 4A, 4B and 6 , humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto; g. the VH of the antibody comprises any one of the amino acid sequence of CDRH1, CDRH2, and CDRH3 as presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, 5A, and 6 or contained in the sequences presented in FIGS. 3A, 3B and 5 ; h. the VL of the CD25 antibody comprises any one of the amino acid sequence of CDRL1, CDRL2, and CDRL3 as presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, 5B and 7, or contained in the sequences presented in FIGS. 4A, 4B and 6 ; and i. the antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 of any one of the combinations presented in Table 6 and the amino acid sequence of CDRL1, CDRL2, and CDRL3 of any one of the combinations presented in Table 7.

In some embodiments, the VH of the antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 combinations as presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, 5A, or 6 or contained in the sequences presented in FIG. 3A, 3B or 5 .

In some embodiments, the VL of the CD25 antibody comprises the amino acid sequence of CDRL1, CDRL2, and CDRL3 combinations as presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, 5B, or 7 or contained in the sequences presented in FIG. 4A, 4B or 6 .

In some embodiments, the CD25 antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 of any one of the combinations presented in Table 6.

In some embodiments, the CD25 antibody comprises the amino acid sequence of CDRL1, CDRL2, and CDRL3 of any one of the combinations presented in Table 7.

In some embodiments the antibody is a human antibody. In some embodiments the antibody is a humanized antibody. In some embodiments the antibody is a chimeric antibody. In some embodiments the antibody is an antibody fragment. In some embodiments the antibody also binds cynomologous monkey CD25.

In another aspect, provided herein is a method of treating a subject in need thereof comprising administering to the subject a therapeutically effective amount of any one of the antibodies or pharmaceutical compositions described herein. In some embodiments, provided herein is a method of depleting the number of regulatory T cells in a subject comprising administering to the subject a therapeutically effective amount of any one of the antibodies or pharmaceutical compositions described herein. In some embodiments, the subject suffers from cancer; in other embodiments, the subject suffers from an autoimmune-related disease or disorder.

In another aspect, provided herein is a method of depleting the number of regulatory T cells in a sample comprising peripheral blood mononuclear cells comprising contacting the sample with any one of the antibodies described herein.

In related aspects, provided herein are pharmaceutical compositions or kits comprising any one or more of the antibodies described herein, nucleic acid sequences encoding any of the antibodies described herein, vectors comprising the nucleic acid and phage expressing any of the antibodies described herein.

All of the above features described herein (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.

DESCRIPTION OF THE DRAWINGS

The present application can be understood by reference to the following description taken in conjunction with the accompanying figures.

FIG. 1 is an exemplary description of the desired characteristics of one of the class of CD25 antibodies described herein: CD25 antibodies that block the alpha chain of the IL-2 receptor (CD25) only, do not block binding of IL-2, do not disrupt signal transduction mediated by IL-2, and leads to depletion of Tregs. Data are collected with Fab clones, but as provided herein, in some embodiments, the CD25 antibodies are full length antibodies, i.e. human IgG1 antibodies.

FIG. 2 is an exemplary workflow for CD25 antibody discovery, in vitro testing, and in vivo testing.

FIG. 3A and FIG. 3B depict variable heavy chain (VH) amino acid sequences of exemplary CD25 antibodies (SEQ ID NOs: 61-107, 1501 and 432-460) of the disclosure.

FIG. 4A and FIG. 4B depict variable light chain (VL) amino acid sequences of exemplary CD25 antibodies (SEQ ID NOs: 703, 705, 707, 709, 715, 717, 722, 724, 725, 727, 728, 739, 742, 745, 747, 749-752, 754-756, 759, 762, 765, 767, 769, 776, 780, 781, 783, 785, 787, 789, 791, 794, 797, 799, 801, 803, 804, 806, 809-811, 813, 815, 818, 824, 827, 829, 835, 841, 842, 844, 846, 848, 849, 851, 853, 875-880, 882, 884, 886, 888, 892, 897, 901-903, 905-908, 914, 917, 919-922) of the disclosure.

FIG. 5 depicts VH amino acid sequences of exemplary CD25 antibodies (SEQ ID NOs: 868, 869, 1222, 1229-1238, 1316-1318 and 1327-1335) of the disclosure.

FIG. 6 depicts VL amino acid sequences of exemplary CD25 antibodies (SEQ ID NOs: 34, 701, 712, 735, 736, 737, 775, 777, 778, 795, 822, 823, 825, 838, 857, 859, 860, 861, 864, 895 and 912) of the disclosure.

FIG. 7 depicts the identification of non IL-2 blockers, using a cross block assay, using a biosensor.

FIG. 8 depicts phage express Fabs of the disclosure that compete with IL-2 non-blocking antibody, 7G7B6, using a biosensor.

FIG. 9 shows that pSTAT5 levels are IL-2 dose dependent and inhibited with an IL-2 blocking antibody, Daclizumab.

FIG. 10 depicts the effect of the D5 Fab of the disclosure on pSTAT5 levels. The data indicate that the D5 Fab is a partial IL-2 blocker.

FIG. 11 depicts the effect of the D5 Fab at different concentrations on pSTAT5 levels, relative to maximum IL-2 pSTAT5 levels.

FIG. 12 depicts differences in pSTAT5 levels between several Fab clones at 1, 2 and 5 ug/mL compared to the controls (IL-2 only, Daclizumab (Dac) and 7G7B6.

FIGS. 13A-13C depict differences in Kd and Koff rates for several Fab clones that were reformatted to human IgG1 antibodies (FIG. 13A). Several reformatted clones have better affinity and Koff rates than commercially available antibodies 7G7B6, Daclizumab and Basiliximab (FIG. 13B, FIG. 13C).

FIGS. 14A-14D show representative data from epitope bining cross competition assays against IL-2 and commercially available antibodies 7G7B6, Daclizumab and Basiliximab, using Fab clones that were reformatted to human IgG1 antibodies. Antibodies had different cross blocking profiles.

FIGS. 15A-15B depicts specific binding of human IgG1 reformatted Fab on CD25+ cell lines SUDHL-1 and HEK IL-2 reporter cells (FIG. 15A) and no binding on CD25− cell line SUDHL-2 (FIG. 15B).

FIGS. 16A-16B show representative dose response curves of human IgG1 reformatted Fab clones on CD25+ cell line SUDHL-1 compared to commercially available antibodies 7G7B6, Daclizumab and Basiliximab (FIG. 16A). Several clones show better EC50 values than IL-2 non-blocker 7G7B6 (FIG. 16B).

FIG. 17 . show representative data of human IgG1 reformatted Fab clones that bind to recombinant cynomolgus monkey CD25 protein (25 nM). Majority of clones bind in a dose dependent manner (starting at 25 nM with 3 fold dilutions).

FIGS. 18A-18B. show differences in pSTAT5 levels across several human IgG1 reformatted Fab clones at 5 ug/ml, compared to IL-2 levels at 0.1 ng/mL (FIG. 18A). FIG. 18B shows pSTAT5 levels with IL-2 dose response curve (starting at 10 ng/mL with 10 fold dilutions) with 5 ug/mL of each antibody. Some clones were shown to be better IL-2 blocker and IL-2 nonblockers than commercially available antibodies, 7G7B6, Daclizumab and Basiliximab at 0.1 ng/mL.

FIGS. 19A-19B. show representative data of human IgG1 reformatted Fab clones at 20 ug/mL, that elicited cell killing in an ADCC assay using PBMCs as effector cells and SUHL-1 cells as targets (FIG. 19A). Several clones showed higher ADCC than 7G7B6 starting at 10 ug/mL with 5 fold dilutions of antibody (FIG. 19B).

DETAILED DESCRIPTION

Provided herein are antibodies that specifically bind to CD25. The antibodies may be human, chimeric or humanized. Also provided herein are methods of use and methods of making the antibodies described. For example, the CD25 antibodies may be used therapeutically to treat cancer, comprising administering to a subject in need thereof an antibody or a pharmaceutical composition thereof. Also provided are methods of producing the CD25 antibodies described herein.

Definitions

Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, exemplary methods and materials are described.

The headings provided herein are not limitations of the various aspects or embodiments of the invention. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

Numeric ranges are inclusive of the numbers defining the range.

The term antibody, as used herein, includes but is not limited to a monoclonal antibody, polyclonal antibody, human antibody, humanized antibody, non-human antibody, chimeric antibody, monovalent antibody and antigen-binding fragments of the antibody (e.g Fab fragment, a Fab′2 fragment, or a scFV). Also provided herein are antibody-drug conjugates, bispecific antibodies, and multispecific antibodies that exhibit specificity for CD25. A non-human antibody (e.g. a mouse antibody) may be “humanized” using conventional techniques (e.g. by introducing changes in the framework region, while retaining mouse CDRs).

The terms “polynucleotide” and “nucleic acid” are used interchangeably herein, and refer to a polymeric form of nucleotides of any length, which may be ribonucleotides or deoxyribonucleotides. The terms include, but are not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. The terms encompass nucleic acids containing known analogues of natural nucleotides and having similar binding properties, and are metabolized in a manner similar to naturally-occurring nucleotides, unless specifically limited or stated otherwise.

When a nucleic acid or amino acid sequence is said to have a certain percent “sequence identity” or “identity” or is a certain percent “identical” to another nucleic acid or amino acid sequence, that percentage of bases or amino acids are the same, and in the same relative position, when the sequences are aligned, when comparing the two sequences.

The terms “individual,” “subject,” and “patient” are used interchangeably herein and refer to any subject for whom treatment or therapy is desired. The subject may be a mammalian subject. Mammalian subjects include, e. g., humans, non-human primates, rodents, (e.g., rats, mice), lagomorphs (e.g., rabbits), ungulates (e.g., cows, sheep, pigs, horses, goats, and the like), etc. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human primate. In some embodiments, the subject is a companion animal (e.g. cats, dogs).

Antibodies

Provided herein are antibodies that specifically bind to CD25. Such antibodies are capable of binding to the CD25 antigen either alone or associated with other molecules to form high affinity IL-2 receptors which is present on regulatory T cells.

In some embodiments, the CD25 antibody is a humanized antibody that specifically binds to CD25.

In some embodiments, the CD25 antibody is a chimeric antibody that for example a mouse-human chimeric antibody, e.g. an antibody that comprises mouse variable domains, and a human constant region.

A CD25 antibody of the disclosure can be any of a human IgA, IgD, IgE, IgG, or IgM antibody. The IgA antibody can be an IgA1 or an IgA2 antibody. The IgG antibody can be an IgG1, IgG2, IgG2a, IgG2b, IgG3 or IgG4 antibody. A combination of any of these antibodies can also be made and used. In some embodiments, the constant region is of the IgG type, e.g. of the human IgG type. In some embodiments, the constant region is of the IgG1 type, e.g. of the human IgG1 type.

In some embodiments, the CD25 antibody exhibits cross reactivity to more than one species, for example specifically binds to both human CD25 and non-human CD25, for example specifically binds to both human CD25 and cynomolgus monkey CD25.

The KD (affinity constant) of the antibodies provided herein range from about 10{circumflex over ( )}−5 to about 10{circumflex over ( )}−14 nM. In some embodiments the KD of the antibodies provided herein range from about 10{circumflex over ( )}−8 to about 10{circumflex over ( )}−12 nM. In exemplary embodiments, the KD of a CD25 antibody is at least about 10{circumflex over ( )}−5 nM, about 10{circumflex over ( )}−6 nM, about 10{circumflex over ( )}−7 nM nM, about 10{circumflex over ( )}−8 nM, about 10{circumflex over ( )}−9 nM, about 10{circumflex over ( )}−10 nM, about 10{circumflex over ( )}−11 nM, about 10{circumflex over ( )}−12 nM, about 10{circumflex over ( )}−13 nM, or even about 10{circumflex over ( )}−14 nM.

The Kd (off-rate constant) of the antibodies provided herein range from about 10{circumflex over ( )}−2 to about 10{circumflex over ( )}−6 1/s.

In some embodiments, the CD25 antibody exhibits the same affinity (KD) for the CD25 antigen at both physiological pH (about 7.4) and non-physiological pH. In some embodiments, the CD25 antibody exhibits the same off-rate (Kd) for the CD25 antigen at both physiological pH (about 7.4) and non-physiological pH.

In some embodiments, the CD25 antibody exhibits different affinities (different KD) for the CD25 antigen at physiological pH (about 7.4) and non-physiological pH. In some embodiments, the CD25 antibody exhibits different off-rate constants (different Kd) for the CD25 antigen at physiological pH (about 7.4) and non-physiological pH.

In some embodiments, the CD25 antibody exhibits a lower affinity (higher KD) for the CD25 antigen at physiological pH (about 7.4) than at a pH that is lower than physiological pH, for example when the pH is 7.3, 7.2, 7.1, 7.0, 6.9, 6.8, 6.7, 6.6, 6.5, 6.4, 6.3, 6.2, 6.1, or lower. In exemplary embodiments, the antibody exhibits a higher affinity for the CD25 antigen at a pH of about 6.5, when compared to the affinity at a pH of about 7.4. In some embodiments, such antibodies are useful for retaining activity, or exhibiting enhanced activity in an acidic environment, a hypoxic environment, for example a tumor microenvironment.

In some embodiments, the antibody is a non IL-2-blocking antibody (a non IL-2 blocker)—that is, the binding of the antibody to CD25 does not disrupt or prevent binding of the IL-2 ligand to CD25 (the IL-2 alpha chain), and does not affect IL-2 mediated signal transduction, e.g. signaling through the IL-2/JAK3/STAT-5 signaling pathway. In some embodiments, the antibody does not disrupt the binding of IL-2 ligand to CD25 (IL-2 alpha chain), and binds to a different epitope than where the 7G7B6 antibody binds. In some embodiments, the antibody does not disrupt the binding of the IL-2 ligand to CD25 (IL-2 alpha chain), but does disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor.

In some embodiments, the antibody is an IL-2 blocking antibody (IL-2 blocker), e.g., the antibody disrupts or prevents binding of the IL-2 ligand to the alpha, beta, and/or gamma chains of the receptor, and decreases or inhibits IL-2 mediated signal transduction. In certain embodiments, the antibody disrupts or prevents binding of the IL-2 ligand to CD25. In some embodiments, the antibody disrupts or prevents the binding of the IL-2 ligand to CD25, and binds to a different epitope than to which either daclizumab or baciliximab bind.

In some embodiments, the CD25 antibody is a partially blocking antibody (partial IL-2 blocker), and partially, but not completely, disrupts binding of the IL-2 ligand to the alpha, beta, and/or gamma chains of the IL-2 receptor (CD25), and/or partially, but not completely decreases IL-2 mediated signal transduction.

In some embodiments, the CD25 antibody disrupts or prevents heterotrimerization of the alpha, beta, and gamma IL-2 chains. In some embodiments, the antibody does not block binding of the IL-2 ligand with CD25, but does disrupt or prevent heterotrimerization of the alpha, beta, and gamma IL-2 chains. In certain embodiments, the antibody selectively binds to regulatory T cells. In other embodiments, the antibody selectively binds T effector cells.

In some embodiments, binding of the CD25 antibody leads to the depletion of regulatory T cells (Tregs), while allowing for expansion of effector T cells (Teff).

In some embodiments, the antibody binds to CD25 in the trans orientation. In other embodiments the antibody binds to CD25 in the cis orientation. In still further embodiments, the antibody is capable of binding to CD25 in either the cis or the trans configuration.

In some embodiments, the CD25 antibody exhibits greater binding affinity to CD25, as compared to the binding of 7G7B6 (anti-human CD25 with mouse IgG2a Fc receptor; IL-2 non blocker; BioXcell) to CD25.

Tables 1A-1L, 2A-2C, 3A-3C, 4A-4B, 5A-5B, 6, and 7 and FIGS. 3A, 3B, 4A, 4B, 5, and 6 provide exemplary sequences for the CD25 antibodies described herein. It is noted that the complementarity determining region (CDR) and framework (FR) sequences shown are based on the IMGT convention for antibody annotation. However a skilled artisan can determine other articulations of CDR and framework sequences based on the presented VH and VL sequences, using other algorithms/conventions for antibody annotation, such as Kabat and Chothia. Accordingly the CDRs and FR sequences of the disclosure are not limited to those exemplary CDRs and FR sequences annotated in the below tables, but rather the CDRs as would be understood and determined by a skilled artisan, given the sequence of the variable region.

TABLE 1A D5 VH Sequences D5 VH - Nucleic Acid catgtgcaactgcagcagtctggagctgagctggtaaggcctgggacttc agtgaagatatcctgcaaggcttctggctacaccttcactaactactggc taggttgggtaaagcagaggcctggacatggacttgagtggattggagat atttaccctggaggtggttatactaactacaatgagaagttcaagggcaa ggccacactgactgcagacacatcctccagcactgcctacatgcagctca gtagcctgacatctgaggactctgctgtctatttctgtgcaagagttact ccggcttcctggggccaaggcaccagtctcacagtctcctcgg (SEQ ID NO: 1) D5 VH - Amino Acid HVQLQQSGAELVRPGTSVKISCKASGYTFTNYWLGWVKQRPGHGLEWIGD IYPGGGYTNYNEKFKGKATLTADTSSSTAYMQLSSLTSEDSAVYFCARVT PASWGQGTSLTVSS (SEQ ID NO: 2) D5 VH CDR1 - IMGT ggctacaccttcactaactactgg (SEQ ID NO: 3) GYTFTNYW (SEQ ID NO: 4) D5 VH CDR2 - IMGT atttaccctggaggtggttatact (SEQ ID NO: 5) IYPGGGYT (SEQ ID NO: 6) D5 VH CDR3 - IMGT gcaagagttactccggcttcc (SEQ ID NO: 7) ARVTPAS (SEQ ID NO: 8)

TABLE 1B D5 VL Sequences D5 VL - Nucleic Acid gatattgtgatgacccagtctcaaaaattcatgtccacatcagtaggaga cagggtcagcgtcacctgcaaggccagtcagaatgtgggtactaatgtag cctggtatcaacagaaaccagggcaatctcctaaagcactgatttactcg gcatcctaccggtacagtggagtccctgatcgcttcacaggcagtggatc tgggacagatttcactctcaccatcagcaatgtgcagtctgaagacttgg cagagtatttctgtcagcaatataacagctatccgtacacgttcggaggg gggaccaagctggaaatgaaac (SEQ ID NO: 9) D5 VL - Amino Acid DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYS ASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFGG GTKLEMK (SEQ ID NO: 10) D5 VL - CDR1-IMGT cagaatgtgggtactaat (SEQ ID NO: 11) QNVGTN (SEQ ID NO: 12) D5 VL - CDR2-IMGT tcggcatcc SAS (SEQ ID NO: 13) D5 VL - CDR3-IMGT cagcaatataacagctatccgtacacg (SEQ ID NO: 14) QQYNSYPYT (SEQ ID NO: 15)

TABLE 1C D11 VH Sequences D11 VH-Nucleic Acid cagatccaactgcagcagcctggggctgagctggtgaggcctggggtttc actgaaaatttcctgcaagggttctggctacacattcactgattatgcta tgcactgggtgaggcagagtcatgcaaagagtctagagtggattggagtt attagtacttactctggtgatgctatctacaaccagaagttcaagggcaa ggccacaatgactgtcgacaaatcctccagcacagcctatctggaacttg ccagactgacatctgacgattctgccatctattactgtgcaagaggggta acttttgactactggggccaaggcaccactgtcacagtctcctcgg (SEQ ID NO: 16) D11 VH - Amino Acid QIQLQQPGAELVRPGVSLKISCKGSGYTFTDYAMHWVRQSHAKSLEWIGV ISTYSGDAIYNQKFKGKATMTVDKSSSTAYLELARLTSDDSAIYYCARGV TFDYWGQGTTVTVSS (SEQ ID NO: 17) D11 VH - CDR1-IMGT ggctacacattcactgattatgct (SEQ ID NO: 18) GYTFTDYA (SEQ ID NO: 19) D11 VH - CDR2-IMGT attagtacttactctggtgatgct (SEQ ID NO: 20) ISTYSGDA (SEQ ID NO: 21) D11 VH - CDR3-IMGT gcaagaggggtaacttttgactac (SEQ ID NO: 22) ARGVTFDY (SEQ ID NO: 23)

TABLE 1D D11 VL Sequences D11 VL-Nucleic Acid gacatccagatgacacagactacatcctccctgtctgcctctctgggaga cagagtcaccatcacttgcagggcaagtcaggacattagcaattatttag aatggtatcagcagaaacagggaaaatctcctcagctcctggtctataat gcaaaaaccttagcagaaggtgtgccatcaaggttcagtggcagtggatc aggcacacagttttctctgaagatcaacagcctgcagcctgaagattttg ggagttattactgtcaacatcattatgatactccgtacacgttcggaggg gggaccaagctggaaataaaac (SEQ ID NO: 24) D11 VL - Amino Acid DIQMTQTTSSLSASLGDRVTITCRASQDISNYLEWYQQKQGKSPQLLVYN AKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYDTPYTFGG GTKLEIK (SEQ ID NO: 25) D11 VL - CDR1-IMGT caggacattagcaattat (SEQ ID NO: 26) QDISNY (SEQ ID NO: 27) D11 VL - CDR2-IMGT aatgcaaaa NAK (SEQ ID NO: 28) D11 VL - CDR3-IMGT caacatcattatgatactccgtacacg (SEQ ID NO: 29) QHHYDTPYT (SEQ ID NO: 30)

TABLE 1E D16 VH Sequences D16 VH - Nucleic Acid caggtgcaaatgcagcagtctggagctgagctggtaaggcctgggacttc agtgaagatatcctgcaaggcttctggctacaccttcactaactactggc taggttgggtaaagcagaggcctggacatggacttgagtggattggagat atttaccctggaggtggttatactaactacaatgagaagttcaagggcaa ggccacactgactgcagacacatcctccagcactgcctacatgcagctca gtagcctgacatctgaggactctgctgtctatttctgtgcaagagttact ccggcttcctggggccaaggcaccactctcacagtctcctcgg (SEQ ID NO: 31) D16 VH - Amino Acid QVQMQQSGAELVRPGTSVKISCKASGYTFTNYWLGWVKQRPGHGLEWIGD IYPGGGYTNYNEKFKGKATLTADTSSSTAYMQLSSLTSEDSAVYFCARVT PASWGQGTTLTVSS (SEQ ID NO: 32) D16 VH - CDR1-IMGT ggctacaccttcactaactactgg (SEQ ID NO: 3) GYTFTNYW (SEQ ID NO: 4) D16 VH - CDR2-IMGT atttaccctggaggtggttatact (SEQ ID NO: 5) IYPGGGYT (SEQ ID NO: 6) D16 VH - CDR3-IMGT gcaagagttactccggcttcc (SEQ ID NO: 7) ARVTPAS (SEQ ID NO: 8)

TABLE 1F D16 VL Sequences D16 VL - Nucleic Acid gatatccagatgacccagtctcaaaaattcatgtccacatcagtaggaga cagggtcagcgtcacctgcaaggccagtcagaatgtgggtactaatgtag cctggtatcaacagaaaccagggcaatctcctaaagcactgatttactcg gcatcctaccggtacagtggagtccctgatcgcttcacaggcagtggatc tgggacagatttcactctcaccatcagcaatgtgcagtctgaagacttgg cagagtatttctgtcagcaatataacagctatccgtggacgttcggtgga ggcaccaagctggaaatcaaac (SEQ ID NO: 33) D16 VL - Amino Acid DIQMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYS ASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPWTFGG GTKLEIK (SEQ ID NO: 34) D16 VL - CDR1-IMGT cagaatgtgggtactaat (SEQ ID NO: 11) QNVGTN (SEQ ID NO: 12) D16 VL - CDR2-IMGT tcggcatcc SAS (SEQ ID NO: 13) D16 VL - CDR3-IMGT cagcaatataacagctatccgtggacg (SEQ ID NO: 35) QQYNSYPWT (SEQ ID NO: 36)

TABLE 1G D17 VH Sequences D17 VH - Nucleic Acid Sequence cagatccaactgcagcagtctggagctgagctggtaaggcctgggacttc agtgaagatatcctgcaaggcttctggctacaccttcactaactactggc taggttgggtaaagcagaggcctggacatggacttgagtggattggagat atttaccctggaggtggttatactaactacaatgagaagttcaagggcaa ggccacactgactgcagacacatcctccagcactgcctacatgcagctca gtagcctgacatctgaggactctgctgtctatttctgtgcaagagttact ccggcttcctggggccaaggcaccactctcacagtctctgcgg (SEQ ID NO: 37) D17 VH - Amino Acid Sequence QIQLQQSGAELVRPGTSVKISCKASGYTFTNYWLGWVKQRPGHGLEWIGD IYPGGGYTNYNEKFKGKATLTADTSSSTAYMQLSSLTSEDSAVYFCARVT PASWGQGTTLTVSA (SEQ ID NO: 38) D17 VH - CDR1-IMGT ggctacaccttcactaactactgg (SEQ ID NO: 3) GYTFTNYW (SEQ ID NO: 4) D17 VH - CDR2-IMGT atttaccctggaggtggttatact (SEQ ID NO: 5) IYPGGGYT (SEQ ID NO: 6) D17 VH - CDR3-IMGT gcaagagttactccggcttcc (SEQ ID NO: 7) ARVTPAS (SEQ ID NO: 8)

TABLE 1H D17 VL Sequences D17 VL - Nucleic Acid Sequence gacattctgctgacccagtctcaaaaattcatgtccacatcagtaggaga cagggtcagcgtcacctgcaaggccagtcagaatgtgggtactaatgtag cctggtatcaacagaaaccagggcaatctcctaaagcactgatttactcg gcatcctaccggtacagtggagtccctgatcgcttcacaggcagtggatc tgggacagatttcactctcaccatcagcaatgtgcagtctgaagacttgg cagagtatttctgtcagcaatataacagctatcctctcacgttcggaggg gggaccaagctggaaataaaac (SEQ ID NO: 39) D17 VL - Amino Acid Sequence DILLTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYS ASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGG GTKLEIK (SEQ ID NO: 40) D17 VL - CDR1-IMGT cagaatgtgggtactaat (SEQ ID NO: 11) QNVGTN (SEQ ID NO: 12) D17 VL - CDR2-IMGT tcggcatcc SAS (SEQ ID NO: 13) D17 VL - CDR3-IMGT cagcaatataacagctatcctctcacg (SEQ ID NO: 41) QQYNSYPLT (SEQ ID NO: 42)

TABLE 1I D34 VH Sequences D34 VH - Nucleic Acid Sequence caggtccaactgcagcagtctggggctgagctggtgaggcctggggtctc agtgaagatttcctgcaagggttctggctacacattcactgattatgcta tgcactgggtgaagcagagtcatgcaaagagtctagagtggattggagtt attagtacttactctggtgatgttagttacaaccagaagttcaagggcaa ggccacaatgactgtcgacaaatcctccagcacagcctatatggaacttg ccagactgacatctgaggattctgccatctattactgtgcaagaggggta acttttgactcctggggccaaggcaccacggtcaccgtctcctcg (SEQ ID NO: 43) D34 VH - Amino Acid Sequence QVQLQQSGAELVRPGVSVKISCKGSGYTFTDYAMHWVKQSHAKSLEWIGV ISTYSGDVSYNQKFKGKATMTVDKSSSTAYMELARLTSEDSAIYYCARGV TFDSWGQGTTVTVSS (SEQ ID NO: 44) D34 VH - CDR1-IMGT ggctacacattcactgattatgct (SEQ ID NO: 18) GYTFTDYA (SEQ ID NO: 19) D34 VH - CDR2-IMGT attagtacttactctggtgatgtt (SEQ ID NO: 45) ISTYSGDV (SEQ ID NO: 46) D34 VH - CDR3-IMGT gcaagaggggtaacttttgactcc (SEQ ID NO: 47) ARGVTFDS (SEQ ID NO: 48)

TABLE 1J D34 VL Sequences D34 VL - Nucleic Acid Sequence gacatccagatgacacagtctccagcctccctatctgcatctgtgggaga aactgtcaccatcacatgtcgagcaagtgagaatagttacagttatttag aatggtatcagcagaaacagggaaaatctcctcagctcctggtctataat gcaaaaactttagcagaaggtgtgccatcaaggttcagtggcagtggatc aggcacacagttttctctgaagatcaacagcctgcagcctgaagattttg ggacttattactgtcaacatcattatggtactccgtacacgttcggaggg gggaccaagctggaaataaaac (SEQ ID NO: 49) D34 VL - Amino Acid Sequence DIQMTQSPASLSASVGETVTITCRASENSYSYLEWYQQKQGKSPQLLVYN AKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGTYYCQHHYGTPYTFGG GTKLEIK (SEQ ID NO: 50) D34 VL - CDR1-IMGT gagaatagttacagttat (SEQ ID NO: 51) ENSYSY (SEQ ID NO: 52) D34 VL - CDR2-IMGT aatgcaaaa NAK (SEQ ID NO: 28) D34 VL - CDR3-IMGT caacatcattatggtactccgtacacg (SEQ ID NO: 53) QHHYGTPYT (SEQ ID NO: 54)

TABLE 1K D36 VH Sequences D36 VH - Nucleic Acid Sequence caggtccaactgcagcagcctggggctgagctggtgaggcctggggtttc actgaagatttcctgcaagggttctggctacacattcactgattatgcta tgcactgggtgaggcagagtcatgcaaagagtctagagtggattggagtt attagtacttactctggtgatgctctctacaaccagaagttcaagggcaa ggccacaatgactgtcgacaaatcctccagcacagcctatctggaacttg ccagactgacatctgaggattctgccatctattactgtgcgcgaggggta acttttgactactggggccaaggcaccactctcacagtctcctcgg (SEQ ID NO: 55) D36 VH - Amino Acid Sequence QVQLQQPGAELVRPGVSLKISCKGSGYTFTDYAMHWVRQSHAKSLEWIGV ISTYSGDALYNQKFKGKATMTVDKSSSTAYLELARLTSEDSAIYYCARGV TFDYWGQGTTLTVSS (SEQ ID NO: 56) D36 VH - CDR1-IMGT ggctacacattcactgattatgct (SEQ ID NO: 18) GYTFTDYA (SEQ ID NO: 19) D36 VH - CDR2-IMGT attagtacttactctggtgatgct (SEQ ID NO: 20) ISTYSGDA (SEQ ID NO: 21) D36 VH - CDR3-IMGT gcgcgaggggtaacttttgactac (SEQ ID NO: 57) ARGVTFDY (SEQ ID NO: 23)

TABLE 1l D36 VL Sequences D36 VL - Nucleic Acid Sequence gatgttgtgatgacccagtctccagcctccctatctgcatctgtgggaga aactgtcaccatcacatgtcgagcaagtgagaatagttacagttatttag aatggtatcagcagaaacagggaaaatctcctcagctcctggtctataat gcaaaaactttagcagaaggtgtgccatcaaggttcagtggcagtggatc aggcacacagttttctctgaagatcaacagcctgcagcctgaagattttg ggacttattactgtcaacatcattatggtactccgtacacgttcggaggg gggaccaagctggaaatgaaac (SEQ ID NO: 58) D36 VL Amino Acid Sequence DVVMTQSPASLSASVGETVTITCRASENSYSYLEWYQQKQGKSPQLLVYN AKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGTYYCQHHYGTPYTFGG GTKLEMK (SEQ ID NO: 59) D36 VL - CDR1-IMGT gagaatagttacagttat (SEQ ID NO: 51) ENSYSY (SEQ ID NO: 52) D36 VL - CDR2-IMGT aatgcaaaa NAK (SEQ ID NO: 28) D36 VL - CDR3-IMGT caacatcattatggtactccgtacacg (SEQ ID NO: 53) QHHYGTPYT (SEQ ID NO: 54)

TABLE 2A Exemplary Clones - Heavy Chain Sequences V-D-J- JUNC- J- H- ID REGION H-FR1 CDRH1 H-FR2 CDRH2 H-FR3 CDRH3 TION REGION FR4 AHH DVKLVESGGGL DVKL GFTFS MSWV ISSGG YYPDS ARGEI CARGE WFAYW WGQG 03702 VKPGGSLKLSC VESG SYA RQTP ST VKGRF WGKAW IWGKA GQGTL TLVT AASGFTFSSYA GGLV (SEQ EKRL (SEQ TISRD FAY WFAYW TVSAV VSA MSWVRQTPEKR KPGG ID EWVA ID NARNI (SEQ (SEQ (SEQ (SEQ LEWVASISSGG SLKL NO: S NO: LYLQM ID ID ID ID STYYPDSVKGR SCAA 151) (SEQ 224) SSLRS NO: NO: NO: NO: FTISRDNARNI S ID EDTAM 297) 345) 392) 421) LYLQMSSLRSE (SEQ NO: YYC DTAMYYCARGE ID 184) (SEQ IWGKAWFAYWG NO: ID QGTLVTVSA 108) NO: (SEQ ID NO: 259) 60) AHH QVQMKQSGPEL QVQM GYTLT MHWV INTET TYADD AWGNH CAWGN YWGQG WGQG 03703 KKPGETVKISC KQSG DYS KQAP GEP FKGRF Y HYW TTVTV TTVT KASGYTLTDYS PELK (SEQ GKGL (SEQ AFSLE (SEQ (SEQ SS VSS MHWVKQAPGKG KPGE ID KWMG ID TSAST ID ID (SEQ (SEQ LKWMGWINTET TVKI NO: W NO: AYLQI NO: NO: ID ID GEPTYADDFKG SCKA 152) (SEQ 225) NNLKN 298) 346) NO: NO: RFAFSLETSAS S ID EDTAT 393) 422) TAYLQINNLKN (SEQ NO: YFC EDTATYFCAWG ID 185) (SEQ NHYWGQGTTVT NO: ID VSS (SEQ ID 109) NO: NO: 61) 260) AHH QIQLQQSGPEL QIQL GYTFT MHWV INPYN KYNEK ARDGY CARDG AYWGQ WGQG 03704 VKPGASVKMSC QQSG SYV KQKP DGT FKGKA YVGPA YYVGP GTLVT TLVT KASGYTFTSYV PELV (SEQ GQGL (SEQ TLTSD Y AYW VSA VSA MHWVKQKPGQG KPGA ID EWIG ID KSSST (SEQ (SEQ (SEQ (SEQ LEWIGYINPYN SVKM NO: Y NO: AYMEL ID ID ID ID DGTKYNEKFKG SCKA 153) (SEQ 226) SSLTS NO: NO: NO: NO: KATLTSDKSSS S ID EDSAV 299) 347) 394) 421) TAYMELSSLTS (SEQ NO: YYC EDSAVYYCARD ID 186) (SEQ GYYVGPAYWGQ NO: ID GTLVTVSA 110) NO: (SEQ ID NO: 261) 62) AHH EVLLVESGGGL EVLL GFAFS MSWV ISSGG YYPDT ARNYR CARNY WFAYW WGQG 03705 VKPGGSLKLSC VESG SYD RQTP GST VKGRF SWFAY RSWFA GQGTL TLVT AASGFAFSSYD GGLV (SEQ EKRL (SEQ TISRD (SEQ YW VTVSA VSA MSWVRQTPEKR KPGG ID EWVA ID NAKNT ID (SEQ (SEQ (SEQ LEWVAYISSGG SLKL NO: Y NO: LYLQM NO: ID ID ID GSTYYPDTVKG SCAA 154) (SEQ 227) SSLKS 300) NO: NO: NO: RFTISRDNAKN S ID EDTAM 348) 392) 421) TLYLQMSSLKS (SEQ NO: YYC EDTAMYYCARN ID 187) (SEQ YRSWFAYWGQG NO: ID TLVTVSA 111) NO: (SEQ ID NO: 262) 63) AHH QVQLQQSGAEL QVQL GYAFT IEWV INPGS NYNEK ARKGS CARKG AYWGQ WGQG 03706 VRPGTSVKVSC QQSG NYL KQRP GGT FKGKA LTGVL SLTGV GTLVT TLVT KASGYAFTNYL AELV (SEQ GQGL (SEQ TLTAD AY LAYW VSA VSA IEWVKQRPGQG RPGT ID EWIG ID KSSST (SEQ (SEQ (SEQ (SEQ LEWIGVINPGS SVKV NO: V NO: AYMQL ID ID ID ID GGTNYNEKFKG SCKA 155) (SEQ 228) SSLTS NO: NO: NO: NO: KATLTADKSSS S ID DDSAV 301) 349) 394) 421) TAYMQLSSLTS (SEQ NO: YFC DDSAVYFCARK ID 188) (SEQ GSLTGVLAYWG NO: ID QGTLVTVSA 112) NO: (SEQ ID NO: 263) 64) AHH QVQLQQSGAEL QVQL GYIFT MNWV IDPSD HYNQM ARRGL CARRG WFAYW WGQG 03707 VRPGASVKLSC QQSG NYW KQRP SET SKDKA RAWFA LRAWF GQGTL TLVT KASGYIFTNYW AELV (SEQ GQGL (SEQ TLTVD Y AYW VTVSA VSA MNWVKQRPGQG RPGA ID EWIG ID KSSST (SEQ (SEQ (SEQ (SEQ LEWIGMIDPSD SVKL NO: M NO: AYMQL ID ID ID ID SETHYNQMSKD SCKA 156) (SEQ 229) SSLTS NO: NO: NO: NO: KATLTVDKSSS S ID EDSAV 302) 350) 392) 421) TAYMQLSSLTS (SEQ NO: YYC EDSAVYYCARR ID 189) (SEQ GLRAWFAYWGQ NO: ID GTLVTVSA 113) NO: (SEQ ID NO: 264) 65) AHH QVQLQQPGAEL QVQL GYTFT MHWV INPST EYNQK ARLDY CARLD FAYWG WGQG 03708 AKPGASVKMSC QQPG SYW KQRP GYT FKDKA YGSSR YYGSS QGTLV TLVT KASGYTFTSYW AELA (SEQ GQGL (SEQ TLTAD GFAY RGFAY TVSA VSA MHWVKQRPGQG KPGA ID EWIG ID KSSST (SEQ W (SEQ (SEQ LEWIGYINPST SVKM NO: Y NO: AYMQL ID (SEQ ID ID GYTEYNQKFKD SCKA 157) (SEQ 230) SSLTS NO: ID NO: NO: KATLTADKSSS S ID EDSAV 303) NO: 395) 421) TAYMQLSSLTS (SEQ NO: YYC 351) EDSAVYYCARL ID 190) (SEQ DYYGSSRGFAY NO: ID WGQGTLVTVSA 114) NO: (SEQ ID NO: 265) 66) AHH QVQLQQSGAEL QVQL GYTFT MYWV INPSN NFNEK TNGGG CTNGG GGWYW WGQG 03709 VKPGASVKLSC QQSG SYY KQRP GGT FKSKA WY GWYW GQGTT TTVT KASGYTFTSYY AELV (SEQ GQGL (SEQ TLTVD (SEQ (SEQ VTVSS VSS MYWVKQRPGQG KPGA ID EWIG ID KSSST ID ID (SEQ (SEQ LEWIGEINPSN SVKL NO: E NO: AYMQL NO: NO: ID ID GGTNFNEKFKS SCKA 158) (SEQ 231) SSLTS 304) 352) NO: NO: KATLTVDKSSS S ID EDSAV 396) 422) TAYMQLSSLTS (SEQ NO: YYC EDSAVYYCTNG ID 191) (SEQ GGWYWGQGTTV NO: ID TVSS (SEQ 115) NO: ID NO: 67) 266) AHH QIQLVQSGPEL QIQL GYTFT MNWV INTYT TYADD ASYYD CASYY FAYWG WGQG 03711 KKPGETVKISC VQSG NYG KQTP GEP FKGRF STYVG DSTYV QGTLV TLVT KASGYTFTNYG PELK (SEQ GKGL (SEQ AFSLE FAY GFAYW TVSA VSA MNWVKQTPGKG KPGE ID KWMG ID TSAST (SEQ (SEQ (SEQ (SEQ LKWMGWINTYT TVKI NO: W NO: AYLQI ID ID ID ID GEPTYADDFKG SCKA 159) (SEQ 232) NNLKN NO: NO: NO: NO: RFAFSLETSAS S ID EDTAT 305) 353) 395) 421) TAYLQINNLKN (SEQ NO: YFC EDTATYFCASY ID 192) (SEQ YDSTYVGFAYW NO: ID GQGTLVTVSA 116) NO: (SEQ ID NO: 260) 68) AHH EVLLVESGGGL EVLL GFTFS MYWV ISNGG YYPDT ASPLG CASPL FAYWG WGQG 03712 VQPGGSLKLSC VESG DYY RQTP GST VKGRF YDGFA GYDGF QGTLV TLVT ATSGFTFSDYY GGLV (SEQ EKRL (SEQ TISRD Y AYW TVSA VSA MYWVRQTPEKR QPGG ID EWVA ID NAKNT (SEQ (SEQ (SEQ (SEQ LEWVAYISNGG SLKL NO: Y NO: LYLQM ID ID ID ID GSTYYPDTVKG SCAT 160) (SEQ 233) SRLKS NO: NO: NO: NO: RFTISRDNAKN S ID EDTAM 306) 354) 395) 421) TLYLQMSRLKS (SEQ NO: YYC EDTAMYYCASP ID 193) (SEQ LGYDGFAYWGQ NO: ID GTLVTVSA 117) NO: (SEQ ID NO: 267) 69) AHH QVQMKQSGPGL QVQM GFSLT VHWV IWAGG NYNSA ARGA CARGA YFDYW WGQG 03713 VAPSQSLSITC KQSG SYG RQPP ST LMSRL YFDY YFDYW GQGTT TTVT TVSGFSLTSYG PGLV (SEQ GKGL (SEQ SISKD (SEQ (SEQ VTVSS VSS VHWVRQPPGKG APSQ ID EWLG ID NSKSQ ID ID (SEQ (SEQ LEWLGVIWAGG SLSI NO: V NO: VFLKM NO: NO: ID ID STNYNSALMSR TCTV 161) (SEQ 234) NSLQT 307) 355) NO: NO: LSISKDNSKSQ S ID DDTAM 397) 422) VFLKMNSLQTD (SEQ NO: YYC DTAMYYCARGA ID 194) (SEQ YFDYWGQGTTV NO: ID TVSS (SEQ 118) NO: ID NO: 70) 268) AHH QVQLQQSGAEL QVQL GYTFT MNWV IDPYD HYNQK ARSP CARSP WFAYW WGQG 03714 VRPGASVKLSC QQSG SYW KQRP SET FKDKA AYYG AYYGN GQGTL TLVT KASGYTFTSYW AELV (SEQ EQGL (SEQ ILTVD NLWF LWFAY VTVSA VSA MNWVKQRPEQG RPGA ID EWIG ID KSSST AY W (SEQ (SEQ LEWIGRIDPYD SVKL NO: R NO: AYMQL (SEQ (SEQ ID ID SETHYNQKFKD SCKA 157) (SEQ 235) SSLTS ID ID NO: NO: KAILTVDKSSS S(SEQ ID EDSAV NO: NO: 392) 421) TAYMQLSSLTS IDNO: NO: YYC 308) 356) EDSAVYYCARS 113) 195) (SEQ PAYYGNLWFAY ID WGQGTLVTVSA NO: (SEQ ID NO: 269) 71) AHH QVQLQQSGAEL QVQL GYTFT IHWV INPSS NYNQK ARWD CARW WGQGT WGQG 03715 ARPGASVKMSC QQSG SYT KQRP GYT FKDKA GAY DGAY PVTVS TPVT KASGYTFTSYT AELA (SEQ GQGL (SEQ TLTAD (SEQ W S VSS IHWVKQRPGQG RPGA ID EWIG ID KSSST ID (SEQ (SEQ (SEQ LEWIGYINPSS SVKM NO: (SEQ NO: AYMQL NO: ID ID ID GYTNYNQKFKD SCKA 162) ID 236) SSLTS 309) NO: NO: NO: KATLTADKSSS S NO: EDSAV 357) 398) 398) TAYMQLSSLTS (SEQ 196) YYC EDSAVYYCARW ID (SEQ DGAYWGQGTPV NO: ID TVSS (SEQ 119) NO: ID NO: 72) 270) AHH DVKLVESGGGL DVKL GFTFS MSWV ISSGG YYPDT ARGG CARGG FAYWG WGQG 03716 VKPGGSLKLSC VESG SYA RQFP SYT VTGRF MITP MITPF QGTLV TLVT AASGFTFSSYA GGLV (SEQ EKRL (SEQ TISRD FAY AYW TVSS VSS MSWVRQFPEKR KPGG ID EWVA ID NAKNT (SEQ (SEQ (SEQ (SEQ LEWVAEISSGG SLKL NO: E NO: LYLEM ID ID ID ID SYTYYPDTVTG SCAA 151) (SEQ 237) SSLRS NO: NO: NO: NO: RFTISRDNAKN S ID EDTAM 310) 358) 399) 413) TLYLEMSSLRS (SEQ NO: YYC EDTAMYYCARG ID 197) (SEQ GMITPFAYWGQ NO: ID GTLVTVSS 108) NO: (SEQ ID NO: 271) 73) AHH QVILKESGPGI QVIL GFSLS VGWI IWWND YYNPA ARIG CARIG YWYFD WGAG 03717 LQPSQTLSLTC KESG TSGMS RQPS DK LKSRL GNDG GNDGY VWGAG TTVT SFSGFSLSTSG PGIL (SEQ GKGL (SEQ TISKD YYWY YWYFD TTVTV VSS MSVGWIRQPSG QPSQ ID EWLA ID TSNNQ FDV VW SS (SEQ KGLEWLAHIWW TLSL NO: H NO: VFLKI (SEQ (SEQ (SEQ ID NDDKYYNPALK TCSF 163) (SEQ 238) ASVVT ID ID ID NO: SRLTISKDTSN S ID ADTAT NO: NO: NO: 423) NQVFLKIASVV (SEQ NO: YYC 311) 359) 400) TADTATYYCAR ID 198) (SEQ IGGNDGYYWYF NO: ID DVWGAGTTVTV 120) NO: SS (SEQ ID 272) NO: 74) AHH EVKIEESGGGL EVKI GFTFS MDWV IRSKA YYAES TPQF CTPQF FAYWG WGQG 03718 VQPGGSMKLSC EESG DAW RQSP NNHAT VKGRF AY AYW QGTTV TTVT AASGFTFSDAW GGLV (SEQ EKGL (SEQ TISRD (SEQ (SEQ TVSS VSS MDWVRQSPEKG QPGG ID EWVA ID DSKSS ID ID (SEQ (SEQ LEWVAEIRSKA SMKL NO: E NO: VYLQM NO: NO: ID ID NNHATYYAESV SCAA 164) (SEQ 239) NSLRA 312) 360) NO: NO: KGRFTISRDDS S ID EDTG 401) 422) KSSVYLQMNSL (SEQ NO: IYYC RAEDTGIYYCT ID 199) (SEQ PQFAYWGQGTT NO: ID VTVSS (SEQ 121) NO: ID NO: 75) 273) AHH EVMLVESGGGL EVML GFTFS MSWV INSNG YYPDS ASHY CASHY YWGQG WGQG 03719 VQPGGSLKLSC VESG SYG RQTP GST VKGRF DEGY DEGYW TSLTV TSLT AASGFTFSSYG GGLV (SEQ DKRL (SEQ TISRD (SEQ (SEQ SS VSS MSWVRQTPDKR QPGG ID ELVA ID NAKNT ID ID (SEQ (SEQ LELVATINSNG SLKL NO: T NO: LYLQM NO: NO: ID ID GSTYYPDSVKG SCAA 165) (SEQ 240) SSLKS 313) 361) NO: NO: RFTISRDNAKN S ID EDTAM 402) 424) TLYLQMSSLKS (SEQ NO: YYC EDTAMYYCASH ID 200) (SEQ YDEGYWGQGTS NO: ID LTVSS (SEQ 122) NO: ID NO: 76) 274) AHH EVKLEESGGGL EVKL GFTFS MNWV IRLKS HYAES TGSDY CTGSD DYWGQ WGQG 03720 VQPGGSMKLSC EESG NYW RQSP NNYAT VKGRF (SEQ YW GTTVT TTVT VASGFTFSNYW GGLV (SEQ EKGL (SEQ TISRD ID (SEQ VSS VSS MNWVRQSPEKG QPGG ID EWVA ID DSKSS NO: ID (SEQ (SEQ LEWVAEIRLKS SMKL NO: E NO: VYLQM 314) NO: ID ID NNYATHYAESV SCVA 166) (SEQ 241) NNLRA 362) NO: NO: KGRFTISRDDS S ID EDTGI 403) 422) KSSVYLQMNNL (SEQ NO: YYC RAEDTGIYYCT ID 201) (SEQ GSDYWGQGTTV NO: ID TVSS (SEQ 123) NO: ID NO: 77) 275) AHH QVQLQQSGPEL QVQL GDTFS IHWV FNPYS KYNEK GSGYD CGSGY WFACW WGQG 03721 VKPGASVKMSC QQSG SYV KQKP DDI FKGKA GYYDW DGYYD GQGTL TLVT KASGDTFSSYV PELV (SEQ GQGL (SEQ TLTSD FAC WFACW VTVSA VSA IHWVKQKPGQG KPGA ID EWIG ID KSSST (SEQ (SEQ (SEQ (SEQ LEWIGYFNPYS SVKM NO: (SEQ NO: AYMEL ID ID ID ID DDIKYNEKFKG SCKA 167) ID 242) SSLTS NO: NO: NO: NO: KATLTSDKSSS S NO: EDSAV 315) 363) 404) 421) TAYMELSSLTS (SEQ 202) YYC EDSAVYYCGSG ID (SEQ YDGYYDWFACW NO: ID GQGTLVTVSA 124) NO: (SEQ ID NO: 261) 78) AHH QIQLAQSGPEL QIQL GYSFT MNWV INTYT TYADD AREPK CAREP DYWGQ WGQG 03722 KKPGETVKISC AQSG KNG KQAP GEP FKGRF TLDY KTLDY GTTVT TTVT KASGYSFTKNG PELK (SEQ GKGL (SEQ AFSLE (SEQ W VSS VSS MNWVKQAPGKG KPGE ID KWMG ID TSAST ID (SEQ (SEQ (SEQ LKWMGWINTYT TVKI NO: W NO: AYLQI NO: ID ID ID GEPTYADDFKG SCKA 168) (SEQ 232) NNLKN 316) NO: NO: NO: RFAFSLETSAS S ID EDTAT 364) 403) 422) TAYLQINNLKN (SEQ NO: YFC EDTATYFCARE ID 203) (SEQ PKTLDYWGQGT NO: ID TVTVSS (SEQ 125) NO: ID NO: 79) 260) AHH QVQLQQSGAEL QVQL GYTFT MNWV IDPSD HYNQK ANWA CANWA WFAYW WGQG 03724 VKPGAPVKLSC QQSG SYW KQRP SET FKDKA WFAY WFAYW GQGTL TLVT KASGYTFTSYW AELV (SEQ GRGL (SEQ TLTVD (SEQ (SEQ VTVSA VSA MNWVKQRPGRG KPGA ID EWIG ID KSSST ID ID (SEQ (SEQ LEWIGRIDPSD PVKL NO: R NO: AYIQL NO: NO: ID ID SETHYNQKFKD SCKA 157) (SEQ 229) SSLTS 317) 365) NO: NO: KATLTVDKSSS S ID EDSAV 392) 421) TAYIQLSSLTS (SEQ NO: YYC EDSAVYYCANW ID 204) (SEQ AWFAYWGQGTL NO: ID VTVSA (SEQ 126) NO: ID NO: 80) 276) AHH QMQLKESGTEL QMQL GYTFN MNWV IDPYD HYNQK ARPY CARPY FAYWG WGQG 03726 VRPGASVKLSC KESG SHW KQRP SET FKDKA DYDG DYDGF QGTLV TLVT KASGYTFNSHW TELV (SEQ EQGL (SEQ ILTVD FAY AYW TVSA VSA MNWVKQRPEQG RPGA ID EWIG ID KSSST (SEQ (SEQ (SEQ (SEQ LEWIGKIDPYD SVKL NO: K NO: AYMQL ID ID ID ID SETHYNQKFKD SCKA 169) (SEQ 235) SSLTS NO: NO: NO: NO: KAILTVDKSSS S ID EDSAV 318) 366) 395) 421) TAYMQLSSLTS (SEQ NO: YYC EDSAVYYCARP ID 205) (SEQ YDYDGFAYWGQ NO: ID GTLVTVSA 127) NO: (SEQ ID NO: 269) 81) AHH QIQLQQSGAEL QIQL GYTF INWV INPYN SYNQK ADGD CADGD YFDYW WGQG 03727 VRPGASVKISC QQSG TNHH KQRP DYT FKGKA YYFD YYFDY GQGTS TSLT KAFGYTFTNHH AELV (SEQ GQGL (SEQ TLTVD Y W LTVSS VSS INWVKQRPGQG RPGA ID DWIG ID KSSST (SEQ (SEQ (SEQ (SEQ LDWIGYINPYN SVKI NO: (SEQ NO: AYMEL ID ID ID ID DYTSYNQKFKG SCKA 170) ID 243) SSLTS NO: NO: NO: NO: KATLTVDKSSS F NO: EDSAV 319) 367) 405) 424) TAYMELSSLTS (SEQ 206) YYC EDSAVYYCADG ID (SEQ DYYFDYWGQGT NO: ID SLTVSS (SEQ 128) NO: ID NO: 82) 277) AHH DVLLVESGGDL DVLL GLTF MSWV ISSGG YYVDS ARQD CARQD FDYWG WGQG 03728 VKPGGSLKLSC VESG SSYG RQTP SYI VKGRF DGYY DGYYR QGTTL TTLT VVSGLTFSSYG GDLV (SEQ DKRL (SEQ TISRD RIFD IFDYW TVSS VSS MSWVRQTPDKR KPGG ID EWVA ID NAKNT Y (SEQ (SEQ (SEQ LEWVATISSGG SLKL NO: T NO: LYLQM (SEQ ID ID ID SYIYYVDSVKG SCWS 171) (SEQ 244) SSLKS ID NO: NO: NO: RFTISRDNAKN (SEQ ID EDTAI NO: 368) 406) 425) TLYLQMSSLKS ID NO: YYC 320) EDTAIYYCARQ NO: 207) (SEQ DDGYYRIFDYW 129) ID GQGTTLTVSS NO: (SEQ ID NO: 278) 83) AHH EVKIEESGGGL EVKI GFTF MDWV IRSKA YYAES TNYG CTNYG DYWGQ WGQG 03729 VQPGGSMKLSC EESG NDAW RQSP NNHAT VKGRF SNPL SNPLD GTTLT TTLT AASGFTFNDAW GGLV (SEQ EKGL (SEQ TISRD DY YW IPS IPS MDWVRQSPEKG QPGG ID EWVA ID DSQSS (SEQ (SEQ (SEQ (SEQ LEWVAEIRSKA SMKL NO: E NO: VYLQM ID ID ID ID NNHATYYAESV SCAA 172) (SEQ 239) NSLRT NO: NO: NO: NO: KGRFTISRDDS S ID ENTGI 321) 369) 407) 426) QSSVYLQMNSL (SEQ NO: YYC RTENTGIYYCT ID 199) (SEQ NYGSNPLDYWG NO: ID QGTTLTIPS 121) NO: (SEQ ID NO: 279) 84) AHH QVTLKESGPGL QVTL GFSL VHWV IWAGG NYNSA AREG CAREG WFAYW WGQG 03730 VAPSQSLSITC KESG TSYG RQPP ST LMSRL TGPW TGPWF GQGTT TTAP TVSGFSLTSYG PGLV (SEQ GKGL (SEQ GISKD FAY AYW APSP SP VHWVRQPPGKG APSQ ID EWLG ID NSKSQ (SEQ (SEQ (SEQ (SEQ LEWLGVIWAGG SLSI NO: V NO: VFLKM ID ID ID ID STNYNSALMSR TCTV 161) (SEQ 234) NSLQT NO: NO: NO: NO: LGISKDNSKSQ S ID DESAF 322) 370) 408) 427) VFLKMNSLQTD (SEQ NO: YYC ESAFYYCAREG ID 194) (SEQ TGPWFAYWGQG NO: ID TTAPSP (SEQ 130) NO: ID NO: 85) 280) AHH DVQLQQSGPDL DVQL GYSI WHWI IHYSG NYNPS ARDP CARDP FAYWG WGQG 03731 VKPSQSLSLTC QQSG TSGY RQFP ST LKSRI PFAY PFAYW QGTLV TLVT TVTGYSITSGY PDLV S GNKL (SEQ SITRD (SEQ (SEQ TVSA VSA SWHWIRQFPGN KPSQ (SEQ EWMG ID TSKNQ ID ID (SEQ (SEQ KLEWMGYIHYS SLSL ID Y NO: FFLQL NO: NO: ID ID GSTNYNPSLKS TCTV NO: (SEQ 245) NSVTT 323) 371) NO: NO: RISITRDTSKN T 173) ID EGTAT 395) 421) QFFLQLNSVTT (SEQ NO: YYC EGTATYYCARD ID 208) (SEQ PPFAYWGQGTL NO: ID VTVSA (SEQ 131) NO: ID NO: 86) 281) AHH QVQLQQSGAEL QVQL GYTF MHWV IDPSD NYNQK AREE CAREE WFAYW WGQG 03733 VKPGASVRLSC QQSG TSYW KQRP SYT FKGKA ITAW ITAWF GQGTL TLVT KASGYTFTSYW AELV (SEQ GQGL (SEQ TLAVD FAY AYW VTVSA VSA MHWVKQRPGQG KPGA ID EWIG ID KSSST (SEQ (SEQ (SEQ (SEQ LEWIGEIDPSD SVRL NO: E NO: AYMQL ID ID ID ID SYTNYNQKFKG SCKA 157) (SEQ 246) SSLTS NO: NO: NO: NO: KATLAVDKSSS S ID EDSAV 324) 372) 392) 421) TAYMQLSSLTS (SEQ NO: YYC EDSAVYYCARE ID 209) (SEQ EITAWFAYWGQ NO: ID GTLVTVSA 132) NO: (SEQ ID NO: 282) 87) AHH QVQLQQPGAEL QVQL GYTFT MHWV IHPGS AYNQK TRNG CTRNG WYFDV WGAG 03734 VRPGASVKLSC QQPG DYE KQTP GGT FKGKA NGNW NGNWY WGAGT TTLT KALGYTFTDYE AELV (SEQ VHGL (SEQ TLTAD YFDV FDVW TLTVS VSS MHWVKQTPVHG RPGA ID EWIG ID KSSST (SEQ (SEQ S (SEQ LEWIGAIHPGS SVKL NO: A NO: AYMEL ID ID (SEQ ID GGTAYNQKFKG SCKA 174) (SEQ 247) SSLTS NO: NO: ID NO: KATLTADKSSS L ID EDSAV 325) 373) NO: 428) TAYMELSSLTS (SEQ NO: YYC 409) EDSAVYYCTRN ID 210) (SEQ GNGNWYFDVWG NO: ID AGTTLTVSS 133) NO: (SEQ ID NO: 283) 88) AHH QVQLQQSGAEL QVQL GYAF MNWV IYPGD YYNGK ARSG CARSG FAYWG WGPG 03737 VRPGSSVKISC QQSG SSYW KQRP GDT FKDKA YRYD YRYDA PGTLV TLVT KASGYAFSSYW AELV (SEQ GQGL (SEQ TLTAD AVFA VFAYW TVSA VSA MNWVKQRPGQG RPGS ID EWIG ID KSSST Y (SEQ (SEQ (SEQ LEWIGQIYPGD SVKI NO: Q NO: AYMHL (SEQ ID ID ID GDTYYNGKFKD SCKA 175) (SEQ 248) SSLTS ID NO: NO: NO: KATLTADKSSS S ID EDSAV NO: 374) 410) 429) TAYMHLSSLTS (SEQ NO: YFC 326) EDSAVYFCARS ID 211) (SEQ GYRYDAVFAYW NO: ID GPGTLVTVSA 134) NO: (SEQ ID NO: 284) 89) AHH EVQLLESGGGL EVQL GFTF MSWV INSNG YYPDS ARGG CARGG YLGQG LGQG 03738 VQPGGSLKLSC LESG SSYG RQTP GST VKGRF NPY NPYL TLVTV TLVT AASGFTFSSYG GGLV (SEQ DKRL (SEQ TISRD (SEQ (SEQ SA VSA MSWVRQTPDKR QPGG ID ELVA ID NAKNT ID ID (SEQ (SEQ LELVATINSNG SLKL NO: T NO: LYLQM NO: NO: ID ID GSTYYPDSVKG SCAA 165) (SEQ 240) SSLKS 327) 375) NO: NO: RFTISRDNAKN S ID EDTAM 411) 430) TLYLQMSSLKS (SEQ NO: YYC EDTAMYYCARG ID 200) (SEQ GNPYLGQGTLV NO: ID TVSA (SEQ 135) NO: ID NO: 90) 274) AHH EVQLVETGGGL EVQL GFTFS MSWV INSDG NYAPS MRYG LLVLR 03739 VQPGGSRGLSC VETG GFW RQTP SAI IKDRF SSYW C EGSGFTFSGFW GGLV (SEQ GKTL (SEQ TIFRD YFD (SEQ MSWVRQTPGKT QPGG ID EWIG ID NDKST (SEQ ID LEWIGDINSDG SRGL NO: D NO: LYLQM ID NO: SAINYAPSIKD SCEG 176) (SEQ 249) SNVRS NO: 412) RFTIFRDNDKS S ID EDTAT 328) TLYLQMSNVRS (SEQ NO: YFC EDTATYFCMRY ID 212) (SEQ GSSYWYFD NO: ID (SEQ ID NO: 136) NO: 91) 285) AHH EVKIEESGGGL EVKI GFTFS MSWV IRLKS HYAES TRYY CTRYY WGQGT WGQG 03740 VQPGGSMKLSC EESG SYW RQSP DNYAT VKGKF YGES YGESW LVTVS TLVT VASGFTFSSYW GGLV (SEQ EKGL (SEQ TISRD (SEQ (SEQ S VSS MSWVRQSPEKG QPGG ID EWVA ID DSKSR ID ID (SEQ (SEQ LEWVAEIRLKS SMKL NO: E NO: LYLQM NO: NO: ID ID DNYATHYAESV SCVA 177) (SEQ 250) NSLRA 329) 376) NO: NO: KGKFTISRDDS S ID EDTGI 413) 413) KSRLYLQMNSL (SEQ NO: YYC RAEDTGIYYCT ID 213) (SEQ RYYYGESWGQG NO: ID TLVTVSS 137) NO: (SEQ ID NO: 286) 92) AHH EVMLVESGGDL EVML GFTFS MSWV ISSGG YYPDS ARHY CARHY YWYFD WGAG 03742 VKPGGSLKLSC VESG SYG RQTP SYT VKGRF YDYD YDYDY VWGAG TTVT AASGFTFSSYG GDLV (SEQ DKRL (SEQ TISRD YWYF WYFDV TTVTV VSS MSWVRQTPDKR KPGG ID EWVA ID NAKNT DV W SS (SEQ LEWVATISSGG SLKL NO: T NO: LYLQM (SEQ (SEQ (SEQ ID SYTYYPDSVKG SCAA 165) (SEQ 237) SSLKS ID ID ID NO: RFTISRDNAKN S ID EDTAM NO: NO: NO: 423) TLYLQMSSLKS (SEQ NO: YYC 330) 377) 400) EDTAMYYCARH ID 207) (SEQ YYDYDYWYFDV NO: ID WGAGTTVTVSS 138) NO: (SEQ ID NO: 274) 93) AHH QVQLQQPGSEL QVQL GYTFT MHWV IYPGS NYDEK TRSG CTRSG WYFDV WGAG 03743 VRPGASVKLSC QQPG SYW KQRY GST FKSKG VEGL VEGLL WGAGT TSLT KASGYTFTSYW SELV (SEQ GQGL (SEQ TLTVD LHWY HWYFD SLTVS VSS MHWVKQRYGQG RPGA ID EWIG ID TSSST FDV VW S (SEQ LEWIGNIYPGS SVKL NO: N NO: AYMHL (SEQ (SEQ (SEQ ID GSTNYDEKFKS SCKA 157) (SEQ 251) SSLTS ID ID ID NO: KGTLTVDTSSS S ID EDSAV NO: NO: NO: 431) TAYMHLSSLTS (SEQ NO: YYC 331) 378) 414) EDSAVYYCTRS ID 214) (SEQ GVEGLLHWYFD NO: ID VWGAGTSLTVS 139) NO: S (SEQ ID 287) NO: 94) AHH EVKIEESGGGL EVKI GFTFS MSWV IRLKS HYAES TCDY CTCDY WFAYW WGQG 03746 VQPGGSMKLSC EESG SYW RQSP DNYAT VKGKF DGGA DGGAW GQGTL TLVT VASGFTFSSYW GGLV (SEQ EKGL (SEQ TISRD WFAY FAYW VTVSA VSA MSWVRQSPEKG QPGG ID EWVA ID DSKSR (SEQ (SEQ (SEQ (SEQ LEWVAEIRLKS SMKL NO: E NO: LYLQM ID ID ID ID DNYATHYAESV SCVA 177) (SEQ 250) NSLRA NO: NO: NO: NO: KGKFTISRDDS S ID EDTGI 332) 379) 392) 421) KSRLYLQMNSL (SEQ NO: YYC RAEDTGIYYCT ID 213) (SEQ CDYDGGAWFAY NO: ID WGQGTLVTVSA 137) NO: (SEQ ID NO: 286) 95) AHH QIQLQQPGPEL QIQL GYTFT MHW IDPSN RLNQK ARCD CARCD GLDYW WGQG 03748 VRPGASVKMSC QQPG SYW VKQR SET FKDKA GYYD GYYDG GQGTT TTLT KASGYTFTSYW PELV (SEQ PGQG (SEQ TLNVD GLDY LDYW LTVSS VSS MHWVKQRPGQG RPGA ID LEWI ID KSSNT (SEQ (SEQ (SEQ (SEQ LEWIGMIDPSN SVKM NO: GM NO: ACMQL ID ID ID ID SETRLNQKFKD SCKA 157) (SEQ 252) SSLTS NO: NO: NO: NO: KATLNVDKSSN S IDNO: EDSAV 333) 380) 415) 425) TACMQLSSLTS (SEQ 215) YYC EDSAVYYCARC ID (SEQ DGYYDGLDYWG NO: ID QGTTLTVSS 140) NO: (SEQ ID NO: 288) 96) AHH QVQLQQPGAEL QVQL GYTFT IHWV INPSS NYNQK AREG CAREG WYFDV WGAG 03749 ARPGASVKMSC QQPG SYT KQRP GYT FKDKA KNWY KNWYF WGAGT TTVT KASGYTFTSYT AELA (SEQ GQGL (SEQ TLTAD FDV DVW TVTVS VSS IHWVKQRPGQG RPGA ID EWIG ID KSSST (SEQ (SEQ S (SEQ LEWIGYINPSS SVKM NO: (SEQ NO: AYMQL ID ID (SEQ ID GYTNYNQKFKD SCKA 162) ID 236) SSLTS NO: NO: ID NO: KATLTADKSSS S NO: EDSAV 334) 381) NO: 423) TAYMQLSSLTS (SEQ 196) YYC 416) EDSAVYYCARE ID (SEQ GKNWYFDVWGA NO: ID GTTVTVSS 141) NO: (SEQ ID NO: 270) 97) AHH QIQLQQSGAEL QIQL GYTFT MHWI INPSN NYNEK ARRI CARRI TLDYW WGQG 03750 VRPGVSVKLSC QQSG SYW KQRP GGT FKSKA YRTL YRTLD GQGTT TTVT KASGYTFTSYW AELV (SEQ EQGL (SEQ TLTVD DY YW VTVSS VSS MHWIKQRPEQG RPGV ID ERIG ID KSSST (SEQ (SEQ (SEQ (SEQ LERIGEINPSN SVKL NO: E NO: AYMQL ID ID ID ID GGTNYNEKFKS SCKA 157) (SEQ 231) SSLTS NO: NO: NO: NO: KATLTVDKSSS S ID EDSAV 335) 382) 417) 422) TAYMQLSSLTS (SEQ NO: YYC EDSAVYYCARR ID 216) (SEQ IYRTLDYWGQG NO: ID TTVTVSS 142) NO: (SEQ ID NO: 289) 98) AHH EVQLQQSGAEL EVQL GYTFT MHWV IYPGN AYNQ TRSG CTRSG WFAYW WGQG 03751 VKPGASVKMSC QQSG SYN KQTP GDT KFKGK GNLW GNLWF GQGTL TLVT KASGYTFTSYN AELV (SEQ GQGL (SEQ ATVTA FAY AYW VTVSA VSA MHWVKQTPGQG KPGA ID EWIG ID DRSSS (SEQ (SEQ (SEQ (SEQ LEWIGVIYPGN SVKM NO: V NO: TAYMQ ID ID ID ID GDTAYNQKFKG SCKA 178) (SEQ 253) LSSLT NO: NO: NO: NO: KATVTADRSSS S ID SEDSA 336) 383) 392) 421) TAYMQLSSLTS (SEQ NO: VYYC EDSAVYYCTRS ID 217) (SEQ GGNLWFAYWGQ NO: ID GTLVTVSA 143) NO: (SEQ ID NO: 290) 99) AHH QIQLQQSGAEL QIQL GYTFS IEWV ILPGS NYNEK ARRT CARRT WFAYW WGQG 03752 MKPGASVKISC QQSG SYW KQRP GST FKGKA YYGN YYGNA GQGTL TLVT KATGYTFSSYW AELM (SEQ GHGL (SEQ TFTAD AWFA WFAYW VTVSA VSA IEWVKQRPGHG KPGA ID EWIG ID TSSNT Y (SEQ (SEQ (SEQ LEWIGEILPGS SVKI NO: E NO: AYMQL (SEQ ID ID ID GSTNYNEKFKG SCKA 179) (SEQ 254) SSLTS ID NO: NO: NO: KATFTADTSSN T ID EDSAV NO: 384) 392) 421) TAYMQLSSLTS (SEQ NO: YYC 337) EDSAVYYCARR ID 218) (SEQ TYYGNAWFAYW NO: ID GQGTLVTVSA 144) NO: (SEQ ID NO: 291) 100) AHH QVKLVESGGGL QVKL GFTFT MSWV IRNKA EYSAS ARDK CARDK WFAYW WGQG 03753 VQPGGSLRLSC VESG DYY RQPP NGYTT VKGRF RITT RITTV GQGTL TLVT ATSGFTFTDYY GGLV (SEQ GKAL (SEQ TISRD VEAW EAWFA VTVSA VSA MSWVRQPPGKA QPGG ID EWLG ID NSQSI FAY YW (SEQ (SEQ LEWLGFIRNKA SLRL NO: F NO: LYLQM (SEQ (SEQ ID ID NGYTTEYSASV SCAT 180) (SEQ 255) NTLRA ID ID NO: NO: KGRFTISRDNS S ID EDSAT NO: NO: 392) 421) QSILYLQMNTL (SEQ NO: YYC 338) 385) RAEDSATYYCA ID 219) (SEQ RDKRITTVEAW NO: ID FAYWGQGTLVT 145) NO: VSA (SEQ ID 292) NO: 101) AHH EVKLVETGGGL EVKL GFTFS MSWV ISSGG YYPDS ARGY CARGY SFAYW WGQG 03754 VKPGGSLKLSC VETG SYA RQTP ST VKGRF GSSF GSSFA GQGTP TPVT AASGFTFSSYA GGLV (SEQ EKRL (SEQ TISRD AY YW VTVSS VSS MSWVRQTPEKR KPGG ID EWVA ID NARNI (SEQ (SEQ (SEQ (SEQ LEWVASISSGG SLKL NO: S NO: LYLQM ID ID ID ID STYYPDSVKGR SCAA 151) (SEQ 224) SSLRS NO: NO: NO: NO: FTISRDNARNI S ID EDTAM 339) 386) 418) 398) LYLQMSSLRSE (SEQ NO: YYC DTAMYYCARGY ID 184) (SEQ GSSFAYWGQGT NO: ID PVTVSS (SEQ 146) NO: ID NO: 102) 259) AHH QVQLQQSGAEL QVQL GYTFT MYWV INPSN NFNEK TRGG CTRGG WFAYW WGQG 03755 VKPGASVKLSC QQSG SYY KQRP SGT FKSKA DYDA DYDAS GQGTL TLVT KASGYTFTSYY AELV (SEQ GQGL (SEQ TLTVD SWFA WFAYW VTVSA VSA MYWVKQRPGQG KPGA ID EWIG ID KSSST Y (SEQ (SEQ (SEQ LEWIGEINPSN SVKL NO: E NO: AYMQL (SEQ ID ID ID SGTNFNEKFKS SCKA 158) (SEQ 256) SSLTS ID NO: NO: NO: KATLTVDKSSS S ID EDSAV NO: 387) 392) 421) TAYMQLSSLTS (SEQ NO: YYC 340) EDSAVYYCTRG ID 191) (SEQ GDYDASWFAYW NO: ID GQGTLVTVSA 115) NO: (SEQ ID NO: 266) 103) AHH QVQMKESGPEP QVQM GYTLT VSWV IYPGS YYNEK ARRT CARRT FDYWG WGQG 03756 VKPGASVKMSC KESG DYV KQRL GST FKDKV ARAF ARAFD QGTTV TTVT RASGYTLTDYV PEPV (SEQ GQGL (SEQ TLTAD DY YW TVSS VSS VSWVKQRLGQG KPGA ID EWIG ID TSSNT (SEQ (SEQ (SEQ (SEQ LEWIGEIYPGS SVKM NO: E NO: VHIQL ID ID ID ID GSTYYNEKFKD SCRA 181) (SEQ 251) SSLTS NO: NO: NO: NO: KVTLTADTSSN S ID EDSAV 341) 388) 419) 422) TVHIQLSSLTS (SEQ NO: YFC EDSAVYFCARR ID 220) (SEQ TARAFDYWGQG NO: ID TTVTVSS 147) NO: (SEQ ID NO: 293) 104) AHH EVKLVESGGGL EVKL GFTFS MSWV ISSGG YYPDS ARRI CARRI WFAYW WGQG 03757 VKPGGSLKLSC VESG SYA RQTP SYT VKGRF GYDG GYDGG GQGTL TLVT AASGFTFSSYA GGLV (SEQ EKRL (SEQ TISRD GGSW GSWFA VTVSA VSA MSWVRQTPEKR KPGG ID EWVA ID NAKNT FAY YW (SEQ (SEQ LEWVATISSGG SLKL NO: T NO: LYLQM (SEQ (SEQ ID ID SYTYYPDSVKG SCAA 151) (SEQ 237) SSLRS ID ID NO: NO: RFTISRDNAKN S ID EDTAM NO: NO: 392) 421) TLYLQMSSLRS (SEQ NO: YYC 342) 389) EDTAMYYCARR ID 221) (SEQ IGYDGGGSWFA NO: ID YWGQGTLVTVS 148) NO: A (SEQ ID 294) NO: 105) AHH EVKIVESGGGL EVKI GFTFN MNWV IRSKS YYADS CERV LCERV CVLGP WGQG 03758 VQPKGSLKLSC VESG TYA RQAP NNYVT LKDRF RRCV RRCVL RDSGH TLVT AASGFTFNTYA GGLV (SEQ EKGL (SEQ TISRD (SEQ (SEQ CLC VSA MNWVRQAPEKG QPKG ID EWVA ID DSQSM ID ID (SEQ (SEQ LEWVARIRSKS SLKL NO: R NO: LYLQM NO: NO: ID ID NNYVTYYADSL SCAA 182) (SEQ 257) NNLKT 343) 390) NO: NO: KDRFTISRDDS S ID EDTCH 420) 421) QSMLYLQMNNL (SEQ NO: VLL KTEDTCHVLLC ID 222) (SEQ ERVRRCVLGPR NO: ID DSGHCLC 149) NO: (SEQ ID NO: 295) 106) AHH QVQLVETGGGL QVQL GFTFS MHWL ITVKS NYAES SRWF CSRWF WFAYW WGQG 03759 VRPGNSLKLSC VETG NYR RQPP DNYGA VKGRF AY AYW GQGTL TLVT VTSGFTFSNYR GGLV (SEQ GKRL (SEQ TISRD (SEQ (SEQ VTVSA VSA MHWLRQPPGKR RPGN ID EWIA ID DSKSS ID ID (SEQ (SEQ LEWIAVITVKS SLKL NO: V NO: VYLQM NO: NO: ID ID DNYGANYAESV SCVT 183) (SEQ 258) NRLRE 344) 391) NO: NO: KGRFTISRDDS S ID EDTAT 392) 421) KSSVYLQMNRL (SEQ NO: YYC REEDTATYYCS ID 223) (SEQ RWFAYWGQGTL NO: ID VTVSA (SEQ 150) NO: ID NO: 107) 296)

TABLE 2B Exemplary Clones-Heavy Chain Sequences JUNC- J- ID V-D-J-REGION H-FR1 CDRH1 H-FR2 CDRH2 H-FR3 CDRH3 TION REGION H-FR4 AHH QVQLQQSGAE QVQL GYTFT MHW IHPGS AYNQ TRSDY CTRSD FAYWGQ WGQG 03760 LVRPGASVKL QQSG DYE VKQT GGT KFKG GSSYE YGSSY GTLVTV TLVT SCKALGYTFT AELVR (SEQ ID PVHG (SEQ ID KAIL FAY EFAYW SS (SEQ VSS DYEMHWVKQ PGASV NO: LGWI NO: TADK (SEQ ID (SEQ ID ID NO: (SEQ TPVHGLGWIG KLSCK 174) GA 247) SSSTA NO: NO: 399) ID NO: AIHPGSGGTAY AL (SEQ YMEL 531) 558) 413) NQKFKGKATL (SEQ ID NO: SSLTS TADKSSSTAY ID NO: 493) EDSA MELSSLTSEDS 461) VYYC AVYYCTRSDY (SEQ GSSYEFAYWG ID NO: QGTLVTVSS 283) (SEQ ID NO: 432) AHH QIQLKESGPGL QIQLK GYSITS WNWI ISYSGS SYNPS ARSRG CARSR YFDYWG WGQG 03765 VKPSQSLSLTC ESGPG DYA RQFP T (SEQ LKSRI NYFDY GNYFD QGTTVT TTVT TVTGYSITSDY LVKPS (SEQ ID GNKL ID NO: SITRD (SEQ ID YW VSS (SEQ VSS AWNWIRQFPG QSLSL NO: EWM 506) TSKN NO: (SEQ ID ID NO: (SEQ NKLEWMGYIS TCTVT 482) GY QFFL 532) NO: 397) ID NO: YSGSTSYNPSL (SEQ (SEQ QLNS 559) 422) KSRISITRDTSK ID NO: ID NO: VTTE NQFFLQLNSVT 462) 494) DTAT TEDTATYYCA YYC RSRGNYFDYW (SEQ GQGTTVTVSS ID NO: (SEQ ID NO: 516) 433) AHH QIQLQQSGAEL QIQLQ GYTFTS IHWV INPSSG NYNQ ARSGL CARSG WFAYW WGQG 03767 ARPGASVRMS QSGAE YT KQRP YT KFKD RQAW LRQA GQGTLV TLVT CKASGYTFTS LARPG (SEQ ID GQGL (SEQ ID KATL FAY WFAY TVSA VSA YTIHWVKQRP ASVR NO: EWIG NO: TADK (SEQ ID W (SEQ (SEQ ID (SEQ GQGLEWIGYIN MSCK 162) (SEQ 236) SSSTA NO: ID NO: NO: 392) ID NO: PSSGYTNYNQ AS ID NO: YMQL 533) 560) 421) KFKDKATLTA (SEQ 196) SSLTS DKSSSTAYMQ ID NO: EDSA LSSLTSEDSAV 463) VYYC YYCARSGLRQ (SEQ AWFAYWGQG ID NO: TLVTVSA (SEQ 270) ID NO: 434) AHH QVQLVETGGG QVQL GFTFSN MHW ITVKS NYAE SRLFA CSRLF FAYWGQ WGQG 03768 LVRPGNSLKLS VETG YR LRQP DNYG SVKG Y (SEQ AYW GTLVTV TLVT CVTSGFTFSNY GGLV (SEQ ID LGKR A (SEQ RFTIS ID NO: (SEQ ID SA (SEQ VSA RMHWLRQPLG RPGNS NO: LEWI ID NO: RODS 534) NO: ID NO: (SEQ KRLEWIAVITV LKLSC 183) AV 258) KSSV 561) 395) ID NO: KSDNYGANYA VTS (SEQ YLQM 421) ESVKGRFTISR (SEQ ID NO: NRLR DDSKSSVYLQ ID NO: 495) EEDT MNRLREEDTA 150) ATYY TYYCSRLFAY C WGQGTLVTVS (SEQ A (SEQ ID NO: ID NO: 435) 296) AHH QVQLQQPGAE QVQL GYTFTS MHW INPSN NYNE TITGFD CTITGF FDVWGA WGAG 03770 LVKPGASVKL QQPG YW VKLR GGT KFKR V (SEQ DVW GTTVTV TTVT SCKASGYTFTS AELV (SEQ ID PGQG (SEQ ID KATL ID NO: (SEQ ID SS (SEQ VSS YWMHWVKLR KPGAS NO: FEWI NO: TVDK 535) NO: ID NO: (SEQ PGQGFEWIGEI VKLSC 157) GE 231) SSSTA 562) 585) ID NO: NPSNGGTNYN KAS (SEQ YMQL 423) EKFKRKATLT (SEQ ID NO: SSLTS VDKSSSTAYM ID NO: 496) EDSA QLSSLTSEDSA 464) VYYC VYYCTITGFDV (SEQ WGAGTTVTVS ID NO: S (SEQ ID NO: 517) 436) AHH QIQLQQSGAEL QIQLQ GYTFT IQWV IFPGTG YYNE ARGGY CARGG FAYWGQ WGQG 03771 VKPGASVKLS QSGAE TYW KQRP TT KFKG YNSSP YYNSS GTLVTV TLVT CKTSGYTFTTY LVKPG (SEQ ID GQGL (SEQ ID KATL FAY PFAYW SA (SEQ VSA WIQWVKQRPG ASVKL NO: GWIG NO: TIDTS (SEQ ID (SEQ ID ID NO: (SEQ QGLGWIGEIFP SCKTS 483) E (SEQ 507) SSTA NO: NO: 395) ID NO: GTGTTYYNEK (SEQ ID NO: YMQL 536) 563) 421) FKGKATLTIDT ID NO: 497) SSLTS SSSTAYMQLSS 465) EDSA LTSEDSAVYFC VYFC ARGGYYNSSP (SEQ FAYWGQGTLV ID NO: TVSA (SEQ ID 518) NO: 437) AHH DVQLVESGGG DVQL GFTFTD MSWV IRNKA EYSA ARDGE CARDG AYWGQ WGQG 03772 LVQPGGSLRLS VESGG YY RQPP NGYTT SVKG VRRAL EVRRA GTLVTV TLVT CATSGFTFTDY GLVQP (SEQ ID GKAL (SEQ ID RFTIS AY LAYW SA (SEQ VSA YMSWVRQPPG GGSLR NO: EWLG NO: RDNS (SEQ ID (SEQ ID ID NO: (SEQ KALEWLGFIR LSCAT 180) F (SEQ 255) QSILY NO: NO: 394) ID NO: NKANGYTTEY S (SEQ ID NO: LQMN 537) 564) 421) SASVKGRFTIS ID NO: 219) TLRA RDNSQSILYLQ 466) EDSA MNTLRAEDSA TYYC TYYCARDGEV (SEQ RRALAYWGQ GTLVTVSA ID NO: (SEQ ID NO: 292) 438) AHH QVQLQQPAAE QVQL GYTFTS MHW INPSSG EYNQ VRHYY CVRHY YFDYWG WGQG 03773 LARPGASVKM QQPA ST (SEQ VKQR YT KFKD FDY YFDY QGTTVT TTVT SCKASGYTFTS AELAR ID NO: PGQG (SEQ ID KTTL (SEQ ID W (SEQ VSS (SEQ VSS STMHWVKQRP PGASV 484) LEWI NO: TADK NO: ID NO: ID NO: (SEQ GQGLEWIGYIN KMSC GY 236) SSSTA 538) 565) 397) ID NO: PSSGYTEYNQ KAS (SEQ YMQL 422) KFKDKTTLTA (SEQ ID NO: SSLTS DKSSSTAYMQ ID NO: 190) EDSA LSSLTSEDSAV 467) VYYC YYCVRHYYFD (SEQ YWGQGTTVTV ID NO: SS (SEQ ID NO: 519) 439) AHH EVMLVESGGG EVML GFTFSS MSWV ISSGG YYLD TRVSA CTRVS YFDVWG WGAG 03774 LVKPGGSLKIS VESGG YT RQNP GYT SVKG KYFDV AKYFD AGTTLT TTLT CAASGFTFSSY GLVKP (SEQ ID EKRL (SEQ ID RFTPS (SEQ ID VW VSS (SEQ VSS TMSWVRQNPE GGSLK NO: EWVA NO: RDNG NO: (SEQ ID ID NO: (SEQ KRLEWVATISS ISCAA 485) T(SEQ 508) KNTL 539) NO: 586) ID NO: GGGYTYYLDS S (SEQ ID NO: NLQM 566) 428) VKGRFTPSRD ID NO: 498) SSLKS NGKNTLNLQM 468) EDTA SSLKSEDTAM MYYC YYCTRVSAKY (SEQ FDVWGAGTTL ID NO: TVSS (SEQ ID 520) NO: 440) AHH QVQLQQSGAE QVQL GYTFT LYWV INPSN NFNE TRSYY CTRSY DWYFDV WGAG 03776 LVKPGASVKL QQSG NFY KQRP GGT KFKS DYDW YD YD WGAGTT TTVT SCKASGYTFT AELV (SEQ ID GQGL (SEQ ID KATL YFDV WYFD VTVSS VSS NFYLYWVKQR KPGAS NO: EWIG NO: TVDK (SEQ ID VW (SEQ ID (SEQ PGQGLEWIGGI VKLSC 486) G 231) SSSTA NO: (SEQ ID NO: 587) ID NO: NPSNGGTNFN KAS (SEQ YMQL 540) NO: 423) EKFKSKATLT (SEQ ID NO: SSLTS 567) VDKSSSTAYM ID NO: 499) EDSA QLSSLTSEDSA 115) VYYC VYYCTRSYYD (SEQ YDWYFDVWG ID NO: AGTTVTVSS 266) (SEQ ID NO: 441) AHH QVQLQQSGAE QVQL GYTFTS INWV IYPSDS NYNQ TRQNY CTRQN WYFDV WGAG 03777 LVRPGASVKL QQSG YW KQRP YT KFKD YGSSH YYGSS WGAGTT TTLT SCKASGYTFTS AELVR (SEQ ID GQGL (SEQ ID KATL WYFD HWYF LTVSS VSS YWINWVKQRP PGASV NO: EWIG NO: TVDK V (SEQ DVW (SEQ ID (SEQ GQGLEWIGNIY KLSCK 157) N 509) SSSTA ID NO: (SEQ ID NO: 409) ID NO: PSDSYTNYNQ AS (SEQ YMQL 541) NO: 428) KFKDKATLTV (SEQ SSPTS 568) DKSSSTAYMQ ID NO: ID NO: EDSA LSSPTSEDSAV 113) 500) VYYC YYCTRQNYYG (SEQ SSHWYFDVW ID NO: GAGTTLTVSS 521) (SEQ ID NO: 442) AHH QVQLQQPGAE QVQL GYTFTS MNW IDPSDS HYNQ ANWA CANW WFAYW WGQG 03778 LVKPGAPVKL QQPG YW VKQR ET KFKD WFAY AWFA GQGTLV TLVT SCKASGYTFTS AELV (SEQ ID PGRG (SEQ ID KATL (SEQ ID YW TVSS VSS YWMNWVKQR KPGAP NO: LEWI NO: TVDK NO: (SEQ ID (SEQ ID (SEQ PGRGLEWIGRI VKLSC 157) GR 229) SSSTA 317) NO: NO: 588) ID NO: DPSDSETHYN KAS (SEQ YIQLS 365) 413) QKFKDKATLT (SEQ ID NO: SLTSE VDKSSSTAYIQ ID NO: 204) DSAV LSSLTSEDSAV 469) YYC YYCANWAWF (SEQ AYWGQGTLVT ID NO: VSS (SEQ ID 276) NO: 443) AHH QIQFAQSGPEL QIQFA GYTFT MHW INTET TYAD ASFYY CASFY YFDYRG RGQG 03779 KKPGETVKISC QSGPE DYS VKQA GEP DFKG GNFAY YGNFA QGTTLT TTLT KAFGYTFTDY LKKPG (SEQ ID PGKG (SEQ ID RFAFS YFDY YYFDY VSS (SEQ VSS SMHWVKQAP ETVKI NO: LKW NO: LETSA (SEQ ID R(SEQ ID NO: (SEQ GKGLKWMGW SCKAF 487) MGW 225) STAY NO: ID NO: 589) ID NO: INTETGEPTYA (SEQ (SEQ LQINN 542) 569) 597) DDFKGRFAFSL ID NO: ID NO: LKNE ETSASTAYLQI 470) 185) DTAT NNLKNEDTAT YFC YFCASFYYGN (SEQ FAYYFDYRGQ ID NO: GTTLTVSS 260) (SEQ ID NO: 444) AHH EVKIEESGGGL EVKIE GFTFSN MNW IRLKS YYAE TRIYD CTRIY WYFDV WGAG 03780 VQPGGAMKLS ESGGG YW VRQS NNYAT SVKG SGSSY DSGSS WGAGTT TTVT CVASGFTFSNY LVQPG (SEQ ID PEKG (SEQ ID RFTIS TWYFD YTWYF VTVSS VSS WMNWVRQSP GAMK NO: LEWV NO: RODS V (SEQ DVW (SEQ ID (SEQ EKGLEWVAEI LSCVA 166) AE 241) QSSV ID NO: (SEQ ID NO: 416) ID NO: RLKSNNYATY S (SEQ (SEQ YLQM 543) NO: 423) YAESVKGRFTI ID NO: ID NO: NDLR 570) SRDDSQSSVYL 471) 201) TEDT QMNDLRTEDT GIYY GIYYCTRIYDS C GSSYTWYFDV (SEQ WGAGTTVTVS ID NO: S (SEQ ID NO: 522) 445) AHH QVILKESGPGI QVILK GFSLST VGWI IWWN YYNP ARIGG CARIG YWYFDV WGAG 03782 LQPSQTLSLTC ESGPG SGMS RQPS DDK ALKS NDGY GNDG WGAGTS TSLTV SFSGFSLSTSG ILQPS (SEQ ID GKGL (SEQ ID RLTIS YWYF YYWY LTVSS SS MSVGWIRQPS QTLSL NO: EWLA NO: KDTP DV FDVW (SEQ ID (SEQ GKGLEWLAHI TCSFS 163) H 238) NNQV (SEQ ID (SEQ ID NO: 590) ID NO: WWNDDKYYN (SEQ (SEQ FLKIA NO: NO: 431) PALKSRLTISK ID NO: ID NO: SWT 311) 359) DTPNNQVFLKI 120) 198) ADTA ASWTADTAT TYYC YYCARIGGND (SEQ GYYWYFDVW ID NO: GAGTSLTVSS 523) (SEQ ID NO: 446) AHH QIQLQQSGAEL QIQLQ GYTFTS MHW INPSN NYNE ARDSS CARDS YGAYW WGQG 03783 VKPGASVKLS QSGAE YW VKQR GRT KFKS GYGA SGYGA GQGTLV TLVT CKASGYTFTS LVKPG (SEQ ID PGQG (SEQ ID KATL Y (SEQ YW TVSS VSS YWMHWVKQR ASVKL NO: LEWI NO: TVDK ID NO: (SEQ ID (SEQ ID (SEQ PGQGLEWIGEI SCKAS 157) GE 510) SSSTA 544) NO: NO: 591) ID NO: NPSNGRTNYN (SEQ (SEQ YMQL 571) 413) EKFKSKATLT ID NO: ID NO: SSLTS VDKSSSTAYM 472) 209) EDSA QLSSLTSEDSA VYYC VYYCARDSSG (SEQ YGAYWGQGT ID NO: LVTVSS (SEQ 289) ID NO: 447) AHH QVQLQQSGAE QVQL GYTFTS MHW INPSTG EYNQ ARYDG CARYD YFDYWG WGQG 03784 LAKPGASVKM QQSG YW VKQR YT KFKD YYYFD GYYYF QGTTLT TTLT SCKASGYTFTS AELA (SEQ ID PGQG (SEQ ID KATL Y (SEQ DYW VSS (SEQ VSS YWMHWVKQR KPGAS NO: LEWI NO: TADK ID NO: (SEQ ID ID NO: (SEQ PGQGLEWIGYI VKMS 157) GY 230) SSSTA 545) NO: 592) ID NO: NPSTGYTEYN CKAS (SEQ YMQL 572) 425) QKFKDKATLT (SEQ ID NO: SSLTS ADKSSSTAYM ID NO: 190) EDSA QLSSLTSEDSA 473) VYYC VYYCARYDGY (SEQ YYFDYWGQG ID NO: TTLTVSS (SEQ 265) ID NO: 448) AHH QVQLQQSGAE QVQL GYTFTS INWV IYPSDS NYNQ TSHYY CTSHY WFAYW WGQG 03785 LVRPGASVKL QQSG YW KQRP YT KFKD GRAW YGRA GQGTLV TLVT SCKASGYTFTS AELVR (SEQ ID GQGL (SEQ ID KATL FAY WFAY TVL (SEQ VL YWINWVKQRP PGASV NO: EWIG NO: TVDK (SEQ ID W (SEQ ID NO: (SEQ GQGLEWIGNIY KLSCK 157) N 509) SSSTA NO: ID NO: 593) ID NO: PSDSYTNYNQ AS (SEQ YMQL 546) 573) 598) KFKDKATLTV (SEQ ID NO: SSPTS DKSSSTAYMQ ID NO: 500) EDSA LSSPTSEDSAV 113) VYYC YYCTSHYYGR (SEQ AWFAYWGQG ID NO: TLVTVL (SEQ 521) ID NO: 449) AHH QIQLQQPGAEL QIQLQ GYTFT MYW INPSN NFNE TKGGF CTKGG FFAYWG WGQG 03786 VKPGASVKLS QPGAE RYY VKQR GGT KFKS YDFFA FYDFF QGTLVT TLVT CKASGYTFTR LVKPG (SEQ ID PGQG (SEQ ID KATL Y (SEQ AYW VSA VSA YYMYWVKQR ASVKL NO: LEWI NO: TVDK ID NO: (SEQ ID (SEQ ID (SEQ PGQGLEWIGEI SCKAS 488) GE 231) SSSTA 547) NO: NO: 594) ID NO: NPSNGGTNFN (SEQ (SEQ YMQL 574) 421) EKFKSKATLT ID NO: ID NO: NSLTS VDKSSSTAYM 474) 191) DDSA QLNSLTSDDSA VYYC VYYCTKGGFY (SEQ DFFAYWGQGT ID NO: LVTVSA (SEQ 524) ID NO: 450) AHH EVMLVESGGG EVML GFTFSS MSWV INSNG YYPD ASLAY CASLA AYWGQ WGQG 03787 LVQPGGSLKLS VESGG YG RQTP GST SVKG (SEQ ID YW GTLVTV TLVT CAASGFTFSSY GLVQP (SEQ ID DKRL (SEQ ID RFTIS NO: (SEQ ID SA (SEQ VSA GMSWVRQTPD GGSLK NO: ELVA NO: RDNA 548) NO: ID NO: (SEQ KRLELVATINS LSCAA 165) T(SEQ 240) KNTL 575) 394) ID NO: NGGSTYYPDS S (SEQ ID NO: YLQM 421) VKGRFTISRDN ID NO: 200) SSLKS AKNTLYLQMS 122) EDTA SLKSEDTAMY MYYC YCASLAYWGQ (SEQ GTLVTVSA ID NO: (SEQ ID NO: 274) 451) AHH QIQLQQSGPDL QIQLQ GYTFT INWM IYPGS KYNE ARVYS CARVY FDVWGA WGAG 03788 VKPGASVKISC QSGPD DYY KQKP GNT KFKG GFDV SGFDV GTTVTV TTVT KASGYTFTDY LVKPG (SEQ ID GQGL (SEQ ID KATL (SEQ ID W (SEQ SS (SEQ VSS YINWMKQKPG ASVKI NO: EWIG NO: TVDT NO: ID NO: ID NO: (SEQ QGLEWIGWIY SCKAS 489) W 511) SSSTA 549) 576) 585) ID NO: PGSGNTKYNE (SEQ (SEQ YMQL 423) KFKGKATLTV ID NO: ID NO: SSLTS DTSSSTAYMQ 475) 501) EDTA LSSLTSEDTAV VYFC YFCARVYSGF (SEQ DVWGAGTTVT ID NO: VSS (SEQ ID 525) NO: 452) AHH QIQLQQSGPEL QIQLQ GYTFTS IHWV IYPGD KYNE ARGDG CARGD WFAYW WGQG 03790 VKPGASVKMS QSGPE YY KQRP GST KFKG YFAWF GYFA GQGTLV TLVT CKAPGYTFTS LVKPG (SEQ ID GQGL (SEQ ID KTTL AY WFAY TVSA VSA YYIHWVKQRP ASVK NO: EWIG NO: TADK (SEQ ID W (SEQ (SEQ ID (SEQ GQGLEWIGWI MSCK 158) W 512) SSSTA NO: ID NO: NO: 392) ID NO: YPGDGSTKYN AP (SEQ YMLL 550) 577) 421) EKFKGKTTLT (SEQ ID NO: SSLTS ADKSSSTAYM ID NO: 502) EDSAI LLSSLTSEDSAI 476) YFC YFCARGDGYF (SEQ AWFAYWGQG ID NO: TLVTVSA (SEQ 526) ID NO: 453) AHH QIQLQQSGAEL QIQLQ GYTFSS IEWV ILPGSG KYNE ARSAH CARSA WFAYW WGQG 03791 MKPGASVKIS QSGAE YW KQRP ST KFKG RYDA HRYDA GQGTLV TLVT CKATGYTFSS LMKP (SEQ ID GHGL (SEQ ID KATF WFAY WFAY TVL (SEQ VL YWIEWVKQRP GASV NO: EWIG NO: TADT (SEQ ID W (SEQ ID NO: (SEQ GHGLEWIGEIL KISCK 179) SEQ 254) SSNT NO: ID NO: 593) ID NO: PGSGSTKYNE AT ID NO: AYMQ 551) 578) 598) KFKGKATFTA (SEQ 218) LSSLT DTSSNTAYMQ ID NO: SEDS LSSLTSEDSAV 144) AVYY YYCARSAHRY C DAWFAYWGQ (SEQ GTLVTVL (SEQ ID NO: ID NO: 454) 527) AHH QIQLQQPGAEL QIQLQ GYTFT MYW INPTN NFNA TRGM CTRGM WFAYW WGQG 03792 VKPGASVKLS QPGAE NYY VNQR GGT KFKN AYRYD AYRYD GQGTPV TPVT CKASGYTFTN LVKPG (SEQ ID PGQG (SEQ ID KATL GAGW GAGW TVSS VSS YYMYWVNQR ASVKL NO: LEWI NO: TVDK FAY FAYW (SEQ ID (SEQ PGQGLEWIGGI SCKAS 490) GG 513) SSNT (SEQ ID (SEQ ID NO: 595) ID NO: NPTNGGTNFN (SEQ (SEQ AYMQ NO: NO: 398) AKFKNKATLT ID NO: ID NO: LSSLT 552) 579) VDKSSNTAYM 474) 503) SEDS QLSSLTSEDSA AVYY VYYCTRGMA C YRYDGAGWF (SEQ AYWGQGTPVT ID NO: VSS (SEQ ID 528) NO: 455) AHH QVQLQQPGAE QVQL GYTFTS MNW IDPYD HYNQ ARGGR CARGG WFAYW WGQG 03793 LVRPGASVKL QQPG YW VKQR SET KFKD GTWFA RGTWF GQGTLV TLVT SCKASGYTFTS AELVR (SEQ ID PEQG (SEQ ID KAILT Y (SEQ AYW TVSA VSA YWMNWVKQR PGASV NO: LEWI NO: VDKS ID NO: (SEQ ID (SEQ ID (SEQ PEQGLEWIGRI KLSCK 157) GR 235) SSTA 553) NO: NO: 392) ID NO: DPYDSETHYN AS (SEQ YMQL 580) 421) QKFKDKAILT (SEQ ID NO: SSLTS VDKSSSTAYM ID NO: 195) EDSA QLSSLTSEDSA 477) VYYC VYYCARGGRG (SEQ TWFAYWGQG ID NO: TLVTVSA (SEQ 269) ID NO: 456) AHH DVMLVESGGG DVML GFTFTD MSWV IRNKA EYSA ARGW CARG WFAYW WGQG 03794 LVQPGGSLRLS VESGG YY RQPP NGYTT SVKG GNWF WGNW GQGTLV TLVT CATSGFTFTDY GLVQP (SEQ ID GKAL (SEQ ID RFTIS AY FAYW TVSA VSA YMSWVRQPPG GGSLR NO: EWLG NO: RDNS (SEQ ID (SEQ ID (SEQ ID (SEQ KALEWLGFIR LSCAT 180) F (SEQ 255) QSILY NO: NO: NO: 392) ID NO: NKANGYTTEY S (SEQ LQMN 554) 581) 421) SASVKGRFTIS ID NO: ID NO: TLRA RDNSQSILYLQ 478) 219) EDSA MNTLRAEDSA TYYC TYYCARGWG (SEQ NWFAYWGQG ID NO: TLVTVSA (SEQ 292) ID NO: 457) AHH EVMLVESGGG EVML GFTFSS IHWV ISGGG SYAD ARWR CARW YFDYWG WGQG 03795 LVQPGGSRKL VESGG FG (SEQ RQAP GTI TVKG GGYFD RGGYF QGTSLT TSLTV SCAASGFTFSS GLVQP ID NO: EKGL (SEQ ID RFTIS Y (SEQ DYW VSS (SEQ SS FGIHWVRQAP GGSR 491) EWVA NO: RDNP ID NO: (SEQ ID ID NO: (SEQ EKGLEWVAYI KLSCA (SEQ 514) KNTL 555) NO: 405) ID NO: SGGGGTISYAD AS ID NO: FLQM 582) 424) TVKGRFTISRD (SEQ 504) TSLRS NPKNTLFLQM ID NO: EDTAI TSLRSEDTAIY 479) YYC YCARWRGGYF (SEQ DYWGQGTSLT ID NO: VSS (SEQ ID 529) NO: 458) AHH QIQLQQSGAEL QIQLQ GYTFTS INWV IYPSDS NYNQ TRTGG CTRTG WFAYW WGQG 03797 VRPGASVKLS QSGAE YW KQRP YT KFKD STMTP GSTMT GQGTLV TLVT CKASGYTFTS LVRPG (SEQ ID GQGL (SEQ ID KATL WFAY PWFAY TVSS VSS YWINWVKQRP ASVKL NO: EWIG NO: TVDK (SEQ ID W (SEQ (SEQ ID (SEQ GQGLEWIGNIY SCKAS 157) N 509) SSSTA NO: ID NO: NO: 588) ID NO: PSDSYTNYNQ (SEQ (SEQ YMQL 556) 583) 413) KFKDKATLTV ID NO: ID NO: SSPTS DKSSSTAYMQ 480) 500) EDSA LSSPTSEDSAV VYYC YYCTRTGGST (SEQ MTPWFAYWG ID NO: QGTLVTVSS 521) (SEQ ID NO: 459) AHH QVTLKESGPGI QVTL GFSLST VSWI IYWDD RYNP ARRAG CARRA FPYWGQ WGQG 03799 LQPSQTLSLTC KESGP SGMG RQPS DK SLKSR DYGNP GDYG GTLVTV TLVT SFSGFSLSTSG GILQP (SEQ ID GKGL (SEQ ID LTISK FPY NPFPY SA (SEQ VSA MGVSWIRQPS SQTLS NO: EWLA NO: DTSR (SEQ ID W (SEQ ID NO: (SEQ GKGLEWLAHI LTCSF 492) H 515) NQVF NO: ID NO: 596) ID NO: YWDDDKRYN S (SEQ (SEQ LKITS 557) 584) 421) PSLKSRLTISK ID NO: ID NO: VDTT DTSRNQVFLKI 481) 505) DTAT TSVDTTDTAT YYC YYCARRAGDY (SEQ GNPFPYWGQG ID NO: TLVTVSA (SEQ 530) ID NO: 460)

TABLE 2C Exemplary Clones-Heavy Chain Sequences JUNC- ID V-D-J-REGION H-FR1 CDRH1 H-FR2 CDRH2 H-FR3 CDRH3 TION >AH04501- QVQLQQPGAELVR QVQLQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH PGTSVKMSCKAAG QPGAEL NY VKQR GDYSN DTSSST (SEQ ID LVTVSA YTFTNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMNLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG KG SLTSEDS 1379) NO: 421) GGDYSNYNEKFKG KAA 990) (SEQ (SEQ AIYYCT KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MNLSSLTSEDSAIY NO: 1458) 692) NO: YCTSRNFAYWGQG 1315) 1044) TLVTVSA (SEQ ID NO: 1318) >AH04515- QVQLQQPGAELVR QVQLQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH PGTSVKMSCKAAG QPGAEL NY VKQR GDYSN DTSSST (SEQ ID LVTVSA YTFTNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMNLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG KG SLTSEDS 1379) NO: 421) GGDYSNYNEKFKG KAA 990) (SEQ (SEQ AIYYCT KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MNLSSLTSEDSAIY NO: 1458) 692) NO: YCTSRNFAYWGQG 1315) 1044) TLVTVSA (SEQ ID NO: 1318) >AH04502- QIQLQQSGAELVRP QIQLQQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH GTSVKMSCKAAGY SGAELV NY VKQR GGYT DTSSST (SEQ ID LVTVSA TFTNYWIGWVKQR RPGTSV (SEQ PGHGL NYNE ADMQLS NO: (SEQ ID PGHGLEWIGDIHPG KMSCK ID NO: EWIG KFKG SLTSEDS 1379) NO: 421) GGYTNYNEKFKGK AA (SEQ 990) (SEQ (SEQ AIYYCT ATLTADTSSSTAD ID NO: ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY 1228) 1458) 696) NO: YCTSRNFAYWGQG 1043) TLVTVSA (SEQ ID NO: 1234) >AH04512- QIQLQQSGAELVRP QIQLQQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH GTSVKMSCKAAGY SGAELV NY VKQR GGYT DTSSST (SEQ ID LVTVSA TFTNYWIGWVKQR RPGTSV (SEQ PGHGL NYNE AYMQLS NO: (SEQ ID PGHGLEWIGDIHPG KMSCK ID NO: EWIG KFKG SLTSEDS 1379) NO: 421) GGYTNYNEKFKGK AA (SEQ 990) (SEQ (SEQ AIYYCT ATLTADTSSSTAY ID NO: ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY 1228) 1458) 696) NO: YCTSRNFAYWGQG 1045) TLVTVSA (SEQ ID NO: 1235) >AH04522- QIQLQQSGAELVRP QIQLQQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH GTSVKMSCKAAGY SGAELV NY VKQR GGYT DTSSST (SEQ ID LVTVSA TFTNYWIGWVKQR RPGTSV (SEQ PGHGL NYNE AYMQLS NO: (SEQ ID PGHGLEWIGDIHPG KMSCK ID NO: EWIG KFKG SLTSEDS 1379) NO: 421) GGYTNYNEKFKGK AA (SEQ 990) (SEQ (SEQ AIYYCT ATLTADTSSSTAY ID NO: ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY 1228) 1458) 696) YCTSRNFAYWGQG NO: TLVTVSA (SEQ ID 1045) NO: 1235) >AH04513- QIQLQQSGAELVRP QIQLQQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH GTSVKMSCKAAGY SGAELV NY VKQR GGYT DTSSST (SEQ ID P VTVSS TFTNYWIGWVKQR RPGTSV (SEQ PGHGL NYNE AYMQLS NO: (SEQ ID PGHGLEWIGDIHPG KMSCK ID NO: EWIG KFKG SLTSEDS 1379) NO: 398) GGYTNYNEKFKGK AA (SEQ 990) (SEQ (SEQ AIYYCT ATLTADTSSSTAY ID NO: ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY 1228) 1458) 696) NO: YCTSRNFAYWGQG 1045) TPVTVSS (SEQ ID NO: 1236) >AH04523- QIQLQQSGAELVRP QIQLQQ GYTFT WIGW DIHPG KATFTA SRNFAK WGQGT VH GTSVKMSCKAAGY SGAELV NY VKQR GSYTN DTSSSTT (SEQ ID PVTVSS TFTNYWIGWVKQR RPGTSV (SEQ PGHGL YNENF YMQLSS NO: (SEQ ID PGHGLEWIGDIHPG KMSCK ID NO: EWIG KG LTSEDS 1377) NO: 398) GSYTNYNENFKGK AA (SEQ 990) (SEQ (SEQ AIYFCT ATFTADTSSSTTYM ID NO: ID NO: ID NO: (SEQ ID QLSSLTSEDSAIYFC 1228) 1458) 697) NO: TSRNFAKWGQGTP 1041) VTVSS (SEQ ID NO: 1237) >AH04503- QVQLQQPGAELVR QVQLQ GYTFS WIGW DIHPG KATLTA SRNFAN WGQGT VH PGTSVKMSCKAAG QPGAEL NY VKQR GGYIN DTSSST (SEQ ID LVTVSA YTFSNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMQLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG TG SLTSEDS 1378) NO: 421) GGGYINYNEKFTG KAA 985) (SEQ (SEQ AIYYCV KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY NO: 1458) 695) NO: YCVSRNFANWGQG 1315) 1046) TLVTVSA (SEQ ID NO: 1316) >AH04529- QVQLQQPGAELVR QVQLQ GYTFS WIGW DIHPG KATLTA SRNFAN WGQGT VH PGTSVKMSCKAAG QPGAEL NY VKQR GGYIN DTSSST (SEQ ID PVTVSS YTFSNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMQLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG TG SLTSEDS 1378) NO: 398) GGGYINYNEKFTG KAA 985) (SEQ (SEQ AIYYCV KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY NO: 1458) 695) NO: YCVSRNFANWGQG 1315) 1046) TPVTVSS (SEQ ID NO: 1317) >AH04510- QVQLQQSGAELVR QVQLQ GYTFS WIGW DIHPG KATLTA SRNFAN WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GGYIN DTSSST (SEQ ID LVTVSA YTFSNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMQLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG TG SLTSEDS 1378) NO: 421) GGGYINYNEKFTG KAA 985) (SEQ (SEQ AIYYCV KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY NO: 1458) 695) NO: YCVSRNFANWGQG 1326) 1046) TLVTVSA (SEQ ID NO: 1327) >AH04528- QVQLQQSGAELVR QVQLQ GYTFS WIGW DIHPG KATLTA SRNFAN WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GGYIN DTSSST (SEQ ID LVTVSA YTFSNYWIGWVKQ VRPGTS (SEQ PGRGL YNEKF AYMQLS NO: (SEQ ID RPGRGLEWIGDIHP VKMSC ID NO: EWIG TG SLTSGD 1378) NO: 421) GGGYINYNEKFTG KAA 985) (SEQ (SEQ SAIYYC KATLTADTSSSTAY (SEQ ID ID NO: ID NO: V (SEQ MQLSSLTSGDSAIY NO: 1459) 695) ID NO: YCVSRNFANWGQG 1326) 1048) TLVTVSA (SEQ ID NO: 1328) >AH04511- QIQLQQSGAELVRP QIQLQQ GYTFS WIGW DIHPG KATLTA SRNFAN WGQGT VH GTSVKMSCKAAGY SGAELV NY VKQR GGYIN DTSSST (SEQ ID LVTVSA TFSNYWIGWVKQR RPGTSV (SEQ PGHGL YNEKF AYMQLS NO: (SEQ ID PGHGLEWIGDIHPG KMSCK ID NO: EWIG TG SLTSEDS 1378) NO: 421) GGYINYNEKFTGK AA (SEQ 985) (SEQ (SEQ AIYYCV ATLTADTSSSTAY ID NO: ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY 1228) 1458) 695) NO: YCVSRNFANWGQG 1046) TLVTVSA (SEQ ID NO: 1229) >AH04504- QIQLQQSGAELVRP QIQLQQ GYTFT WIGW DIHPG KATLTA SRNFAN WGQGT VH GTSVKMSCKAAGY SGAELV KY VKQR GGYIN DTSSST (SEQ ID LVTVSA TFTKYWIGWVKQR RPGTSV (SEQ SGHGL YNEKF AYMQLS NO: (SEQ ID SGHGLEWIGDIHPG KMSCK ID NO: EWIG TG SLTSEDS 1378) NO: 421) GGYINYNEKFTGK AA (SEQ 989) (SEQ (SEQ AIYYCV ATLTADTSSSTAY ID NO: ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY 1228) 1460) 695) NO: YCVSRNFANWGQG 1046) TLVTVSA (SEQ ID NO: 1230) >AH04520- QIQLQQPGAELVRP QIQLQQ GYTFT WIGW DIHPG KATLTA SRNFAN WGQGT VH GTSVKMSCKAAGY PGAELV KY VKQR GGYIN GTSSST (SEQ ID LVTVSA TFTKYWIGWVKQR RPGTSV (SEQ PGHGL YNEKF AYMQLS NO: (SEQ ID PGHGLEWIGDIHPG KMSCK ID NO: EWIG TG SLTSEDS 1378) NO: 421) GGYINYNEKFTGK AA (SEQ 989) (SEQ (SEQ AIYYCV ATLTAGTSSSTAY ID NO: ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY 1221) 1458) 695) NO: YCVSRNFANWGQG 1050) TLVTVSA (SEQ ID NO: 1222) >AH04507- QVQLQQSGAELVR QVQLQ GYTFT WIGW DIHPG KATLTA SRNFAK WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GGYID DTSSST (SEQ ID LVTVSA YTFTNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMQLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG TG SLTSEDS 1377) NO: 421) GGGYIDYNEKFTG KAA 990) (SEQ (SEQ AIYYCV KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY 1458) 694) YCVSRNFAKWGQG NO: NO: TLVTVSA (SEQ ID 1326) 1046) NO: 1334) >AH04527- QVQLQQSGAELVR QVQLQ GYTFT WIGW DIHPG KATLTA SRNFAK WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GGYID DTSSST (SEQ ID LVTVSA YTFTNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMQLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG TG SLTSEDS 1377) NO: 421) GGGYIDYNEKFTG KAA 990) (SEQ (SEQ AIYYCV KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY NO: 1458) 694) NO: YCVSRNFAKWGQG 1326) 1046) TLVTVSA (SEQ ID NO: 1334) >AH04505- DVQLQQSGAELVR DVQLQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GGYT DTSSST (SEQ ID LVTVSA YTFTNYWIGWVKQ VRPGTS (SEQ PGHGL NYNE AYMQLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG KFKG SLTSEGS 1379) NO: 421) GGGYTNYNEKFKG KAA 990) (SEQ (SEQ AIYYCT KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MQLSSLTSEGSAIY NO: 867) 1458) 696) NO: YCTSRNFAYWGQG 1047) TLVTVSA (SEQ ID NO: 869) >AH04516- QVQLQQSGAELVR QVQLQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GGYT DTSSST (SEQ ID LVTVSA YTFTNYWIGWVKQ VRPGTS (SEQ PGHGL NYNE AYMQLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG KFKG SLTSEDS 1379) NO: 421) GGGYTNYNEKFKG KAA 990) (SEQ (SEQ AIYYCT KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY NO: 1458) 696) NO: YCTSRNFAYWGQG 1326) 1045) TLVTVSA (SEQ ID NO: 1335) >AH04525- QVQLQQSGAELVR QVQLQ GYTFT WIGWI DIHPG KATLTA GRNFAY WGQGT VH PGTSVKMSCKAAG QSGAEL NY KQRP GDYT DTFSST (SEQ ID LVTVSS YTFTNYWIGWIKQ VRPGTS (SEQ GHGL NYNE AYMQLS NO: 982) (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG KFKG SLTSEDS NO: 413) GGDYTNYNEKFKG KAA 990) (SEQ (SEQ AIYYCT KATLTADTFSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY NO: 1456) 693) NO: YCTGRNFAYWGQ 1326) 1042) GTLVTVSS (SEQ ID NO: 1329) >AH04509- QIQLQQSGAELVRP QIQLQQ GYTFT WIGW DFYPG KATLTA SRNFAY WGQGT VH GTSVKMSCKAAGY SGAELV NY VKQR GDYIN DTSSST (SEQ ID PVTVSS TFTNYWIGWVKQR RPGTSV (SEQ PGHGL YNEKF AYMQLS NO: (SEQ ID PGHGLEWIGDFYP KMSCK ID NO: EWIG KG SLTSEDS 1379) NO: 398) GGDYINYNEKFKG AA (SEQ 990) (SEQ (SEQ AIYYCT KATLTADTSSSTAY ID NO: ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY 1228) 1458) 691) NO: YCTSRNFAYWGQG 1045) TPVTVSS (SEQ ID NO: 1231) >AH04521- QVQLQQSGAELVR QVQLQ GYTFT WIGW DFYPG KATLTA SRNFAY WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GDYIN DTSSST (SEQ ID LVTVSA YTFTNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMQLS NO: (SEQ ID RPGHGLEWIGDFYP VKMSC ID NO: EWIG KG SLTSEDS 1379) NO: 421) GGDYINYNEKFKG KAA 990) (SEQ (SEQ AIYYCT KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MQLSSLTSEDSAIY NO: 1458) 691) NO: YCTSRNFAYWGQG 1326) 1045) TLVTVSA (SEQ ID NO: 1331) >AH04526- QVQLQQSGAELVR QVQLQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GDYSN DTSSST (SEQ ID PVTVSS YTFTNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMNLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG KG SLTSEDS 1379) NO: 398) GGDYSNYNEKFKG KAA 990) (SEQ (SEQ AIYYCT KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MNLSSLTSEDSAIY NO: 1458) 692) NO: YCTSRNFAYWGQG 1326) 1044) TPVTVSS (SEQ ID NO: 1332) >AH04514- QIQLQQSGAELVRP QIQLQQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH GTSVKMSCKAAGY SGAELV NY VKQR GDYSN DTSSST (SEQ ID LVTVSS TFTNYWIGWVKQR RPGTSV (SEQ PGHGL YNEKF AYMNLS NO: (SEQ ID PGHGLEWIGDIHPG KMSCK ID NO: EWIG KG SLTSEDS 1379) NO: 413) GDYSNYNEKFKGK AA (SEQ 990) (SEQ (SEQ AIYYCT ATLTADTSSSTAY ID NO: ID NO: ID NO: (SEQ ID MNLSSLTSEDSAIY 1228) 1458) 692) NO: YCTSRNFAYWGQG 1044) TLVTVSS (SEQ ID NO: 1232) >AH04524- QIQLQQSGAELVRP QIQLQQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH GTSVKMSCKAAGY SGAELV NY VKQR GDYSN DTSSST (SEQ ID LVTVSA TFTNYWIGWVKQR RPGTSV (SEQ PGHGL YNEKF AYMSLS NO: (SEQ ID PGHGLEWIGDIHPG KMSCK ID NO: EWIG KG SLTSEDS 1379) NO: 421) GDYSNYNEKFKGK AA (SEQ 990) (SEQ (SEQ AIYYCT ATLTADTSSSTAY ID NO: ID NO: ID NO: (SEQ ID MSLSSLTSEDSAIY 1228) 1458) 692) NO: YCTSRNFAYWGQG 1049) TLVTVSA (SEQ ID NO: 1233) >AH04530- QIQLQQSGAELVRP QIQLQQ GYTST WIGW DIHPG KATLTA SRNFAY WGQGT VH GTSVKMSCKAAGY SGAELV NY VKQR GDYSN DTSSST (SEQ ID LVTVSA TSTNYWIGWVKQR RPGTSV (SEQ PGHGL YNEKF AYMNLS NO: (SEQ ID PGHGLEWIGDIHPG KMSCK ID NO: EWIG KG SLTSEDS 1379) NO: 421) GDYSNYNEKFKGK AA (SEQ 996) (SEQ (SEQ AIYYCT ATLTADTSSSTAY ID NO: ID NO: ID NO: (SEQ ID MNLSSLTSEDSAIY 1228) 1458) 692) NO: YCTSRNFAYWGQG 1044) TLVTVSA (SEQ ID NO: 1238) >AH04517- DVQLQQSGAELVR DVQLQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GDYSN DTSSST (SEQ ID LVTVSA YTFTNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMNLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG KG SLTSEDS 1379) NO: 421) GGDYSNYNEKFKG KAA 990) (SEQ (SEQ AIYYCT KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MNLSSLTSEDSAIY NO: 867) 1458) 692) NO: YCTSRNFAYWGQG 1044) TLVTVSA (SEQ ID NO: 868) >AH04506- QVQLQQSGAELVR QVQLQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GDYSN DTSSST (SEQ ID LVTVSA YTFTNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMNLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG KG SLTSEDS 1379) NO: 421) GGDYSNYNEKFKG KAA 990) (SEQ (SEQ AIYYCT KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MNLSSLTSEDSAIY NO: 1458) 692) NO: YCTSRNFAYWGQG 1326) 1044) TLVTVSA (SEQ ID NO: 1333) >AH04508- QVQLQQSGAELVR QVQLQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GDYSN DTSSST (SEQ ID LVTVSA YTFTNYWIGWVKQ VRPGTS (SEQ PGHGL YNEKF AYMNLS NO: (SEQ ID RPGHGLEWIGDIHP VKMSC ID NO: EWIG KG SLTSEDS 1379) NO: 421) GGDYSNYNEKFKG KAA 990) (SEQ (SEQ AIYYCT KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MNLSSLTSEDSAIY NO: 1458) 692) NO: YCTSRNFAYWGQG 1326) 1044) TLVTVSA (SEQ ID NO: 1333) >AH04518- QVQLQQSGAELVR QVQLQ GYTFT WIGW DIHPG KATLTA SRNFAY WGQGT VH PGTSVKMSCKAAG QSGAEL NY VKQR GDYSN DTSSST (SEQ ID LVTVSA YTFTNYWIGWVKQ VRPGTS (SEQ PGHDL YNEKF AYMNLS NO: (SEQ ID RPGHDLEWIGDIHP VKMSC ID NO: EWIG KG SLTSEDS 1379) NO: 421) GGDYSNYNEKFKG KAA 990) (SEQ (SEQ AIYYCT KATLTADTSSSTAY (SEQ ID ID NO: ID NO: (SEQ ID MNLSSLTSEDSAIY NO: 1457) 692) NO: YCTSRNFAYWGQG 1326) 1044) TLVTVSA (SEQ ID NO: 1330)

TABLE 3A Exemplary Clones-Light Chain Sequences JUNC- J- ID V-J-REGION L-FR1 CDRL1 L-FR2 CDRL2 L-FR3 CDRL3 TION REGION L-FR4 AHH DTTVTQSHKF DTTV QDVST VAWY SAS YRYT QQHYS CQQHY WTFGGG FGGG 03703 MSTSVGDRVS TQSH A (SEQ QQKP (SEQ ID GVPD TPWT STPWT TKLEIK TKLEI ITCKASQDVST KFMS ID NO: GQSP NO: 13) RFTGS (SEQ ID F (SEQ (SEQ ID K AVAWYQQKP TSVG 1209) KLLIY GSGT NO: ID NO: NO: 1467) (SEQ GQSPKLLIYSA DRVSI (SEQ DFTFT 1264) 656) ID NO: SYRYTGVPDR TCKA ID NO: ISSVQ 959) FTGSGSGTDFT S (SEQ 1427) AEDL FTISSVQAEDL ID NO: AVYY AVYYCQQHY 840) C STPWTFGGGT (SEQ KLEIK (SEQ ID ID NO: NO: 841) 1491) AHH DILMTQSPSSL DILM QSLLY LAWY WAS TRES QQYYS CQQYY WTFGGG FGGG 03704 AVSVGEKVT TQSPS SSNQK QQKP (SEQ ID GVPD YPWT SYPWT TKLEMK TKLE MSCKSSQSLL SLAV NY GQSP NO: RFTGS (SEQ ID F (SEQ (SEQ ID MK YSSNQKNYLA SVGE (SEQ ID KLLIY 1450) GSGT NO: ID NO: NO: 1468) (SEQ WYQQKPGQSP KVTM NO: (SEQ DFTLT 1294) 676) ID NO: KLLIYWASTR SCKSS 1304) ID NO: ISSVK 961) ESGVPDRFTG (SEQ 1066) AEDL SGSGTDFTLTI ID NO: AVYY SSVKAEDLAV 708) C YYCQQYYSYP (SEQ WTFGGGTKLE ID NO: MK (SEQ ID 1411) NO: 709) AHH DIQMTQTTSSL DIQM QGISN LNWY YTS SLHS QQYSK CQQYS WTFGGG FGGG 03706 SASLGDRVTIS TQTTS Y (SEQ QQKP (SEQ ID GVPS LPWT KLPWT TKLEMK TKLE CSASQGISNYL SLSAS ID NO: DGTV NO: RFSGS (SEQ ID F (SEQ (SEQ ID MK NWYQQKPDG LGDR 1211) KLLIY 1495) GSGT NO: ID NO: NO: 1468) (SEQ TVKLLIYYTSS VTISC (SEQ DYSL 1289) 672) ID NO: LHSGVPSRFSG SAS ID NO: TISNL 961) SGSGTDYSLTI (SEQ 1088) EPEDI SNLEPEDIATY ID NO: ATYY YCQQYSKLPW 761) C TFGGGTKLEM (SEQ K (SEQ ID NO: ID NO: 762) 1368) AHH DIQMNQSPSY DIQM KSISK LAWY SGS TLQS QQHNE CQQHN TFGGGT FGGG 03707 LAASPGETITI NQSPS Y (SEQ QEKP (SEQ ID GIPSR YPWT EYPWT KLEIK TKLEI NCRASKSISKY YLAA ID NO: GKTN NO: FSGSG (SEQ ID F (SEQ (SEQ ID K LAWYQEKPG SPGET 1059) KLLIY 1365) SGTD NO: ID NO: NO: 1393) (SEQ KTNKLLIYSGS ITINC (SEQ FTLTI 1257) 651) ID NO: TLQSGIPSRFS RAS ID NO: SSLEP 959) GSGSGTDFTL (SEQ 1064) EDFA TISSLEPEDFA ID NO: MYYC MYYCQQHNE 716) (SEQ YPWTFGGGTK ID NO: LEIK (SEQ ID 1405) NO: 717) AHH DVVMTQTPLT DWM QSLLD LNWL LVS KLDS WQGT CWQG TFGGGT FGGG 03708 LSVTIGQPASI TQTPL SDGKT LQRP (SEQ ID GVPD HFPRT THFPR KLEIK TKLEI SCKSSQSLLDS TLSVT Y (SEQ GQSP NO: RFTGS (SEQ ID TF (SEQ ID K DGKTYLNWL IGQPA ID NO: KRLIY 1116) GSGT NO: (SEQ ID NO: 1393) (SEQ LQRPGQSPKR SISCK 1301) (SEQ DFTL 1464) NO: ID NO: LIYLVSKLDSG SS ID NO: KINR 688) 959) VPDRFTGSGS (SEQ 1083) VEAE GTDFTLKINR ID NO: DLGV VEAEDLGVYY 904) YYC CWQGTHFPRT (SEQ FGGGTKLEIK ID NO: (SEQ ID NO: 1055) 905) AHH DIVMTQSPKS DIVM ENVGT VSWY GAS NRYT GQSYS CGQSY YTFGGG FGGG 03709 MSMSVGERVT TQSP Y (SEQ QQKP (SEQ ID GVPD YPYT SYPYT TKLEIK TKLEI LSCKASENVG KSMS ID NO: EQSP NO: RFTGS (SEQ ID F (SEQ (SEQ ID K TYVSWYQQK MSVG 933) KLLIY 975) GSAT NO: ID NO: NO: 1493) (SEQ PEQSPKLLIYG ERVT (SEQ DFTLT 981) 624) ID NO: ASNRYTGVPD LSCK ID NO: ISSVQ 959) RFTGSGSATD AS 1446) AEDL FTLTISSVQAE (SEQ ADYH DLADYHCGQS ID NO: C YSYPYTFGGG 808) (SEQ TKLEIK (SEQ ID NO: ID NO: 810) 1162) AHH DIVMTQSQKF DIVM QNVRT VAWY MAS NRHT LQHW CLQH YTFGGG FGGG 03710 MSTSVGDRVT TQSQ A (SEQ HQKP (SEQ ID GVPD NYPYT WNYP TKLEIK TKLEI ITCKASQNVR KFMS ID NO: GQSP NO: RFTGS (SEQ ID YTF (SEQ ID K TAVAWYHQK TSVG 1247) KALIY 1122) GSGA NO: (SEQ ID NO: 1493) (SEQ PGQSPKALIY DRVTI (SEQ DFTLT 1093) NO: ID NO: MASNRHTGVP TCKA ID NO: ITNVQ 630) 959) DRFTGSGSGA S (SEQ 1421) SEDL DFTLTITNVQS ID NO: ADYF EDLADYFCLQ 826) C HWNYPYTFG (SEQ GGTKLEIK ID NO: (SEQ ID NO: 1161) 827) AHH DIQMTQTPKF DIQM QSVSN VAWY YAS NRYT QQDYS CQQDY WTFGGG FGGG 03711 LLVSAGDRVT TQTP D (SEQ QQKP (SEQ ID GVPD SPWT SSPWT TKLEIK TKLEI ITCKASQSVSN KFLL ID NO: GQSP NO: RFTGS (SEQ ID F (SEQ (SEQ ID K DVAWYQQKP VSAG 1310) KLLIY 1476) GYGT NO: ID NO: NO: 1467) (SEQ GQSPKLLIYY DRVTI (SEQ DFTFT 1251) 647) ID NO: ASNRYTGVPD TCKA ID NO: ISTVQ 959) RFTGSGYGTD S (SEQ 1427) AEDL FTFISTVQAE ID NO: AVYF DLAVYFCQQD 746) C YSSPWTFGGG (SEQ TKLEIK (SEQ ID NO: ID NO: 747) 1164) AHH DIQMTQTPSSL DIQM QEISG LSWL AAS TLDS LQYIS CLQYI TFGGGT FGGG 03713 SASLGERVSLT TQTPS Y (SEQ QQKP (SEQ ID GVPK YPRT SYPRT KLEIK TKLEI CRASQEISGYL SLSAS ID NO: DGTIK NO: RFSGS (SEQ ID F (SEQ (SEQ ID K SWLQQKPDGT LGER 1210) RLIY 599) RSGS NO: ID NO: NO: 1393) (SEQ IKRLIYAASTL VSLT (SEQ DYSL 1107) 640) ID NO: DSGVPKRFSG CRAS ID NO: TISSL 959) SRSGSDYSLTI (SEQ 1111) ESEDF SSLESEDFADY ID NO: ADYY YCLQYISYPRT 753) C FGGGTKLEIK (SEQ (SEQ ID NO: ID NO: 756) 1402) AHH DIVMTQSQKF DIVM QNVGT VAWY SAS YRYS QQYNS CQQYN TFGGGT FGGG 03714 MSTSVGDRVS TQSQ N (SEQ QQKP (SEQ ID GVPD YPRT SYPRT KLEIK TKLEI VTCKASQNVG KFMS ID NO: GQSP NO: 13) RFTGS (SEQ ID F (SEQ (SEQ ID K TNVAWYQQK TSVG 12) KALIY GSGT NO: ID NO: NO: 1393) (SEQ PGQSPKALIYS DRVS (SEQ DFTLT 1286) 670) ID NO: ASYRYSGVPD VTCK ID NO: ISNVQ 959) RFTGSGSGTD AS 1425) SEDL FTLTISNVQSE (SEQ AEYL DLAEYLCQQY ID NO: C NSYPRTFGGG 821) (SEQ TKLEIK (SEQ ID NO: ID NO: 824) 1485) AHH DIQMTQSPAS DIQM ENIYS LAWY AAT NLAD QHFW CQHF TFGGGT FGGG 03715 LSVSVGETVTI TQSP N (SEQ QQKQ (SEQ ID GVPS GTPPT WGTPP KLEIK TKLEI TCRASENIYSN ASLS ID NO: GKSP NO: RFSGS (SEQ ID TF (SEQ ID K LAWYQQKQG VSVG 929) QLLV 600) GSGT NO: (SEQ ID NO: 1393) (SEQ KSPQLLVYAA ETVTI (SEQ QYSL 1212) NO: ID NO: TNLADGVPSR TCRA ID NO: KINSL 642) 959) FSGSGSGTQY S (SEQ 1069) QSED SLKINSLQSED ID NO: FGSY FGSYYCQHFW 723) YC GTPPTFGGGT (SEQ KLEIK (SEQ ID ID NO: NO: 724) 1143) AHH DVVMTQTPLT DWM QSLLD LNWL LVS KLDS WQGT CWQG TFGGGT FGGG 03716 LSVTIGQPASI TQTPL SDGKT LQRP (SEQ ID GVPD HFRT THFRT KLEMK TKLE SCKSSQSLLDS TLSVT Y (SEQ GQSP NO: RFTGS (SEQ ID F (SEQ (SEQ ID MK DGKTYLNWL IGQPA ID NO: KRLIY 1116) GSGT NO: ID NO: NO: 1394) (SEQ LQRPGQSPKR SISCK 1301) (SEQ DFTL 1466) 690) ID NO: LIYLVSKLDSG SS ID NO: KISRV 961) VPDRFTGSGS (SEQ 1083) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYYC 904) YC WQGTHFRTFG (SEQ GGTKLEMK ID NO: (SEQ ID NO: 1056) 906) AHH DVVLTQTPLS DWL QSLVH LHWY KVS NRFS SQSTH CSQST LTFGAG FGAG 03717 LPVSLGDQVSI TQTPL NNGNT LQKP (SEQ ID GVPD VPLT HVPLT TKLEIK TKLEI SCRSGQSLVH SLPVS Y (SEQ GQSP NO: RFSGS (SEQ ID F (SEQ (SEQ ID K NNGNTYLHW LGDQ ID NO: KLLIY 1062) GSGT NO: ID NO: NO: 1114) (SEQ YLQKPGQSPK VSISC 1305) (SEQ DFTL 1370) 679) ID NO: LLIYKVSNRFS RSG ID NO: KISRV 958) GVPDRFSGSG (SEQ 1076) EAED SGTDFTLKISR ID NO: LGVY VEAEDLGVYF 881) FC CSQSTHVPLTF (SEQ GAGTKLEIK ID NO: (SEQ ID NO: 1157) 882) AHH DIQMTQSTSSL DIQM QDISN LNWY FTS RLYS QQGNT CQQGN TFGGGT FGGG 03718 SASLGDRVTIS TQSTS Y (SEQ QQKP (SEQ ID GVPS LPRT TLPRT KLEIK TKLEI CRASQDISNY SLSAS ID NO: DGTV NO: RFSGS (SEQ ID F (SEQ (SEQ ID K LNWYQQKPD LGDR 27) KLLIY 972) GSGA NO: ID NO: NO: 1393) (SEQ GTVKLLIYFTS VTISC (SEQ DYSL 1254) 648) ID NO: RLYSGVPSRFS RAS ID NO: TISNL 959) GSGSGADYSL (SEQ 1088) EQEDI TISNLEQEDIA ID NO: ATYF TYFCQQGNTL 738) C PRTFGGGTKL (SEQ EIK (SEQ ID ID NO: NO: 739) 1358) AHH DIQMNQSPSSL DIQM QDIGS LNWL ATS SLDS LQYAS CLQYA YTFGGG FGGG 03719 SASLGERVSLT NQSPS S (SEQ QQEP (SEQ ID GVPK SPYT SSPYTF TKLEIK TKLEI CRASQDIGSSL SLSAS ID NO: DGTIK NO: RFSGS (SEQ ID (SEQ ID (SEQ ID K NWLQQEPDGT LGER 1199) RLIY 618) RSGS NO: NO: NO: 1493) (SEQ IKRLIYATSSL VSLT (SEQ DYSL 1101) 637) ID NO: DSGVPKRFSG CRAS ID NO: TISSL 959) SRSGSDYSLTI (SEQ 1085) ESEDF SSLESEDFVDY ID NO: VDYY YCLQYASSPY 714) C TFGGGTKLEIK (SEQ (SEQ ID NO: ID NO: 715) 1366) AHH DVVMTQTTSS DWM QDISN LNWY YTS RLHS QQVYT CQQVY WTFGGG FGGG 03720 LSASLGDRVTI TQTTS Y (SEQ QQRP (SEQ ID GVPS LPWT TLPWT TKLEIK TKLEI SCRASQDISNY SLSAS ID NO: DGTV NO: RFSGS (SEQ ID F (SEQ (SEQ ID K LNWYQQRPD LGDR 27) KLLIY 1495) GSGT NO: ID NO: NO: 1467) (SEQ GTVKLLIYYTS VTISC (SEQ DFSLT 1273) 663) ID NO: RLHSGVPSRFS RAS ID NO: ISNLE 959) GSGSGTDFSLT (SEQ 1090) QEDIA ISNLEQEDIAT ID NO: TYFC YFCQQVYTLP 913) (SEQ WTFGGGTKLE ID NO: IK (SEQ ID NO: 1351) 914) AHH DIQMTQSPSSL DIQM QEISG LSWL AAS TLDS LQYAS CLQYA TFGGGT FGGG 03721 SASLGERVSLT TQSPS Y (SEQ QQKP (SEQ ID GVPK YPRT SYPRT KLEIK TKLEI CRASQEISGYL SLSAS ID NO: DGTIK NO: RFSGS (SEQ ID F (SEQ (SEQ ID K SWLQQKPDGT LGER 1210) RLIY 599) RSGS NO: ID NO: NO: 1393) (SEQ IKRLIYAASTL VSLT (SEQ DYSL 1102) 638) ID NO: DSGVPKRFSG CRAS ID NO: TISSL 959) SRSGSDYSLTI (SEQ 1111) ESEDF SSLESEDFADY ID NO: ADYY YCLQYASYPR 726) C TFGGGTKLEIK (SEQ (SEQ ID NO: ID NO: 728) 1402) AHH DTTVTQSPAS DTTV QSVDY MNW AAS NLES QQSNE CQQSN YTFGGG FGGG 03724 LAVSLGQRAT TQSP DGDSY YQQK (SEQ ID GIPAR DPYT EDPYT TKLEMK TKLE ISCKASQSVD ASLA (SEQ ID PGQPP NO: FSGSG (SEQ ID F (SEQ (SEQ ID MK YDGDSYMNW VSLG NO: KLLIY 599) SGTD NO: ID NO: NO: 1494) (SEQ YQQKPGQPPK QRATI 1308) (SEQ FTLNI 1270) 662) ID NO: LLIYAASNLES SCKA ID NO: HPVE 961) GIPARFSGSGS S (SEQ 1135) EEDA GTDFTLNIHPV ID NO: ATYY EEEDAATYYC 847) C QQSNEDPYTF (SEQ GGGTKLEMK ID NO: (SEQ ID NO: 1148) 848) AHH DVVMTQTPLT DWM QSLLD LNWL LVS KLDS WQGT CWQG WTFGGG FGGG 03725 LSVTIGQPASI TQTPL SDGKT LQRP (SEQ ID GVPD HFPWT THFPW TKLEIK TKLEI SCKSSQSLLDS TLSVT Y (SEQ GQSP NO: RFTGS (SEQ ID TF (SEQ ID K DGKTYLNWL IGQPA ID NO: KRLIY 1116) GSGT NO: (SEQ ID NO: 1467) (SEQ LQRPGQSPKR SISCK 1301) (SEQ DFTL 1465) NO: ID NO: LIYLVSKLDSG SS ID NO: KISRV 689) 959) VPDRFTGSGS (SEQ 1083) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYYC 904) YC WQGTHFPWTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1056) 907) AHH DVVLTQTPLS DWL QSLVH LHWY KVS NRFS SQSTH CSQST WTFGGG FGGG 03727 LPVSLGDQASI TQTPL SNGNT LQKP (SEQ ID GVPD VPWT HVPWT TKLEIK TKLEI SCRSSQSLVHS SLPVS Y (SEQ GQSP NO: RFSGS (SEQ ID F (SEQ (SEQ ID K NGNTYLHWY LGDQ ID NO: KLLIY 1062) GSGT NO: ID NO: NO: 1467) (SEQ LQKPGQSPKL ASISC 1306) (SEQ DFTL 1374) 682) ID NO: LIYKVSNRFSG RSS ID NO: KISRV 959) VPDRFSGSGS (SEQ 1076) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 874) FC SQSTHVPWTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1157) 876) AHH DTTVTQSHRF DTTV QDVNT VAWY SAS YRYT QQHFN CQQHF YTFGGG FGGG 03728 MSTSVEDRVT TQSH A (SEQ QHKP (SEQ ID GVPD SPYT NSPYT TKLEIK TKLEI IACKASQDVN RFMS ID NO: GQSP NO: 13) RFTGS (SEQ ID F (SEQ (SEQ ID K TAVAWYQHK TSVE 1206) KLLIY GSRT NO: ID NO: NO: 1493) (SEQ PGQSPKLLIYS DRVTI (SEQ DFTFT 1256) 650) ID NO: ASYRYTGVPD ACKA ID NO: ISSVQ 959) RFTGSGSRTDF S (SEQ 1422) AEDL TFTISSVQAED ID NO: AVYY LAVYYCQQHF 843) C NSPYTFGGGT (SEQ KLEIK (SEQ ID ID NO: NO: 844) 1492) AHH DIVMSQSPASL DIVM QSVDY MNW ATS NLES QQSNE CQQSN LTFGAG FGAG 03729 AVSLGQRATIS SQSPA DGDSY YQQK (SEQ ID GIPAR DPLT EDPLT TKLEIK TKLEI CKASQSVDYD SLAV (SEQ ID PGQPP NO: FSGSG (SEQ ID F (SEQ (SEQ ID K GDSYMNWYQ SLGQ NO: KLLIY 618) SGTD NO: ID NO: NO: 1114) (SEQ QKPGQPPKLLI RATIS 1308) (SEQ FTLNI 1268) 660) ID NO: YATSNLESGIP CKAS ID NO: HPVE 958) ARFSGSGSGT (SEQ 1135) EEDA DFTLNIHPVEE ID NO: ATYY EDAATYYCQQ 786) C SNEDPLTFGA (SEQ GTKLEIK (SEQ ID NO: ID NO: 787) 1148) AHH DIQMTRSPSSL DIQM QDIGS LNWL ATS SLDS LQYAS CLQYA WTFGGG FGGG 03730 SASLGERVSLT TRSPS S (SEQ QQEP (SEQ ID GVPK SPWT SSPWT TKLEIK TKLEI CRASQDIGSSL SLSAS ID NO: DGTIK NO: RFSGS (SEQ ID F (SEQ (SEQ ID K NWLQQEPDGT LGER 1199) RLIY 618) RSGS NO: ID NO: NO: 1467) (SEQ IKRLIYATSSL VSLT (SEQ DYSL 1100) 636) ID NO: DSGVPKRFSG CRAS ID NO: TISSL 959) SRSGSDYSLTI (SEQ 1085) ESEDF SSLESEDFVDY ID NO: VDYY YCLQYASSPW 764) C TFGGGTKLEIK (SEQ (SEQ ID NO: ID NO: 765) 1366) AHH DIVMTQSPAI DIVM SSVSY MHW DTS KLAS QQWSS CQQW FGGGTK FGGG 03731 MSASPGEKVT TQSP (SEQ ID YQQK (SEQ ID GVPA NPPT SSNPPT LEIK TKLEI MTCSASSSVS AIMS NO: SGTSP NO: RFSGS (SEQ ID F (SEQ (SEQ ID K YMHWYQQKS ASPG 1385) KRWI 839) GSGT NO: ID NO: NO: 959) (SEQ GTSPKRWIYD EKVT (SEQ SYSLT 1274) 664) ID NO: TSKLASGVPA MTCS ID NO: ISSME 959) RFSGSGSGTSY AS 1131) AEDA SLTISSMEAED (SEQ ATYY AATYYCQQW ID NO: C SSNPPTFGGGT 802) (SEQ KLEIK (SEQ ID ID NO: NO: 803) 1052) AHH DTTVTQSPAI DTTV SSIGY MHW DTS KLAS HQRGS CHQRG WTFGGG FGGG 03732 MSASPGEKVT TQSP (SEQ ID YQQK (SEQ ID GVPA YPWT SYPWT TKLEIK TKLEI MTCSASSSIGY AIMS NO: PGTSP NO: RFSGS (SEQ ID F (SEQ (SEQ ID K MHWYQQKPG ASPG 1381) KRWI 839) GSGT NO: ID NO: NO: 1467) (SEQ TSPKRWIYDT EKVT (SEQ SYSLT 999) 626) ID NO: SKLASGVPAR MTCS ID NO: ISSME 959) FSGSGSGTSYS AS 1130) AEDA LTISSMEAEDA (SEQ ATYY ATYYCHQRGS ID NO: C YPWTFGGGTK 846) (SEQ LEIK (SEQ ID ID NO: NO: 846) 1052) AHH DVVLTQTPLS DWL QSIVH LEWY KVS NRFS FQGSH CFQGS YTFGGG FGGG 03733 LPVSLGDQASI TQTPL SNGNT LQKP (SEQ ID GVPD VPYT HVPYT TKLEIK TKLEI SCRSSQSIVHS SLPVS Y (SEQ GQSP NO: RFSGS (SEQ ID F (SEQ (SEQ ID K NGNTYLEWY LGDQ ID NO: KLLIY 1062) GSGT NO: ID NO: NO: 1493) (SEQ LQKPGQSPKL ASISC 1299) (SEQ DFTL 970) 621) ID NO: LIYKVSNRFSG RSS ID NO: KISRV 959) VPDRFSGSGS (SEQ 1071) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYYC 874) YC FQGSHVPYTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1158) 875) AHH DTTVTQSHKF DTTV QDVST VAWY SAS YRYT QQHYS CQQHY WTFGGG FGGG 03734 MSTSVGDRVS TQSH A (SEQ QQKP (SEQ ID GVPD TPWT STPWT TKLEIK TKLEI ITCKASQDVST KFMS ID NO: GQSP NO: 13) RFTGS (SEQ ID F (SEQ (SEQ ID K AVAWYQQKP TSVG 1209) KLLIY GSGT NO: ID NO: NO: 1467) (SEQ GQSPKLLIYSA DRVSI (SEQ DFTFT 1264) 656) ID NO: SYRYTGVPDR TCKA ID NO: ISSVQ 959) FTGSGSGTDFT S (SEQ 1427) AEDL FTISSVQAEDL ID NO: AVYY AVYYCQQHY 840) C STPWTFGGGT (SEQ KLEIK (SEQ ID ID NO: NO: 841) 1491) AHH DIVLTQSPASL DIVLT ESVDN MNWF AAS NQGS QQSKE CQQSK YTFGGG FGGG 03735 AVSLGQRATIS QSPAS YGISF QKKP (SEQ ID GVPA VPYT EVPYT TKLEIK TKLEI CRASESVDNY LAVS (SEQ ID GQPP NO: RFSGS (SEQ ID F (SEQ (SEQ ID K GISFMNWFQK LGQR NO: KLLIY 599) GSGT NO: ID NO: NO: 1493) (SEQ KPGQPPKLLIY ATISC 934) (SEQ DFSL 1267) 659) ID NO: AASNQGSGVP RAS ID NO: NIHP 959) ARFSGSGSGT (SEQ 1133) MEED DFSLNIHPMEE ID NO: DTAM DDTAMYFCQ 768) YFC QSKEVPYTFG (SEQ GGTKLEIK ID NO: (SEQ ID NO: 1152) 769) AHH DNVLTQSPSSL DNVL QSLLY LAWY WAS TRES QQYYS CQQYY TFGGGT FGGG 03736 AVSVGEKVT TQSPS SSNQK QQKP (SEQ ID GVPD YRT SYRTF KLEIK TKLEI MSCKSSQSLL SLAV NY GQSP NO: RFTGS (SEQ ID (SEQ ID (SEQ ID K YSSNQKNYLA SVGE (SEQ ID KLLIY 1450) GSGT NO: NO: NO: 1393) (SEQ WYQQKPGQSP KVTM NO: (SEQ DFTLT 1295) 677) ID NO: KLLIYWASTR SCKSS 1304) ID NO: ISSVK 959) ESGVPDRFTG (SEQ 1066) AEDL SGSGTDFTLTI ID NO: AVYY SSVKAEDLAV 834) C YYCQQYYSYR (SEQ TFGGGTKLEIK ID NO: (SEQ ID NO: 1411) 835) AHH DIVMTQSPKS DIVM ENVAT VSWY GAS NRYT GQSYR CGQSY YTFGGG FGGG 03737 MSMSVGERVT TQSP Y (SEQ QQKP (SEQ ID GVPD YPYT RYPYT TKLEMK TKLE LSCKASENVA KSMS ID NO: EQSP NO: RFTGS (SEQ ID F (SEQ (SEQ ID MK TYVSWYQQK MSVG 932) KLLIY 975) GSAT NO: ID NO: NO: 1494) (SEQ PEQSPKLLIYG ERVT (SEQ DFTLT 979) 622) ID NO: ASNRYTGVPD LSCK ID NO: ISSVQ 961) RFTGSGSATD AS 1446) AEDL FTLTISSVQAE (SEQ AD YR DLADYRCGQS ID NO: C YRYPYTFGGG 808) (SEQ TKLEMK (SEQ ID NO: ID NO: 809) 1163) AHH DVVVTQTPLS DVW QSLVH LHWY KVS NRFS SQSTH CSQST TFGGGT FGGG 03738 LPVSLGDQASI TQTPL SNGNT LQKP (SEQ ID GVPD VPT HVPTF KLEIK TKLEI SCRSSQSLVHS SLPVS Y (SEQ GQSP NO: RFSGS (SEQ ID (SEQ ID (SEQ ID K NGNTYLHWY LGDQ ID NO: KLLIY 1062) GSGT NO: NO: NO: 1393) (SEQ LQKPGQSPKL ASISC 1306) (SEQ DFTL 1373) 681) ID NO: LIYKVSNRFSG RSS ID NO: KISRV 959) VPDRFSGSGS (SEQ 1076) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 918) FC SQSTHVPTFG (SEQ GGTKLEIK ID NO: (SEQ ID NO: 1157) 920) AHH DVVVTQSPAS DVW ESVDS MHW LAS NLES QQNNE CQQNN YTFGGG FGGG 03739 LAVSLGQRAT TQSP YGNSF YQQK (SEQ ID GVPA DPYT EDPYT TKLEIK TKLEI ISCRASESVDS ASLA (SEQ ID PGQPP NO: RFSGS (SEQ ID F (SEQ (SEQ ID K YGNSFMHWY VSLG NO: KLLIY 1063) GSRT NO: ID NO: NO: 1493) (SEQ QQKPGQPPKL QRATI 935) (SEQ DFTLT 1266) 658) ID NO: LIYLASNLESG SCRA ID NO: IDPVE 959) VPARFSGSGS S (SEQ 1129) ADDA RTDFTLTIDPV ID NO: ATYY EADDAATYYC 916) C QQNNEDPYTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1150) 917) AHH DVVMTQSQKF DWM QNVGT VAWY SAS YRYS QQYNS CQQYN YTFGGG FGGG 03740 MSTSVGDRVN TQSQ N (SEQ QQKP (SEQ ID GVPD YPYT SYPYT TKLEIK TKLEI VTCKASQNVG KFMS ID NO: GQSP NO: 13) RFTGS (SEQ ID F (SEQ (SEQ ID K TNVAWYQQK TSVG 12) KALIY GSGT NO: 15) ID NO: NO: 1493) (SEQ PGQSPKALIYS DRVN (SEQ DFTLT 671) ID NO: ASYRYSGVPD VTCK ID NO: ISNVQ 959) RFTGSGSGTD AS 1425) SEDL FTLTISNVQSE (SEQ AEYF DLAEYFCQQY ID NO: C NSYPYTFGGG 891) (SEQ TKLEIK (SEQ ID NO: ID NO: 892) 1483) AHH DVVMTQTPLS DWM QSLVH LHWY KVS NRFS SQSTH CSQST WTFGGG FGGG 03741 LPVSLGDQASI TQTPL SNGNT LQKP (SEQ ID GVPD VPWT HVPWT TKLEIK TKLEI SCRSSQSLVHS SLPVS Y (SEQ GQSP NO: RFSGS (SEQ ID F (SEQ (SEQ ID K NGNTYLHWY LGDQ ID NO: KLLIY 1062) GSGT NO: ID NO: NO: 1467) (SEQ LQKPGQSPKL ASISC 1306) (SEQ DFTL 1374) 682) ID NO: LIYKVSNRFSG RSS ID NO: KISRV 959) VPDRFSGSGS (SEQ 1076) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 900) FC SQSTHVPWTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1157) 901) AHH DIVMTQSPKS DIVM ENVGT VSWY GAS NRYT GQSYS CGQSY YTFGGG FGGG 03742 MSMSVGERVT TQSP Y (SEQ QQKP (SEQ ID GVPD YPYT SYPYT TKLEIK TKLEI LSCKASENVG KSMS ID NO: EQSP NO: RFTGS (SEQ ID F (SEQ (SEQ ID K TYVSWYQQK MSVG 933) KLLIY 975) GSAT NO: ID NO: NO: 1493) (SEQ PEQSPKLLIYG ERVT (SEQ DFTLT 981) 624) ID NO: ASNRYTGVPD LSCK ID NO: ISSVQ 959) RFTGSGSATD AS 1446) AEDL FTLTISSVQAE (SEQ ADYH DLADYHCGQS ID NO: C YSYPYTFGGG 808) (SEQ TKLEIK (SEQ ID NO: ID NO: 810) 1162) AHH DVVMTQSHKF DWM QDVST VAWY SAS YRYT QQHYS CQQHY WTFGRG FGRG 03743 MSTSVGDRVS TQSH A (SEQ QQKP (SEQ ID GVPD TPPWT STPPW TKLEIK TKLEI ITCKASQDVST KFMS ID NO: GQSP NO: 13) RFTGS (SEQ ID TF (SEQ ID K AVAWYQQKP TSVG 1209) KLLIY GSGT NO: (SEQ ID NO: 1469) (SEQ GQSPKLLIYSA DRVSI (SEQ DFTFT 1262) NO: ID NO: SYRYTGVPDR TCKA ID NO: ISSVQ 654) 964) FTGSGSGTDFT S (SEQ 1427) AEDL FTISSVQAEDL ID NO: AVYY AVYYCQQHY 885) C STPPWTFGRG (SEQ TKLEIK (SEQ ID NO: ID NO: 886) 1491) AHH DIVMTQSPKS DIVM ENVGT VSWY GAS NRYT GQSYS CGQSY WTFGGG FGGG 03744 MSMSVGERVT TQSP Y (SEQ QQKP (SEQ ID GVPD YPWT SYPWT TKLEIK TKLEI LSCKASENVG KSMS ID NO: EQSP NO: RFTGS (SEQ ID F (SEQ (SEQ ID K TYVSWYQQK MSVG 933) KLLIY 975) GSAT NO: ID NO: NO: 1467) (SEQ PEQSPKLLIYG ERVT (SEQ DFTLT 980) 623) ID NO: ASNRYTGVPD LSCK ID NO: ISSVQ 959) RFTGSGSATD AS 1446) AEDL FTLTISSVQAE (SEQ ADYH DLADYHCGQS ID NO: C YSYPWTFGGG 808) (SEQ TKLEIK (SEQ ID NO: ID NO: 811) 1162) AHH DIQMTQTPSSL DIQM QDIGS LNWL ATS SLDS LQYAS CLQYA TFGGGT FGGG 03745 SASLGERVSLT TQTPS S (SEQ QQEP (SEQ ID GVPK SPRT SSPRTF KLEIK TKLEI CRASQDIGSSL SLSAS ID NO: DGTIK NO: RFSGS (SEQ ID (SEQ ID (SEQ ID K NWLQQEPDGT LGER 1199) RLIY 618) RSGS NO: NO: NO: 1393) (SEQ IKRLIYATSSL VSLT (SEQ DYSL 1099) 635) ID NO: DSGVPKRFSG CRAS ID NO: TISSL 959) SRSGSDYSLTI (SEQ 1085) ESEDF SSLESEDFVDY ID NO: VDYY YCLQYASSPR 753) C TFGGGTKLEIK (SEQ (SEQ ID NO: ID NO: 755) 1366) AHH DIVMTQSPLSL DIVM QSLLY LNWL QVS KLDP LQGTY CLQGT WTFGGG FGGG 03746 SVTIGQPASIS TQSPL SNGKT QQRP (SEQ ID GIPDR YPTWT YYPTW TKLEIK TKLEI CKSSQSLLYS SLSVT Y (SEQ GQAP NO: FSGSG (SEQ ID TF (SEQ ID K NGKTYLNWL IGQPA ID NO: KHLM 1344) SETDF NO: (SEQ ID NO: 1467) (SEQ QQRPGQAPKH SISCK 1303) (SEQ TLKIS 1092) NO: ID NO: LMYQVSKLDP SS ID NO: RVEA 629) 959) GIPDRFSGSGS (SEQ 1086) EDLG ETDFTLKISRV ID NO: VYYC EAEDLGVYYC 812) (SEQ LQGTYYPTWT ID NO: FGGGTKLEIK 1053) (SEQ ID NO: 813) AHH DIVMSQSHKF DIVM QDVGT VAWY WAS TRHT QQYSS CQQYS TFGGGT FGGG 03747 MSTSVGDRVS SQSH A (SEQ QQKP (SEQ ID GVPD YPLT SYPLT KLEIK TKLEI ITCKASQDVG KFMS ID NO: GQSP NO: RFTGS (SEQ ID F (SEQ (SEQ ID K TAVAWYQQK TSVG 1204) KLLIY 1450) GSGT NO: ID NO: NO: 1393) (SEQ PGQSPKLLIY DRVSI (SEQ DFTLT 1291) 673) ID NO: WASTRHTGVP TCKA ID NO: ISIVQ 959) DRFTGSGSGT S (SEQ 1427) SEDL DFTLTISIVQSE ID NO: ADYF DLADYFCQQY 779) C SSYPLTFGGGT (SEQ KLEIK (SEQ ID ID NO: NO: 780) 1412) AHH DVVLTQTPLS DWL QSLVH LHWY KVS NRFS SQSTH CSQST WTFGGG FGGG 03748 LPVSLGDQASI TQTPL SNGNT LQKP (SEQ ID GVPD VPWT HVPWT TKLEMK TKLE SCRSSQSLVHS SLPVS Y (SEQ GQSP NO: RFSGS (SEQ ID F (SEQ (SEQ ID MK NGNTYLHWY LGDQ ID NO: KLLIY 1062) GSGT NO: ID NO: NO: 1468) (SEQ LQKPGQSPKL ASISC 1306) (SEQ DFTL 1374) 682) ID NO: LIYKVSNRFSG RSS ID NO: KISRV 961) VPDRFSGSGS (SEQ 1076) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 874) FC SQSTHVPWTF (SEQ GGGTKLEMK ID NO: (SEQ ID NO: 1157) 877) AHH DIVMTQSHKF DIVM QDVST VAWY SAS YRYT QQHYS CQQHY TFGGGT FGGG 03749 MSTSVGDRVS TQSH A (SEQ QQKP (SEQ ID GVPD TPPT STPPTF KLEIK TKLEI ITCKASQDVST KFMS ID NO: GQSP NO: 13) RFTGS (SEQ ID (SEQ ID (SEQ ID K AVAWYQQKP TSVG 1209) KLLIH GSGT NO: NO: NO: 1393) (SEQ GQSPKLLIHSA DRVSI (SEQ DFTFT 1261) 653) ID NO: SYRYTGVPDR TCKA ID NO: ISSVQ 959) FTGSGSGTDFT S (SEQ 1426) AEDL FTISSVQAEDL ID NO: AVYY AVYYCQQHY 800) C STPPTFGGGTK (SEQ LEIK (SEQ ID ID NO: NO: 801) 1491) AHH DIVMTQSPLTL DIVM QSLLD LNWL LVS KLDS WQGT CWQG WTFGGG FGGG 03750 SVTIGQPASIS TQSPL SDGKT LQRP (SEQ ID GVPD HFPWT THFPW TKLEIK TKLEI CKSSQSLLDS TLSVT Y (SEQ GQSP NO: RFTGS (SEQ ID TF (SEQ ID K DGKTYLNWL IGQPA ID NO: KRLIY 1116) GSGT NO: (SEQ ID NO: 1467) (SEQ LQRPGQSPKR SISCK 1301) (SEQ DFTL 1465) NO: ID NO: LIYLVSKLDSG SS ID NO: KISRV 689) 959) VPDRFTGSGS (SEQ 1083) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYYC 814) YC WQGTHFPWTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1056) 815) AHH DIQMTQTPLT DIQM QSLLD LNWL LVS KLDS WQGA CWQG WTFGGG FGGG 03751 LSVTIGQPASI TQTPL SDGKT LQRP (SEQ ID GVPD HFPWT AHFPW TKLEIK TKLEI SCKSSQSLLDS TLSVT Y (SEQ GQSP NO: RFTGS (SEQ ID TF (SEQ ID K DGKTYLNWL IGQPA ID NO: KRLIY 1116) GSGT NO: (SEQ ID NO: 1467) (SEQ LQRPGQSPKR SISCK 1301) (SEQ DFTL 1461) NO: ID NO: LIYLVSKLDSG SS ID NO: KISRV 685) 959) VPDRFTGSGS (SEQ 1083) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYYC 748) YC WQGAHFPWT (SEQ FGGGTKLEIK ID NO: (SEQ ID NO: 1056) 749) AHH DIQMTQTPLT DIQM QSLLD LNWL LVS KLDS WQGT CWQG TFGGGT FGGG 03752 LSVTIGQPASI TQTPL SDGKT LQRP (SEQ ID GVPD HFPQT THFPQ KLEMK TKLE SCKSSQSLLDS TLSVT Y (SEQ GQSP NO: RFTGS (SEQ ID TF (SEQ ID MK DGKTYLNWL IGQPA ID NO: KRLIY 1116) GSGT NO: (SEQ ID NO: 1394) (SEQ LQRPGQSPKR SISCK 1301) (SEQ DFTL 1463) NO: ID NO: LIYLVSKLDSG SS ID NO: KISRV 687) 961) VPDRFTGSGS (SEQ 1083) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYYC 748) YC WQGTHFPQTF (SEQ GGGTKLEMK ID NO: (SEQ ID NO: 1056) 750) AHH DIVITQSQKFM DIVIT QNVGS VAWY SAS YRYS QQYDS CQQYD YTFGGG FGGG 03753 STSVGDRVSV QSQK N (SEQ QQKP (SEQ ID GVPD YPYT SYPYT TKLEIK TKLEI TCKASQNVGS FMST ID NO: GQSP NO: 13) RFTGS (SEQ ID F (SEQ (SEQ ID K NVAWYQQKP SVGD 1244) KALIY GSGT NO: ID NO: NO: 1493) (SEQ GQSPKALIYSA RVSV (SEQ DFTLT 1280) 669) ID NO: SYRYSGVPDR TCKA ID NO: ISNVQ 959) FTGSGSGTDFT S (SEQ 1425) SEDL LTISNVQSEDL ID NO: AEYF AEYFCQQYDS 766) C YPYTFGGGTK (SEQ LEIK (SEQ ID ID NO: NO: 767) 1483) AHH DIQMTQSPSSL DIQM QDIGS LNWL ATS SLDS LQYAS CLQYA TFGGGT FGGG 03754 SASLGERVSLT TQSPS S (SEQ QQEP (SEQ ID GVPK SPHT SSPHTF KLEIK TKLEI CRASQDIGSSL SLSAS ID NO: DGTIK NO: RFSGS (SEQ ID (SEQ ID (SEQ ID K NWLQQEPDGT LGER 1199) RLIY 618) RSGS NO: NO: NO: 1393) (SEQ IKRLIYATSSL VSLT (SEQ DYSL 1098) 634) ID NO: DSGVPKRFSG CRAS ID NO: TISSL 959) SRSGSDYSLTI (SEQ 1085) ESEDF SSLESEDFVDY ID NO: VDYY YCLQYASSPH 726) C TFGGGTKLEIK (SEQ (SEQ ID NO: ID NO: 727) 1366) AHH DIQMTQSPAS DIQM ENIYS LAWY AAT NLAD QHFW CQHF WTFGGG FGGG 03755 LSVSVGETVTI TQSP N (SEQ QQKQ (SEQ ID GVPS GTPWT WGTP TKLEMK TKLE TCRASENIYSN ASLS ID NO: GKSP NO: RFSGS (SEQ ID WTF (SEQ ID MK LAWYQQKQG VSVG 929) QLLV 600) GSGT NO: (SEQ ID NO: 1468) (SEQ KSPQLLVYAA ETVTI (SEQ QYSL 1213) NO: ID NO: TNLADGVPSR TCRA ID NO: KINSL 643) 961) FSGSGSGTQY S (SEQ 1069) QSED SLKINSLQSED ID NO: FGSY FGSYYCQHFW 723) YC GTPWTFGGGT (SEQ KLEMK (SEQ ID NO: ID NO: 725) 1143) AHH DTTVTQSHKF DTTV QDVST VAWY SAS YRYT QQHYS CQQHY YTFGGG FGGG 03756 MSTSVGDRVS TQSH A (SEQ QQKP (SEQ ID GVPD TPYT STPYT TKLEIK TKLEI ITCKASQDVST KFMS ID NO: GQSP NO: 13) RFTGS (SEQ ID F (SEQ (SEQ ID K AVAWYQQKP TSVG 1209) KLLIY GSGT NO: ID NO: NO: 1493) (SEQ GQSPKLLIYSA DRVSI (SEQ DFTFT 1265) 657) ID NO: SYRYTGVPDR TCKA ID NO: ISSVQ 959) FTGSGSGTDFT S (SEQ 1427) AEDL FTISSVQAEDL ID NO: AVYY AVYYCQQHY 840) C STPYTFGGGT (SEQ KLEIK (SEQ ID ID NO: NO: 842) 1491) AHH DIQMTQSPAS DIQM ENIYS LAWY AAT NLAD QHFW CQHF WTFGGG FGGG 03757 LSVSVGETVAI TQSP N (SEQ QQKQ (SEQ ID GVPS GTPWT WGTP TKLEMK TKLE TCRASENIYSN ASLS ID NO: GKSP NO: RFSGS (SEQ ID WTF (SEQ ID MK LAWYQQKQG VSVG 929) QLLV 600) GSGT NO: (SEQ ID NO: 1468) (SEQ KSPQLLVYAA ETVAI (SEQ QYSL 1213) NO: ID NO: TNLADGVPSR TCRA ID NO: KINSL 643) 961) FSGSGSGTQY S (SEQ 1069) QSED SLKINSLQSED ID NO: FGSY FGSYYCQHFW 721) YC GTPWTFGGGT (SEQ KLEMK (SEQ ID NO: ID NO: 722) 1143)

TABLE 3B Exemplary Clones-Light Chain Sequences JUNC- J- ID V-J-REGION L-FR1 CDRL1 L-FR2 CDRL2 L-FR3 CDRL3 TION REGION L-FR4 AHH DILMTQSPASL DILM TDIDD MNWY EGN TLRP LQSDN CLQS TFGGGT FGGG 03758 SVATGEKVTI TQSP D (SEQ QQKPG (SEQ ID GVPS MPLT DNMP KLEIK TKLEI RCITSTDIDDD ASLS ID NO: EPPKL NO: RFSSS (SEQ LTF (SEQ ID K MNWYQQKPG VATG 1391) LIS 925) GYGT ID NO: (SEQ NO: 1393) (SEQ EPPKLLISEGN EKVTI (SEQ ID DFVF 1094) ID NO: ID NO: TLRPGVPSRFS RCITS NO: TIENT 631) 959) SSGYGTDFVF (SEQ 1134) LSED TIENTLSEDVA ID NO: VADY DYYCLQSDN 704) YC MPLTFGGGTK (SEQ LEIK (SEQ ID ID NO: NO: 705) 1406) AHH DTTVTQSPAS DTTV QSVDY MNWY AAS NLES QQSNE CQQS YTFGGG FGGG 03759 LAVSLGQRAT TQSP DGDSY QQKPG (SEQ ID GIPAR DPYT NEDP TKLEMK TKLE ISCKASQSVD ASLA (SEQ ID QPPKL NO: FSGSG (SEQ YTF (SEQ ID MK YDGDSYMNW VSLG NO: LIY 599) SGTD ID NO: (SEQ NO: 1494) (SEQ YQQKPGQPPK QRATI 1308) (SEQ ID FTLNI 1270) ID NO: ID NO: LLIYAASNLES SCKA NO: HPVE 662) 961) GIPARFSGSGS S (SEQ 1135) EEDA GTDFTLNIHPV ID NO: ATYY EEEDAATYYC 847) C QQSNEDPYTF (SEQ GGGTKLEMK ID NO: (SEQ ID NO: 1148) 848) AHH DVVMTQTPKF DVVM QSVSN VAWY YAS NRYT QQDY CQQD TFGGGT FGGG 03760 LLVSAGDRVT TQTP D (SEQ QQKPG (SEQ ID GVPD SSPPT YSSPP KLEIK TKLEI ITCKASQSVSN KFLL ID NO: QSPKL NO: RFTGS (SEQ TF (SEQ ID K DVAWYQQKP VSAG 1310) LIY 1476) GYGT ID NO: (SEQ NO: 1393) (SEQ GQSPKLLIYY DRVTI (SEQ ID dftft 1250) ID NO: ID NO: ASNRYTGVPD TCKA NO: ISTVQ 646) 959) RFTGSGYGTD S (SEQ 1427) AEDL FTFTISTVQAE ID NO: AVYF DLAVYFCQQD 896) C YSSPPTFGGGT (SEQ KLEIK (SEQ ID ID NO: NO: 897) 1164) AHH DVVLTQTPLS DVVL QTLLH LKWY QVS NRFS FQGSH CFQG WTFGGG FGGG 03761 LPVTLGDPASI TQTPL SDGNT LQKPG (SEQ ID GVPD VPWT SHVP TKLEIK TKLEI SCRSSQTLLHS SLPVT Y (SEQ QSPKL NO: RFTGS (SEQ WTF (SEQ ID K DGNTYLKWY LGDP ID NO: LIY 1344) GSGT ID NO: (SEQ NO: 1467) (SEQ LQKPGQSPKL ASISC 1311) (SEQ ID DFTL 969) ID NO: ID NO: LIYQVSNRFSG RSS NO: KISRV 620) 959) VPDRFTGSGS (SEQ 1080) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYHC 883) HC FQGSHVPWTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1160) 884) AHH DIQMTQTPLT DIQM QSLLD LNWLL LVS KLDS WQGT CWQG TFGGGT FGGG 03763 LSVTIGQPASI TQTPL SDGKT QRPGQ (SEQ ID GVPD HFPRT THFPR KLEIK TKLEI SCKSSQSLLDS TLSVT Y (SEQ SPKRLI NO: RFTGS (SEQ TF (SEQ ID K DGKTYLNWL IGQPA ID NO: Y (SEQ 1116) GSGT ID NO: (SEQ NO: 1393) (SEQ LQRPGQSPKR SISCK 1301) ID NO: DFTL 1464) ID NO: ID NO: LIYLVSKLDSG SS 1083) KISRV 688) 959) VPDRFTGSGS (SEQ EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYYC 748) YC WQGTHFPRTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1056) 751) AHH DVVMTQSPAI DVVM ssvsss LHWY STS NLAS HQYH CHQY FGGGTK FGGG 03764 MSASLGERVT TQSP Y (SEQ QQKPG (SEQ ID GVPA RSPPT HRSPP LEIK TKLEI MTCTASSSVS AIMS ID NO: SSPKL NO: RFSGS (SEQ TF (SEQ ID K SSYLHWYQQ ASLG 1384) WIY 1386) GSGT ID NO: (SEQ NO: 959) (SEQ KPGSSPKLWI ERVT (SEQ ID SYSLT 1001) ID NO: ID NO: YSTSNLASGV MTCT ISSME 628) 959) PARFSGSGSGT AS NO: AEDA SYSLTISSMEA (SEQ 1077) ATYY EDAATYYCHQ ID NO: C YHRSPPTFGG 887) (SEQ GTKLEIK (SEQ ID NO: ID NO: 888) 1144) AHH DIVMTQSPAI DIVM SSVSY MHWY DTS KLAS QQWS CQQW YTFGGG FGGG 03765 MSASPGEKVT TQSP (SEQ ID QQKSG (SEQ ID GVPA SNPPY SSNPP TKLEMK TKLE MTCSASSSVS AIMS NO: TSPKR NO: RFSGS T (SEQ YTF (SEQ ID MK YMHWYQQKS ASPG 1385) WIY 839) GSGT ID NO: (SEQ NO: 1494) (SEQ GTSPKRWIYD EKVT (SEQ ID SYSLT 1275) ID NO: ID NO: TSKLASGVPA MTCS NO: ISSME 665) 961) RFSGSGSGTSY AS 1131) AEDA SLTISSMEAED (SEQ ATYY AATYYCQQW ID NO: C SSNPPYTFGG 802) (SEQ GTKLEMK ID NO: (SEQ ID NO: 1052) 804) AHH DVVMTQTPLS DVVM QSLVH LRWYL KVS NRFS SQSTH CSQST WTFGGG FGGG 03766 LPVSLGDQASI TQTPL SNGNT QKPGQ (SEQ ID GVPD VPWT HVPW TKLEIK TKLEI SCRSSQSLVHS SLPVS Y (SEQ SPKLLI NO: RFSGS (SEQ TF (SEQ ID K NGNTYLRWY LGDQ ID NO: Y (SEQ 1062) GSGT ID NO: (SEQ NO: 1467) (SEQ LQKPGQSPKL ASISC 1306) ID NO: DFTL 1374) ID NO: ID NO: LIYKVSNRFSG RSS 1108) KISRV 682) 959) VPDRFSGSGS (SEQ EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 900) FC SQSTHVPWTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1157) 903) AHH DVVMTQTPLT DVVM QSLLD LNWLL LVS KLDS WQGT CWQG TFGGGT FGGG 03767 LSVTIGQPASI TQTPL SDGKT QRPGQ (SEQ ID GVPD HFPRT THFPR KLEIK TKLEI SCKSSQSLLDS TLSVT Y (SEQ SPKRLI NO: GFTG (SEQ TF (SEQ ID K DGKTYLNWL IGQPA ID NO: Y (SEQ 1116) SGSG ID NO: (SEQ NO: 1393) (SEQ LQRPGQSPKR SISCK 1301) ID NO: TDFTL 1464) ID NO: ID NO: LIYLVSKLDSG SS 1083) KISRV 688) 959) VPDGFTGSGS (SEQ EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYYC 904) YC WQGTHFPRTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1054) 908) AHH DIQMTQTSSSF DIQM EDIYN LAWY GAT SLETG QQYW CQQY TFGGGT FGGG 03768 SVSLGDRVTIT TQTSS R(SEQ QQKPG (SEQ ID VPSRF STPPT WSTP KLEIK TKLEI CKASEDIYNR SFSVS ID NO: NAPRL NO: SGSGS (SEQ PTF (SEQ ID K LAWYQQKPG LGDR 924) LIS 976) GKDY ID NO: (SEQ NO: 1393) (SEQ NAPRLLISGAT VTITC (SEQ ID TLSIT 1292) ID NO: ID NO: SLETGVPSRFS KAS NO: SLQTE 674) 959) GSGSGKDYTL (SEQ 1065) DVAT SITSLQTEDVA ID NO: YYC TYYCQQYWS 758) (SEQ TPPTFGGGTK ID NO: LEIK (SEQ ID 1367) NO: 759) AHH DVVLTQTPLS DVVL QSLVH LHWY KVS NRFS SQSTH CSQST TFGGGT FGGG 03769 LPVSLGDQASI TQTPL SNGNT LQKPG (SEQ ID GVPD VPRT HVPR KLEIK TKLEI SCRSSQSLVHS SLPVS Y (SEQ QSPKL NO: RFSGS (SEQ TF (SEQ ID K NGNTYLHWY LGDQ ID NO: LIY 1062) GSGT ID NO: (SEQ NO: 1393) (SEQ LQKPGQSPKL ASISC 1306) (SEQ ID DFTL 1372) ID NO: ID NO: LIYKVSNRFSG RSS NO: KISRV 680) 959) VPDRFSGSGS (SEQ 1076) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 874) FC SQSTHVPRTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1157) 878) AHH DIVMSQSPSSL DIVM QSLLY LAWY WAS TRES QQYY CQQY FGGGTK FGGG 03770 AVSVGEKVT SQSPS SSNQK QQKPG (SEQ ID GVPD SYP YSYPF LEIK TKLEI MSCKSSQSLL SLAV NY QSPKL NO: RFTGS (SEQ (SEQ (SEQ ID K YSSNQKNYLA SVGE (SEQ ID LIY 1450) GSGT ID NO: ID NO: NO: 959) (SEQ WYQQKPGQSP KVTM NO: (SEQ ID DFTLT 1293) 675) ID NO: KLLIYWASTR SCKSS 1304) NO: ISSVK 959) ESGVPDRFTG (SEQ 1066) AEDL SGSGTDFTLTI ID NO: AVYY SSVKAEDLAV 790) C YYCQQYYSYP (SEQ FGGGTKLEIK ID NO: (SEQ ID NO: 1411) 791) AHH DVVVTQTPLS DVW QSLVH LHWY KVS NRFS SQSTH CSQST YTFGGG FGGG 03771 LPVSLGDQASI TQTPL SNGNT LQKPG (SEQ ID GVPD VYT HVYT TKLEMK TKLE SCRSSQSLVHS SLPVS Y (SEQ QSPKL NO: RFSGS (SEQ F (SEQ (SEQ ID MK NGNTYLHWY LGDQ ID NO: LIY 1062) GSGT ID NO: ID NO: NO: 1494) (SEQ LQKPGQSPKL ASISC 1306) (SEQ ID DFTL 1376) 684) ID NO: LIYKVSNRFSG RSS NO: KISRV 961) VPDRFSGSGS (SEQ 1076) DAED GTDFTLKISRV ID NO: LGVY DAEDLGVYFC 918) FC SQSTHVYTFG (SEQ GGTKLEMK ID NO: (SEQ ID NO: 1155) 921) AHH DIQMTQTPAS DIQM ENIYS LAWY NAK TLAE QHHY CQHH WTFGGG FGGG 03772 LSASVGETVTI TQTP Y (SEQ QQKQ (SEQ ID GVPS GTPW YGTP TKLEIK TKLEI TCRASENIYSY ASLS ID NO: GKSPQ NO: 28) RFSGS T (SEQ WTF (SEQ ID K LAWYQQKQG ASVG 930) LLVY GSGT (SEQ NO: 1467) (SEQ KSPQLLVYNA ETVTI (SEQ ID QFSL ID NO: ID NO: ID NO: KTLAEGVPSR TCRA NO: KINSL 1217) 644) 959) FSGSGSGTQFS S (SEQ 1069) QPED LKINSLQPEDF ID NO: FGSY GSYYCQHHY 744) YC GTPWTFGGGT (SEQ KLEIK (SEQ ID ID NO: NO: 745) 1398) AHH DVVLTQTPLS DVVL QSLVH LHWY KVS NRFS SQSTH CSQST TFGGGT FGGG 03773 LPVSLGDQASI TQTPL SNGNT LQKPG (SEQ ID GVPD VPT HVPT KLEIK TKLEI SCRSSQSLVHS SLPVS Y (SEQ QSPKL NO: RFSGS (SEQ F (SEQ (SEQ ID K NGNTYLHWY LGDQ ID NO: LIY 1062) GSGT ID NO: ID NO: NO: 1393) (SEQ LQKPGQSPKL ASISC 1306) (SEQ ID DFTL 1373) 681) ID NO: LIYKVSNRFSG RSS NO: KISRV 959) VPDRFSGSGS (SEQ 1076) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 874) FC SQSTHVPTFG (SEQ GGTKLEIK ID NO: (SEQ ID NO: 1157) 879) AHH DIVMSQSPAI DIVM SSVSY MYWY DTS NLAS QQWS CQQW SGGGTK SGGG 03774 MSASPGEKVT SQSPA (SEQ ID QQKPG (SEQ ID GVPV SYPYT SSYPY LEIK TKLEI MTRSASSSVS IMSAS NO: SSPRLL NO: RFSGS (SEQ TS (SEQ ID K YMYWYQQKP PGEK 1385) IY (SEQ 839) GSGT ID NO: (SEQ NO: 1364) (SEQ GSSPRLLIYDT VTMT ID NO: SYSLT 1278) ID NO: ID NO: SNLASGVPVR RSAS 1140) ISRME 667) 1364) FSGSGSGTSYS (SEQ AEDA LTISRMEAED ID NO: ATYY AATYYCQQW 784) C SSYPYTSGGG (SEQ TKLEIK (SEQ ID NO: ID NO: 785) 1146) AHH DIVMTQSPAL DIVM SSVSY MYWY LTP NLAS QQWS CQQW FGGGTK FGGG 03775 MSASPGEKVT TQSP (SEQ ID QQKPR (SEQ ID GVPA SNPYT SSNPY LEIK TKLEI MTCSASSSVS ALMS NO: SSPKP NO: RFSGS (SEQ TF (SEQ ID K YMYWYQQKP ASPG 1385) WIY 1115) GSGT ID NO: (SEQ NO: 959) (SEQ RSSPKPWIYLT EKVT (SEQ ID SYSLT 1276) ID NO: ID NO: PNLASGVPAR MTCS NO: ISSME 666) 959) FSGSGSGTSYS AS 1141) AEDA LTISSMEAEDA (SEQ ATYY ATYYCQQWSS ID NO: C NPYTFGGGTK 805) (SEQ LEIK (SEQ ID ID NO: NO: 806) 1144) AHH DIVMSQSPASL DIVM TDIDD MNWY EGN TLRP LQSDN CLQS YTFGGG FGGG 03776 SVATGEKVTI SQSPA D (SEQ QQKPG (SEQ ID GVPS MPYT DNMP TKLEIK TKLEI RCITSTDIDDD SLSV ID NO: EPPKL NO: RFSSS (SEQ YTF (SEQ ID K MNWYQQKPG ATGE 1391) LIS 925) GYGT ID NO: (SEQ NO: 1493) (SEQ EPPKLLISEGN KVTIR (SEQ ID DFVF 1095) ID NO: ID NO: TLRPGVPSRFS CITS NO: TIENT 632) 959) SSGYGTDFVF (SEQ 1134) LSED TIENTLSEDVA ID NO: VADY DYYCLQSDN 788) YC MPYTFGGGTK (SEQ LEIK (SEQ ID ID NO: NO: 789) 1406) AHH DIQMTQTPLT DIQM QSLLD LNWLL LVS KLDS WQGT CWQG VRRGDQ FGGG 03777 LSVTIGQPASI TQTPL SDGKT QRPGQ (SEQ ID GVPD FSSH TFSSH AGNE TKLE SCKSSQSLLDS TLSVT Y (SEQ SPKRLI NO: RFTGS (SEQ V (SEQ ID MK DGKTYLNWL IGQPA ID NO: Y (SEQ 1116) GSGT ID NO: (SEQ NO: 1441) (SEQ LQRPGQSPKR SISCK 1301) ID NO: DFTL 1462) ID NO: ID NO: LIYLVSKLDSG SS 1083) KISRV 686) 961) VPDRFTGSGS (SEQ EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYYC 748) YC WQGTFSSHVR (SEQ RGDQAGNE ID NO: (SEQ ID NO: 1056) 752) AHH DIVMSQSHKF DIVM QDVIT VAWY SAS YRYT QQHY CQQH TFGGGT FGGG 03778 MSTSVGDRVS SQSH A (SEQ QQKPG (SEQ ID GVPD STPRT YSTPR KLEIK TKLEI ITCKASQDVIT KFMS ID NO: QSPKL NO: 13) RFTGS (SEQ TF (SEQ ID K AVAWYQQKP TSVG 1205) PIY GSGT ID NO: (SEQ NO: 1393) (SEQ GQSPKLPIYSA DRVSI (SEQ ID dftft 1263) ID NO: ID NO: SYRYTGVPDR TCKA NO: ISSVQ 655) 959) FTGSGSGTDFT S (SEQ 1428) AEDL FTISSVQAEDL ID NO: AVYY AVYYCQQHY 779) C STPRTFGGGT (SEQ KLEIK (SEQ ID ID NO: NO: 781) 1491) AHH DIVMTQSPSPL DIVM QEISG LSWLQ AAS TLDS LQYAS CLQY TFGGGT FGGG 03779 SASLGERVSLT TQSPS Y (SEQ QKPDG (SEQ ID GVPK YPRT ASYP KLEIK TKLEI CRASQEISGYL PLSAS ID NO: TIKRLI NO: RFSGS (SEQ RTF (SEQ ID K SWLQQKPDGT LGER 1210) Y (SEQ 599) RSGS ID NO: (SEQ NO: 1393) (SEQ IKRLIYAASTL VSLT ID NO: DYSL 1102) ID NO: ID NO: DSGVPKRFSG CRAS 1111) TISSL 638) 959) SRSGSDYSLTI (SEQ ESEDF SSLESEDFADY ID NO: ADYY YCLQYASYPR 817) C TFGGGTKLEIK (SEQ (SEQ ID NO: ID NO: 818) 1402) AHH DTTVTQSPAS DTTV ESVDS MHWY RAS NLES QQSNE CQQS TFGGGT FGGG 03780 LAVSLGQRAT TQSP YGNSF QQKPG (SEQ ID GIPAR DPRT NEDP KLEMK TKLE ISCRASESVDS ASLA (SEQ ID QPPKL NO: FSGSG (SEQ RTF (SEQ ID MK YGNSFMHWY VSLG NO: LIY 1346) SRTGF ID NO: (SEQ NO: 1394) (SEQ QQKPGQPPKL QRATI 935) (SEQ ID TLTIN 1269) ID NO: ID NO: LIYRASNLESG SCRA PVEA 661) 961) IPARFSGSGSR S (SEQ NO: DDVA TGFTLTINPVE ID NO: 1129) TYYC ADDVATYYC 850) (SEQ QQSNEDPRTF ID NO: GGGTKLEMK 1149) (SEQ ID NO: 851) AHH DILMTQSPATL DILM QSISD LHWY YAS QSISG QNGH CQNG TFGGGT FGGG 03781 SVTPGDRVSL TQSP Y (SEQ QQKSH (SEQ ID IPSRF SFPRT HSFPR KLEIK TKLEI SCRASQSISDY ATLS ID NO: ESPRL NO: SGSGS (SEQ TF (SEQ ID K LHWYQQKSH VTPG 1296) LIK 1476) GSDF ID NO: (SEQ NO: 1393) (SEQ ESPRLLIKYAS DRVS (SEQ ID TLSIN 1242) ID NO: ID NO: QSISGIPSRFSG LSCR NO: SVEPE 645) 959) SGSGSDFTLSI AS 1079) DVGV NSVEPEDVGV (SEQ YYC YYCQNGHSFP ID NO: (SEQ RTFGGGTKLEI 706) ID NO: K (SEQ ID NO: 1297) 707) AHH DVVMTQTPLS DVVM QSLVH LHWY KVS NRFS SQSTH CSQST WTFGGG FGGG 03782 LPVSLGDQASI TQTPL SNGNT LQKPG (SEQ ID GVPD VPWT HVPW TKLEIK TKLEI SCRSSQSLVHS SLPVS Y (SEQ QSPKL NO: RFSGS (SEQ TF (SEQ ID K NGNTYLHWY LGDQ ID NO: LIY 1062) GSGT ID NO: (SEQ NO: 1467) (SEQ LQKPGQSPKL ASISC 1306) (SEQ ID DFTL 1374) ID NO: ID NO: LIYKVSNRFSG RSS NO: KISRV 682) 959) VPDRFSGSGS (SEQ 1076) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 900) FC SQSTHVPWTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1157) 901) AHH DTTVTQSPAS DTTV QSVDY MNWY AAS NLES QQSNE CQQS YTFGGG FGGG 03783 LAVSLGQRAT TQSP DGDSY QQKPG (SEQ ID GIPAR DPYT NEDP TKLEIK TKLEI ISCKASQSVD ASLA (SEQ ID QPPKL NO: FSGSG (SEQ YTF (SEQ ID K YDGDSYMNW VSLG NO: LIY 599) SGTD ID NO: (SEQ NO: 1493) (SEQ YQQKPGQPPK QRATI 1308) (SEQ ID FTLNI 1270) ID NO: ID NO: LLIYAASNLES SCKA NO: HPVE 662) 959) GIPARFSGSGS S (SEQ 1135) EEDA GTDFTLNIHPV ID NO: ATYY EEEDAATYYC 847) C QQSNEDPYTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1148) 849) AHH DTTVTQSPSSL DTTV QSLLN LAWY FAS TRES QQHY CQQH YTFGGG FGGG 03784 AMSVGQKVT TQSPS SSNQK QQKPG (SEQ ID GVPD STPYT YSTP TKLEIK TKLEI MSCKSSQSLL SLAM NY QSPKL NO: RFIGS (SEQ YTF (SEQ ID K NSSNQKNYLA SVGQ (SEQ ID LVY 957) GSGT ID NO: (SEQ NO: 1493) (SEQ WYQQKPGQSP KVTM NO: (SEQ ID DFTLT 1265) ID NO: ID NO: KLLVYFASTR SCKSS 1302) NO: ISSVQ 657) 959) ESGVPDRFIGS (SEQ 1067) AEDL GSGTDFTLTIS ID NO: ADYF SVQAEDLADY 852) C FCQQHYSTPY (SEQ TFGGGTKLEIK ID NO: (SEQ ID NO: 1410) 853) AHH DIQMTQTHKF DIQM QDVST VAWY SAS YRYT QQHY CQQH VHVRRG FGGG 03785 MSTSVGDRVS TQTH A (SEQ QQKPG (SEQ ID GVPD STHVH YSTH DQAGNQ TKLEI ITCKASQDVST KFMS ID NO: QSPKL NO: 13) RFTGS (SEQ VHV (SEQ ID K AVAWYQQKP TSVG 1209) LIY GSGT ID NO: (SEQ NO: 1434) (SEQ GQSPKLLIYSA DRVSI (SEQ ID dftft 1259) ID NO: ID NO: SYRYTGVPDR TCKA NO: ISSVQ 652) 959) FTGSGSGTDFT S (SEQ 1427) AEDL FTISSVQAEDL ID NO: AVYY AVYYCQQHY 741) C STHVHVRRGD (SEQ QAGNQ (SEQ ID NO: ID NO: 742) 1491) AHH DVVVTQTPLS DVW QSLVH LHWY KVS NRFS SQSTH CSQST WTFGGG FGGG 03786 LPVSLGDQASI TQTPL SNGNT LQKPG (SEQ ID GVPD VPWT HVPW TKLEIK TKLEI SCRSSQSLVHS SLPVS Y (SEQ QSPKL NO: RFSGS (SEQ TF (SEQ ID K NGNTYLHWY LGDQ ID NO: LIY 1062) GSGT ID NO: (SEQ NO: 1467) (SEQ LQKPGQSPKL ASISC 1306) (SEQ ID DFTL 1374) ID NO: ID NO: LIYKVSNRFSG RSS NO: KISRV 682) 959) VPDRFSGSGS (SEQ 1076) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 918) FC SQSTHVPWTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1157) 922) AHH DILMTQSPAIM DILM SSVIY MHWY DTS KLAS QQWT CQQW FGGGTK FGGG 03787 SASPGEKVTM TQSP (SEQ ID QQKSG (SEQ ID GVPA SNPPT TSNPP LEIK TKLEI TCSASSSVIYM AIMS NO: TSPKR NO: RFSGS (SEQ TF (SEQ ID K HWYQQKSGT ASPG 1383) WIY 839) GSGT ID NO: (SEQ NO: 959) (SEQ SPKRWIYDTS EKVT (SEQ ID SYSLS 1279) ID NO: ID NO: KLASGVPARF MTCS NO: ISSME 668) 959) SGSGSGTSYSL AS 1131) TEDA SISSMETEDAA (SEQ ATYY TYYCQQWTS ID NO: C NPPTFGGGTK 702) (SEQ LEIK (SEQ ID ID NO: NO: 703) 1051) AHH DIVLTQSQKF DIVLT QNVGT VAWY SAS YRYS SQSTH CSQST YTFGGG FGGG 03788 MSTSVGDRVS QSQK N (SEQ QQKPG (SEQ ID GVPD VPYT HVPY TKLEIK TKLEI VTCKASQNVG FMST ID NO: QSPKA NO: 13) RFTGS (SEQ TF (SEQ ID K TNVAWYQQK SVGD 12) LIY GSGT ID NO: (SEQ NO: 1493) (SEQ PGQSPKALIYS RVSV (SEQ ID DFTL 1375) ID NO: ID NO: ASYRYSGVPD TCKA NO: KISRV 683) 959) RFTGSGSGTD S (SEQ 1425) EAED FTLKISRVEAE ID NO: LGVY DLGVYFCSQS 773) FC THVPYTFGGG (SEQ TKLEIK (SEQ ID NO: ID NO: 776) 1479) AHH DVVMTQTPLS DVVM QSLVH LHWY KVS NRFS SQSTH CSQST WTFGGG FGGG 03789 LPVSLGDQASI TQTPL SNGNT LQKPG (SEQ ID GVPD VPWT HVPW TKLEIK TKLEI SCRSSQSLVHS SLPVS Y (SEQ QSPKL NO: RFSGS (SEQ TF (SEQ ID K NGNTYLHWY LGDQ ID NO: LIY 1062) GSGT ID NO: (SEQ NO: 1467) (SEQ LQKPGQSPKL ASISC 1306) (SEQ ID DFTL 1374) ID NO: ID NO: LIYKVSNRFSG RSS NO: KISRV 682) 959) VPDRFSGSGS (SEQ 1076) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 900) FC SQSTHVPWTF (SEQ GGGTKLEIK ID NO: (SEQ ID NO: 1157) 901) AHH DIVMSQSPAIL DIVM SRVTY MHWY DTS TLTSG HQRS CHQR YTFGGG FGGG 03790 SASPGEKVTM SQSPA (SEQ ID QQKPG (SEQ ID VP AR GYSYT SGYS TKLEMK TKLE TCSASSRVTY ILSAS NO: TSPKR NO: FSGSG (SEQ YTF (SEQ ID MK MHWYQQKPG PGEK 1380) WIY 839) SGTS ID NO: (SEQ NO: 1494) (SEQ TSPKRWIYDT VTMT (SEQ ID YSLTI 1000) ID NO: ID NO: STLTSGVPARF CSAS NO: SGME 627) 961) SGSGSGTSYSL (SEQ 1130) AEDA TISGMEAEDA ID NO: ATYY ATYYCHQRSG 782) C YSYTFGGGTK (SEQ LEMK (SEQ ID ID NO: NO: 783) 1407) AHH DIVMSQSQKF DIVM QNVGT VAWY SAS YRYS QQYN CQQY TFGGGT FGGG 03791 MSTSVGDRVS SQSQ N (SEQ QQKPG (SEQ ID GVPD SYPRT NSYP KLEIK TKLEI VTCKASQNVG KFMS ID NO: QSPKA NO: 13) RFTGS (SEQ RTF (SEQ ID K TNVAWYQQK TSVG 12) LIY GSGT ID NO: (SEQ NO: 1393) (SEQ PGQSPKALIYS DRVS (SEQ ID DFTLT 1286) ID NO: ID NO: ASYRYSGVPD VTCK NO: ISNVQ 670) 959) RFTGSGSGTD AS 1425) SEDL FTLTISNVQSE (SEQ AEYF DLAEYFCQQY ID NO: C NSYPRTFGGG 793) (SEQ TKLEIK (SEQ ID NO: ID NO: 794) 1483) AHH DIVMTQAAPS DIVM KSLLH LYWFL RMS NLAS MQHL CMQH TFGGGT FGGG 03792 VPVTPGESVSI TQAA SNGNT QRPGQ (SEQ ID GVPD EYPYT LEYP KLEIK TKLEI SCRSSKSLLHS PSVPV Y (SEQ SPQLLI NO: RFSGS (SEQ YTF (SEQ ID K NGNTYLYWFL TPGES ID NO: Y (SEQ 1360) GSGT ID NO: (SEQ NO: 1393) (SEQ QRPGQSPQLLI VSISC 1060) ID NO: AFTL 1136) ID NO: ID NO: YRMSNLASGV RSS 1121) RISRV 641) 959) PDRFSGSGSGT (SEQ EAED AFTLRISRVEA ID NO: VGVY EDVGVYYCM 796) YC QHLEYPYTFG (SEQ GGTKLEIK ID NO: (SEQ ID NO: 1145) 797) AHH DIVMTQSTSSL DIVM QDISN LNWY YTS RLHS QQGN CQQG WTFGGG FGGG 03794 SASLGDRVTIS TQSTS Y (SEQ QQKPD (SEQ ID GVPS TLPWT NTLP TKLEIK TKLEI CRASQDISNY SLSAS ID NO: GTVKL NO: RFSGS (SEQ WTF (SEQ ID K LNWYQQKPD LGDR 27) LIY 1495) GSGT ID NO: (SEQ NO: 1467) (SEQ GTVKLLIYYTS VTISC (SEQ ID DYSL 1255) ID NO: ID NO: RLHSGVPSRFS RAS NO: TISNL 649) 959) GSGSGTDYSL (SEQ 1088) EQEDI TISNLEQEDIA ID NO: ATYF TYFCQQGNTL 828) C PWTFGGGTKL (SEQ EIK (SEQ ID ID NO: NO: 829) 1353) AHH DIVMTQDELS DIVM KSLLY LNCFL LMS TRAS HQLV CHQL YTFGGG FGGG 03796 NPVTSGESVSI TQDE KDGKT QRPGQ (SEQ ID GVSN EYPYT VEYP TKLEMK TKLE SCRSSKSLLYK LSNP Y (SEQ SPQLLI NO: RFSGS (SEQ YTF (SEQ ID MK DGKTYLNCFL VTSG ID NO: Y (SEQ 1081) GSGT ID NO: (SEQ NO: 1494) (SEQ QRPGQSPQLLI ESVSI 1061) ID NO: DFTLE 998) ID NO: ID NO: YLMSTRASGV SCRSS 1082) ISRVK 625) 961) SNRFSGSGSGT (SEQ AEDV DFTLEISRVKA ID NO: GVYY EDVGVYYCH 798) C QLVEYPYTFG (SEQ GGTKLEMK ID NO: (SEQ ID NO: 1409) 799) AHH DVVVTQTPLS DVW QSLEN LNWY RVS NRFS LQVT CLQV FAFGSGT FGSG 03797 LPVSLGDQASI TQTPL SNGNT LQKPG (SEQ ID GVLD HVPFA THVP KLEIK TKLEI SCRSSQSLENS SLPVS Y (SEQ QSPQL NO: RFSGS (SEQ FAF (SEQ ID K NGNTYLNWY LGDQ ID NO: LIY 1361) GSGT ID NO: (SEQ NO: 956) (SEQ LQKPGQSPQL ASISC 1300) (SEQ ID DFTL 1096) ID NO: ID NO: LIYRVSNRFSG RSS NO: KISRV 633) 965) VLDRFSGSGS (SEQ 1087) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 918) FC LQVTHVPFAF (SEQ GSGTKLEIK ID NO: (SEQ ID NO: 1153) 919) AHH DVVMTQTPLS DVVM QSLVH LHWY KVS NRFS SQSTH CSQST LTFGAG FGAG 03798 LPVSLGDQASI TQTPL SNGNT LQKPG (SEQ ID GVPD VPLT HVPL TKLEIK TKLEI SCRSSQSLVHS SLPVS Y (SEQ QSPKL NO: RFSGS (SEQ TF (SEQ ID K NGNTYLHWY LGDQ ID NO: LIY 1062) GSGT ID NO: (SEQ NO: 1114) (SEQ LQKPGQSPKL ASISC 1306) (SEQ ID DFTL 1370) ID NO: ID NO: LIYKVSNRFSG RSS NO: KISRV 679) 958) VPDRFSGSGS (SEQ 1076) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 900) FC SQSTHVPLTFG (SEQ AGTKLEIK ID NO: (SEQ ID NO: 1157) 902) AHH DVVLTQTPLS DVVL QSLVH LHWY KVS NRFS SQSTH CSQST TFGGGT FGGG 03799 LPVSLGDQASI TQTPL SYGNT LQKPG (SEQ ID GVPD VPHT HVPH KLEMK TKLE SCRSSQSLVHS SLPVS Y (SEQ QSPKL NO: RFSGS (SEQ TF (SEQ ID MK YGNTYLHWY LGDQ ID NO: LIY 1062) GSGT ID NO: (SEQ NO: 1394) (SEQ LQKPGQSPKL ASISC 1307) (SEQ ID DFTL 1369) ID NO: ID NO: LIYKVSNRFSG RSS NO: KISRV 678) 961) VPDRFSGSGS (SEQ 1076) EAED GTDFTLKISRV ID NO: LGVY EAEDLGVYFC 874) FC SQSTHVPHTF (SEQ GGGTKLEMK ID NO: (SEQ ID NO: 1157) 880) AHH DIQMTQTPSSL DIQM QDIGS LNWL ATS SLDS LQYA CLQY YTFGGG FGGG 03800 SASLGERVSLT TQTPS S (SEQ QQEPD (SEQ ID GVPK TFPYT ATFP TKLEIK TKLEI CRASQDIGSSL SLSAS ID NO: GTIKR NO: RFSGS (SEQ YTF (SEQ ID K NWLQQEPDGT LGER 1199) LIS 618) RSGS ID NO: (SEQ NO: 1493) (SEQ IKRLISATSSL VSLT (SEQ ID DYSL 1104) ID NO: ID NO: DSGVPKRFSG CRAS NO: TISSL 639) 959) SRSGSDYSLTI (SEQ 1084) ESEDF SSLESEDFVDY ID NO: VDYY YCLQYATFPY 753) C TFGGGTKLEIK (SEQ (SEQ ID NO: ID NO: 754) 1366)

TABLE 3C Exemplary Clones-Light Chain Sequences JUNC- ID V-J-REGION L-FR1 CDRL1 L-FR2 CDRL2 L-FR3 CDRL3 TION >AH04501- DVVMTQTQKFTSTSVG DVVMT KASQN WYQQ SASYR VPDRF QQYN FGGGT VL DRVSVTCKASQNVGTN QTQKFT VGTNV KPGQS YSG TGSGS SYPYT KLEIK VAWYQQKPGQSPKALI STSVGD A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ YSASYRYSGVPDRFTGS RVSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GSGTDFTLTISNVQSEDL (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) AEYFCQQYNSYPYTFGG NO: 910) 1471) LAEYF GTKLEIK (SEQ ID NO: C (SEQ 912) ID NO: 1439) >AH04502- DIVMTQSQKFMSTSVGD DIVMTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGINVA SQKFMS VGINV KPGQS YSG TGSGS SYPYT KLEIK WYQQKPGQSPKALIYSA TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ SYRYSGVPDRFTGSGSG VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: TDFTLTISNVQSEDLAEY (SEQ ID 1037) ID NO: 1362) VQSED 15) 959) FCQQYNSYPYTFGGGTK NO: 819) 1471) LAEYF LEIK (SEQ ID NO: 822) C (SEQ ID NO: 1439) >AH04503- DIQMTQSQKFMSTSVGD DIQMTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPW KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT T (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 36) 959) YFCQQYNSYPWTFGGG NO: 733) 1471) LAEYF TKLEIK (SEQ ID NO: 34) C (SEQ ID NO: 1439) >AH04504- DTTVTQSQKFMSTSVGD DTTVTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 855) 1471) LAEYF KLEIK (SEQ ID NO: 859) C (SEQ ID NO: 1439) >AH04505- DTTVTQSQKFMSTSVGD DTTVTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEM AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ K (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 961) YFCQQYNSYPYTFGGGT NO: 855) 1471) LAEYF KLEMK (SEQ ID NO: 860) C (SEQ ID NO: 1439) >AH04506- DIQMTQSQKFMSTSVGD DIQMTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPW KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT T (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 36) 959) YFCQQYNSYPWTFGGG NO: 733) 1471) LAEYF TKLEIK (SEQ ID NO: 34) C (SEQ ID NO: 1439) >AH04507- DTTVTQSQKFMSTSVGD DTTVTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 855) 1471) LAEYF KLEIK (SEQ ID NO: 859) C (SEQ ID NO: 1439) >AH04508- DIVLTQSQKFMSTSVGD DIVLTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG AGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFAGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 772) 1471) LAEYF KLEIK (SEQ ID NO: 775) C (SEQ ID NO: 1437) >AH04509- DTTVTQSQRFMSTSVGD DTTVTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQRFMS VGTNV KPGQS YSG TGSGS NSPLT KLEIK AWYQQKPGQSPKPLIYS TSVGDR A (SEQ PKPLI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTINN ID NO: ID NO: GTDFTLTINNVQSEDLA (SEQ ID 1038) ID NO: 1362) VQSED 1282) 959) EYFCQQYNNSPLTFGGG NO: 862) 1473) LAEYF TKLEIK (SEQ ID NO: 864) C (SEQ ID NO: 1438) >AH04510- DIVMTQSQKFMSTSVGD DIVMTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 819) 1471) LAEYF KLEIK (SEQ ID NO: 823) C (SEQ ID NO: 1439) >AH04511- DIVMSQSQKFMSTSVGD DIVMSQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 792) 1471) LAEYF KLEIK (SEQ ID NO: 795) C (SEQ ID NO: 1439) >AH04512- DIQMTQSQKFMSTSVGD DIQMTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEM AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ K (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 961) YFCQQYNSYPYTFGGGT NO: 733) 1471) LAEYF KLEMK (SEQ ID NO: 735) C (SEQ ID NO: 1439) >AH04513- DILMTQSQKFMSTSVGD DILMTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 710) 1471) LAEYF KLEIK (SEQ ID NO: 712) C (SEQ ID NO: 1439) >AH04514- DIQMTQSQKFMSTSVGD DIQMTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 733) 1471) LAEYF KLEIK (SEQ ID NO: 736) C (SEQ ID NO: 1439) >AH04515- DIVLTQSQKFMSTSVGD DIVLTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEM AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ K (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 961) YFCQQYNSYPYTFGGGT NO: 772) 1471) LAEYF KLEMK (SEQ ID NO: 777) C (SEQ ID NO: 1439) >AH04516- DTTVTQSQKFMSTSVGD DTTVTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPW KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT T (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 36) 959) YFCQQYNSYPWTFGGG NO: 855) 1471) LAEYF TKLEIK (SEQ ID NO: 861) C (SEQ ID NO: 1439) >AH04517- DIQMTQSQKFMSTSVGD DIQMTQ KASQS WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQSVGTNVA SQKFMS VGTNV KPGQS YSG TGSGS NYPW KLEIK WYQQKPGQSPKALIYSA TSVGDR A (SEQ PKALI (SEQ GTDFT T (SEQ (SEQ SYRYSGVPDRFTGSGSG VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: TDFTLTISNVQSEDLAEY (SEQ ID 1040) ID NO: 1362) VQSED 1284) 959) FCQQYNNYPWTFGGGT NO: 733) 1471) LAEYF KLEIK (SEQ ID NO: 737) C (SEQ ID NO: 1439) >AH04518- DILLTQSQKFMSTSVGD DILLTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 699) 1471) LAEYF KLEIK (SEQ ID NO: 701) C (SEQ ID NO: 1439) >AH04520- DIQMTQSQKFMSTSVGD DIQMTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEM AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ K (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 961) YFCQQYNSYPYTFGGGT NO: 733) 1471) LAEYF KLEMK (SEQ ID NO: 735) C (SEQ ID NO: 1439) >AH04521- DTTVTQSQKFMSTSVGD DTTVTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 855) 1471) LAEYF KLEIK (SEQ ID NO: 859) C (SEQ ID NO: 1439) >AH04522- DTTVTQSQKFMSTSVGD DTTVTQ KAGQ WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKAGQNVGTNV SQKFMS NVGTN KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR VA PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC (SEQ ID Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID NO: ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 855) 1036) 1471) LAEYF KLEIK (SEQ ID NO: 857) C (SEQ ID NO: 1439) >AH04523- DIVLTQSQKFMSTSVGD DIVLTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 772) 1471) LAEYF KLEIK (SEQ ID NO: 778) C (SEQ ID NO: 1439) >AH04524- DIVMTQSQKFMSTSVGD DIVMTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 819) 1471) LAEYF KLEIK (SEQ ID NO: 825) C (SEQ ID NO: 1439) >AH04525- DNVLTQSQKFMSTSVGD DNVLT KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV QSQKF VGTNV KPGQS YSG TGSGS SYPYT KLEM AWYQQKPGQSPKALIYS MSTSV A (SEQ PKALI (SEQ GTDFT (SEQ K (SEQ ASYRYSGVPDRFTGSGS GDRVS ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE VTC 1038) ID NO: 1362) VQSED 15) 961) YFCQQYNSYPYTFGGGT (SEQ ID 1471) LAEYF KLEMK (SEQ ID NO: 838) NO: 836) C (SEQ ID NO: 1439) >AH04526- DTTVTQSQKFMSTSVGD DTTVTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEM AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ K (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 961) YFCQQYNSYPYTFGGGT NO: 855) 1471) LAEYF KLEMK (SEQ ID NO: 860) C (SEQ ID NO: 1439) >AH04527- DVVMTQSQKFMSTSVG DVVMT KASQN WYQQ SASYR VPDRF QQYN FGGGT VL DRVSVTCKASQNVGTN QSQKF VGTNV KPGQS YSG TGSGS SYPYT KLEIK VAWYQQKPGQSPKALI MSTSV A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ YSASYRYSGVPDRFTGS GDRVS ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GSGTDFTLTISNVQSEDL VTC 1038) ID NO: 1362) VQSED 15) 959) AEYFCQQYNSYPYTFGG (SEQ ID 1471) LAEYF GTKLEIK (SEQ ID NO: NO: 893) C (SEQ 895) ID NO: 1439) >AH04528- DIQMTQSQKFMSTSVGD DIQMTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 733) 1471) LAEYF KLEIK (SEQ ID NO: 736) C (SEQ ID NO: 1439) >AH04529- DTTVTQSQKFMSTSVGD DTTVTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPYT KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 15) 959) YFCQQYNSYPYTFGGGT NO: 855) 1471) LAEYF KLEIK (SEQ ID NO: 859) C (SEQ ID NO: 1439) >AH04530- DTTVTQSQKFMSTSVGD DTTVTQ KASQN WYQQ SASYR VPDRF QQYN FGGGT VL RVSVTCKASQNVGTNV SQKFMS VGTNV KPGQS YSG TGSGS SYPW KLEIK AWYQQKPGQSPKALIYS TSVGDR A (SEQ PKALI (SEQ GTDFT T (SEQ (SEQ ASYRYSGVPDRFTGSGS VSVTC ID NO: Y (SEQ ID NO: LTISN ID NO: ID NO: GTDFTLTISNVQSEDLAE (SEQ ID 1038) ID NO: 1362) VQSED 36) 959) YFCQQYNSYPWTFGGG NO: 855) 1471) LAEYF TKLEIK (SEQ ID NO: 861) C (SEQ ID NO: 1439)

TABLE 4A Exemplary Clones-Heavy Chain Sequences ID HFR1 CDRH1 HFR2 CDRH2 HFR3 CDRH3 HFR4 BL_592989- QVQLQQSGAELVRP GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2015_G2_P8_G02 GTSLKMSCKAA NYW QRPGH GYT KATLTADTS AY GTPV (SEQ ID NO: 1324) (SEQ ID GLEWI (SEQ ID SSTTYMQLS (SEQ ID TVSS NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1181) NO: 1010) 398) BL_592989- PGPTQQPGSELVRPG GYTFT MHWV IYPGSG NYDEKFKSK TRSGV VWG 2016_H2_P8_H02 ASVKLSCKAS (SEQ SYW KQRHG ST (SEQ GTLTVDTSS EGLLH AGTT ID NO: 1191) (SEQ ID QGLEW ID NO: STAYMHLSS WYFD VTVS NO: IGN 251) LASEDSAVY (SEQ ID S 157) (SEQ ID YC (SEQ ID NO: (SEQ NO: NO: 1166) 1416) ID 1123) NO: 1448) BL_592989- QVQLQQSGSELVRP GYTFT MHWV IYPGSG NYDEKFKSK TRWIT WGR 2017_A3_P8_A03 GASVKLSCKAS (SEQ SYW KQRHG ST (SEQ GTLTVDTSS TDHYF GTTL ID NO: 1342) (SEQ ID QGLEW ID NO: STAYMHLSS DY TVSS NO: IGN 251) LTSEDSAVY (SEQ ID (SEQ 157) (SEQ ID CC (SEQ ID NO: ID NO: NO: 1167) 1417) NO: 1123) 1455) BL_592989- QIQLQQPGAELVRPG GYTFT LGWV IYPGG NYNEKFKG ARVSP WGQ 2018_B3_P8_B03 TSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTL ID NO: 1220) (SEQ ID HGLEW (SEQ ID SSTAYMQLN (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: (SEQ (SEQ ID YFC (SEQ ID 615) ID NO: NO: 1176) NO: 1075) 425) BL_592989- QVQLQQPGAELVRP GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ 2019_C3_P8_C03 GTSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTL ID NO: 1314) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 425) BL_592989- QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2021_E3_P8_E03 TSVKMSCKAA (SEQ NYW QRPGH GYT KATLTADTS AY GTPV ID NO: 1228) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1177) NO: 1010) 398) BL_592989- QVQLQQSGAELVRP GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2022_F3_P8_F03 GTSVKMSCKAA NYW QRPGH GYT KATLTADTS AY GTLV (SEQ ID NO: 1326) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSA NO: 4) GD NO: SLTSEGSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1179) NO: 1010) 421) BL_592989- PGPTQQPGSELVRPG GYTFT MHWV IYPGSG NYDEKFKSK TRSGV VWG 2023_G3_P8_G03 ASVKLSCKAS (SEQ SYW KQRHG ST (SEQ GTLTVDTSS EGLLH AGTT ID NO: 1191) (SEQ ID QGLEW ID NO: STAYMHLSS WYFD VTVS NO: IGN 251) LASEDSAVY (SEQ ID S 157) (SEQ ID YC (SEQ ID NO: (SEQ NO: NO: 1166) 1416) ID 1123) NO: 1448) BL_592989- QVQLQQSGAEVAKP GYTST MHWV INPSTG EYNQKFEDK ARGGY WGQ 2024_H3_P8_H03 GASVKMSCKAS GYW KQRPG YT ATLTADKSS FDY GTSL (SEQ ID NO: 1340) (SEQ ID QGLEW (SEQ ID NTAYMQLSS (SEQ ID TVSS NO: IGY NO: LTSEDSAVY NO: (SEQ 995) (SEQ ID 230) YC (SEQ ID 606) ID NO: NO: 954) NO: 190) 424) BL_592989- QVQLQQSGAELVRP GYTFT LGWIK IYPGG NYNEKFKG ARVTP WGQ 2025_A4_P8_A04 GTSVKISCKAS (SEQ NYW QRPGH GYT KATLTADTS AS GTSL ID NO: 1325) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) GD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1074) 424) BL_592989- QAYLQQSGAELVRP GYTFT MHWV ISTYSG SYNQKFKG ARGVT WGQ 2026_B4_P8_B04 GVSVKISCKGS (SEQ DYA KQSHA DV KATMTVDK FDS GTTL ID NO: 1196) (SEQ ID KSLEW (SEQ ID SSSTAYMEL (SEQ ID TVSS NO: 19) IGV NO: 46) ARLTPEDSAI NO: 48) (SEQ (SEQ ID YYC (SEQ ID ID NO: NO: 1388) NO: 1126) 425) BL_592989- QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ 2027_C4_P8_C04 GTSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTV ID NO: 1325) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 422) BL_592989- QVQLQQSGAELVRP GYTFT IGWIK IHPGG NYNEKFKG TGRNF WGQ 2029_E4_P8_E04 GTSVKMSCKAA NYW QRPGH DYT KATLTADTF AY GTLV (SEQ ID NO: 1326) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1013) YC (SEQ ID 1395) ID NO: NO: 1171) NO: 1007) 413) BL_592989- QVQLQQPGAELVRP GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2030_F4_P8_F04 GTSVKMSCKAA NYW QRPGH GYT KATLTADTS AY GTLV (SEQ ID NO: 1315) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1177) NO: 1010) 421) BL_592989- QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2031_G4_P8_G04 TSLKMSCKAA (SEQ NYW QRPGH GYT KATLTADTS AY GTLV ID NO: 1226) (SEQ ID GLEWI (SEQ ID SSTTYMQLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1181) NO: 1010) 421) BL_592989- QVQLQQSGAELVRP GYTFS IGWVK IHPGG NYNEKFTGK VSRNF WGQ 2032_H4_P8_H04 GTSVKMSCKAA NYW QRPGH GYI ATLTADTSS AN GTLV (SEQ ID NO: 1326) (SEQ ID GLEWI (SEQ ID STAYMQLSS (SEQ ID TVSA NO: GD NO: LTSEDSAIY NO: (SEQ 986) (SEQ ID 1014) YC (SEQ ID 1445) ID NO: NO: 1184) NO: 1010) 421) BL_592989- QVQLQQSGAELVRP GYTFT MHWV ISTYSG SYNQKFKG ARGVT WGQ 2033_A5_P8_A05 GVSVKISCKGS (SEQ DYA KQSHA DV KATMTVDK FDS GTTL ID NO: 1338) (SEQ ID KSLEW (SEQ ID SSSTAYMEL (SEQ ID TVSS NO: 19) IGV NO: 46) ARLTSEDSAI NO: 48) (SEQ (SEQ ID YYC (SEQ ID ID NO: NO: 1389) NO: 1126) 425) BL_592989- QVQLQQSGAELVRP GYTFT LGWIK IYPGG NYNEKFKG ARVTP WGQ 2034_B5_P8_B05 GTSVKISCKAS (SEQ NYW QRPGH GYT KATLTADTS AS GTSL ID NO: 1325) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) GD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1074) 424) BL_592989- QVQLQQPGAELVRP GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ 2035_C5_P8_C05 GTSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTSL ID NO: 1314) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 424) BL_592989- QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2037_E5_P8_E05 TSVKMSCKAA (SEQ NYW QRPGH DYS KATLTADTS AY GTLV ID NO: 1228) (SEQ ID GLEWI (SEQ ID SSTAYMNLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1012) YC (SEQ ID 1419) ID NO: NO: 1174) NO: 1010) 421) BL_592989- QVQLQQPGAELVRP GYTFT IGWVK IHPGG NYNEKFTGK VSRNF WGQ 2038_F5_P8_F05 GTSVKMSCKAA NYW QRPGH GYI ATLTADTSS AN GTLV (SEQ ID NO: 1315) (SEQ ID GLEWI (SEQ ID STAYMQLSS (SEQ ID TVSA NO: 4) GD NO: LTSEDSAIY NO: (SEQ (SEQ ID 1014) YC (SEQ ID 1445) ID NO: NO: 1184) NO: 1010) 421) BL_592989- QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2039_G5_P8_G05 TSVKMSCKAA (SEQ NYW QRPGH GYT KATLTADTS AY GTLV ID NO: 1228) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1177) NO: 1010) 421) BL_592989- QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2040_H5_P8_H05 TSVKMSCKAA (SEQ NYW QRPGH GYT KATLTADTS AY GTLV ID NO: 1228) (SEQ ID GLEWV (SEQ ID SSTAYMQLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1177) NO: 1011) 421) BL_592989- QVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFKGK ARGVT WGQ 2041_A6_P8_A06 GVSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTV ID NO: 1337) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1033) NO: 1128) 422) BL_592989- QIQLQQSGAEMVRP GYTFT MHWV ISTYSG SYNQKFKG ARGVT WGQ 2042_B6_P8_B06 GVSVKISCKGS (SEQ DYA RQSHA DV KATMTVDK FDS GTTL ID NO: 1241) (SEQ ID KSLEW (SEQ ID SSSTAYMEL (SEQ ID TVSS NO: 19) IGV NO: 46) ARLTSEDSAI NO: 48) (SEQ (SEQ ID YYC (SEQ ID ID NO: NO: 1389) NO: 1128) 425) BL_592989- QIQLQQSGAEMVRP GYTFT MHWV ISTYSG SYNQKFKG ARGVT WGQ 2043_C6_P8_C06 GVSVKISCKGS (SEQ DYA RQSHA DV KATMTVDK FDS GTTL ID NO: 1241) (SEQ ID KSLEW (SEQ ID SSSTAYMEL (SEQ ID TVSS NO: 19) IGV NO: 46) ARLTSEDSAI NO: 48) (SEQ (SEQ ID YYC (SEQ ID ID NO: NO: 1389) NO: 1128) 425) BL_592989- QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ 2044_D6_P8_D06 GTSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTL ID NO: 1325) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 425) BL_592989- QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2045_E6_P8_E06 TSVKMSCKAA (SEQ NYW QRPGH DYS KATLTADTS AY GTLV ID NO: 1228) (SEQ ID GLEWI (SEQ ID SSTAYMNLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1012) YC (SEQ ID 1419) ID NO: NO: 1174) NO: 1010) 421) BL_592989- QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2046_F6_P8_F06 TSVKMSCKAA (SEQ NYW QRPGH DYS KATLTADTS AY GTLV ID NO: 1228) (SEQ ID GLEWI (SEQ ID SSTAYMNLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1012) YC (SEQ ID 1419) ID NO: NO: 1174) NO: 1010) 421) BL_592989- QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2047_G6_P8_G06 TSVKMSCKAA (SEQ NYW QRPGH GYT KATLTADTS AY GTLV ID NO: 1228) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1177) NO: 1010) 421) BL_592989- QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2048_H6_P8_H06 TSVKMSCKAA (SEQ NYW QRPGH DYS KATLTADTS AY GTLV ID NO: 1228) (SEQ ID GLEWI (SEQ ID SSTAYMNLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1012) YC (SEQ ID 1419) ID NO: NO: 1174) NO: 1010) 421) BL_592989- QIQLQQSGAEMVRP GYTFT MHWV ISTYSG SYNQKFKG ARGVT WGQ 2049_A7_P8_A07 GVSVKISCKGS (SEQ DYA RQSHA DV KATMTVDK FDS GTTL ID NO: 1241) (SEQ ID KSLEW (SEQ ID SSSTAYMEL (SEQ ID TVSS NO: 19) IGV NO: 46) ARLTSEDSAI NO: 48) (SEQ (SEQ ID YYC (SEQ ID ID NO: NO: 1389) NO: 1128) 425) BL_592989- QVQLQQSGAELVRP GYTFT LGWIK IYPGG NYNEKFKG ARVTP WGQ 2051_C7_P8_C07 GTSVKISCKAS (SEQ NYW QRPGH GYT KATLTADTS AS GTSL ID NO: 1325) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) GD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1074) 424) BL_592989- QAYLQQSGAELVRS GFNIK IHWVK IDPDN EYAPKFQGK TVFWY WGQ 2052_D7_P8_D07 GASVKLSCTAS (SEQ DYY QRPEQ GET ATMTADTSS GNNYA GTLV ID NO: 1197) (SEQ ID GLEWI (SEQ ID NTAHLQLSS GFAY TVSA NO: GW NO: LTSEDTAVY (SEQ ID (SEQ 977) (SEQ ID 1003) YC (SEQ ID NO: ID NO: NO: 946) 1420) NO: 1017) 421) BL_592989- QVQLQQSGAELVRP GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2054_F7_P8_F07 GTSVKMSCKAA NYW QRPGH DYS KATLTADTS AY GTLV (SEQ ID NO: 1326) (SEQ ID GLEWI (SEQ ID SSTAYMNLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1012) YC (SEQ ID 1419) ID NO: NO: 1174) NO: 1010) 421) BL_592989- QIQLQQSGAELVRPG GYTFT IGWVK INPGG NYNEKFEGK TSRNF WGQ 2055_G7_P8_G07 TSVKMSCKAA (SEQ NYW LRPGH GYT ATLTADTSS AY GTLV ID NO: 1228) (SEQ ID GLEWI (SEQ ID STAYMQLSS (SEQ ID TVSA NO: 4) GD NO: LTSEDSAIY NO: (SEQ (SEQ ID 1023) YC (SEQ ID 1419) ID NO: NO: 1168) NO: 1008) 421) BL_592989- QIQLQQSGAELVRPG GYTFT LGWV IYPGG NYNEKFKG VRVTP WGQ 2059_C8_P8_C08 TSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTV ID NO: 1227) (SEQ ID HGLEW (SEQ ID PSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: (SEQ (SEQ ID YFC (SEQ ID 1443) ID NO: NO: 1172) NO: 1075) 422) BL_592989- QIQLQQSGAELVRPG GYTFT MQWV ISTYSG IYNQKFKGK ARGVT WGQ 2060_D8_P8_D08 VSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTL ID NO: 1239) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSEDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1034) NO: 1137) 425) BL_592989- QVQLQQSGAELVRP GYTFT IGWVK IHPGG NYNEKFTGK VSRNF WGQ 2061_E8_P8_E08 GTSVKMSCKAA NYW QRPGH GYI ATLTADTSS AN GTPV (SEQ ID NO: 1326) (SEQ ID GLEWI (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) GD NO: LTSEDSAIY NO: (SEQ (SEQ ID 1014) YC (SEQ ID 1445) ID NO: NO: 1184) NO: 1010) 398) BL_592989- QVQLQQSGAELVRP GYTFT MHWV IITYSG LYNQKFKG AXGVT WGQ 2062_F8_P8_F08 GVSLKISCKGS (SEQ DYA RQSHA DA KATMTVDK FDY GTSL ID NO: 1337) (SEQ ID KNLEW (SEQ ID SSSTAYLEL (SEQ ID TVSS NO: 19) IGV NO: ARLTSDDSA NO: (SEQ (SEQ ID 1020) IYYC (SEQ 619) ID NO: ID NO: NO: 1127) 1119) 424) BL_592989- PIQLQQSGAELVRPG GYTFT MNWV IDPYDS HYNQKFKD AREAS YWG 2063_G8_P8_G08 ASVKLSCKAS (SEQ SYW KQRPE ET (SEQ KAILTVDKS YYYGN QGTL ID NO: 1192) (SEQ ID QGLEW ID NO: SSTAYMQLS AWFA VTAL NO: IGR 235) SLTSEDSAV (SEQ ID S 157) (SEQ ID YYC NO: (SEQ NO: (SEQ ID 601) ID 195) NO: 269) NO: 1496) BL_592989- QIQLQQSGAELVRPG GYTST IGWVK IHPGG NYNEKFKG TSRNF WGQ 2064_H8_P8_H08 TSVKMSCKAA (SEQ NYW QRPGH DYS KATLTADTS AY GTLV ID NO: 1228) (SEQ ID GLEWI (SEQ ID SSTAYMNLS (SEQ ID TVSA NO: GD NO: SLTSEDSAIY NO: (SEQ 997) (SEQ ID 1012) YC (SEQ ID 1419) ID NO: NO: 1174) NO: 1010) 421) BL_592989- QVQLQQSGAELVRP gytft MHWV ISTYSG LYNQKFKG ARGVT WGQ 2065_A9_P8_A09 GVSLKISCKGS (SEQ DYA RQSHA DA KATMTVDK FDY GTSL ID NO: 1337) (SEQ ID KSLEW (SEQ ID SSSTAYLEL (SEQ ID TVSS NO: 19) IGV NO: 21) ARLTSDDSA NO: 23) (SEQ (SEQ ID IYYC (SEQ ID NO: ID NO: NO: 1128) 1119) 424) BL_592989- QIQLQQPGAELVRPG GYAFT LGWV IYPGG NYNEKFKG ARVTP WGQ 2067_C9_P8_C09 TSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTV ID NO: 1220) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: IGD NO: 6) SLTSEDSAV NO: 8) (SEQ 984) (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 422) BL_592989- QVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFKGK ARGVT WGQ 2068_D9_P8_D09 GVSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTV ID NO: 1337) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1033) NO: 1128) 422) BL_592989- QAYLQQSGAELVRP GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2069_E9_P8_E09 GTSVKMSCKAA NYW QRPGH DYS KATLTADTS AY GTLV (SEQ ID NO: 1194) (SEQ ID GLEWI (SEQ ID SSTAYMNLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1012) YC (SEQ ID 1419) ID NO: NO: 1174) NO: 1010) 421) BL_592989- QIQLQQSGAELVRPG GYTFT MHWV ISTYSG SYNQKFKG ARGVT WGQ 2070_F9_P8_F09 VSVKISCKGS (SEQ DYA KQSHA DV KATMTVDK FDS GTSL ID NO: 1240) (SEQ ID KSLEW (SEQ ID SSSTAYMEL (SEQ ID TVSS NO: 19) IGV NO: 46) ARLTSEDSAI NO: 48) (SEQ (SEQ ID YYC (SEQ ID ID NO: NO: 1389) NO: 1126) 424) BL_592989- QVQLQQSGAELVRP GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2071_G9_P8_G09 GTSVRMSCKAA NYW QRPGH GYT KATLTADTS AY GTLV (SEQ ID NO: 1336) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1177) NO: 1010) 421) BL_592989- QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ 207_4B_10P_8B10 GTSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTL ID NO: 1325) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 425) BL_592989- QIQLQQPGAELVRPG GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ 2076_D10_P8_D10 TSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTSL ID NO: 1220) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 424) BL_592989- QVQLQQPGAELVRP GYTFT IGWVK IHPGG NYNEKFEGK TSRNF WGQ 2077_E10_P8_E10 GTSVKMSCKAA NYW QRPGH GYT ATLTADTSS AY GTLV (SEQ ID NO: 1315) (SEQ ID GLEWI (SEQ ID STAYMQLSS (SEQ ID TVSA NO: 4) GD NO: LTSEGSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1169) NO: 1010) 421) BL_592989- QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ 2078_F10_P8_F10 TSVKMSCKAA (SEQ NYW QRPGH DYS KATLTADTS AY GTLV ID NO: 1228) (SEQ ID GLEWI (SEQ ID SSTAYMNLS (SEQ ID TVSA NO: 4) GD NO: SLTSGDSAIY NO: (SEQ (SEQ ID 1012) YC (SEQ ID 1419) ID NO: NO: 1175) NO: 1010) 421) BL_592989- QVQLQQSGAELVRP GYTFT IGWVK FYPGG NYNEKFKG TSRNF WGQ 2079_G10_P8_G10 GTSVKMSCKAA NYW QRPGH DYI KATLTADTS AY GTLV (SEQ ID NO: 1326) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 973) YC (SEQ ID 1419) ID NO: NO: 1177) NO: 1010) 421) BL_592989- QIQLQQSGAELAKPG GYTFT MHWV INPSTG EYNEKFEDK ARWG WGQ 2080_H10_P8_H10 ASVKMSCKAS (SEQ RYW KQRPG YT ATLTADKSS NFDY GTSL ID NO: 1225) (SEQ ID QGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: IGY NO: LTSEDSAVY NO: (SEQ 992) (SEQ ID 230) YC (SEQ ID 617) ID NO: NO: 950) NO: 190) 424) BP003-T2P1A7 QIQLQQSGAEMVRP GYTFT MHWV ISTYSG SYNQKFKG ARGVT WGQ GVSVKISCKGS (SEQ DYA RQSHA DV KATMTVDK FDS GTTL ID NO: 1241) (SEQ ID KSLEW (SEQ ID SSSTAYMEL (SEQ ID TVSS NO: 19) IGV NO: 46) ARLTSEDSAI NO: 48) (SEQ (SEQ ID YYC (SEQ ID ID NO: NO: 1389) NO: 1128) 425) BP003-T2P1C8 QIQLQQSGAELVRPG GYTFT LGWV IYPGG NYNEKFKG VRVTP WGQ TSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTV ID NO: 1227) (SEQ ID HGLEW (SEQ ID PSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: (SEQ (SEQ ID YFC (SEQ ID 1443) ID NO: NO: 1172) NO: 1075) 422) BP003-T2P1F4 QVQLQQPGAELVRP GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ GTSVKMSCKAA NYW QRPGH GYT KATLTADTS AY GTLV (SEQ ID NO: 1315) (SEQ ID GLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1177) NO: 1010) 421) BP003-T2P1G2 QVQLQQSGAELVRP GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ GTSLKMSCKAA NYW QRPGH GYT KATLTADTS AY GTPV (SEQ ID NO: 1324) (SEQ ID GLEWI (SEQ ID SSTTYMQLS (SEQ ID TVSS NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1181) NO: 1010) 398) BP003-T2P1G4 QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ TSLKMSCKAA (SEQ NYW QRPGH GYT KATLTADTS AY GTLV ID NO: 1226) (SEQ ID GLEWI (SEQ ID SSTTYMQLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1181) NO: 1010) 421) BP003-T2P1G7 QIQLQQSGAELVRPG GYTFT IGWVK INPGG NYNEKFEGK TSRNF WGQ TSVKMSCKAA (SEQ NYW LRPGH GYT ATLTADTSS AY GTLV ID NO: 1228) (SEQ ID GLEWI (SEQ ID STAYMQLSS (SEQ ID TVSA NO: 4) GD NO: LTSEDSAIY NO: (SEQ (SEQ ID 1023) YC (SEQ ID 1419) ID NO: NO: 1168) NO: 1008) 421) BP003-T2P1H5 QIQLQQSGAELVRPG GYTFT IGWVK IHPGG NYNEKFKG TSRNF WGQ TSVKMSCKAA (SEQ NYW QRPGH GYT KATLTADTS AY GTLV ID NO: 1228) (SEQ ID GLEWV (SEQ ID SSTAYMQLS (SEQ ID TVSA NO: 4) GD NO: SLTSEDSAIY NO: (SEQ (SEQ ID 1015) YC (SEQ ID 1419) ID NO: NO: 1177) NO: 1011) 421) BP003T3P2-1 QVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFKGK ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTV ID NO: 1337) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1033) NO: 1128) 422) BP003T3P2-10 QVQLQQSGAELVRP GYTFT MHWV ISTYSG LYNQKFKG ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA KATMTVDK FDY GTTL ID NO: 1337) (SEQ ID KSLEW (SEQ ID SSSTAYLEL (SEQ ID TVSS NO: 19) IGV NO: 21) ARLTSDDSA NO: 23) (SEQ (SEQ ID IYYC (SEQ ID NO: ID NO: NO: 1128) 1119) 425) BP003T3P2-11 QVQLQQSGAELVRP GYTFT MHWV ISTYSG LYNQKFKG ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA KATMTVDK FDY GTTL ID NO: 1337) (SEQ ID KSLEW (SEQ ID SSSTAYLEL (SEQ ID TVSS NO: 19) IGV NO: 21) ARLTSDDSA NO: 23) (SEQ (SEQ ID IYYC (SEQ ID NO: ID NO: NO: 1128) 1119) 425) BP003T3P2-12 QAYLQQSGAELVRP GYTFT MHWV ISTYSG LYNQKFGK ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTL ID NO: 1195) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1118) NO: 1128) 425) BP003T3P2-13 QVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFGKA ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA TMTVDKSSS FDY GTTV ID NO: 1337) (SEQ ID KSLEW (SEQ ID TAYLELARL (SEQ ID TVSS NO: 19) IGV NO: 21) TSDDSAIYY NO: 23) (SEQ (SEQ ID C (SEQ ID ID NO: NO: 1031) NO: 1128) 422) BP003T3P2-14 QIQLQQPGAELVRPG GYTFT MHWV ISTYSG IYNQKFGKA ARGVT WGQ VSLKISCKGS (SEQ DYA RQSHA DA TMTVDKSSS FDY GTTV ID NO: 1223) (SEQ ID KSLEW (SEQ ID TAYLELARL (SEQ ID TVSS NO: 19) IGV NO: 21) TSDDSAIYY NO: 23) (SEQ (SEQ ID C (SEQ ID ID NO: NO: 1031) NO: 1128) 422) BP003T3P2-15 QVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFGKA ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA TMTVDKSSS FDY GTTV ID NO: 1337) (SEQ ID KSLEW (SEQ ID TAYLELARL (SEQ ID TVSS NO: 19) IGV NO: 21) TSDDSAIYY NO: 23) (SEQ (SEQ ID C (SEQ ID ID NO: NO: 1031) NO: 1128) 422) BP003T3P2-16 EVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFGKA ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA TMTVDKSSS FDY GTTL ID NO: 940) (SEQ ID KSLEW (SEQ ID TAYLELARL (SEQ ID TVSS NO: 19) IGV NO: 21) TSDDSAIYY NO: 23) (SEQ (SEQ ID C (SEQ ID ID NO: NO: 1031) NO: 1128) 425) BP003T3P2-17 QIQLQQSGAELVRPG GYTFT MHWV ISTYSG IYNQKFGKA ARGVT WGQ VSLKISCKGS (SEQ DYA RQSHA DA TMTVDKSSS FDY GTSL ID NO: 1239) (SEQ ID KSLEW (SEQ ID TAYLELARL (SEQ ID TVSS NO: 19) IGV NO: 21) TSDDSAIYY NO: 23) (SEQ (SEQ ID C (SEQ ID ID NO: NO: 1031) NO: 1128) 424) BP003T3P2-18 QVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFGKA ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA TMTVDKSSS FDY GTTL ID NO: 1337) (SEQ ID KSLEW (SEQ ID TAYLELARL (SEQ ID TVSS NO: 19) IGV NO: 21) TSDDSAIYY NO: 23) (SEQ (SEQ ID C (SEQ ID ID NO: NO: 1031) NO: 1128) 425) BP003T3P2-19 QVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFGKA ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA TMTVDKSSS FDY GTTL ID NO: 1337) (SEQ ID KSLEW (SEQ ID TAYLELARL (SEQ ID TVSS NO: 19) IGV NO: 21) TSEDSAIYY NO: 23) (SEQ (SEQ ID C (SEQ ID ID NO: NO: 1032) NO: 1128) 425) BP003T3P2-2 QVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFKGK ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTV ID NO: 1337) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1033) NO: 1128) 422) BP003T3P2-20 QVQLQQSGAGLVRP GYTFT MHWV ISTYSG IYNQKFGKA ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA TMTVDKSSS FDY GTTL ID NO: 1341) (SEQ ID KSLEW (SEQ ID TAYLELARL (SEQ ID TVSS NO: 19) IGV NO: 21) TSEDSAIYY NO: 23) (SEQ (SEQ ID C (SEQ ID ID NO: NO: 1032) NO: 1128) 425) BP003T3P2-21 QVQLQQSGAELVRP GYTFT MQWV ISTYSG IYNQKFGKA ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA TMTVDKSSS FDY GTSL ID NO: 1337) (SEQ ID KSLEW (SEQ ID TAYLELARL (SEQ ID TVSS NO: 19) IGV NO: 21) TSEDSAIYY NO: 23) (SEQ (SEQ ID C (SEQ ID ID NO: NO: 1032) NO: 1137) 424) BP003T3P2-22 QVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFDKA ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA TMTVDKSSS FDY GTTL ID NO: 1337) (SEQ ID KSLEW (SEQ ID TAYLELARL (SEQ ID TVSS NO: 19) IGV NO: 21) TSEDSAIYY NO: 23) (SEQ (SEQ ID C (SEQ ID ID NO: NO: 1030) NO: 1128) 425) BP003T3P2-23 QVQLQQSGAELVRP GYTFT MHWV ISTYSG SYNQKFKG ARGVT WGQ GVSVKISCKGS (SEQ DYA KQSHA DV KATMTVDK FDS GTTL ID NO: 1338) (SEQ ID KSLEW (SEQ ID SSSTAYMEL (SEQ ID TVSS NO: 19) IGV NO: 46) ARLTSEDSAI NO: 48) (SEQ (SEQ ID YYC (SEQ ID ID NO: NO: 1389) NO: 1126) 425) BP003T3P2-24 QVQLQQSGAELVRP GYTFT MHWV ISTYSG SYNQKFKG ARGVT WGQ GVSVKISCKGS (SEQ DYA KQSHA DV KATMTVDK FDS GTTL ID NO: 1338) (SEQ ID KSLEW (SEQ ID SSSTAYMEL (SEQ ID TVSS NO: 19) IGV NO: 46) ARLTSEDSAI NO: 48) (SEQ (SEQ ID YYC (SEQ ID ID NO: NO: 1389) NO: 1126) 425) BP003T3P2-25 QIQLQQSGAELVRPG GYTFT MHWV ISTYSG SYNQKFKG ARGVT WGQ VSVKISCKGS (SEQ DYA KQSHA DV KATMTVDK FDS GTSL ID NO: 1240) (SEQ ID KSLEW (SEQ ID SSSTAYMEL (SEQ ID TVSS NO: 19) IGV NO: 46) ARLTSEDSAI NO: 48) (SEQ (SEQ ID YYC (SEQ ID ID NO: NO: 1389) NO: 1126) 424) BP003T3P2-26 QVQLQQSGAELVRP GYTFT MRWV IXTYSG SYNQKFGK ARGVT WGR GISVKISCKGS (SEQ DYA KQSHA DV ATMTVDKSS FDS GTSL ID NO: 1323) (SEQ ID KSLEW (SEQ ID STAYMELAR (SEQ ID TVSS NO: 19) IGV NO: LTSEDSAIY NO: 48) (SEQ (SEQ ID 1029) YC (SEQ ID ID NO: NO: 1387) NO: 1138) 1454) BP003T3P2-27 QVQLQQSGAELVRP GYTFT MRWV ISTYSG NYNQKFGK ARGVT XGR GISVKISCKGS (SEQ DYG KQSPA DV ATMTVDKSS FDS GTXL ID NO: 1323) (SEQ ID XSLEW (SEQ ID STAYMELAR (SEQ ID TVSS NO: IGV NO: 46) LTSEDSAIY NO: 48) (SEQ 987) (SEQ ID YC (SEQ ID ID NO: NO: 1190) NO: 1139) 1474) BP003T3P2-28 QVQLQQSGAELAKP GYTFT IHWVK INPRTD EYNQKFKD ARHGY WGQ GASVKMSCKAS RYW QRPGQ YT KATLTADKS FDY GTTL (SEQ ID NO: 473) (SEQ ID DLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: GY NO: SLTSDDSAV NO: (SEQ 992) (SEQ ID 1025) YYC 611) ID NO: (SEQ ID NO: 1018) NO: 955) 425) BP003T3P2-29 QVQLQQPGAELAKP GYTFT IHWVK INPRTD EYNQKFKD ARHGY WGQ GASVKMSCKAS RYW QRPGQ YT KATLTADKS FDY GTTL (SEQ ID NO: 114) (SEQ ID DLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: GY NO: SLTSDDSAV NO: (SEQ 992) (SEQ ID 1025) YYC (SEQ ID 611) ID NO: NO: 955) NO: 1018) 425) BP003T3P2-3 QVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFKGK ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTV ID NO: 1337) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1033) NO: 1128) 422) BP003T3P2-30 QVQLQQPGAELAKP GYTFT IHWVK INPRTD EYNQKFKD ARHGY WGQ GASVKMSCKAS RYW QRPGQ YT KATLTADKS FDY GTTL (SEQ ID NO: 114) (SEQ ID DLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: GY NO: SLTSDDSAV NO: (SEQ 992) (SEQ ID 1025) YYC 611) ID NO: (SEQ ID NO: 1018) NO: 955) 425) BP003T3P2-31 QVQLQQPGAELAKP GYTFT IHWVK INPRTD EYNQKFKD ARHGY WGQ GASVKMSCKAS RYW QRPGQ YT KATLTADKS FDY GTTL (SEQ ID NO: 114) (SEQ ID DLEWI (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: GY NO: SLTSDDSAV NO: (SEQ 992) (SEQ ID 1025) YYC 611) ID NO: (SEQ ID NO: 1018) NO: 955) 425) BP003T3P2-32 QVQLQQSGAELAKP GYTFT IHWVK INPRTD EYNQKFDK ARHGY WGQ GASVKMSCKAS RYW QRPGQ YT ATLTADKSS FDY GTTL (SEQ ID NO: 473) (SEQ ID DLEWI (SEQ ID STAYMQLXS (SEQ ID TVSS NO: GY NO: LTSDDSAVY NO: (SEQ 992) (SEQ ID 1025) YC (SEQ ID 611) ID NO: NO: 952) NO: 1018) 425) BP003T3P2-33 QVQLQQPGAELAKP GYTFT IHWVK INPRTD EYNQKFDK ARHGY WGQ GASVKMSCKAS RYW QRPGQ YT ATLTADKSS FDY GTTL (SEQ ID NO: 114) (SEQ ID DLEWI (SEQ ID STAYMQLSS (SEQ ID TVSS NO: GY NO: LTSDDSAVY NO: (SEQ 992) (SEQ ID 1025) YC (SEQ ID 611) ID NO: NO: 951) NO: 1018) 425) BP003T3P2-34 QVQLQQPGAELAKP GYTFT IHWVK INPRTD EYNQKFDK ARHGY WGQ GASVKMSCKAS RYW QRPGQ YT ATLTADKSS FDY GTTL (SEQ ID NO: 114) (SEQ ID DLEWI (SEQ ID STAYMQLSS (SEQ ID TVSS NO: GY NO: LTSDDSAVY NO: (SEQ 992) (SEQ ID 1025) YC (SEQ ID 611) ID NO: NO: 951) NO: 1018) 425) BP003T3P2-35 QVQLQQSGAELAKP GYTFT IHWVK INPRTD EYNQKFDK ARHGY WGQ GASVKMSCKAS RYW QRPGQ YT ATLTADKSS FDY GTTL (SEQ ID NO: 473) (SEQ ID DLEWI (SEQ ID STAYMQLSS (SEQ ID TVSS NO: GY NO: LTSDDSAVY NO: (SEQ 992) (SEQ ID 1025) YC (SEQ ID 611) ID NO: NO: 951) NO: 1018) 425) BP003T3P2-36 QVQLQQSGAELAKP GYTFT MHWV INPRTD EYNQKFDK ARHGY WGQ GASVKMSCKAS RYW KQRPG YT ATLTADKSS FDY GTTL (SEQ ID NO: 473) (SEQ ID QDLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: IGY NO: LTSDDSAVY NO: (SEQ 992) (SEQ ID 1025) YC (SEQ ID 611) ID NO: NO: 951) NO: 1125) 425) BP003T3P2-37 QIQLQQPGAELAKPG GYTFT MHWV INPRTD EYNQKFDK ARHGY WGQ ASVKMSCKAS (SEQ RYW KQRPG YT ATLTADKSS FDY GTTV ID NO: 1218) (SEQ ID QDLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: IGY NO: LTSDDSAVY NO: (SEQ 992) (SEQ ID 1025) YC (SEQ ID 611) ID NO: NO: 951) NO: 1125) 422) BP003T3P2-38 QVQMKQSGAELAKP GYTFT MHWV INPSSD EYNQKFKD ARGTV WGQ GASVKMSCKAS RYW KQRPG YT KATLTADKS WDY GTTV (SEQ ID NO: 1343) (SEQ ID QGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: IGY NO: SLTSEDSAV NO: (SEQ 992) (SEQ ID 1026) YYC (SEQ ID 608) ID NO: NO: 265) NO: 190) 422) BP003T3P2-39 QIQLQQSGAELAKPG GYTFT MHWV INPSTD EYNEKFDKA VRSPIL WGQ ASVKMSCKAS (SEQ RYW KQRPG YT TLTADKSSS DY GTSL ID NO: 1225) (SEQ ID QGLEW (SEQ ID TAYMQLSSL (SEQ ID TVSS NO: IGY NO: TSEDSAVYF NO: (SEQ 992) (SEQ ID 1027) C (SEQ ID 1442) ID NO: NO: 949) NO: 190) 424) BP003T3P2-4 QVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFKGK ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTV ID NO: 1337) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1033) NO: 1128) 422) BP003T3P2-40 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTSL ID NO: 1325) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 424) BP003T3P2-41 QAYLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTSL ID NO: 1193) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 424) BP003T3P2-42 QVQLQQPGAELVRP GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTL ID NO: 1314) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 425) BP003T3P2-43 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTV ID NO: 1325) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 422) BP003T3P2-44 QVQLQPGAELVRPG GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ TSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTV ID NO: 1313) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 422) BP003T3P2-45 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFKG ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT KATLTADTS AS GTTL ID NO: 1325) (SEQ ID HGLEW (SEQ ID SSTAYMQLS (SEQ ID TVSS NO: 4) IGD NO: 6) SLTSEDSAV NO: 8) (SEQ (SEQ ID YFC (SEQ ID ID NO: NO: 1178) NO: 1075) 425) BP003T3P2-46 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTTV ID NO: 1325) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1075) 422) BP003T3P2-47 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ GASVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTTL ID NO: 1322) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1075) 425) BP003T3P2-48 QVQLQQSGAELVRP GYTFT LGWIK IYPGG NYNEKFGK ARVTP WGQ GTSVKISCKAS (SEQ NYW QRPGH GYT ATLTADTSS AS GTSL ID NO: 1325) (SEQ ID GLEWI (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) GD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1074) 424) BP003T3P2-49 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTTV ID NO: 1325) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1075) 422) BP003T3P2-5 QIQLQQSGAELVRPG GYTFT MHWV ISTYSG IYNQKFKGK ARGVT WGQ VSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTSL ID NO: 1239) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1033) NO: 1128) 424) BP003T3P2-50 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTTL ID NO: 1325) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1075) 425) BP003T3P2-51 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTTV ID NO: 1325) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1075) 422) BP003T3P2-52 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTTV ID NO: 1325) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1075) 422) BP003T3P2-53 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTTL ID NO: 1325) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1075) 425) BP003T3P2-54 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYA ATLTADTSS AS GTTL ID NO: 1325) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: LTSEDSAVY NO: 8) (SEQ (SEQ ID 1035) FC (SEQ ID ID NO: NO: 1170) NO: 1075) 425) BP003T3P2-55 QIQLQQSGAELVRPG GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ TSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTTL ID NO: 1227) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1075) 425) BP003T3P2-56 QIQLQQSGAELVRPG GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ TSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTSL ID NO: 1227) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1075) 424) BP003T3P2-57 QIQLQQSGAELVRPG GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ TSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTTL ID NO: 1227) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1075) 425) BP003T3P2-58 QIQLQQSGAELVRPG GYTFT LGWV IYPGG NYNEKFGK ARVTP WGQ TSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTSL ID NO: 1227) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1170) NO: 1075) 424) BP003T3P2-59 QIQLQQSGAELVRPG GYTFT LGWV IYPGG NYNEKFKK ARVTP WGQ TSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTTV ID NO: 1227) (SEQ ID HGLEW (SEQ ID VTAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1183) NO: 1075) 422) BP003T3P2-6 EVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFKGK ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTL ID NO: 940) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1033) NO: 1128) 425) BP003T3P2-60 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFKK ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTTL ID NO: 1325) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1182) NO: 1075) 425) BP003T3P2-61 QVQLQQSGAELVRP GYTFT LGWV IYPGG NYNEKFKK ARVTP WGQ GTSVKISCKAS (SEQ NYW KQRPG GYT ATLTADTSS AS GTSL ID NO: 1325) (SEQ ID HGLEW (SEQ ID STAYMQLSS (SEQ ID TVSS NO: 4) IGD NO: 6) LTSEDSAVY NO: 8) (SEQ (SEQ ID FC (SEQ ID ID NO: NO: 1182) NO: 1075) 424) BP003T3P2-62 EVQLQESGADLMKP GYTFS IEWIKQ ILPGSG NYNENFGK ARGGT WGQ GASVKISCKAS (SEQ NYW RPGHG FT (SEQ ATFTADTSS SVVHF GTTL ID NO: 939) (SEQ ID LEWVG ID NO: NTTYMQLSS DY TVSS NO: E (SEQ 1021) LTSEDSAVY (SEQ ID (SEQ 986) ID NO: YC (SEQ ID NO: ID 1006) NO: 1185) 605) NO: 425) BP003T3P2-63 QVQLQQSGADLMKP GYTFS IEWIKQ ILPGSG NYNENFKG ARGGT WGQ GASVKMSCRAS NYW RPGHG FT (SEQ KATFTADTS SVVHF GTSL (SEQ ID NO: 1321) (SEQ ID LEWIG ID NO: SNTTYMLLS DS TVSS NO: E (SEQ 1021) SLSSEDSAV (SEQ ID (SEQ 986) ID NO: YYC (SEQ ID NO: ID 1005) NO: 1187) 604) NO: 424) BP003T3P2-64 QIQLQQSGADLMKP GYTFS IEWIKQ ILPGSG NYNENFKG ARGGT WGQ GASVKISCKAS (SEQ NYW RPGHG FT (SEQ KATFTADTS SVVHF GTTL ID NO: 1224) (SEQ ID LEWVG ID NO: SNTTYMQLS DY TVSS NO: E (SEQ 1021) SLTSEDSAV (SEQ ID (SEQ 986) ID NO: YYC (SEQ ID NO: ID 1006) NO: 1188) 605) NO: 425) BP003T3P2-65 EVLLQQSGADLMKP GYTFS IEWIKQ ILPGSG NYNENFKG ARGGT WGQ GASVKISCKAS (SEQ NYW RPGHG FT (SEQ KATFTADTS SVVHF GTTV ID NO: 938) (SEQ ID LEWIG ID NO: SNTTYMQLS DFDY TVSS NO: E (SEQ 1021) SLTSEDSAV (SEQ ID (SEQ 986) ID NO: YYC (SEQ ID NO: ID 1005) NO: 1188) 603) NO: 422) BP003T3P2-66 EVRLQQSGAELVRS GFNIK MHWV IDPENG EYAPKFQGK NVITT WGQ GASVKLSCTAS (SEQ DYY KQRPE DT ATMTADTSS ATTWF GTLV ID NO: 943) (SEQ ID QGLEW (SEQ ID NTAYLQLSS AY TVSS NO: IGW NO: LTSEDTAVY (SEQ ID (SEQ 977) (SEQ ID 1004) YC (SEQ ID NO: ID NO: NO: 947) 1165) NO: 1124) 413) BP003T3P2-67 EVLLQQFGAELVRSG GFNIK IHWVK IDPDN EYAPKFQGK TVFWY WGQ ASVKLSCTAS (SEQ DYY QRPEQ GET ATMTTDTSS GNNYA GTLV ID NO: 937) (SEQ ID GLEWI (SEQ ID NTAHLQLSS GFAY TVSS NO: GW NO: LTSEDTAVY (SEQ ID (SEQ 977) (SEQ ID 1003) YC (SEQ ID NO: ID NO: NO: 948) 1420) NO: 1017) 413) BP003T3P2-68 EVHLQQSGAELVRS GFNIK IHWVK IDPDN EYAPKFQGK TVFWY WGA GASVKLSCTAS (SEQ DYY QRPEQ GET ATMTADTSS GNNYA GTSL ID NO: 936) (SEQ ID GLEWI (SEQ ID NTAHLQLSS GFAY TVSS NO: GW NO: LTSEDTAVY (SEQ ID (SEQ 977) (SEQ ID 1003) YC (SEQ ID NO: ID NO: NO: 946) 1420) NO: 1017) 431) BP003T3P2-69 EVRLQQSGAELVRS GFNIK IHWVK IDPDN EYAPKFQGK TVFWY WGQ GASVKLSCTAS (SEQ DYY QRPEQ GET ATMTADTSS GNNYA GTLV ID NO: 943) (SEQ ID GLEWI (SEQ ID NTAHLQLSS GFAY TVSA NO: GW NO: LTSEDTAVY (SEQ ID (SEQ 977) (SEQ ID 1003) YC (SEQ ID NO: ID NO: NO: 946) 1420) NO: 1017) 421) BP003T3P2-7 EVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFKGK ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTL ID NO: 940) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1033) NO: 1128) 425) BP003T3P2-70 QAYLQQSGAELVRS GFNIK IHWVK IDPDN EYAPKFGKA TVFWY WGQ GASVKLSCTAS (SEQ DYY QRPEQ GET TMTADTSSN GNNYA GTTV ID NO: 1197) (SEQ ID GLEWI (SEQ ID TAHLQLSSL GFAY SA NO: GW NO: TSEDTAVYY (SEQ ID (SEQ 977) (SEQ ID 1003) C (SEQ ID NO: ID NO: NO: 945) 1420) NO: 1017) 1453) BP003T3P2-71 QAYLQQSGAELVRS GFNIK IHWVK IDPDN EYAPKFGKA TVFWY WGQ GASVKLSCTAS (SEQ DYY QRPEQ GET TMTADTSSN GNNYA GTTV ID NO: 1197) (SEQ ID GLEWI (SEQ ID TAHLQLSSL GFAY SA NO: GW NO: TSEDTAVYY (SEQ ID (SEQ 977) (SEQ ID 1003) C (SEQ ID NO: ID NO: NO: 945) 1420) NO: 1017) 1453) BP003T3P2-72 QVQLQQSGAELVRS GFNIK IHWVK IDPDN EYAPKFGKA TVFWY WGQ GASVKLSCTAS (SEQ DYY QRPEQ GET TMTADTSSN GNNYA GTTV ID NO: 1339) (SEQ ID GLEWI (SEQ ID TAHLQLSSL GFAY SA NO: GW NO: TSEDTAVYY (SEQ ID (SEQ 977) (SEQ ID 1003) C (SEQ ID NO: ID NO: NO: 945) 1420) NO: 1017) 1453) BP003T3P2-73 EVRLQQSGAELVRS GFNIK IHWVK IDPDN EYAPKFGKA TVFWY WGQ GASVKLPCTAS (SEQ DYY QRPEQ GET TMTADTSSN GNNYA GTTV ID NO: 942) (SEQ ID GLEWI (SEQ ID TAHLQLSSL GFAY SA NO: GW NO: TSEDTAVYY (SEQ ID (SEQ 977) (SEQ ID 1003) C (SEQ ID NO: ID NO: NO: 945) 1420) NO: 1017) 1453) BP003T3P2-74 EVLLQQFGAELVRSG GFNIK IHWVK IDPDN EYAPKFGKA TVFWY WGQ ASVKLSCTAS (SEQ DYY QRPEQ GET TMTADTSSN GNNYA GTTV ID NO: 937) (SEQ ID GLEWI (SEQ ID TAHLQLSSL GFAY SA NO: GW NO: TSEDTAVYY (SEQ ID (SEQ 977) (SEQ ID 1003) C (SEQ ID NO: ID NO: NO: 945) 1420) NO: 1017) 1453) BP003T3P2-75 QIQLQQSGAELVRPG GYTFT MHWV ISTYSG SYNQKFKG ARGVT WGQ VSVKISCKGS (SEQ DYA KQSHA DV KATMTVDK FDS GTTV ID NO: 1240) (SEQ ID KSLEW (SEQ ID SSSTAYMEL (SEQ ID TVSS NO: 19) IGV NO: 46) ARLTSEDSAI NO: 48) (SEQ (SEQ ID YYC (SEQ ID ID NO: NO: 1389) NO: 1126) 422) BP003T3P2-8 EVQLQQSGAELVRP GYTFT MHWV ISTYSG IYNQKFKGK ARGVT WGQ GVSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTL ID NO: 940) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1033) NO: 1128) 425) BP003T3P2-9 QIQLQQSGAELVRPG GYTFT MHWV ISTYSG IYNQKFKGK ARGVT WGQ VSLKISCKGS (SEQ DYA RQSHA DA ATMTVDKSS FDY GTTL ID NO: 1239) (SEQ ID KSLEW (SEQ ID STAYLELAR (SEQ ID TVSS NO: 19) IGV NO: 21) LTSDDSAIY NO: 23) (SEQ (SEQ ID YC (SEQ ID ID NO: NO: 1033) NO: 1128) 425)

TABLE 4B Exemplary Clones-Light Chain Sequences ID LFR1 CDRL1 LFR2 CDRL2 LFR3 CDRL3 LFR4 BL_592989- DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2015_G2_P8_G02 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 734) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BL_592989- DVVMTQTPLSLPVS QSLVH LHWYL EVS NRFSGVPD SQSTH FGGGT 2016_H2_P8_H02 LGDQASISCRSS SNGNT QKPGQ (SEQ ID RFSGSGSGT VPYT KLEIK (SEQ ID NO: 900) Y (SEQ SPKLLI NO: DFTLKISRV (SEQ (SEQ ID ID NO: Y (SEQ 944) EAEDLGVY ID NO: NO: 1306) ID NO: FC (SEQ ID 1375) 959) 1076) NO: 1157) BL_592989- DIVMTQSPPTLSLSP QDVNT WYQQ WAS TRHTGVPS QQHY FGGGT 2017_A3_P8_A03 GERVTLSCKAS AVA KPGQA (SEQ ID RFSGSGSGT SSPWT KLEIK (SEQ ID NO: 816) (SEQ ID PRLLIY NO: DFTLTISSL (SEQ (SEQ ID NO: (SEQ ID 1450) QPEDFATY ID NO: NO: 1207) NO: YC (SEQ ID 1258) 959) 1470) NO: 1414) BL_592989- DVVMTQSQKFMST QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2018_B3_P8_B03 SVGDRVSVTCKAS N (SEQ KPGQS (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 894) ID NO: PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAE ID NO: NO: NO: YFC (SEQ 15) 959) 1430) ID NO: 1483) BL_592989- DVVMTQSQKFMST QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2019_C3_P8_C03 SVGDRVSVTCKAS N (SEQ KPGQS (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 894) ID NO: PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAE ID NO: NO: NO: YFC (SEQ 15) 959) 1430) ID NO: 1483) BL_592989- DIVLTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2021_E3_P8_E03 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 773) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BL_592989- DVVMTQTQKFMST QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2022_F3_P8_F03 SVGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 909) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BL_592989- DVVMTQTPLSLPVS QSLVH LHWYL EVS NRFSGVPD SQSTH FGGGT 2023_G3_P8_G03 LGDQASISCRSS SNGNT QKPGQ (SEQ ID RFSGSGSGT VPYT KLEIK (SEQ ID NO: 900) Y (SEQ SPKLLI NO: DFTLKISRV (SEQ (SEQ ID ID NO: Y (SEQ 944) EAEDLGVY ID NO: NO: 1306) ID NO: FC (SEQ ID 1375) 959) 1076) NO: 1157) BL_592989- DIVMTQTTSSLSASL QDIRN LNYQQ YTS RLYSGVPS QQGN FGGGT 2024 H3P8H03 GDRVTISCRAS (SEQ Y (SEQ KPDGT (SEQ ID RFSGSGSGT TLPPT KLEIK ID NO: 831) ID NO: VKLLIY NO: DYSLTISNL (SEQ (SEQ ID 1202) (SEQ ID 1495) EQEDIATYF ID NO: NO: NO: C (SEQ ID 1253) 959) 1091) NO: 1359) BL_592989- DIQMTQSQKFMSTS QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2025_A4_P8_A04 VGDRVSVTCKAS N (SEQ KPGQS (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 734) ID NO: PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAE ID NO: NO: NO: YFC (SEQ 15) 959) 1430) ID NO: 1483) BL_592989- DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT 2026_B4_P8_B04 VGESVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT GSPYT KLEIK (SEQ ID NO: 718) NO: 930) SPQLL NO: 28) QFSLRINSL (SEQ (SEQ ID VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 1216) 959) NO: NO: 1400) 1072) BL_592989- DIQMTQSQKFMSAS QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2027_C4_P8_C04 VGDRVSVTCKAS N (SEQ KPGQS (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 729) ID NO: PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAE ID NO: NO: NO: YFC (SEQ 15) 961) 1430) ID NO: 1483) BL_592989- DNVLTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2029_E4_P8_E04 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 837) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BL_592989- DIVLTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2030_F4_P8_F04 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPW KLEIK (SEQ ID NO: 773) ID NO: QSPKA NO: 13) TDFTLTISN T (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 36) 959) NO: ID NO: 1425) 1483) BL_592989- DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2031_G4_P8_G04 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 734) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BL_592989- DVVMTQSQKFMST QNVGT VAWY SAS YRYSGVPG QQYN FGGGT 2032_H4_P8_H04 SVGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 894) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1490) BL_592989- DIQMTQTPASLSAS ENIYSY LEWFQ NAK TLAEGVPS QHHY FGGGT 2033_A5_P8_A05 VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSVSGSGT GIPYT KLEIK (SEQ ID NO: 744) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 1214) 959) NO: NO: 1401) 1070) BL_592989- DIQMTQSQKFMSTS QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2034_B5_P8_B05 VGDRVSVTCKAS N (SEQ KPGQS (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 734) ID NO: PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAE ID NO: NO: NO: YFC (SEQ 15) 959) 1430) ID NO: 1483) BL_592989- DIVMTQSQKFMSTS QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2035_C5_P8_C05 VGDRVSVTCKAS N (SEQ KPGQS (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 821) ID NO: PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAE NO: YFC (SEQ ID NO: NO: 1430) ID NO: 1483) 15) 959) BL_592989- DIVMSQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2037_E5_P8_E05 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 793) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BL_592989- DIVMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2038_F5_P8_F05 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 821) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BL_592989- DIVMSQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2039_G5_P8_G05 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG NYPW KLEIK (SEQ ID NO: 793) ID NO: QSPKA NO: 13) TDFTLTISN T (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 1284) 959) NO: ID NO: 1425) 1483) BL_592989- DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2040_H5_P8_H05 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 734) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BL_592989- DVVMTQSPASLSAS ENSYS LEWYQ NAK TLAEGVPS QHHY FGGGT 2041_A6_P8_A06 VGETVTITCRAS Y (SEQ QKQGK (SEQ ID RFSGSGSGT GTPYT KLEIK (SEQ ID NO: 890) ID NO: SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID 52) VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 54) 959) NO: NO: 1399) 1072) BL_592989- DIQMTQSPASLSAS ENSYS LEWYQ NAK TLAEGVPS QHHY FGGGT 2042_B6_P8_B06 VGETVTITCRAS Y (SEQ QKQGK (SEQ ID RFSGSGSGT GTPYT KLEIK (SEQ ID NO: 720) ID NO: SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID 52) VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 54) 959) NO: NO: 1399) 1072) BL_592989- DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT 2043_C6_P8_C06 VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT GTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 54) 959) NO: NO: 1398) 1072) BL_592989- DIVLTQSQKFMSTS QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2044_D6_P8_D06 VGDRVSVTCKAS N (SEQ KPGQS (SEQ ID RFTGSGSG TYPYT KLEMK (SEQ ID NO: 773) ID NO: PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAE ID NO: NO: NO: YFC (SEQ 1287) 961) 1430) ID NO: 1483) BL_592989- DIVMSQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2045_E6_P8_E06 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 793) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BL_592989- DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2046_F6_P8_F06 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 734) ID NO: QSPKA NO: 13) TGFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1487) BL_592989- DIVMSQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2047_G6_P8_G06 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG NYPW KLEIK (SEQ ID NO: 793) ID NO: QSPKA NO: 13) TDFTLTISN T (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 1284) 959) NO: ID NO: 1425) 1483) BL_592989- DIVMSQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2048_H6_P8_H06 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 793) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BL_592989- DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT 2049_A7_P8_A07 VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT GTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 54) 959) NO: NO: 1398) 1072) BL_592989- DIQMTQSQKFMSTS QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2051_C7_P8_C07 VGDRVSVTCKAS N (SEQ KPGQS (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 734) ID NO: PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAE ID NO: NO: NO: YFC (SEQ 15) 959) 1430) ID NO: 1483) BL_592989- DVVLTQTPLSLPVSL QSIVHS LEWYL KVS NRFSGVPD FQGSH FGGGT 2052 D7P8D07 GDQASISCRSS (SEQ NGNTY QKPGQ (SEQ ID RFSGSGSGT VPPT KLEIK ID NO: 874) (SEQ ID SPKLLI NO: DFTLKISKV (SEQ (SEQ ID NO: Y (SEQ 1062) EAEDLGVY ID NO: NO: 1299) ID NO: YC (SEQ ID 966) 959) 1071) NO: 1154) BL_592989- DTTVTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2054_F7_P8_F07 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG NHPYT KLEIK (SEQ ID NO: 858) ID NO: QSPKPL NO: 13) TDFTLTISN (SEQ (SEQ ID 12) IY (SEQ VQSEDLAE ID NO: NO: ID NO: YFC (SEQ 1281) 959) 1429) ID NO: 1483) BL_592989- DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2055_G7_P8_G07 VGDRASVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPW KLEIK (SEQ ID NO: 731) ID NO: QSPKA NO: 13) TDFTLTISN T (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 36) 959) NO: ID NO: 1425) 1483) BL_592989- DIVMTQSQKFMSTS QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2059_C8_P8_C08 VGDRVSVTCKAS N (SEQ KPGQS (SEQ ID RFTGSGSG TYPYT KLEIK (SEQ ID NO: 821) ID NO: PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAD ID NO: NO: NO: YFC (SEQ 1287) 959) 1430) ID NO: 1482) BL_592989- DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT 2060_D8_P8_D08 VGESVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT GSPYT KLEMK (SEQ ID NO: 718) NO: 930) SPQLL NO: 28) QFSLRINSL (SEQ (SEQ ID VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 1216) 961) NO: NO: 1400) 1072) BL_592989- DTTVTQSQKFMSTS QNVGT VAWY SAS YRYGGVPD QQYN FGGGT 2061_E8_P8_E08 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 858) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1477) BL_592989- DIVMTQSPASLSAS ENIYSF LVWYQ NAK TLAEGVPS QHHY FGGGT 2062_F8_P8_F08 VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGIGSGT GTPYT KLEIK (SEQ ID NO: 807) NO: 928) SPHLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 54) 959) NO: NO: 1396) 1117) BL_592989- DIQMTQSQKFMSTS QNVGT WYQQ SAS YRYSGVPD QQYN FGGGT 2063_G8_P8_G08 VGDRVGVTCKAS NVA KPGQS (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 732) (SEQ ID PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID NO: (SEQ ID VQSEDLAE ID NO: NO: 1246) NO: YFC (SEQ 15) 961) 1471) ID NO: 1483) BL_592989- DTTVTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2064_H8_P8_H08 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPW KLEIK (SEQ ID NO: 858) ID NO: QSPKA NO: 13) TDFTLTISN T (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 36) 959) NO: ID NO: 1425) 1483) BL_592989- DIVMTQSPASLSAS ENIYSF LVWYQ NAK TLAEGVPS QHHY FGGGT 2065 A9P8A09 VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGIGSGT GTPYT KLEIK (SEQ ID NO: 807) NO: 928) SPHLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 54) 959) NO: NO: 1396) 1117) BL_592989- DILMTQSQKFMSTS QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2067_C9_P8_C09 VGDRVSVTCKAS N (SEQ KPGQS (SEQ ID RFTGSGSG NYPLT KLEIK (SEQ ID NO: 711) ID NO: PKPLIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAE ID NO: NO: NO: YFC (SEQ 1283) 959) 1432) ID NO: 1483) BL_592989- DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLVEGVPS QHHY FGGGT 2068 D9P8D09 VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1408) 1072) BL_592989- DTTVTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2069_E9_P8_E09 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 858) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BL_592989- DVVMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT 2070F9P8F09 VGESVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT GSPYT KLEIK (SEQ ID NO: 889) NO: 930) SPQLL NO: 28) QFSLRINSL (SEQ (SEQ ID VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 1216) 959) NO: NO: 1400) 1072) BL_592989- DTTVTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2071_G9_P8_G09 VGDRVSVACKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 854) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BL_592989- DTTVTQSQKFMSTS QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2074_B10_P8_B10 VGDRVSVTCKAS N (SEQ KPGQS (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 858) ID NO: PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAE ID NO: NO: NO: YFC (SEQ 15) 961) 1430) ID NO: 1483) BL_592989- DIVITQSQKFMSTSV QNVGT VAYQQ SAS YRYSGVPD QQYN FGGGT 2076_D10_P8_D10 GDRVSVTCKAS N (SEQ KPGQS (SEQ ID RLTGSGSG RYPYT KLEIK (SEQ ID NO: 766) ID NO: PKALIY NO: 13) TDFTLTISN (SEQ (SEQ ID 12) (SEQ ID VQSEDLAE ID NO: NO: NO: YFC (SEQ 1285) 959) 1430) ID NO: 1489) BL_592989- DIQMTQTQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2077_E10_P8_E10 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPW KLEIK (SEQ ID NO: 757) ID NO: QSPKA NO: 13) TDFTLTISN T (SEQ (SEQ ID 12) LIY VQSEDLTE ID NO: NO: (SEQ ID YFC (SEQ 36) 959) NO: ID NO: 1425) 1486) BL_592989- DTTVTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2078_F10_P8_F10 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 858) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BL_592989- DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT 2079_G10_P8_G10 VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPW KLEMK (SEQ ID NO: 734) ID NO: QSPKA NO: 13) TDFTLTISN T (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 36) 961) NO: ID NO: 1425) 1483) BL_592989- DIQMTQSTSSLSASL QDIRN LNYQQ YTS RLHSGVPS QQGN FGGGT 2080_H10_P8_H10 GDRVTISCRAS (SEQ Y (SEQ KPDGT (SEQ ID RFSGSGSGT TLPPT KLEIK ID NO: 738) ID NO: VKLLIY NO: DYSLTISNL (SEQ (SEQ ID 1202) (SEQ ID 1495) EQEDIATYF ID NO: NO: NO: C (SEQ ID 1253) 959) 1091) NO: 1353) BP003-T2P1A7 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT GTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 54) 959) NO: NO: 1398) 1072) BP003-T2P1C8 DIVMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG TYPYT KLEIK (SEQ ID NO: 821) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAD ID NO: NO: (SEQ ID YFC (SEQ 1287) 959) NO: ID NO: 1425) 1482) BP003-T2P1F4 DIVLTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPW KLEIK (SEQ ID NO: 773) ID NO: QSPKA NO: 13) TDFTLTISN T (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 36) 959) NO: ID NO: 1425) 1483) BP003-T2P1G2 DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 734) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BP003-T2P1G4 DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 734) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BP003-T2P1G7 DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRASVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPW KLEIK (SEQ ID NO: 731) ID NO: QSPKA NO: 13) TDFTLTISN T (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 36) 959) NO: ID NO: 1425) 1483) BP003-T2P1H5 DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 734) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BP003T3P2-1 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLVEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1408) 1072) BP003T3P2-10 DVQMTQSPSSMYAS QDINR LSWFQ RAN RLVDGVPS LQYD FGGGT LGERVTFTCKAS Y (SEQ QKPGK (SEQ ID RFSGSGSG EFPYT KLEIK (SEQ ID NO: 872) ID NO: SPKTLI NO: QNYSLTISS (SEQ (SEQ ID 1201) Y (SEQ 1345) LEYEDMGI ID NO: NO: ID NO: YYC (SEQ 1106) 959) 1109) ID NO: 1357) BP003T3P2-11 DVQMTQSPSSMYAS QDINR LSWFQ RAN RLVDGVPS LQYD FGGGT LGERVTFTCKAS Y (SEQ QKPGK (SEQ ID RFSGSGSG EFPYT KLEIK (SEQ ID NO: 872) ID NO: SPKTLI NO: QNYSLTISS (SEQ (SEQ ID 1201) Y (SEQ 1345) LEYEDMGI ID NO: NO: ID NO: YYC (SEQ 1106) 959) 1109) ID NO: 1357) BP003T3P2-12 DVQMNQSPSSMYA QDINNF LSWFQ RAN RLVDGVPS LQYD FGGGT SLGERVTITCKAS (SEQ ID QKPGK (SEQ ID RFSGSGSG EFPWT KLEIK (SEQ ID NO: 870) NO: SPQTLI NO: QHYSLTISG (SEQ (SEQ ID 1200) Y (SEQ 1345) LEYEDLGIY ID NO: NO: ID NO: YC (SEQ ID 1105) 959) 1110) NO: 1356) BP003T3P2-13 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGESVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT GSPYT KLEIK (SEQ ID NO: 718) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 1216) 959) NO: NO: 1398) 1072) BP003T3P2-14 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1398) 1072) BP003T3P2-15 DVVMTQSPASLSAS ENSYS LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS Y (SEQ QKQGK (SEQ ID RFSGSGSGT GTPYT KLEIK (SEQ ID NO: 890) ID NO: SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID 52) VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 54) 959) NO: NO: 1399) 1072) BP003T3P2-16 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1398) 1072) BP003T3P2-17 DVQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 871) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1398) 1072) BP003T3P2-18 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGESVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT GSPYT KLEMK (SEQ ID NO: 718) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 1216) 961) NO: NO: 1398) 1072) BP003T3P2-19 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1398) 1072) BP003T3P2-2 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLVEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1408) 1072) BP003T3P2-20 DIVMTQSPASLSAS KNSYS LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS Y (SEQ QKQGK (SEQ ID RFSGSGSGT GTPYT KLEIK (SEQ ID NO: 807) ID NO: SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID 1057) VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 54) 959) NO: NO: 1399) 1072) BP003T3P2-21 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT GTPYT KLEMK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 54) 961) NO: NO: 1398) 1072) BP003T3P2-22 DIQMTQSPASLSAS ENSYS LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS Y (SEQ QKQGK (SEQ ID RFSGSGSGT GTPYT KLEIK (SEQ ID NO: 720) ID NO: SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID 52) VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 54) 959) NO: NO: 1399) 1072) BP003T3P2-23 DIQMTQSPASLSAS ENSYS LEWYQ NAK TLAEGVPS QHHY FGGGT VGESVTITCRAS Y (SEQ QKQGK (SEQ ID RFSGSGSGT GSPYT KLEIK (SEQ ID NO: 718) ID NO: SPQLL NO: 28) QFSLRINSL (SEQ (SEQ ID 52) VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 1216) 959) NO: NO: 1400) 1072) BP003T3P2-24 DIQMTQSPASLSAS ENSYS LEWYQ NAK TLAEGVPS QHHY FGGGT VGESVTITCRAS Y (SEQ QKQGK (SEQ ID RFSGSGSGT GSPYT KLEIK (SEQ ID NO: 718) ID NO: SPQLL NO: 28) QFSLRINSL (SEQ (SEQ ID 52) VY QPEDFGTY ID NO: NO: (SEQ ID YC (SEQ ID 1216) 959) NO: NO: 1400) 1072) BP003T3P2-25 DIQMTQSPASLSAS ENSYS LEWYQ NAK TLAEGVPS QHHY FGGGT VGESVTITCRTS Y (SEQ QKQGK (SEQ ID RFSGSGSGT GSPYT KLEMK (SEQ ID NO: 719) ID NO: SPQLL NO: 28) QFSLRINSL (SEQ (SEQ ID 52) VY QPEDFGTY ID NO: NO: (SEQ ID YC 1216) 961) NO: (SEQ ID 1072) NO: 1400) BP003T3P2-26 DIVLTQSPASLSASV ENIYSY VEWYQ NAK TLAEGVPS QHHY FGGGT GESVTITCRAS (SEQ (SEQ ID QKQGK (SEQ ID RFSGSGSGT GSPYT KLEMK ID NO: 770) NO: 930) SPQLL NO: 28) HFSLKINSL (SEQ (SEQ ID VY QPEDFGNY ID NO: NO: (SEQ ID YC (SEQ ID 1216) 961) NO: NO: 1397) 1433) BP003T3P2-27 DIXMTQSTSSLSASL QDISNY VNWY YAS RLHSGVPS QQGN FGGGT GDRXTITCRAS (SEQ (SEQ ID QQKPD (SEQ ID RFSGSGSGT TLPWT KLEIK ID NO: 832) NO: 27) GTVKL NO: DYSLTISNL (SEQ (SEQ ID LIY 1476) EQEDFANY ID NO: NO: (SEQ ID FC (SEQ ID 1255) 959) NO: NO: 1352) 1436) BP003T3P2-28 DIQMTQTTSSLSASL QDISNY LNWYQ HTS NLQSGVPS QQSNT FGGGT GDRVTISCRAS (SEQ (SEQ ID QKPDG (SEQ ID RFTGSGSG LPPT KLEIK ID NO: 760) NO: 27) TVKLLI NO: TDYSLTISN (SEQ (SEQ ID Y (SEQ 1002) LEQEDIATY ID NO: NO: ID NO: FC (SEQ ID 1272) 959) 1088) NO: 1151) BP003T3P2-29 DIQMTQTTSSLSASL QDISNY LNWYQ HTS RLQSGVPS QQSNS FGGGT GDRVTISCRAS (SEQ (SEQ ID QKPDG (SEQ ID RFTGSGSG LPPT KLEIK ID NO: 760) NO: 27) TVKLLI NO: TDYSLTISN (SEQ (SEQ ID Y (SEQ 1002) LEQEDIATY ID NO: NO: ID NO: FC (SEQ ID 1271) 959) 1088) NO: 1355) BP003T3P2-3 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLVEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1408) 1072) BP003T3P2-30 DIQMTQTTSSLSASL QDISNY LNWYQ HTS RLQSGVPS QQSNS FGGGT GDRVTISCRAS (SEQ (SEQ ID QKPDG (SEQ ID RFTGSGSG LPPT KLEIK ID NO: 760) NO: 27) TVKLLI NO: TDYSLTISN (SEQ (SEQ ID Y (SEQ 1002) LEQEDIATY ID NO: NO: ID NO: FC (SEQ ID 1271) 959) 1088) NO: 1355) BP003T3P2-31 DIQMTQTTSSLSASL QDISNY LNWYQ HTS RLQSGVPS QQSNS FGGGT GDRVTISCRAS (SEQ (SEQ ID QKPDG (SEQ ID RFTGSGSG LPPT KLEIK ID NO: 760) NO: 27) TVKLLI NO: TDYSLTISN (SEQ (SEQ ID Y (SEQ 1002) LEQEDIATY ID NO: NO: ID NO: FC (SEQ ID 1271) 959) 1088) NO: 1355) BP003T3P2-32 DIQMTQSTSSLSASL QDISNY LNWYQ YTS RLHSGVPS QQGN FGGGT GDRVTISCRAS (SEQ (SEQ ID QKPDG (SEQ ID RFSGSGSGT TLPPT KLEIK ID NO: 738) NO: 27) TVKLLI NO: DYSLTISNL (SEQ (SEQ ID Y (SEQ 1495) EQEDIATYF ID NO: C (SEQ ID ID NO: NO: 1088) NO: 1353) 1253) 959) BP003T3P2-33 DIQMTQTTSSLSASL QDISNY LNWYQ HTS RLQSGVPS QQSNS FGGGT GDRVTISCRAS (SEQ (SEQ ID QKPDG (SEQ ID RFTGSGSG LPPT KLEIK ID NO: 760) NO: 27) TVKLLI NO: TDYSLTISN (SEQ (SEQ ID Y (SEQ 1002) LEQEDIATY ID NO: NO: ID NO: FC (SEQ ID 1271) 959) 1088) NO: 1355) BP003T3P2-34 DIQMTQTTSSLSASL QDISNY LNWYQ HTS RLQSGVPS QQSNS FGGGT GDRVTISCRAS (SEQ (SEQ ID QKPDG (SEQ ID RFTGSGSG LPPT KLEIK ID NO: 760) NO: 27) TVKLLI NO: TDYSLTISN (SEQ (SEQ ID Y (SEQ 1002) LEQEDIATY ID NO: NO: ID NO: FC (SEQ ID 1271) 959) 1088) NO: 1355) BP003T3P2-35 DIQMTQTTSSLSASL QDISNY LNWYQ HTS NLQSGVPS QQSNT FGGGT GDRVTISCRAS (SEQ (SEQ ID QKPDG (SEQ ID RFTGSGSG LPPT KLEIK ID NO: 760) NO: 27) TVKLLI NO: TDYSLTISN (SEQ (SEQ ID Y (SEQ 1002) LEQEDIATY ID NO: NO: ID NO: FC (SEQ ID 1272) 959) 1088) NO: 1151) BP003T3P2-36 DIQMTQSTSSLSASL QDISNY LNWYQ HTS RLHSGVPS QQSNT FGGGT GDRVTITCRAS (SEQ (SEQ ID QKPDG (SEQ ID RFSGSESGT LPPT KLEIK ID NO: 740) NO: 27) TVKLLI NO: DYSLTISNL (SEQ (SEQ ID Y (SEQ 1002) EQEDIATYF ID NO: NO: ID NO: C (SEQ ID 1272) 959) 1088) NO: 1350) BP003T3P2-37 DVVMTQTTSSLSAS QDISNY LNWYQ HTS RLHSGVPS QQGN FGGGT LGDRVTITCRAS (SEQ ID QKPDG (SEQ ID RFSGSESGT TLPPT KLEIK (SEQ ID NO: 915) NO: 27) TVKLLI NO: DYSLTISNL (SEQ (SEQ ID Y (SEQ 1002) EQEDIATYF ID NO: NO: ID NO: C (SEQ ID 1253) 959) 1088) NO: 1350) BP003T3P2-38 DIQMTQSTSSLSASL QDISNY LNWYQ YTS RLHSGVPS QQGN FGGGT GDRVTISCRAS (SEQ (SEQ ID QKPDG (SEQ ID RFSGSGSGT TLPPT KLEIK ID NO: 738) NO: 27) TVKLLI NO: DYSLTISNL (SEQ (SEQ ID Y (SEQ 1495) EQEDIATYF ID NO: NO: ID NO: C (SEQ ID 1253) 959) 1088) NO: 1353) BP003T3P2-39 DIVMTQSTSSLSASL QDISNY LNWYQ HTS RLHSGVPS QQGN FGGGT GDRVTISCRAS (SEQ (SEQ ID QKPDG (SEQ ID RFSGSESGT TLPPT KLEIK ID NO: 828) NO: 27) TVKLLI NO: DYSLTISNL (SEQ (SEQ ID Y (SEQ 1002) EQEDIATYF ID NO: NO: ID NO: C (SEQ ID 1253) 959) 1088) NO: 1350) BP003T3P2-4 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLVEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1408) 1072) BP003T3P2-40 DIVMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 821) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1483) 1425) BP003T3P2-41 DIVITQSQKFMSTSV QNVGT VAWY SAS YRYSGVPD QQYN FGGGT GDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 766) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1483) 1425) BP003T3P2-42 DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 734) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1483) 1425) BP003T3P2-43 DIVLTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RITGRGSGT TYPYT KLEIK (SEQ ID NO: 773) ID NO: QSPKA NO: 13) DFTLTISNV (SEQ (SEQ ID 12) LIY QSEDLADY ID NO: NO: (SEQ ID FC (SEQ ID 1287) 959) NO: NO: 1488) 1425) BP003T3P2-44 DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT AGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 730) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BP003T3P2-45 DIVLTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG TYPYT KLEMK (SEQ ID NO: 773) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 1287) 961) NO: ID NO: 1425) 1483) BP003T3P2-46 RCPDDPSPSSLSASL QDIGLN LNWLQ ATS SLDSGVPK LQYAS FGAGT GERVSLTCRAS (SEQ ID QEPDG (SEQ ID RFSGSRSGS SPFT KLEIK (SEQ ID NO: 1347) NO: TIKRLI NO: DYSLTISSL (SEQ (SEQ ID 1198) Y (SEQ 618) ESEDFVDY ID NO: NO: ID NO: YC (SEQ ID 1097) 958) 1085) NO: 1366) BP003T3P2-47 DIVLTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RITGRGSGT TYPYT KLEIK (SEQ ID NO: 773) ID NO: QSPKA NO: 13) DFTLTISNV (SEQ (SEQ ID 12) LIY QSEDLADY ID NO: NO: (SEQ ID FC (SEQ ID 1287) 959) NO: NO: 1488) 1425) BP003T3P2-48 DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 734) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BP003T3P2-49 DTTVTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 858) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BP003T3P2-5 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1398) 1072) BP003T3P2-50 DIVMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 821) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BP003T3P2-51 MLVMTQTPLSLPVS QSLVH LHWYL KVS NRFSGVPD SQSTH FGGGT LGDQASISCRSS SNGNT QKPGQ (SEQ ID RFSVSGSGT VPPT KLEIK (SEQ ID NO: 1132) Y (SEQ SPKLLI NO: DFTLKISRV (SEQ (SEQ ID ID NO: Y (SEQ 1062) EAEDLGVY ID NO: NO: 1306) ID NO: FC (SEQ ID 1371) 959) 1076) NO: 1159) BP003T3P2-52 DTTVTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 858) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BP003T3P2-53 DVQMTQSQKFMST QNVGT VAWY SAS YRYSGVPD QQYN FGGGT SVGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 873) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ YFC (SEQ 15) 959) ID ID NO: NO: 1483) 1425) BP003T3P2-54 DIQMTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 734) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1425) 1483) BP003T3P2-55 DILLTQSQKFMSTSV QNVGT VAWY SAS YRYSGVPD QQYN FGGGT GDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 700) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BP003T3P2-56 DIVLTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQEPG (SEQ ID RFTGSGSG SYPYT KLEIK (SEQ ID NO: 773) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 959) NO: ID NO: 1423) 1483) BP003T3P2-57 DILLTQSQKFMSTSV QNVGT VAWY SAS YRYSGVPD QQYN FGGGT GDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 700) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BP003T3P2-58 DVVMTQSQKFMST QNVGT VAWY SAS YRYSGVPD QQYN FGGGT SVGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT KLEMK (SEQ ID NO: 894) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 15) 961) NO: ID NO: 1425) 1483) BP003T3P2-59 RHCESQSHKFMSTSI QDVRT VAWY STS YRYSGVPD QQYS GAGTK GDRVSITCKAS A (SEQ QQKPG (SEQ ID RFTGSGSG NYLTF LEIK (SEQ ID NO: ID NO: QSPKL NO: TDFTLTINS (SEQ (SEQ ID 1349) 1208) LIY 1386) VQSEDLAD ID NO: NO: (SEQ ID YFC (SEQ 1290) 974) NO: ID NO: 1427) 1481) BP003T3P2-6 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1398) 1072) BP003T3P2-60 DIVLTQSQKFMSTS QNVGT VAWY SAS YRYSGVPD QQYN FGGGT VGDRVSVTCKAS N (SEQ QQKPG (SEQ ID RITGRGSGT TYPYT KLEIK (SEQ ID NO: 773) ID NO: QSPKA NO: 13) DFTLTISNV (SEQ (SEQ ID 12) LIY QSEDLADY ID NO: NO: (SEQ ID FC (SEQ ID 1287) 959) NO: NO: 1488) 1425) BP003T3P2-61 DVHMNQSQKFMST QNVGT VXWY SAS YRYNGVPD XQYN FGGGT SVGNRVSVTCKGS N (SEQ QQKPG (SEQ ID RFTGSGSG SYPYT XLEIK (SEQ ID NO: 865) ID NO: QSPKA NO: 13) TDFTLTISN (SEQ (SEQ ID 12) LIY VQSEDLAE ID NO: NO: (SEQ ID YFC (SEQ 1475) 963) NO: ID NO: 1449) 1478) BP003T3P2-62 DIVMTQTPKFLLVS QSVNN WWY YAS NRYTGVPD QQAY FGGGT AGDRVTITCKAS D (SEQ QQKPG (SEQ ID RFTGSGYG WSPY KLEIK (SEQ ID NO: 830) ID NO: QSPKL NO: TDFTFTIST T (SEQ (SEQ ID 1309) LIY 1476) VQAEDLAV ID NO: NO: (SEQ ID YFC (SEQ 1248) 959) NO: ID NO: 1447) 1164) BP003T3P2-63 DIVMTQSPPTLSLSP QDVNT VAWY WAS TRHTGVPS QQHY FGGGT GERVTLSCKAS A (SEQ QQKPG (SEQ ID RFSGSGSGT SSPWT KLEIK (SEQ ID NO: 816) ID NO: QAPRL NO: DFTLTISSL (SEQ (SEQ ID 1206) LIY 1450) QPEDFATY ID NO: NO: (SEQ ID YC (SEQ ID 1258) 959) NO: NO: 1414) 1424) BP003T3P2-64 EIVMTQSPPTLSLSP QDVNT VAWY WAS TRHTGVPS QQHY FGGGT GERVTLSCKAS A (SEQ QQKPG (SEQ ID RFSGSGSGT SSPWT KLEIK (SEQ ID NO: 926) ID NO: QAPRL NO: DFTLTISSL (SEQ (SEQ ID 1206) LIY 1450) QPEDFATY ID NO: NO: (SEQ ID YC (SEQ ID 1258) 959) NO: NO: 1414) 1424) BP003T3P2-65 DIVMTQSPPTLSLSP QDVNT VAWY WAS TRHTGVPS QQHY FGGGT GERVTLSCKAS A (SEQ QQKPG (SEQ ID GFSGSGSG SSPWT KLEIK (SEQ ID NO: 816) ID NO: QAPRL NO: TDFTLTISS (SEQ (SEQ ID 1206) LIY 1450) LQPEDFAT ID NO: NO: (SEQ ID YYC (SEQ 1258) 959) NO: ID NO: 1424) 1413) BP003T3P2-66 RCQMNQSPSSLSAS QEISGY LSWLQ AAS TLDSGVPK LQYAS FGGGT LGERVSLTCRAS (SEQ ID QKPDG (SEQ ID RFSGSRSGS YPYT KLEMK (SEQ ID NO: 1348) NO: TIKRLT NO: DYSLTISSL (SEQ (SEQ ID 1210) Y (SEQ 599) ESEDFADY ID NO: NO: ID NO: YC (SEQ ID 1103) 961) 1112) NO: 1402) BP003T3P2-67 DVVLTQTPLSLPVSL QSIVHS LEWYL KVS NRFSGVPD FQGSH FGGGT GDQASISCRSS (SEQ NGNTY QKPGQ (SEQ ID RFSGSGSGT VPPT KLEMK ID NO: 874) (SEQ ID SPKLLI NO: DFTLKISRV (SEQ (SEQ ID NO: Y (SEQ 1062) EAEDLGVY ID NO: NO: 1299) ID NO: YC (SEQ ID 966) 961) 1071) NO: 1158) BP003T3P2-68 DVVVTQTPLSLPVS QSIVHS LEWYL KVS NRFSGVPD FQGSH FGGGT LGDQASISCRSS NGNTY QKPGQ (SEQ ID RFSGSGSGT VPRT KLEIK (SEQ ID NO: 918) (SEQ ID SPKLLI NO: DFTLKISRV (SEQ (SEQ ID NO: Y (SEQ 1062) EAEDLGVY ID NO: NO: 1299) ID NO: YC (SEQ ID 967) 959) 1071) NO: 1158) BP003T3P2-69 DVVMTQTPLSLPVS QSIVHN LEWYL KVS NRFSGVPD FQGSY FGGGT LGDQASISCRSN NGNTY QKPGQ (SEQ ID RFSGSGSGT VPRT KLEIK (SEQ ID NO: 899) (SEQ ID SPKLLI NO: DFTLKISRV (SEQ (SEQ ID NO: Y (SEQ 1062) EAEDLGVY ID NO: NO: 1298) ID NO: YC (SEQ ID 971) 959) 1071) NO: 1158) BP003T3P2-7 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1398) 1072) BP003T3P2-70 DVVMTQTPLSLPVS QSIVHS LEWYL KVS NRFSGVPD FQGSH FGGGT LGDQASISCRSS NGNTY QKPGQ (SEQ ID RFSGSGSGT VPPT KLEIK (SEQ ID NO: 900) (SEQ ID SPKLLI NO: DFTLKISRV (SEQ (SEQ ID NO: Y (SEQ 1062) EAEDLGVY ID NO: NO: 1299) ID NO: YC (SEQ ID 966) 959) 1071) NO: 1158) BP003T3P2-71 DVVLTQTPLSLPVSL QSIVHS LEWYL KVS NRFSGVPD FQGSH FGGGT GDQASISCRSS (SEQ NGNTY QKPGQ (SEQ ID RFSGSGSGT VPPT KLEIK ID NO: 874) (SEQ ID SPKLLI NO: DFTLKISRV (SEQ (SEQ ID NO: Y (SEQ 1062) EAEDLGVY ID NO: NO: 1299) ID NO: YC (SEQ ID 966) 959) 1071) NO: 1158) BP003T3P2-72 DVVMTQTPLSLPVS QSIVHS LEWYL KVS NRFSGVPD FQGSH GGGTK LGDQASISCRSS NGNTY QKPGQ (SEQ ID RFSGSGSGT VPTF KLEIK (SEQ ID NO: 900) (SEQ ID SPKLLI NO: DFTLKISRV (SEQ (SEQ ID NO: Y (SEQ 1062) EAEDLGVY ID NO: NO: 1299) ID NO: YC (SEQ ID 968) 978) 1071) NO: 1158) BP003T3P2-73 DVVVTQTPLSLPVS QSIVHS LEWYL KVS NRFSGVPD FQGSH FGGGT LGDQASISCRSS NGNTY QKPGQ (SEQ ID RFSGSGSGT VPPT KLEIK (SEQ ID NO: 918) (SEQ ID SPKLLI NO: DFTLKISRV (SEQ (SEQ ID NO: Y (SEQ 1062) EAEDLGVY ID NO: NO: 1299) ID NO: YC (SEQ ID 966) 959) 1071) NO: 1158) BP003T3P2-74 DVVLTQTPLSLPVSL QSIVHS LEWYL KVS NRFSGVPD FQGSH FGGGT GDQASISCRSS (SEQ NGNTY QKPGQ (SEQ ID RFSGSGSGT VPPT KLEIK ID NO: 874) (SEQ ID SPKLLI NO: DFTLKISRV (SEQ (SEQ ID NO: Y 1062) EAEDLGVY ID NO: NO: 1299) (SEQ YC 966) 959) ID NO: (SEQ ID 1071) NO: 1158) BP003T3P2-75 DIQMNQSHKFMSTS QDVST VAWY SAS YRYTGVPD QQHY FGGGT VGDRVSITCKAS A (SEQ QQKPG (SEQ ID RFTGSGSG STPYT KLEIK (SEQ ID NO: 713) ID NO: QSPKL NO: 13) TDFTFTISS (SEQ (SEQ ID 1209) LIY VQAEDLAV ID NO: NO: (SEQ ID YYC (SEQ 1265) 959) NO: ID NO: 1427) 1491) BP003T3P2-8 DIQMTQSPASLSAS ENIYSY LEWYQ NAK TLAEGVPS QHHY FGGGT VGETVTITCRAS (SEQ ID QKQGK (SEQ ID RFSGSGSGT DTPYT KLEIK (SEQ ID NO: 720) NO: 930) SPQLL NO: 28) QFSLKINSL (SEQ (SEQ ID VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 30) 959) NO: NO: 1398) 1072) BP003T3P2-9 DIVMTQSPASLSAS DNIYN LEWYQ NAK TLGEGVPS QHHY FGGGT VGETVTITCRAS Y (SEQ QKQGK (SEQ ID RFSGSGSGT GSPW KLEIK (SEQ ID NO: 807) ID NO: SPQLL NO: 28) QFYLKINSL T (SEQ (SEQ ID 833) VY QPEDFGSY ID NO: NO: (SEQ ID YC (SEQ ID 1215) 959) NO: NO: 1404) 1072)

TABLE 5A Exemplary Clones-Heavy Chain Sequences ID HFR1 CDRH1 HFR2 CDRH2 HFR3 CDRH3 HFR4 AH04507 QVQLQQSGAELVRPG GYTFTNYW IGWVK IHPGGG DYNEKFT VSRNFA WGQGT TSVKMSCKAA (SEQ (SEQ ID NO: QRPGH YI (SEQ GKATLTA K (SEQ ID LVTVSA ID NO: 1326) 4) GLEWI ID NO: DTSSSTA NO: 1444) (SEQ ID GD 1014) YMQLSSL NO: 421) (SEQ ID TSEDSAIY NO: YC (SEQ 1010) ID NO: 923) AH04522 QIQLQQSGAELVRPGT GYTFTNYW IGWVK IHPGGG NYNEKFK TSRNFAY WGQGT SVKMSCKAA (SEQ (SEQ ID NO: QRPGH YT (SEQ GKATLTA (SEQ ID LVTVSA ID NO: 1228) 4) GLEWI ID NO: DTSSSTA NO: 1419) (SEQ ID GD 1015) YMQLSSL NO: 421) (SEQ ID TSEDSAIY NO: YC (SEQ 1010) ID NO: 1177) AH04526 QVQLQQSGAELVRPG GYTFTNYW IGWVK IHPGGD NYNEKFK TSRNFAY WGQGT TSVKMSCKAA (SEQ (SEQ ID NO: QRPGH YS (SEQ GKATLTA (SEQ ID PVTVSS ID NO: 1326) 4) GLEWI ID NO: DTSSSTA NO: 1419) (SEQ ID GD 1012) YMNLSSL NO: 398) (SEQ ID TSEDSAIY NO: YC (SEQ 1010) ID NO: 1174) AH04527 QVQLQQSGAELVRPG GYTFTNYW IGWVK IHPGGG DYNEKFT VSRNFA WGQGT TSVKMSCKAA (SEQ (SEQ ID NO: QRPGH YI (SEQ GKATLTA K (SEQ ID LVTVSA ID NO: 1326) 4) GLEWI ID NO: DTSSSTA NO: 1444) (SEQ ID GD 1014) YMQLSSL NO: 421) (SEQ ID TSEDSAIY NO: YC (SEQ 1010) ID NO: 923) AH04734 QVQLQQPAAELARPG GYTFTTST MHWV INPRSG EYNQKFK ARHYYF WGQGT ASVKMSCKAS (SEQ (SEQ ID NO: KQRPG YT (SEQ DKTTLTA DY (SEQ TVTVSS ID NO: 467) 993) QGLEW ID NO: DKSSSTA ID NO: (SEQ ID IGY 1024) YMQLSSL 612) NO: 422) (SEQ ID TSEDSAV NO: YYC (SEQ 190) ID NO: 519) AH04750 QVQLQQPGAEMAKP GYTSTAYW IHWVK ITPSTGY EYNQKFE ARGGYF WGQGT GASVKMSCKAS (SEQ (SEQ ID NO: QRPGQ T (SEQ DKATLTA DY (SEQ TVTVSS ID NO: 1320) 994) GLEWI ID NO: DKSSNTA ID NO: (SEQ ID GY 1028) YMQLNSL 606) NO: 422) (SEQ ID TSEDSAV NO: YYC (SEQ 196) ID NO: 953) AH05214 QIQLQQPGAELVKPG GYTFTSYW MHWV INPSNG NYNEKFK ARQLAA WGQGT ASVKLPCKAS (SEQ (SEQ ID NO: KQRPG RT (SEQ SKATLTV Y (SEQ ID TVTVSS ID NO: 1219) 157) QGLEW ID NO: DKSSSTA NO: 614) (SEQ ID IGE 510) YMQLSSL NO: 422) (SEQ ID TSEDSAV NO: YYC (SEQ 209) ID NO: 289) AH05247 QVQLQQSGADLMKP GYTFSNYW IEWIKQ ILPGSGF NYNENFK ARGGTS WGQGT GASVKMSCRAS (SEQ (SEQ ID NO: RPGHG T (SEQ GKATFTA WHFDS TLTVSS ID NO: 1321) 986) LEWIG ID NO: DTSSNTT (SEQ ID (SEQ ID E (SEQ 1021) YMLLSSL NO: 604) NO: 425) ID NO: SSEDSAV 1005) YYC (SEQ ID NO: 1187) AH05249 QVQLQQSGADLMKP GYTFSNYW IEWIKQ ILPGSGF NYNENFK ARGGTS WGQGT GASVKMSCRAS (SEQ (SEQ ID NO: RPGHG T (SEQ GKATFTA WHFDS TLTVSS ID NO: 1321) 986) LEWIG ID NO: DTSSNTT (SEQ ID (SEQ ID E (SEQ 1021) YMLLSSL NO: 604) NO: 425) ID NO: SSEDSAV 1005) YYC (SEQ ID NO: 1187) AH05251 EVRLQQSGAELVRSG GFNIKDYY IHWVK IDPDNG EYAPKFQ TVFWYG WGQGT ASVKLSCTAS (SEQ (SEQ ID NO: QRPEQ ET (SEQ GKATMT NNYAGF LVTVSS ID NO: 943) 977) GLEWI ID NO: ADTSSNT AY (SEQ (SEQ ID GW 1003) AHLQLSS ID NO: NO: 413) (SEQ ID LTSEDTA 1420) NO: VYYC 1017) (SEQ ID NO: 946) AH05256 QVQLQQPGAELAKPG GYTFTRYW IHWVK INPRTD EYNQKFK ARHGYF WGQGT ASVKMSCKAS (SEQ (SEQ ID NO: QRPGQ YT (SEQ DKATLTA DY (SEQ TLTVSS ID NO: 114) 992) DLEWI ID NO: DKSSSTA ID NO: (SEQ ID GY 1025) YMQLSSL 611) NO: 425) (SEQ ID TSDDSAV NO: YYC (SEQ 1018) ID NO: 955) AH05257 QVQLQQSGAELVRPG GYTFTDYA MHWV ISTYSG IYNQKFK ARGVTF WGQGT VSLKISCKGS (SEQ (SEQ ID NO: RQSHA DA (SEQ GKATMT DY (SEQ TLTVSA ID NO: 1337) 19) KSLEW ID NO: VDKSSST ID NO: (SEQ ID IGV 21) AYLELAR 23) NO: (SEQ ID LTSEDSAI 1452) NO: YYC (SEQ 1128) ID NO: 1034) AH05258 QIQLQQSGAELVRPG GYTFTDYA MHWV ISTYSG SYNQKFK ARGVTF WGQGT VSVKISCKGS (SEQ (SEQ ID NO: KQSHA DV (SEQ GKATMT DS (SEQ TLTVSS ID NO: 1240) 19) KSLEW ID NO: VDKSSST ID NO: (SEQ ID IGV 46) AYMELA 48) NO: 425) (SEQ ID RLTSEDS NO: AIYYC 1126) (SEQ ID NO: 1389) AH05259 QVQLQQSGAELVRPG GYTFTDYA MHWV ISTYSG SYNQKFK ARGVTF WGQGT VSVKISCKGS (SEQ (SEQ ID NO: KQSHA DV (SEQ GKATMT DS (SEQ SLTVSS ID NO: 1338) 19) KSLEW ID NO: VDKSSST ID NO: (SEQ ID IGV 46) AYMELA 48) NO: 424) (SEQ ID RLTSEDS NO: AIYYC 1126) (SEQ ID NO: 1389) AH05268 QVQLQQSGAELVRPG GYTFTDYA MHWV ISTYSG LYNQKFK ARGVTF WGQGT VSLKISCKGS (SEQ (SEQ ID NO: RQSHA DA (SEQ GKATMT DY (SEQ TLTVSS ID NO: 1337) 19) KSLEW ID NO: VDKSSST ID NO: (SEQ ID IGV 21) AYLELAR 23) NO: 425) (SEQ ID LTSDDSAI NO: YYC (SEQ 1128) ID NO: 1119) AH05271 QVQLQQSGAELVRPG GYTFTDYA MHWV ISTYSG SYNQKFK ARGVTF WGQGT VSVKISCKGS (SEQ (SEQ ID NO: KQSHA DV (SEQ GKATMT DS (SEQ TLTVSS ID NO: 1338) 19) KSLEW ID NO: VDKSSST ID NO: (SEQ ID IGV 46) AYMELA 48) NO: 425) (SEQ ID RLTSEDS NO: ATYYC 1126) (SEQ ID NO: 1390) AH05274 QVQLQQSGAELVRPG GYTFTNYW LGWIK IYPGGG NYNEKFK ARVTPAS WGQGT TSVKISCKAS (SEQ (SEQ ID NO: QRPGH YT (SEQ GKATLTA (SEQ ID SLTVSS ID NO: 1325) 4) GLEWI ID NO: 6) DTSSSTA NO: 8) (SEQ ID GD YMQLSSL NO: 424) (SEQ ID TSEDSAV NO: YFC (SEQ 1074) ID NO: 1178) AH05280 EVRLQQSGADLMKPG GYTFSNYW TEWIK ILPGSGF NYNENFK ARGGTS WGQGT ASVKISCKTS (SEQ (SEQ ID NO: QRPGH T (SEQ GKATFTA WHFDY SLTVSS ID NO: 941) 986) GLEWI ID NO: DTSSNTT (SEQ ID (SEQ ID GE 1021) YMQLSSL NO: 605) NO: 424) (SEQ ID TSEDSAV NO: YYC (SEQ 1392) ID NO: 1188) AHO5285 DVQLQESGAELAKPG GYTFTRFW MHWV INPSTD EYNQKFK ARGTW WGQGA ASVKMSCKAS (SEQ (SEQ ID NO: KQRPG YT (SEQ DKATLTA DY (SEQ TVTVSS ID NO: 866) 991) QGLEW ID NO: DKSSSTA ID NO: (SEQ ID IGY 1027) YMQLSSL 607) NO: (SEQ ID TSEDSAV 1451) NO: YYC (SEQ 190) ID NO: 265) AH05286 QVQLKQSGADLMKP GYTFSNYW IEWIKQ ILPGSG NYNENFK ARGGTSF WGQGT GASVKISCKAS (SEQ (SEQ ID NO: RPGHG YT (SEQ GKATFTA VHFDY TLTVSS ID NO: 1312) 986) LEWIG ID NO: DTSSNTT (SEQ ID (SEQ ID E (SEQ 1022) YIQLSSLS NO: 602) NO: 425) ID NO: SEDSAVY 1005) YC (SEQ ID NO: 1186) AH4501 QVQLQQPGAELVRPG GYTFTNYW IGWVK IHPGGD NYNEKFK TSRNFAY WGQGT TSVKMSCKAA (SEQ (SEQ ID NO: QRPGH YS (SEQ GKATLTA (SEQ ID LVTVSA ID NO: 1315) 4) GLEWI ID NO: DTSSSTA NO: 1419) (SEQ ID GD 1012) YMNLSSL NO: 421) (SEQ ID TSEDSAIY NO: YC (SEQ 1010) ID NO: 1174) AH4502 QIQLQQSGAELVRPGT GYTFTNYW IGWVK IHPGGG NYNEKFK TSRNFAY WGQGT SVKMSCKAA (SEQ (SEQ ID NO: QRPGH YT (SEQ GKATLTA (SEQ ID LVTVSA ID NO: 1228) 4) GLEWI ID NO: DTSSSTA NO: 1419) (SEQ ID GD 1015) DMQLSSL NO: 421) (SEQ ID TSEDSAIY NO: YC (SEQ 1010) ID NO: 1173) AH4503 QVQLQQPGAELVRPG GYTFSNYW IGWVK IHPGGG NYNEKFT VSRNFA WGQGT TSVKMSCKAA (SEQ (SEQ ID NO: QRPGH YI (SEQ GKATLTA N (SEQ ID LVTVSA ID NO: 1315) 986) GLEWI ID NO: DTSSSTA NO: 1445) (SEQ ID GD 1014) YMQLSSL NO: 421) (SEQ ID TSEDSAIY NO: YC (SEQ 1010) ID NO: 1184) AH4505 DVQLQQSGAELVRPG GYTFTNYW IGWVK IHPGGG NYNEKFK TSRNFAY WGQGT TSVKMSCKAA (SEQ (SEQ ID NO: QRPGH YT (SEQ GKATLTA (SEQ ID LVTVSA ID NO: 867) 4) GLEWI ID NO: DTSSSTA NO: 1419) (SEQ ID GD 1015) YMQLSSL NO: 421) (SEQ ID TSEGSAIY NO: YC (SEQ 1010) ID NO: 1179) AH4509 QIQLQQSGAELVRPGT GYTFTNYW IGWVK FYPGGD NYNEKFK TSRNFAY WGQGT SVKMSCKAA (SEQ (SEQ ID NO: QRPGH YI (SEQ GKATLTA (SEQ ID PVTVSS ID NO: 1228) 4) GLEWI ID NO: DTSSSTA NO: 1419) (SEQ ID GD 973) YMQLSSL NO: 398) (SEQ ID TSEDSAIY NO: YC (SEQ 1010) ID NO: 1177) AH4511 QIQLQQSGAELVRPGT GYTFSNYW IGWVK IHPGGG NYNEKFT VSRNFA WGQGT SVKMSCKAA (SEQ (SEQ ID NO: QRPGH YI (SEQ GKATLTA N (SEQ ID LVTVSA ID NO: 1228) 986) GLEWI ID NO: DTSSSTA NO: 1445) (SEQ ID GD 1014) YMQLSSL NO: 421) (SEQ ID TSEDSAIY NO: YC (SEQ 1010) ID NO: 1184) AH4518 QVQLQQSGAELVRPG GYTFTNYW IGWVK IHPGGD NYNEKFK TSRNFAY WGQGT TSVKMSCKAA (SEQ (SEQ ID NO: QRPGH YS (SEQ GKATLTA (SEQ ID LVTVSA ID NO: 1326) 4) DLEWI ID NO: DTSSSTA NO: 1419) (SEQ ID GD 1012) YMNLSSL NO: 421) (SEQ ID TSEDSAIY NO: YC (SEQ 1009) ID NO: 1174) AH4523 QIQLQQSGAELVRPGT GYTFTNYW IGWVK IHPGGS NYNENFK TSRNFAK WGQGT SVKMSCKAA (SEQ (SEQ ID NO: QRPGH YT (SEQ GKATFTA (SEQ ID PVTVSS ID NO: 1228) 4) GLEWI ID NO: DTSSSTT NO: 1418) (SEQ ID GD 1016) YMQLSSL NO: 398) (SEQ ID TSEDSAIY NO: FC (SEQ 1010) ID NO: 1189) AH4524 QIQLQQSGAELVRPGT GYTFTNYW IGWVK IHPGGD NYNEKFK TSRNFAY WGQGT SVKMSCKAA (SEQ (SEQ ID NO: QRPGH YS (SEQ GKATLTA (SEQ ID LVTVSA ID NO: 1228) 4) GLEWI ID NO: DTSSSTA NO: 1419) (SEQ ID GD 1012) YMSLSSL NO: 421) (SEQ ID TSEDSAIY NO: YC (SEQ 1010) ID NO: 1180) AH4525 QVQLQQSGAELVRPG GYTFTNYW IGWIK IHPGGD NYNEKFK TGRNFA WGQGT TSVKMSCKAA (SEQ (SEQ ID NO: QRPGH YT (SEQ GKATLTA Y (SEQ ID LVTVSS ID NO: 1326) 4) GLEWI ID NO: DTFSSTA NO: 1395) (SEQ ID GD 1013) YMQLSSL NO: 413) (SEQ ID TSEDSAIY NO: YC (SEQ 1007) ID NO: 1171) D11 QIQLQQPGAELVRPG GYTFTDYA MHWV ISTYSG IYNQKFK ARGVTF WGQGT VSLKISCKGS (SEQ (SEQ ID NO: RQSHA DA (SEQ GKATMT DY (SEQ TVTVSS ID NO: 1223) 19) KSLEW ID NO: VDKSSST ID NO: (SEQ ID IGV 21) AYLELAR 23) NO: 422) (SEQ ID LTSDDSAI NO: YYC (SEQ 1128) ID NO: 1033) D17 QIQLQQSGAELVRPGT GYTFTNYW LGWV IYPGGG NYNEKFK ARVTPAS WGQGT SVKISCKAS (SEQ (SEQ ID NO: KQRPG YT (SEQ GKATLTA (SEQ ID TLTVSA ID NO: 1227) 4) HGLEW ID DTSSSTA NO: 8) (SEQ ID IGD NO: 6) YMQLSSL NO: (SEQ ID TSEDSAV 1452) NO: YFC (SEQ 1075) ID NO: 1178) D34 QVQLQQSGAELVRPG GYTFTDYA MHWV ISTYSG SYNQKFK ARGVTF WGQGT VSVKISCKGS (SEQ (SEQ ID NO: KQSHA DV (SEQ GKATMT DS (SEQ TVTVSS ID NO: 1338) 19) KSLEW ID NO: VDKSSST ID NO: (SEQ ID IGV 46) AYMELA 48) NO: 422) (SEQ ID RLTSEDS NO: AIYYC 1126) (SEQ ID NO: 1389) D36 QVQLQQPGAELVRPG GYTFTDYA MHWV ISTYSG LYNQKFK ARGVTF WGQGT VSLKISCKGS (SEQ (SEQ ID NO: RQSHA DA (SEQ GKATMT DY (SEQ TLTVSS ID NO: 1319) 19) KSLEW ID NO: VDKSSST ID NO: (SEQ ID IGV 21) AYLELAR 23) NO: 425) (SEQ ID LTSEDSAI NO: YYC (SEQ 1128) ID NO: 1120) D5 QVQLQQSGAELVRPG GYTFTNYW LGWV IYPGGG NYNEKFK ARVTPAS WGQGT TSVKISCKAS (SEQ (SEQ ID NO: KQRPG YT (SEQ GKATLTA (SEQ ID SLTVSS ID NO: 1325) 4) HGLEW ID DTSSSTA NO: 8) (SEQ ID IGD NO: 6) YMQLSSL NO: 424) (SEQ ID TSEDSAV NO: YFC (SEQ 1075) ID NO: 1178) BP003- QVQLQQSGAELVRPG GYTFTNYW LGWV IYPGGG NYNEKFK ARVTPAS WGQGT T2P1C4 TSVKISCKAS (SEQ (SEQ ID NO: KQRPG YT (SEQ GKATLTA (SEQ ID TVTVSS ID NO: 1325) 4) HGLEW ID DTSSSTA NO: 8) (SEQ ID IGD NO: 6) YMQLSSL NO: 422) (SEQ ID TSEDSAV NO: YFC (SEQ 1075) ID NO: 1178) BP003- QIQLQQPGAELVRPGT GYTFTNYW LGWV IYPGGG NYNEKFK ARVTPAS WGQGT T2P1D10 SVKISCKAS (SEQ (SEQ ID NO: KQRPG YT (SEQ GKATLTA (SEQ ID SLTVSS ID NO: 1220) 4) HGLEW ID DTSSSTA NO: 8) (SEQ ID IGD NO: 6) YMQLSSL NO: 424) (SEQ ID TSEDSAV NO: YFC (SEQ 1075) ID NO: 1178) BP003- QAYLQQSGAELVRSG GFNIKDYY IHWVK IDPDNG EYAPKFQ TVFWYG WGQGT T2P1D7 ASVKLSCTAS (SEQ (SEQ ID NO: QRPEQ ET (SEQ GKATMT NNYAGF LVTVSA ID NO: 1197) 977) GLEWI ID NO: ADTSSNT AY (SEQ (SEQ ID GW 1003) AHLQLSS ID NO: NO: 421) (SEQ ID LTSEDTA 1420) NO: VYYC 1017) (SEQ ID NO: 946) BP003- QIQLQQSGAELVRPGT GYTFTNYW IGWVK IHPGGG NYNEKFK TSRNFAY WGQGT T2P1E3 SVKMSCKAA (SEQ (SEQ ID NO: QRPGH YT (SEQ GKATLTA (SEQ ID PVTVSS ID NO: 1228) 4) GLEWI ID NO: DTSSSTA NO: 1419) (SEQ ID GD 1015) YMQLSSL NO: 398) (SEQ ID TSEDSAIY NO: YC (SEQ 1010) ID NO: 1177) BP003- QVQLQQSGAELVRPG GYTFTDYA MHWV ISTYSG IYNQKFK ARGVTF WGQGT T2P1D1 VSLKISCKGS (SEQ (SEQ ID NO: RQSHA DA (SEQ GKATMT DY (SEQ TVTVSS ID NO: 1337) 19) KSLEW ID NO: VDKSSST ID NO: (SEQ ID IGV 21) AYLELAR 23) NO: 422) (SEQ ID LTSDDSAI NO: YYC (SEQ 1128) ID NO: 1033)

TABLE 5B Exemplary Clones-Light Chain Sequences ID LFR1 CDRL1 LFR2 CDRL2 LFR3 CDRL3 LFR4 AH04507 DTTVTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK (SEQ ID NO: 858) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 959) AH04522 DTTVTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKA (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK G (SEQ ID NO: 856) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 959) AH04526 DTTVTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEMK (SEQ ID NO: 858) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 961) AH04527 DVVMTQSQKFMS QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT TSVGDRVSVTCKA (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK S (SEQ ID NO: 894) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 959) AH04734 DIQMTQSTSSLSAS QDIRNY LNWYQQK YTS RLHSGVPSRFS QQGNT SGGGT LGDRVTISCRAS (SEQ ID PDGTVKLL (SEQ ID GSGSGTDYSL LPPT KLEIK (SEQ ID NO: 738) NO: 1202) IY (SEQ ID NO: TISNLEQEDIA (SEQ ID (SEQ ID NO: 1088) 1495) TYFC (SEQ ID NO: NO: NO: 1353) 1253) 1364) AH04750 DIQMTQTTSSLSA QDISNY LNWYQQK YTS RLHSGVPSRFS QQGNT FGGGT SLGDRVTISCRAS (SEQ ID PDGTVKLL (SEQ ID GSGSGTDYSL LPPT KLEMK (SEQ ID NO: 760) NO: 27) IY (SEQ ID NO: TISNLEQEDIA (SEQ ID (SEQ ID NO: 1088) 1495) TYFC (SEQ ID NO: NO: NO: 1353) 1253) 961) AH05214 DILLTQSPALMAA SSISSSN LHWYQQK GTS NLASGVPVRF QQWSS FGGGT SPGEKVTITCSVS (SEQ ID SETSPKPW (SEQ ID SGSGSGTSYSL YPLT KLEIK (SEQ ID NO: 698) NO: 1382) IY (SEQ ID NO: 983) TISSMEAEDA (SEQ ID (SEQ ID NO: 1078) ATYYC (SEQ NO: NO: ID NO: 1147) 1277) 959) AH05247 DIVMTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPLT KLEIK (SEQ ID NO: 821) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 42) NO: ID NO: 1483) 959) AH05249 DIVMTQTPKFLLV QSVNND VVWYQQK YAS NRYTGVPDRF QQDYR FGGGT SAGDRVTITCKAS (SEQ ID PGQSPKLL (SEQ ID TGSGYGTDFT SPYT KLEIK (SEQ ID NO: 830) NO: 1309) IY (SEQ ID NO: FTISTVQAEDL (SEQ ID (SEQ ID NO: 1447) 1476) AVYFC (SEQ NO: NO: ID NO: 1164) 1249) 959) AH05251 DVVMTQTPLSLPV QSIVHSN LEWYLQK KVS NRFSGVPDRF FQGSH FGGGT NLGDQASISCRSS GNTY PGQSPKLL (SEQ ID SGSGSGTDFTL VPPT KLEIK (SEQ ID NO: 898) (SEQ ID IY (SEQ ID NO: KISRVEAEDL (SEQ ID (SEQ ID NO: 1299) NO: 1071) 1062) GIYYC (SEQ ID NO: NO: NO: 1156) 966) 959) AH05256 DIQMTQTTSSLSA QDISNY LNWYQQK HTS RLQSGVPSRFT QQSNS FGGGT SLGDRVTISCRAS (SEQ ID PDGTVKLL (SEQ ID GSGSGTDYSL LPPT KLEIK (SEQ ID NO: 760) NO: 27) IY (SEQ ID NO: TISNLEQEDIA (SEQ ID (SEQ ID NO: 1088) 1002) TYFC (SEQ ID NO: NO: NO: 1355) 1271) 959) AH05257 DIVMTQSTSSLSAS QDISNY LSWYQQK YTS RLHSGVSSRFS QQGHT FGGGT LGDRVTISCRAS (SEQ ID PDGTIKLLI (SEQ ID GSGSGTDYSL LPPT KLEIK (SEQ ID NO: 828) NO: 27) Y (SEQ ID NO: TISNLEQEDFA (SEQ ID (SEQ ID NO: 1113) 1495) TYFC (SEQ ID NO: NO: NO: 1354) 1252) 959) AH05258 DIVMTQSHKFMST QDVSTA VAWYQQK SAS YRYTGVPDRF QQHYS FGSGT SVGDRVSITCKAS (SEQ ID PGQSPKLL (SEQ ID TGSGSGTDFTF TPFT KLEIK (SEQ ID NO: 800) NO: 1209) IY (SEQ ID NO: 13) TISSVQAEDLA (SEQ ID (SEQ ID NO: 1427) VYYC (SEQ ID NO: NO: NO: 1491) 1260) 965) AH05259 DIQMTQTPASLSA ENIYSF LEWFQQK NAK TLAEGVPSRFS QHHYG FGGGT SVGETVTITCRAS (SEQ ID QGKSPQLL (SEQ ID VSGSGTQFSL IPYT KLEIK (SEQ ID NO: 744) NO: 928) VY (SEQ ID NO: 28) KINSLQPEDFG (SEQ ID (SEQ ID NO: 1070) SYYC (SEQ ID NO: NO: NO: 1401) 1214) 959) AH05268 DVQMTQSPSSMY QDINRY LSWFQQK RAN RLVDGVPSRF LQYDE FGGGT ASLGERVTFTCKA (SEQ ID PGKSPKTL (SEQ ID SGSGSGQNYS FPYT KLEIK S (SEQ ID NO: 872) NO: 1201) IY (SEQ ID NO: LTISSLEYEDM (SEQ ID (SEQ ID NO: 1109) 1345) GIYYC (SEQ ID NO: NO: NO: 1357) 1106) 959) AH05271 DIQMTQTPASLAA ENIYFS LAWYQQK NAN TLEDGVPSRFS KQAYD FGGGT SVGETVTITCRAS (SEQ ID QGKSPQLL (SEQ ID GSGSGTQFSM VPWT KLEIK (SEQ ID NO: 743) NO: 927) IY (SEQ ID NO: KINNMQPEDT (SEQ ID (SEQ ID NO: 1068) 1142) ATYFC (SEQ NO: NO: ID NO: 1403) 1058) 959) AH05274 DIQMTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK (SEQ ID NO: 734) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 959) AH05280 DIVMTQTPKFLLV QSVNND VLWYQQK YAS NRYTGVPDRF QQAY FGGGT SAGDRVTITCKAS (SEQ ID PGQSPKLL (SEQ ID TGSGYGTDFT WSPYT KLEIK (SEQ ID NO: 830) NO: 1309) IY (SEQ ID NO: FTISTVQAEDL (SEQ ID (SEQ ID NO: 1435) 1476) AVYFC (SEQ NO: NO: ID NO: 1164) 1248) 959) AH05285 DIQMTQTTSSLSA QDISNY LNWYQQK YTS RLHSGVPSRFS QQGNT FGGGT SLGDRVTISCRAS (SEQ ID SDGTVKLL (SEQ ID GSGSGTDYSL LPPT KLEMK (SEQ ID NO: 760) NO: 27) IY (SEQ ID NO: TISNLEQEDIA (SEQ ID (SEQ ID NO: 1089) 1495) TYFC (SEQ ID NO: NO: NO: 1353) 1253) 961) AH05286 DIVLTQSPPTLSLS QDVNTA VAWYQQK WAS TRHTGVPSRFS QQHYS FGGGT PGERVTLSCKAS (SEQ ID PGQAPRLL (SEQ ID GSGSGTDFTL SPWT KLEIK (SEQ ID NO: 771) NO: 1206) IY (SEQ ID NO: TISSLQPEDFA (SEQ ID (SEQ ID NO: 1424) 1450) TYYC (SEQ ID NO: NO: NO: 1414) 1258) 959) AH4501 DVVMTQTQKFTS QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT TSVGDRVSVTCKA (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK S (SEQ ID NO: 911) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 959) AH4502 DIVMTQSQKFMST QNVGIN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK (SEQ ID NO: 821) NO: 1243) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 959) AH4503 DIQMTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPWT KLEIK (SEQ ID NO: 734) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 36) NO: ID NO: 1483) 959) AH4505 DTTVTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEMK (SEQ ID NO: 858) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 961) AH4509 DTTVTQSQRFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNN FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKPLI (SEQ ID TGSGSGTDFT SPLT KLEIK (SEQ ID NO: 863) NO: 12) Y (SEQ ID NO: 13) LTINNVQSEDL (SEQ ID (SEQ ID NO: 1429) AEYFC (SEQ NO: NO: ID NO: 1480) 1282) 959) AH4511 DIVMSQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK (SEQ ID NO: 793) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 959) AH4518 DILLTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK (SEQ ID NO: 700) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 959) AH4523 DIVLTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK (SEQ ID NO: 773) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 959) AH4524 DIVMTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK (SEQIDNO: 821) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 959) AH4525 DNVLTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEMK (SEQ ID NO: 837) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 961) D11 DIQMTQTTSSLSA QDISNY LEWYQQK NAK TLAEGVPSRFS QHHYD FGGGT SLGDRVTITCRAS (SEQ ID QGKSPQLL (SEQ ID GSGSGTQFSL TPYT KLEIK (SEQ ID NO: 763) NO: 27) VY (SEQ ID NO: 28) KINSLQPEDFG (SEQ ID (SEQ ID NO: 1072) SYYC (SEQ ID NO: 30) NO: NO: 1398) 959) D17 DILLTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPLT KLEIK (SEQ ID NO: 700) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 42) NO: ID NO: 1483) 959) D34 DIQMTQSPASLSA ENSYSY LEWYQQK NAK TLAEGVPSRFS QHHYG FGGGT SVGETVTITCRAS (SEQ ID QGKSPQLL (SEQ ID GSGSGTQFSL TPYT KLEIK (SEQ ID NO: 720) NO: 52) VY (SEQ ID NO: 28) KINSLQPEDFG (SEQ ID (SEQ ID NO: 1072) TYYC (SEQ ID NO: 54) NO: NO: 1399) 959) D36 DVVMTQSPASLSA ENSYSY LEWYQQK NAK TLAEGVPSRFS QHHYG FGGGT SVGETVTITCRAS (SEQ ID QGKSPQLL (SEQ ID GSGSGTQFSL TPYT KLEMK (SEQ ID NO: 890) NO: 52) VY (SEQ ID NO: 28) KINSLQPEDFG (SEQ ID (SEQ ID NO: 1072) TYYC (SEQ ID NO: 54) NO: NO: 1399) 961) D5 DIVMTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEMK (SEQ ID NO: 821) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 961) BP003- DIQMTQSQKFMSA QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT T2P1C4 SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEMK (SEQ ID NO: 729) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 961) BP003- DIVITQSQKFMSTS QNVGTN VAWYQQK SAS YRYSGVPDRL QQYNR FGGGT T2P1D10 VGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK (SEQ ID NO: 766) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: NO: ID NO: 1489) 1285) 959) BP003- DVVLTQTPLSLPV QSIVHSN LEWYLQK KVS NRFSGVPDRF FQGSH FGGGT T2P1D7 SLGDQASISCRSS GNTY PGQSPKLL (SEQ ID SGSGSGTDFTL VPPT KLEIK (SEQ ID NO: 874) (SEQ ID IY (SEQ ID NO: KISKVEAEDL (SEQ ID (SEQ ID NO: 1299) NO: 1071) 1062) GVYYC (SEQ NO: NO: ID NO: 1154) 966) 959) BP003- DIVLTQSQKFMST QNVGTN VAWYQQK SAS YRYSGVPDRF QQYNS FGGGT T2P1E3 SVGDRVSVTCKAS (SEQ ID PGQSPKAL (SEQ ID TGSGSGTDFT YPYT KLEIK (SEQ ID NO: 773) NO: 12) IY (SEQ ID NO: 13) LTISNVQSEDL (SEQ ID (SEQ ID NO: 1425) AEYFC (SEQ NO: 15) NO: ID NO: 1483) 959) BP003- DVVMTQSPASLSA ENSYSY LEWYQQK NAK TLAEGVPSRFS QHHYG FGGGT T2P1D1 SVGETVTITCRAS (SEQ ID QGKSPQLL (SEQ ID GSGSGTQFSL TPYT KLEIK (SEQ ID NO: 890) NO: 52) VY (SEQ ID NO: 28) KINSLQPEDFG (SEQ ID (SEQ ID NO: 1072) TYYC (SEQ ID NO: 54) NO: NO: 1399) 959)

TABLE 6 Heavy Chain CDRs Combination CDRH1 CDRH2 CDRH3 1 GDTFSSYV (SEQ ID NO: 167) FNPYSDDI (SEQ ID NO: 242) GSGYDGYYDWFAC (SEQ ID NO: 315) 2 GFAFSSYD (SEQ ID NO: 154) ISSGGGST (SEQ ID NO: 227) ARNYRSWFAY (SEQ ID NO: 300) 3 GFNIKDYY (SEQ ID NO: 977) IDPDNGET (SEQ ID NO: TVFWYGNNYAGFAY (SEQ 1003) ID NO: 1420) 4 GFNIKDYY (SEQ ID NO: 977) IDPENGDT (SEQ ID NO: NVITTATTWFAY (SEQ ID 1004) NO: 1165) 5 GFSLSTSGMG (SEQ ID NO: IYWDDDK (SEQ ID NO: 515) ARRAGDYGNPFPY (SEQ ID 492) NO: 557) 6 GFSLSTSGMS (SEQ ID NO: IWWNDDK (SEQ ID NO: 238) ARIGGNDGYYWYFDV 163) (SEQ ID NO: 311) 7 GFSLTSYG (SEQ ID NO: 161) IWAGGST (SEQ ID NO: 234) ARGAYFDY (SEQ ID NO: 307) 8 GFSLTSYG (SEQ ID NO: 161) IWAGGST (SEQ ID NO: 234) AREGTGPWFAY (SEQ ID NO: 322) 9 GFTFNDAW (SEQ ID NO: IRSKANNHAT (SEQ ID NO: TNYGSNPLDY (SEQ ID NO: 172) 239) 321) 10 GFTFNTYA (SEQ ID NO: 182) IRSKSNNYVT (SEQ ID NO: CERVRRCV (SEQ ID NO: 257) 343) 11 GFTFSDAW (SEQ ID NO: IRSKANNHAT (SEQ ID NO: TPQFAY (SEQ ID NO: 312) 164) 239) 12 GFTFSDYY (SEQ ID NO: 160) ISNGGGST (SEQ ID NO: 233) ASPLGYDGFAY (SEQ ID NO: 306) 13 GFTFSGFW (SEQ ID NO: 176) INSDGSAI (SEQ ID NO: 249) MRYGSSYWYFD (SEQ ID NO: 328) 14 GFTFSNYR (SEQ ID NO: 183) ITVKSDNYGA (SEQ ID NO: SRWFAY (SEQ ID NO: 344) 258) 15 GFTFSNYR (SEQ ID NO: 183) ITVKSDNYGA (SEQ ID NO: SRLFAY (SEQ ID NO: 534) 258) 16 GFTFSNYW (SEQ ID NO: IRLKSNNYAT (SEQ ID NO: TGSDY (SEQ ID NO: 314) 166) 241) 17 GFTFSNYW (SEQ ID NO: IRLKSNNYAT (SEQ ID NO: TRIYDSGSSYTWYFDV 166) 241) (SEQ ID NO: 543) 18 GFTFSSFG (SEQ ID NO: 491) ISGGGGTI (SEQ ID NO: 514) ARWRGGYFDY (SEQ ID NO: 555) 19 GFTFSSYA (SEQ ID NO: 151) ISSGGST (SEQ ID NO: 224) ARGEIWGKAWFAY (SEQ ID NO: 297) 20 GFTFSSYA (SEQ ID NO: 151) ISSGGSYT (SEQ ID NO: 237) ARGGMITPFAY (SEQ ID NO: 310) 21 GFTFSSYA (SEQ ID NO: 151) ISSGGST (SEQ ID NO: 224) ARGYGSSFAY (SEQ ID NO: 339) 22 GFTFSSYA (SEQ ID NO: 151) ISSGGSYT (SEQ ID NO: 237) ARRIGYDGGGSWFAY (SEQ ID NO: 342) 23 GFTFSSYG (SEQ ID NO: 165) INSNGGST (SEQ ID NO: 240) ASHYDEGY (SEQ ID NO: 313) 24 GFTFSSYG (SEQ ID NO: 165) INSNGGST (SEQ ID NO: 240) ARGGNPY (SEQ ID NO: 327) 25 GFTFSSYG (SEQ ID NO: 165) ISSGGSYT (SEQ ID NO: 237) ARHYYDYDYWYFDV (SEQ ID NO: 330) 26 GFTFSSYG (SEQ ID NO: 165) INSNGGST (SEQ ID NO: 240) ASLAY (SEQ ID NO: 548) 27 GFTFSSYT (SEQ ID NO: 485) ISSGGGYT (SEQ ID NO: 508) TRVSAKYFDV (SEQ ID NO: 539) 28 GFTFSSYW (SEQ ID NO: 177) IRLKSDNYAT (SEQ ID NO: TRYYYGES (SEQ ID NO: 250) 329) 29 GFTFSSYW (SEQ ID NO: 177) IRLKSDNYAT (SEQ ID NO: TCDYDGGAWFAY (SEQ ID 250) NO: 332) 30 GFTFTDYY (SEQ ID NO: 180) IRNKANGYTT (SEQ ID NO: ARDKRITTVEAWFAY (SEQ 255) ID NO: 338) 31 GFTFTDYY (SEQ ID NO: 180) IRNKANGYTT (SEQ ID NO: ARDGEVRRALAY (SEQ ID 255) NO: 537) 32 GFTFTDYY (SEQ ID NO: 180) IRNKANGYTT (SEQ ID NO: ARGWGNWFAY (SEQ ID 255) NO: 554) 33 GLTFSSYG (SEQ ID NO: 171) ISSGGSYI (SEQ ID NO: 244) ARQDDGYYRIFDY (SEQ ID NO: 320) 34 GYAFSSYW (SEQ ID NO: IYPGDGDT (SEQ ID NO: 248) ARSGYRYDAVFAY (SEQ ID 175) NO: 326) 35 GYAFTNYL (SEQ ID NO: INPGSGGT (SEQ ID NO: 228) ARKGSLTGVLAY (SEQ ID 155) NO: 301) 36 GYAFTNYW (SEQ ID NO: IYPGGGYT (SEQ ID NO: 6) ARVTPAS (SEQ ID NO: 8) 984) 37 GYIFTNYW (SEQ ID NO: 156) IDPSDSET (SEQ ID NO: 229) ARRGLRAWFAY (SEQ ID NO: 302) 38 GYSFTKNG (SEQ ID NO: 168) INTYTGEP (SEQ ID NO: 232) AREPKTLDY (SEQ ID NO: 316) 39 GYSITSDYA (SEQ ID NO: ISYSGST (SEQ ID NO: 506) ARSRGNYFDY (SEQ ID NO: 482) 532) 40 GYSITSGYS (SEQ ID NO: IHYSGST (SEQ ID NO: 245) ARDPPFAY (SEQ ID NO: 173) 323) 41 GYTFNSHW (SEQ ID NO: IDPYDSET (SEQ ID NO: 235) ARPYDYDGFAY (SEQ ID 169) NO: 318) 42 GYTFSNY (SEQ ID NO: 985) DIHPGGGYINYNEKFTG SRNFAN (SEQ ID NO: 1378) (SEQ ID NO: 695) 43 GYTFSNYW (SEQ ID NO: IHPGGGYI (SEQ ID NO: 1014) VSRNFAN (SEQ ID NO: 986) 1445) 44 GYTFSNYW (SEQ ID NO: ILPGSGFT (SEQ ID NO: 1021) ARGGTSVVHFDY (SEQ ID 986) NO: 605) 45 GYTFSNYW (SEQ ID NO: ILPGSGFT (SEQ ID NO: 1021) ARGGTSVVHFDS (SEQ ID 986) NO: 604) 46 GYTFSNYW (SEQ ID NO: ILPGSGFT (SEQ ID NO: 1021) ARGGTSVVHFDFDY (SEQ 986) ID NO: 603) 47 GYTFSNYW (SEQ ID NO: ILPGSGFT (SEQ ID NO: 1021) ARGGTSVVHFDS (SEQ ID 986) NO: 604) 48 GYTFSNYW (SEQ ID NO: ILPGSGFT (SEQ ID NO: 1021) ARGGTSVVHFDY (SEQ ID 986) NO: 605) 49 GYTFSNYW (SEQ ID NO: ILPGSGYT (SEQ ID NO: 1022) ARGGTSFVHFDY (SEQ ID 986) NO: 602) 50 GYTFSSYW (SEQ ID NO: ILPGSGST (SEQ ID NO: 254) ARRTYYGNAWFAY (SEQ 179) ID NO: 337) 51 GYTFSSYW (SEQ ID NO: ILPGSGST (SEQ ID NO: 254) ARSAHRYDAWFAY (SEQ 179) ID NO: 551) 52 GYTFTDYA (SEQ ID NO: 19) ISTYSGDV (SEQ ID NO: 46) ARGVTFDS (SEQ ID NO: 48) 53 GYTFTDYA (SEQ ID NO: 19) ISTYSGDA (SEQ ID NO: 21) ARGVTFDY (SEQ ID NO: 23) 54 GYTFTDYA (SEQ ID NO: 19) IITYSGDA (SEQ ID NO: 1020) AXGVTFDY (SEQ ID NO: 619) 55 GYTFTDYA (SEQ ID NO: 19) ISTYSGDV (SEQ ID NO: 46) ARGVTFDS (SEQ ID NO: 48) 56 GYTFTDYA (SEQ ID NO: 19) ISTYSGDA (SEQ ID NO: 21) ARGVTFDY (SEQ ID NO: 23) 57 GYTFTDYA (SEQ ID NO: 19) IXTYSGDV (SEQ ID NO: ARGVTFDS (SEQ ID NO: 48) 1029) 58 GYTFTDYA (SEQ ID NO: 19) ISTYSGDA (SEQ ID NO: 21) ARGVTFDY (SEQ ID NO: 23) 59 GYTFTDYA (SEQ ID NO: 19) ISTYSGDA (SEQ ID NO: 21) ARGVTFDY (SEQ ID NO: 23) 60 GYTFTDYA (SEQ ID NO: 19) ISTYSGDV (SEQ ID NO: 46) ARGVTFDS (SEQ ID NO: 48) 61 GYTFTDYA (SEQ ID NO: 19) ISTYSGDA (SEQ ID NO: 21) ARGVTFDY (SEQ ID NO: 23) 62 GYTFTDYE (SEQ ID NO: 174) IHPGSGGT (SEQ ID NO: 247) TRNGNGNWYFDV (SEQ ID NO: 325) 63 GYTFTDYE (SEQ ID NO: 174) IHPGSGGT (SEQ ID NO: 247) TRSDYGSSYEFAY (SEQ ID NO: 531) 64 GYTFTDYG (SEQ ID NO: ISTYSGDV (SEQ ID NO: 46) ARGVTFDS (SEQ ID NO: 48) 987) 65 GYTFTDYS (SEQ ID NO: 487) INTETGEP (SEQ ID NO: 225) ASFYYGNFAYYFDY (SEQ ID NO: 542) 66 GYTFTDYY (SEQ ID NO: IYPGSGNT (SEQ ID NO: 511) ARVYSGFDV (SEQ ID NO: 489) 549) 67 GYTFTKY (SEQ ID NO: 989) DIHPGGGYINYNEKFTG SRNFAN (SEQ ID NO: 1378) (SEQ ID NO: 695) 68 GYTFTNFY (SEQ ID NO: 486) INPSNGGT (SEQ ID NO: 231) TRSYYDYDWYFDV (SEQ ID NO: 540) 69 GYTFTNHH (SEQ ID NO: INPYNDYT (SEQ ID NO: 243) ADGDYYFDY (SEQ ID NO: 170) 319) 70 GYTFTNY (SEQ ID NO: 990) DIHPGGDYSNYNEKFKG SRNFAY (SEQ ID NO: 1379) (SEQ ID NO: 692) 71 GYTFTNY (SEQ ID NO: 990) DIHPGGGYTNYNEKFKG SRNFAY (SEQ ID NO: 1379) (SEQ ID NO: 696) 72 GYTFTNY (SEQ ID NO: 990) DIHPGGSYTNYNENFKG SRNFAK (SEQ ID NO: 1377) (SEQ ID NO: 697) 73 GYTFTNY (SEQ ID NO: 990) DIHPGGGYIDYNEKFTG SRNFAK (SEQ ID NO: 1377) (SEQ ID NO: 694) 74 GYTFTNY (SEQ ID NO: 990) DIHPGGDYTNYNEKFKG GRNFAY (SEQ ID NO: 982) (SEQ ID NO: 693) 75 GYTFTNY (SEQ ID NO: 990) DFYPGGDYINYNEKFKG SRNFAY (SEQ ID NO: 1379) (SEQ ID NO: 691) 76 GYTFTNYG (SEQ ID NO: INTYTGEP (SEQ ID NO: 232) ASYYDSTYVGFAY (SEQ ID 159) NO: 305) 77 GYTFTNYW (SEQ ID NO: 4) IHPGGGYT (SEQ ID NO: TSRNFAY (SEQ ID NO: 1015) 1419) 78 GYTFTNYW (SEQ ID NO: 4) IYPGGGYT (SEQ ID NO: 6) ARVSPAS (SEQ ID NO: 615) 79 GYTFTNYW (SEQ ID NO: 4) IYPGGGYT (SEQ ID NO: 6) ARVTPAS (SEQ ID NO: 8) 80 GYTFTNYW (SEQ ID NO: 4) IHPGGDYT (SEQ ID NO: TGRNFAY (SEQ ID NO: 1013) 1395) 81 GYTFTNYW (SEQ ID NO: 4) IHPGGDYS (SEQ ID NO: TSRNFAY (SEQ ID NO: 1012) 1419) 82 GYTFTNYW (SEQ ID NO: 4) IHPGGGYI (SEQ ID NO: 1014) VSRNFAN (SEQ ID NO: 1445) 83 GYTFTNYW (SEQ ID NO: 4) INPGGGYT (SEQ ID NO: TSRNFAY (SEQ ID NO: 1023) 1419) 84 GYTFTNYW (SEQ ID NO: 4) IYPGGGYT (SEQ ID NO: 6) VRVTPAS (SEQ ID NO: 1443) 85 GYTFTNYW (SEQ ID NO: 4) FYPGGDYI (SEQ ID NO: 973) TSRNFAY (SEQ ID NO: 1419) 86 GYTFTNYW (SEQ ID NO: 4) IYPGGGYT (SEQ ID NO: 6) VRVTPAS (SEQ ID NO: 1443) 87 GYTFTNYW (SEQ ID NO: 4) IHPGGGYT (SEQ ID NO: TSRNFAY (SEQ ID NO: 1015) 1419) 88 GYTFTNYW (SEQ ID NO: 4) INPGGGYT (SEQ ID NO: TSRNFAY (SEQ ID NO: 1023) 1419) 89 GYTFTNYW (SEQ ID NO: 4) IYPGGGYA (SEQ ID NO: ARVTPAS (SEQ ID NO: 8) 1035) 90 GYTFTNYW (SEQ ID NO: 4) IHPGGGYI (SEQ ID NO: 1014) VSRNFAK (SEQ ID NO: 1444) 91 GYTFTNYW (SEQ ID NO: 4) IHPGGGYT (SEQ ID NO: TSRNFAY (SEQ ID NO: 1015) 1419) 92 GYTFTNYW (SEQ ID NO: 4) IHPGGDYS (SEQ ID NO: TSRNFAY (SEQ ID NO: 1012) 1419) 93 GYTFTNYW (SEQ ID NO: 4) IYPGGGYT (SEQ ID NO: 6) ARVTPAS (SEQ ID NO: 8) 94 GYTFTNYW (SEQ ID NO: 4) IHPGGSYT (SEQ ID NO: TSRNFAK (SEQ ID NO: 1016) 1418) 95 GYTFTNYW (SEQ ID NO: 4) IYPGGGYT (SEQ ID NO: 6) ARVTPAS (SEQ ID NO: 8) 96 GYTFTNYW (SEQ ID NO: 4) IYPGGGYT (SEQ ID NO: 6) ARVTPAS (SEQ ID NO: 8) 97 GYTFTNYY (SEQ ID NO: INPTNGGT (SEQ ID NO: 513) TRGMAYRYDGAGWFAY 490) (SEQ ID NO: 552) 98 GYTFTRFW (SEQ ID NO: INPSTDYT (SEQ ID NO: 1027) ARGTVVDY (SEQ ID NO: 991) 607) 99 GYTFTRYW (SEQ ID NO: INPSTGYT (SEQ ID NO: 230) ARWGNFDY (SEQ ID NO: 992) 617) 100 GYTFTRYW (SEQ ID NO: INPRTDYT (SEQ ID NO: ARHGYFDY (SEQ ID NO: 992) 1025) 611) 101 GYTFTRYW (SEQ ID NO: INPSSDYT (SEQ ID NO: 1026) ARGTVVVDY (SEQ ID NO: 992) 608) 102 GYTFTRYW (SEQ ID NO: INPSTDYT (SEQ ID NO: 1027) VRSPILDY (SEQ ID NO: 992) 1442) 103 GYTFTRYW (SEQ ID NO: INPRTDYT (SEQ ID NO: ARHGYFDY (SEQ ID NO: 992) 1025) 611) 104 GYTFTRYY (SEQ ID NO: 488) INPSNGGT (SEQ ID NO: 231) TKGGFYDFFAY (SEQ ID NO: 547) 105 GYTFTSST (SEQ ID NO: 484) INPSSGYT (SEQ ID NO: 236) VRHYYFDY (SEQ ID NO: 538) 106 GYTFTSYN (SEQ ID NO: 178) IYPGNGDT (SEQ ID NO: 253) TRSGGNLWFAY (SEQ ID NO: 336) 107 GYTFTSYT (SEQ ID NO: 162) INPSSGYT (SEQ ID NO: 236) ARWDGAY (SEQ ID NO: 309) 108 GYTFTSYT (SEQ ID NO: 162) INPSSGYT (SEQ ID NO: 236) AREGKNWYFDV (SEQ ID NO: 334) 109 GYTFTSYT (SEQ ID NO: 162) INPSSGYT (SEQ ID NO: 236) ARSGLRQAWFAY (SEQ ID NO: 533) 110 GYTFTSYV (SEQ ID NO: 153) INPYNDGT (SEQ ID NO: 226) ARDGYYVGPAY (SEQ ID NO: 299) 111 GYTFTSYW (SEQ ID NO: IYPGSGST (SEQ ID NO: 251) TRSGVEGLLHWYFD (SEQ 157) ID NO: 1416) 112 GYTFTSYW (SEQ ID NO: IYPGSGST (SEQ ID NO: 251) TRWITTDHYFDY (SEQ ID 157) NO: 1417) 113 GYTFTSYW (SEQ ID NO: IYPGSGST (SEQ ID NO: 251) TRSGVEGLLHWYFD (SEQ 157) ID NO: 1416) 114 GYTFTSYW (SEQ ID NO: IDPYDSET (SEQ ID NO: 235) AREASYYYGNAWFA (SEQ 157) ID NO: 601) 115 GYTFTSYW (SEQ ID NO: INPSNGRT (SEQ ID NO: 510) ARQLAAY (SEQ ID NO: 614) 157) 116 GYTFTSYW (SEQ ID NO: INPSTGYT (SEQ ID NO: 230) ARLDYYGSSRGFAY (SEQ 157) ID NO: 303) 117 GYTFTSYW (SEQ ID NO: IDPYDSET (SEQ ID NO: 235) ARSPAYYGNLWFAY (SEQ 157) ID NO: 308) 118 GYTFTSYW (SEQ ID NO: IDPSDSET (SEQ ID NO: 229) ANWAWFAY (SEQ ID NO: 157) 317) 119 GYTFTSYW (SEQ ID NO: IDPSDSYT (SEQ ID NO: 246) AREEITAWFAY (SEQ ID 157) NO: 324) 120 GYTFTSYW (SEQ ID NO: IYPGSGST (SEQ ID NO: 251) TRSGVEGLLHWYFDV (SEQ 157) ID NO: 331) 121 GYTFTSYW (SEQ ID NO: IDPSNSET (SEQ ID NO: 252) ARCDGYYDGLDY (SEQ ID 157) NO: 333) 122 GYTFTSYW (SEQ ID NO: INPSNGGT (SEQ ID NO: 231) ARRIYRTLDY (SEQ ID NO: 157) 335) 123 GYTFTSYW (SEQ ID NO: INPSNGGT (SEQ ID NO: 231) TITGFDV (SEQ ID NO: 535) 157) 124 GYTFTSYW (SEQ ID NO: IYPSDSYT (SEQ ID NO: 509) TRQNYYGSSHWYFDV 157) (SEQ ID NO: 541) 125 GYTFTSYW (SEQ ID NO: IDPSDSET (SEQ ID NO: 229) ANWAWFAY (SEQ ID NO: 157) 317) 126 GYTFTSYW (SEQ ID NO: INPSNGRT (SEQ ID NO: 510) ARDSSGYGAY (SEQ ID NO: 157) 544) 127 GYTFTSYW (SEQ ID NO: INPSTGYT (SEQ ID NO: 230) ARYDGYYYFDY (SEQ ID 157) NO: 545) 128 GYTFTSYW (SEQ ID NO: IYPSDSYT (SEQ ID NO: 509) TSHYYGRAWFAY (SEQ ID 157) NO: 546) 129 GYTFTSYW (SEQ ID NO: IDPYDSET (SEQ ID NO: 235) ARGGRGTWFAY (SEQ ID 157) NO: 553) 130 GYTFTSYW (SEQ ID NO: IYPSDSYT (SEQ ID NO: 509) TRTGGSTMTPWFAY (SEQ 157) ID NO: 556) 131 GYTFTSYY (SEQ ID NO: 158) INPSNGGT (SEQ ID NO: 231) TNGGGWY (SEQ ID NO: 304) 132 GYTFTSYY (SEQ ID NO: 158) INPSNSGT (SEQ ID NO: 256) TRGGDYDASWFAY (SEQ ID NO: 340) 133 GYTFTSYY (SEQ ID NO: 158) IYPGDGST (SEQ ID NO: 512) ARGDGYFAWFAY (SEQ ID NO: 550) 134 GYTFTTST (SEQ ID NO: 993) INPRSGYT (SEQ ID NO: ARHYYFDY (SEQ ID NO: 1024) 612) 135 GYTFTTYW (SEQ ID NO: IFPGTGTT (SEQ ID NO: 507) ARGGYYNSSPFAY (SEQ ID 483) NO: 536) 136 GYTLTDYS (SEQ ID NO: 152) INTETGEP (SEQ ID NO: 225) AWGNHY (SEQ ID NO: 298) 137 GYTLTDYV (SEQ ID NO: IYPGSGST (SEQ ID NO: 251) ARRTARAFDY (SEQ ID NO: 181) 341) 138 GYTSTAYW (SEQ ID NO: ITPSTGYT (SEQ ID NO: 1028) ARGGYFDY (SEQ ID NO: 994) 606) 139 GYTSTGYW (SEQ ID NO: INPSTGYT (SEQ ID NO: 230) ARGGYFDY (SEQ ID NO: 995) 606) 140 GYTSTNY (SEQ ID NO: 996) DIHPGGDYSNYNEKFKG SRNFAY (SEQ ID NO: 1379) (SEQ ID NO: 692) 141 GYTSTNYW (SEQ ID NO: IHPGGDYS (SEQ ID NO: TSRNFAY (SEQ ID NO: 997) 1012) 1419)

TABLE 7 Light Chain CDRs Combination CDRL1 CDRL2 CDRL3 1 DNIYNY (SEQ ID NO: 833) NAK (SEQ ID NO: 28) QHHYGSPWT (SEQ ID NO: 1215) 2 EDIYNR (SEQ ID NO: 924) GAT (SEQ ID NO: 976) QQYWSTPPT (SEQ ID NO: 1292) 3 ENIYFS (SEQ ID NO: 927) NAN (SEQ ID NO: 1142) KQAYDVPWT (SEQ ID NO: 1058) 4 ENIYSY (SEQ ID NO: 930) NAK (SEQ ID NO: 28) QHHYDTPYT (SEQ ID NO: 30) 5 ENIYSY (SEQ ID NO: 930) NAK (SEQ ID NO: 28) QHHYGSPYT (SEQ ID NO: 1216) 6 ENIYSY (SEQ ID NO: 930) NAK (SEQ ID NO: 28) QHHYDTPYT (SEQ ID NO: 30) 7 ENIYSF (SEQ ID NO: 928) NAK (SEQ ID NO: 28) QHHYGTPYT (SEQ ID NO: 54) 8 ENIYSF (SEQ ID NO: 928) NAK (SEQ ID NO: 28) QHHYGIPYT (SEQ ID NO: 1214) 9 ENIYSN (SEQ ID NO: 929) AAT (SEQ ID NO: 600) QHFWGTPPT (SEQ ID NO: 1212) 10 ENIYSN (SEQ ID NO: 929) AAT (SEQ ID NO: 600) QHFWGTPWT (SEQ ID NO: 1213) 11 ENIYSN (SEQ ID NO: 929) AAT (SEQ ID NO: 600) QHFWGTPWT (SEQ ID NO: 1213) 12 ENIYSY (SEQ ID NO: 930) NAK (SEQ ID NO: 28) QHHYGSPYT (SEQ ID NO: 1216) 13 ENIYSY (SEQ ID NO: 930) NAK (SEQ ID NO: 28) QHHYGIPYT (SEQ ID NO: 1214) 14 ENIYSY (SEQ ID NO: 930) NAK (SEQ ID NO: 28) QHHYGTPYT (SEQ ID NO: 54) 15 ENIYSY (SEQ ID NO: 930) NAK (SEQ ID NO: 28) QHHYDTPYT (SEQ ID NO: 30) 16 ENIYSY (SEQ ID NO: 930) NAK (SEQ ID NO: 28) QHHYGTPWT (SEQ ID NO: 1217) 17 ENIYSY (SEQ ID NO: 930) NAK (SEQ ID NO: 28) QHHYGTPYT (SEQ ID NO: 54) 18 ENIYSY (SEQ ID NO: 930) NAK (SEQ ID NO: 28) QHHYDTPYT (SEQ ID NO: 30) 19 ENSYSY (SEQ ID NO: 52) NAK (SEQ ID NO: 28) QHHYGTPYT (SEQ ID NO: 54) 20 ENSYSY (SEQ ID NO: 52) NAK (SEQ ID NO: 28) QHHYGTPYT (SEQ ID NO: 54) 21 ENVATY (SEQ ID NO: 932) GAS (SEQ ID NO: 975) GQSYRYPYT (SEQ ID NO: 979) 22 ENVGTY (SEQ ID NO: 933) GAS (SEQ ID NO: 975) GQSYSYPYT (SEQ ID NO: 981) 23 ENVGTY (SEQ ID NO: 933) GAS (SEQ ID NO: 975) GQSYSYPYT (SEQ ID NO: 981) 24 ENVGTY (SEQ ID NO: 933) GAS (SEQ ID NO: 975) GQSYSYPWT (SEQ ID NO: 980) 25 ESVDNYGISF (SEQ ID NO: AAS (SEQ ID NO: 599) QQSKEVPYT (SEQ ID NO: 934) 1267) 26 ESVDSYGNSF (SEQ ID NO: LAS (SEQ ID NO: 1063) QQNNEDPYT (SEQ ID NO: 935) 1266) 27 ESVDSYGNSF (SEQ ID NO: RAS (SEQ ID NO: 1346) QQSNEDPRT (SEQ ID NO: 935) 1269) 28 KAGQNVGTNVA (SEQ ID SASYRYSG (SEQ ID NO: QQYNSYPYT (SEQ ID NO: NO: 1036) 1362) 15) 29 KASQNVGINVA (SEQ ID SASYRYSG (SEQ ID NO: QQYNSYPYT (SEQ ID NO: NO: 1037) 1362) 15) 30 KASQNVGTNVA (SEQ ID SASYRYSG (SEQ ID NO: QQYNSYPYT (SEQ ID NO: NO: 1038) 1362) 15) 31 KASQNVGTNVA (SEQ ID SASYRYSG (SEQ ID NO: QQYNSYPWT (SEQ ID NO: NO: 1038) 1362) 36) 32 KASQNVGTNVA (SEQ ID SASYRYSG (SEQ ID NO: QQYNNSPLT (SEQ ID NO: NO: 1038) 1362) 1282) 33 KASQSVGTNVA (SEQ ID SASYRYSG (SEQ ID NO: QQYNNYPWT (SEQ ID NO: NO: 1040) 1362) 1284) 34 KNSYSY (SEQ ID NO: 1057) NAK (SEQ ID NO: 28) QHHYGTPYT (SEQ ID NO: 54) 35 KSISKY (SEQ ID NO: 1059) SGS (SEQ ID NO: 1365) QQHNEYPWT (SEQ ID NO: 1257) 36 KSLLHSNGNTY (SEQ ID RMS (SEQ ID NO: 1360) MQHLEYPYT (SEQ ID NO: NO: 1060) 1136) 37 KSLLYKDGKTY (SEQ ID LMS (SEQ ID NO: 1081) HQLVEYPYT (SEQ ID NO: NO: 1061) 998) 38 QDIGLN (SEQ ID NO: 1198) ATS (SEQ ID NO: 618) LQYASSPFT (SEQ ID NO: 1097) 39 QDIGSS (SEQ ID NO: 1199) ATS (SEQ ID NO: 618) LQYASSPYT (SEQ ID NO: 1101) 40 QDIGSS (SEQ ID NO: 1199) ATS (SEQ ID NO: 618) LQYASSPWT (SEQ ID NO: 1100) 41 QDIGSS (SEQ ID NO: 1199) ATS (SEQ ID NO: 618) LQYASSPRT (SEQ ID NO: 1099) 42 QDIGSS (SEQ ID NO: 1199) ATS (SEQ ID NO: 618) LQYASSPHT (SEQ ID NO: 1098) 43 QDIGSS (SEQ ID NO: 1199) ATS (SEQ ID NO: 618) LQYATFPYT (SEQ ID NO: 1104) 44 QDINNF (SEQ ID NO: 1200) RAN (SEQ ID NO: 1345) LQYDEFPWT (SEQ ID NO: 1105) 45 QDINRY (SEQ ID NO: 1201) RAN (SEQ ID NO: 1345) LQYDEFPYT (SEQ ID NO: 1106) 46 QDINRY (SEQ ID NO: 1201) RAN (SEQ ID NO: 1345) LQYDEFPYT (SEQ ID NO: 1106) 47 QDIRNY (SEQ ID NO: 1202) YTS (SEQ ID NO: 1495) QQGNTLPPT (SEQ ID NO: 1253) 48 QDIRNY (SEQ ID NO: 1202) YTS (SEQ ID NO: 1495) QQGNTLPPT (SEQ ID NO: 1253) 49 QDISNY (SEQ ID NO: 27) HTS (SEQ ID NO: 1002) QQSNTLPPT (SEQ ID NO: 1272) 50 QDISNY (SEQ ID NO: 27) HTS (SEQ ID NO: 1002) QQSNSLPPT (SEQ ID NO: 1271) 51 QDISNY (SEQ ID NO: 27) YTS (SEQ ID NO: 1495) QQGNTLPPT (SEQ ID NO: 1253) 52 QDISNY (SEQ ID NO: 27) YAS (SEQ ID NO: 1476) QQGNTLPWT (SEQ ID NO: 1255) 53 QDISNY (SEQ ID NO: 27) YTS (SEQ ID NO: 1495) QQGNTLPPT (SEQ ID NO: 1253) 54 QDISNY (SEQ ID NO: 27) HTS (SEQ ID NO: 1002) QQSNSLPPT (SEQ ID NO: 1271) 55 QDISNY (SEQ ID NO: 27) HTS (SEQ ID NO: 1002) QQSNTLPPT (SEQ ID NO: 1272) 56 QDISNY (SEQ ID NO: 27) HTS (SEQ ID NO: 1002) QQGNTLPPT (SEQ ID NO: 1253) 57 QDISNY (SEQ ID NO: 27) FTS (SEQ ID NO: 972) QQGNTLPRT (SEQ ID NO: 1254) 58 QDISNY (SEQ ID NO: 27) YTS (SEQ ID NO: 1495) QQVYTLPWT (SEQ ID NO: 1273) 59 QDISNY (SEQ ID NO: 27) YTS (SEQ ID NO: 1495) QQGNTLPWT (SEQ ID NO: 1255) 60 QDISNY (SEQ ID NO: 27) YTS (SEQ ID NO: 1495) QQGNTLPPT (SEQ ID NO: 1253) 61 QDISNY (SEQ ID NO: 27) HTS (SEQ ID NO: 1002) QQSNSLPPT (SEQ ID NO: 1271) 62 QDISNY (SEQ ID NO: 27) YTS (SEQ ID NO: 1495) QQGHTLPPT (SEQ ID NO: 1252) 63 QDISNY (SEQ ID NO: 27) NAK (SEQ ID NO: 28) QHHYDTPYT (SEQ ID NO: 30) 64 QDVGTA (SEQ ID NO: 1204) WAS (SEQ ID NO: 1450) QQYSSYPLT (SEQ ID NO: 1291) 65 QDVITA (SEQ ID NO: 1205) SAS (SEQ ID NO: 13) QQHYSTPRT (SEQ ID NO: 1263) 66 QDVNTA (SEQ ID NO: 1206) WAS (SEQ ID NO: 1450) QQHYSSPWT (SEQ ID NO: 1258) 67 QDVNTA (SEQ ID NO: 1206) WAS (SEQ ID NO: 1450) QQHYSSPWT (SEQ ID NO: 1258) 68 QDVNTA (SEQ ID NO: 1206) WAS (SEQ ID NO: 1450) QQHYSSPWT (SEQ ID NO: 1258) 69 QDVNTA (SEQ ID NO: 1206) SAS (SEQ ID NO: 13) QQHFNSPYT (SEQ ID NO: 1256) 70 QDVNTA (SEQ ID NO: 1206) WAS (SEQ ID NO: 1450) QQHYSSPWT (SEQ ID NO: 1258) 71 QDVNTAVA (SEQ ID NO: WAS (SEQ ID NO: 1450) QQHYSSPWT (SEQ ID NO: 1207) 1258) 72 QDVRTA (SEQ ID NO: 1208) STS (SEQ ID NO: 1386) QQYSNYLTF (SEQ ID NO: 1290) 73 QDVSTA (SEQ ID NO: 1209) SAS (SEQ ID NO: 13) QQHYSTPYT (SEQ ID NO: 1265) 74 QDVSTA (SEQ ID NO: 1209) SAS (SEQ ID NO: 13) QQHYSTPWT (SEQ ID NO: 1264) 75 QDVSTA (SEQ ID NO: 1209) SAS (SEQ ID NO: 13) QQHYSTPPWT (SEQ ID NO: 1262) 76 QDVSTA (SEQ ID NO: 1209) SAS (SEQ ID NO: 13) QQHYSTPPT (SEQ ID NO: 1261) 77 QDVSTA (SEQ ID NO: 1209) SAS (SEQ ID NO: 13) QQHYSTPYT (SEQ ID NO: 1265) 78 QDVSTA (SEQ ID NO: 1209) SAS (SEQ ID NO: 13) QQHYSTHVH (SEQ ID NO: 1259) 79 QDVSTA (SEQ ID NO: 1209) SAS (SEQ ID NO: 13) QQHYSTPFT (SEQ ID NO: 1260) 80 QEISGY (SEQ ID NO: 1210) AAS (SEQ ID NO: 599) LQYASYPYT (SEQ ID NO: 1103) 81 QEISGY (SEQ ID NO: 1210) AAS (SEQ ID NO: 599) LQYISYPRT (SEQ ID NO: 1107) 82 QEISGY (SEQ ID NO: 1210) AAS (SEQ ID NO: 599) LQYASYPRT (SEQ ID NO: 1102) 83 QEISGY (SEQ ID NO: 1210) AAS (SEQ ID NO: 599) LQYASYPRT (SEQ ID NO: 1102) 84 QGISNY (SEQ ID NO: 1211) YTS (SEQ ID NO: 1495) QQYSKLPWT (SEQ ID NO: 1289) 85 QNVGIN (SEQ ID NO: 1243) SAS (SEQ ID NO: 13) QQYNSYPYT (SEQ ID NO: 15) 86 QNVGSN (SEQ ID NO: 1244) SAS (SEQ ID NO: 13) QQYDSYPYT (SEQ ID NO: 1280) 87 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNSYPYT (SEQ ID NO: 15) 88 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNTYPYT (SEQ ID NO: 1287) 89 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNSYPYT (SEQ ID NO: 15) 90 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNSYPWT (SEQ ID NO: 36) 91 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNNYPWT (SEQ ID NO: 1284) 92 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNTYPYT (SEQ ID NO: 1287) 93 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNNHPYT (SEQ ID NO: 1281) 94 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNNYPLT (SEQ ID NO: 1283) 95 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNRYPYT (SEQ ID NO: 1285) 96 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) XQYNSYPYT (SEQ ID NO: 1475) 97 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNNSPLT (SEQ ID NO: 1282) 98 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNSYPRT (SEQ ID NO: 1286) 99 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) SQSTHVPYT (SEQ ID NO: 1375) 100 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNSYPRT (SEQ ID NO: 1286) 101 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNSYPYT (SEQ ID NO: 15) 102 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNTYPYT (SEQ ID NO: 1287) 103 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNSYPWT (SEQ ID NO: 36) 104 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNSYPLT (SEQ ID NO: 42) 105 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNSYPLT (SEQ ID NO: 42) 106 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNRYPYT (SEQ ID NO: 1285) 107 QNVGTN (SEQ ID NO: 12) SAS (SEQ ID NO: 13) QQYNSYPYT (SEQ ID NO: 15) 108 QNVGTNVA (SEQ ID NO: SAS (SEQ ID NO: 13) QQYNSYPYT (SEQ ID NO: 1246) 15) 109 QNVRTA (SEQ ID NO: 1247) MAS (SEQ ID NO: 1122) LQHWNYPYT (SEQ ID NO: 1093) 110 QSISDY (SEQ ID NO: 1296) YAS (SEQ ID NO: 1476) QNGHSFPRT (SEQ ID NO: 1242) 111 QSIVHNNGNTY (SEQ ID KVS (SEQ ID NO: 1062) FQGSYVPRT (SEQ ID NO: NO: 1298) 971) 112 QSIVHSNGNTY (SEQ ID NO: KVS (SEQ ID NO: 1062) FQGSHVPPT (SEQ ID NO: 1299) 966) 113 QSIVHSNGNTY (SEQ ID NO: KVS (SEQ ID NO: 1062) FQGSHVPRT (SEQ ID NO: 1299) 967) 114 QSIVHSNGNTY (SEQ ID NO: KVS (SEQ ID NO: 1062) FQGSHVPTF (SEQ ID NO: 1299) 968) 115 QSIVHSNGNTY (SEQ ID NO: KVS (SEQ ID NO: 1062) FQGSHVPYT (SEQ ID NO: 1299) 970) 116 QSLENSNGNTY (SEQ ID RVS (SEQ ID NO: 1361) LQVTHVPFA (SEQ ID NO: NO: 1300) 1096) 117 QSLLDSDGKTY (SEQ ID LVS (SEQ ID NO: 1116) WQGTHFPRT (SEQ ID NO: NO: 1301) 1464) 118 QSLLDSDGKTY (SEQ ID LVS (SEQ ID NO: 1116) WQGTHFRT (SEQ ID NO: NO: 1301) 1466) 119 QSLLDSDGKTY (SEQ ID LVS (SEQ ID NO: 1116) WQGTHFPWT (SEQ ID NO: NO: 1301) 1465) 120 QSLLDSDGKTY (SEQ ID LVS (SEQ ID NO: 1116) WQGAHFPWT (SEQ ID NO: NO: 1301) 1461) 121 QSLLDSDGKTY (SEQ ID LVS (SEQ ID NO: 1116) WQGTHFPQT (SEQ ID NO: NO: 1301) 1463) 122 QSLLDSDGKTY (SEQ ID LVS (SEQ ID NO: 1116) WQGTFSSH (SEQ ID NO: NO: 1301) 1462) 123 QSLLNSSNQKNY (SEQ ID FAS (SEQ ID NO: 957) QQHYSTPYT (SEQ ID NO: NO: 1302) 1265) 124 QSLLYSNGKTY (SEQ ID QVS (SEQ ID NO: 1344) LQGTYYPTWT (SEQ ID NO: NO: 1303) 1092) 125 QSLLYSSNQKNY (SEQ ID WAS (SEQ ID NO: 1450) QQYYSYPWT (SEQ ID NO: NO: 1304) 1294) 126 QSLLYSSNQKNY (SEQ ID WAS (SEQ ID NO: 1450) QQYYSYRT (SEQ ID NO: NO: 1304) 1295) 127 QSLLYSSNQKNY (SEQ ID WAS (SEQ ID NO: 1450) QQYYSYP (SEQ ID NO: NO: 1304) 1293) 128 QSLVHNNGNTY (SEQ ID KVS (SEQ ID NO: 1062) SQSTHVPLT (SEQ ID NO: NO: 1305) 1370) 129 QSLVHSNGNTY (SEQ ID EVS (SEQ ID NO: 944) SQSTHVPYT (SEQ ID NO: NO: 1306) 1375) 130 QSLVHSNGNTY (SEQ ID KVS (SEQ ID NO: 1062) SQSTHVPPT (SEQ ID NO: NO: 1306) 1371) 131 QSLVHSNGNTY (SEQ ID KVS (SEQ ID NO: 1062) SQSTHVPWT (SEQ ID NO: NO: 1306) 1374) 132 QSLVHSNGNTY (SEQ ID KVS (SEQ ID NO: 1062) SQSTHVPT (SEQ ID NO: NO: 1306) 1373) 133 QSLVHSNGNTY (SEQ ID KVS (SEQ ID NO: 1062) SQSTHVPRT (SEQ ID NO: NO: 1306) 1372) 134 QSLVHSNGNTY (SEQ ID KVS (SEQ ID NO: 1062) SQSTHVYT (SEQ ID NO: NO: 1306) 1376) 135 QSLVHSNGNTY (SEQ ID KVS (SEQ ID NO: 1062) SQSTHVPLT (SEQ ID NO: NO: 1306) 1370) 136 QSLVHSYGNTY (SEQ ID KVS (SEQ ID NO: 1062) SQSTHVPHT (SEQ ID NO: NO: 1307) 1369) 137 QSVDYDGDSY (SEQ ID NO: AAS (SEQ ID NO: 599) QQSNEDPYT (SEQ ID NO: 1308) 1270) 138 QSVDYDGDSY (SEQ ID NO: ATS (SEQ ID NO: 618) QQSNEDPLT (SEQ ID NO: 1308) 1268) 139 QSVNND (SEQ ID NO: 1309) YAS (SEQ ID NO: 1476) QQAYWSPYT (SEQ ID NO: 1248) 140 QSVNND (SEQ ID NO: 1309) YAS (SEQ ID NO: 1476) QQDYRSPYT (SEQ ID NO: 1249) 141 QSVNND (SEQ ID NO: 1309) YAS (SEQ ID NO: 1476) QQAYWSPYT (SEQ ID NO: 1248) 142 QSVSND (SEQ ID NO: 1310) YAS (SEQ ID NO: 1476) QQDYSSPWT (SEQ ID NO: 1251) 143 QSVSND (SEQ ID NO: 1310) YAS (SEQ ID NO: 1476) QQDYSSPPT (SEQ ID NO: 1250) 144 QTLLHSDGNTY (SEQ ID QVS (SEQ ID NO: 1344) FQGSHVPWT (SEQ ID NO: NO: 1311) 969) 145 SRVTY (SEQ ID NO: 1380) DTS (SEQ ID NO: 839) HQRSGYSYT (SEQ ID NO: 1000) 146 SSIGY (SEQ ID NO: 1381) DTS (SEQ ID NO: 839) HQRGSYPWT (SEQ ID NO: 999) 147 SSISSSN (SEQ ID NO: 1382) GTS (SEQ ID NO: 983) QQWSSYPLT (SEQ ID NO: 1277) 148 SSVIY (SEQ ID NO: 1383) DTS (SEQ ID NO: 839) QQWTSNPPT (SEQ ID NO: 1279) 149 SSVSSSY (SEQ ID NO: 1384) STS (SEQ ID NO: 1386) HQYHRSPPT (SEQ ID NO: 1001) 150 SSVSY (SEQ ID NO: 1385) DTS (SEQ ID NO: 839) QQWSSNPPT (SEQ ID NO: 1274) 151 SSVSY (SEQ ID NO: 1385) DTS (SEQ ID NO: 839) QQWSSNPPYT (SEQ ID NO: 1275) 152 SSVSY (SEQ ID NO: 1385) DTS (SEQ ID NO: 839) QQWSSYPYT (SEQ ID NO: 1278) 153 SSVSY (SEQ ID NO: 1385) LTP (SEQ ID NO: 1115) QQWSSNPYT (SEQ ID NO: 1276) 154 TDIDDD (SEQ ID NO: 1391) EGN (SEQ ID NO: 925) LQSDNMPLT (SEQ ID NO: 1094) 155 TDIDDD (SEQ ID NO: 1391) EGN (SEQ ID NO: 925) LQSDNMPYT (SEQ ID NO: 1095)

In some embodiments, the CD25 antibody comprises a “V-D-J-region” heavy chain sequence presented in any one of Table 2A, Table 2B, and Table 2C, and a “V-J-region” light chain sequence presented in any one of Table 3A, Table 3B, and Table 3C, humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. In some embodiments, the antibody comprises the heavy chain variable region sequence from a particular antibody clone so named by its given “ID” (or a humanized version thereof) and the light chain variable region sequence from the same antibody clone (e.g. the light chain from clone identified by the same “ID”) (or a humanized version thereof). Thus, the antibody clone of origin can be identified by the ID shown in Tables 2A-2C or 3A-3C. For example, in such embodiments, the CD25 antibody comprises the heavy chain variable region of antibody clone “AHH03760” as presented in row 1 of Table 2B (or a humanized version thereof) and the light chain variable region of antibody clone “AHH03760” as presented in row 3 of Table 3B (or a humanized version thereof). In other embodiments, the CD25 antibody comprises the heavy chain variable region sequence from a particular antibody clone so named by its given “ID” (or a humanized version thereof) and the light chain variable region sequence from a different antibody clone (e.g. the light chain from clone identified by the same “ID”) (or a humanized version thereof).

In some embodiments, the CD25 antibody comprises a CDRH1, a CDRH2, and a CDRH3 presented in any one of Table 2A, Table 2B, and Table 2C, and a CDRL1, a CDRL2, and a CDRL3 presented in any one of Table 3A, Table 3B, and Table 3C. In such embodiments, the CD25 antibody comprises the CDRH1, CDRH2, and CDRH3 from a particular antibody clone and the CDRL1, CDRL2, and CDRL3 from the same antibody clone. As discussed above, the antibody clone of origin can be identified by the ID shown in Tables 2A-2C or 3A-3C.

In some embodiments, the CD25 antibody comprises a heavy chain variable region presented in Table 4A, humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. The variable region may include the contiguous HFR1, CDRH1, HFR2, CDRH2, HFR3, CDRH3, HRF4 sequences to form a complete variable region, humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. In some embodiments, the CD25 antibody comprises a light chain variable region presented in Table 4B, humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. The variable region may include the contiguous LFR1, CDRL1, LFR2, CDRL2, LFR3, CDRL3, LRF4 sequences to form a complete variable region, humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. In some embodiments, the CD25 antibody comprises a complete heavy chain variable region as presented in Table 4A and a complete light chain variable region as presented in Table 4B, including humanized versions thereof, and amino acid sequences comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. In some embodiments, the CD25 antibody comprises the heavy chain variable region sequence from a particular antibody clone and the light chain variable region sequence from the same antibody clone, including humanized versions thereof and amino acid sequences comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. In some embodiments, the CD25 antibody comprises the heavy chain variable region sequence from a particular antibody clone and the light chain variable region sequence from a different antibody clone, including humanized versions thereof and amino acid sequences comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. The antibody clone of origin can be identified by the ID shown in Tables 4A and 4B.

In some embodiments, the CD25 antibody comprises a CDRH1, a CDRH2, and a CDRH3 presented in Table 4A, and a CDRL1, a CDRL2, and a CDRL3 presented in Table 4B. In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, and CDRH3 from a particular antibody clone and the CDRL1, CDRL2, and CDRL3 from the same antibody clone. In other embodiments, the CD25 antibody comprises the CDRH1, CDRH2, and CDRH3 from a particular antibody clone and the CDRL1, CDRL2, and CDRL3 from a different antibody clone. As discussed above, the antibody clone of origin can be identified by the ID shown in Tables 4A and 4B.

In some embodiments, the CD25 antibody comprises a heavy chain variable region presented in Table 5A, including humanized versions thereof and amino acid sequences comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. The variable region may include the contiguous HFR1, CDRH1, HFR2, CDRH2, HFR3, CDRH3, HRF4 sequences to form a complete variable region, including humanized versions thereof and amino acid sequences comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. In some embodiments, the CD25 antibody comprises a light chain variable region presented in Table 5B, including humanized versions thereof and amino acid sequences comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. The variable region may include the contiguous LFR1, CDRL1, LFR2, CDRL2, LFR3, CDRL3, LRF4 sequences to form a complete variable region, including humanized versions thereof and amino acid sequences comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. In some embodiments, the CD25 antibody comprises a complete heavy chain variable region as presented in Table 5A and a complete light chain variable region as presented in Table 5B, including humanized versions thereof and amino acid sequences comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. In some embodiments, the CD25 antibody comprises the heavy chain variable region sequence from a particular antibody clone and the light chain variable region sequence from the same antibody clone, including humanized versions thereof and amino acid sequences comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. In other embodiments, the CD25 antibody comprises the heavy chain variable region sequence from a particular antibody clone and the light chain variable region sequence from a different antibody clone, including humanized versions thereof and amino acid sequences comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. The antibody clone of origin can be identified by the ID shown in Tables 5A and 5B.

In some embodiments, the CD25 antibody comprises a CDRH1, a CDRH2, and a CDRH3 presented in Table 5A, and a CDRL1, a CDRL2, and a CDRL3 presented in Table 5B. In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, and CDRH3 from a particular antibody clone and the CDRL1, CDRL2, and CDRL3 from the same antibody clone. In other embodiments, the CD25 antibody comprises the CDRH1, CDRH2, and CDRH3 from a particular antibody clone and the CDRL1, CDRL2, and CDRL3 from a different antibody clone. As discussed above, the antibody clone of origin can be identified by the ID shown in Tables 5A and 5B.

In some embodiments, the CD25 antibody comprises the amino acid sequence of any one of the variable heavy chains presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, and 5A or FIGS. 3A, 3B and 5 , or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. In some embodiments, the CD25 antibody comprises the amino acid sequence of any one of the variable heavy chains presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, and 5A or FIGS. 3A, 3B and 5 that has been further humanized.

In some embodiments, the CD25 antibody comprises the amino acid sequence of any one of the variable light chains presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, and 5B or FIGS. 4A, 4B and 6 , or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto. In some embodiments, the CD25 antibody comprises the amino acid sequence of any one of the variable heavy chains presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, and 5B or FIGS. 4A, 4B and 6 that has been further humanized, using conventional techniques

In some embodiments, the CD25 antibody comprises the amino acid sequence of any one of the variable heavy chains presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, and 5A or FIGS. 3A, 3B and 5 , humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto; and the CD25 antibody comprises the amino acid sequence of any one of the variable light chains presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, and 5B or FIGS. 4A, 4B and 6 , humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto.

In some embodiments, VH of the CD25 antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 as presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, or 5A, or contained in the sequences presented in FIG. 3A, 3B or 5 . In some embodiments, VH of the CD25 antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 as presented in Table 6.

In some embodiments, VL of the CD25 antibody comprises the amino acid sequence of CDRL1, CDRL2, and CDRL3 as presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, or 5B, or contained in the sequences presented in FIG. 4A, 4B or 6 . In some embodiments, VL of the CD25 antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 as presented in Table 7.

In some embodiments, VH of the CD25 antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 as presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, or 5A, or contained in the sequences presented in FIG. 3A, 3B or 5 ; and the VL of the CD25 antibody comprises the amino acid sequence of CDRL1, CDRL2, and CDRL3 as presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, or 5B, or contained in the sequences presented in FIG. 4A, 4B or 6 . In some embodiments, VH of the CD25 antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 as presented in Table 6 and the VL of the CD25 antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 as presented in Table 7.

In some embodiments, the VH of the antibody comprises the CDR1, CDR2, and CDR3 amino acid sequences presented in Table 5A. In some embodiments, the VL of the antibody comprises the CDR1, CDR2, and CDR3 amino acid sequences presented in Table 5B. In some embodiments, the antibody comprises a VH comprising the CDR1, CDR2, and CDR3 amino acid sequences presented in Table 5A, and a VL comprising the CDR1, CDR2, and CDR3 amino acid sequences presented in Table 5B.

In some embodiments, the antibody comprises the D5 CDR1, CDR2, and CDR3 amino acid sequences, the D5 VH and D5 VL amino acid sequences presented in Tables 1A and 1B, or humanized versions of the D5 VH and D5 VL amino acid sequences presented in Tables 1A and 1B.

In some embodiments, the antibody comprises the D11 CDR1, CDR2, and CDR3 amino acid sequences, the D11 VH and D11 VL amino acid sequences presented in Tables 1C and 1D, or humanized versions of the D11 VH and D11 VL amino acid sequences presented in Tables 1C and 1D.

In some embodiments, the antibody comprises the D16 CDR1, CDR2, and CDR3 amino acid sequences, the D16 VH and D16 VL amino acid sequences presented in Tables 1E and 1F, or humanized versions of the D16 VH and D16 VL amino acid sequences presented in Tables 1E and 1F.

In some embodiments, the antibody comprises the D17 CDR1, CDR2, and CDR3 amino acid sequences, the D17 VH and D17 VL amino acid sequences presented in Tables 1G and 1H, or humanized versions of the D17 VH and D17 VL amino acid sequences presented in Tables 1G and 1H.

In some embodiments, the antibody comprises the D34 CDR1, CDR2, and CDR3 amino acid sequences, the D34 VH and D34 VL amino acid sequences presented in Tables 11 and 1J, or humanized versions of the D34 VH and D34 VL amino acid sequences presented in Tables 11 and 1J.

In some embodiments, the antibody comprises the D36 CDR1, CDR2, and CDR3 amino acid sequences, the D36 VH and D36 VL amino acid sequences presented in Tables 1K and 1L, or the humanized versions of the D36 VH and D36 VL amino acid sequences presented in Tables 1K and 1L.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of any one of the AH04507, AH04522, AH04526, AH04527, AH04734, AH04750, AH05214, AH05247, AH05249, AH05251, AH05256, AH05257, AH05258, AH05259, AH05268, AH05271, AH05274, AH05280, AH05285, AH05286, AH4501, AH4502, AH4503, AH4505, AH4509, AH4511, AH4518, AH4523, AH4524, AH4525, D11, D17, D34, D36, D5, BP003-T2P1C4, BP003-T2P1D10, BP003-T2P1D7, BP003-T2P1E3, or BP003-T2P1D1 clones presented in Table 5A.

In some embodiments, the CD25 antibody comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of any one of the AH04507, AH04522, AH04526, AH04527, AH04734, AH04750, AH05214, AH05247, AH05249, AH05251, AH05256, AH05257, AH05258, AH05259, AH05268, AH05271, AH05274, AH05280, AH05285, AH05286, AH4501, AH4502, AH4503, AH4505, AH4509, AH4511, AH4518, AH4523, AH4524, AH4525, D11, D17, D34, D36, D5, BP003-T2P1C4, BP003-T2P1D10, BP003-T2P1D7, BP003-T2P1E3, or BP003-T2P1D1 clones presented in Table 5B.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of any one of the AH04507, AH04522, AH04526, AH04527, AH04734, AH04750, AH05214, AH05247, AH05249, AH05251, AH05256, AH05257, AH05258, AH05259, AH05268, AH05271, AH05274, AH05280, AH05285, AH05286, AH4501, AH4502, AH4503, AH4505, AH4509, AH4511, AH4518, AH4523, AH4524, AH4525, D11, D17, D34, D36, D5, BP003-T2P1C4, BP003-T2P1D10, BP003-T2P1D7, BP003-T2P1E3, or BP003-T2P1D1 clones presented in Table 5A; and the CD25 antibody comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of any one of the AH04507, AH04522, AH04526, AH04527, AH04734, AH04750, AH05214, AH05247, AH05249, AH05251, AH05256, AH05257, AH05258, AH05259, AH05268, AH05271, AH05274, AH05280, AH05285, AH05286, AH4501, AH4502, AH4503, AH4505, AH4509, AH4511, AH4518, AH4523, AH4524, AH4525, D11, D17, D34, D36, D5, BP003-T2P1C4, BP003-T2P1D10, BP003-T2P1D7, BP003-T2P1E3, or BP003-T2P1D1 clones presented in Table 5B.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH04507 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH04522 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH04526 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH04527 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH04734 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH04750 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05214 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05247 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05249 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05251 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05256 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05257 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05258 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05259 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05268 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05271 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05274 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05280 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05285 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH05286 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH4501 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH4502 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH4503 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH4505 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH4509 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH4511 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH4518 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH4523 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH4524 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of AH4525 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of D11 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of D17 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of D34 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of D36 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of D5 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of BP003-T2P1C4 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of BP003-T2P1D10 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of BP003-T2P1D7 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of BP003-T2P1E3 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody comprises the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, AND CDRL3 amino acid sequences of BP003-T2P1D1 (presented in Tables 5A and 5B respectively); in some embodiments, the CD25 antibody is a humanized antibody.

In some embodiments, the CD25 antibody is conjugated for a variety of purposes including, but not limited to, for use in therapeutics and detection/diagnostics.

Also provided herein are nucleic acid sequences encoding any of the CD25 antibodies provided herein. Exemplary nucleic acid sequences encoding the D5, D11, D16, D17, D34, and D36 VH and VL regions are provided in Tables 1A-1L—one can use humanized versions thereof. Also provided herein are vectors comprising any of the nucleic acids encoding the antibodies, phage comprising such vectors, and host cells comprising such vectors.

Antibody Generation and Testing

FIG. 2 is an exemplary non-limiting workflow for CD25 antibody discovery, in vitro testing, and in vivo testing, but one of skill in the art recognizes that there are alternative ways to approach antibody discovery and testing.

The CD25 antibodies described herein can be generated by injection of a CD25 complete or partial immunogen into an animal, e.g. a mouse or a rabbit. CD25 immunoge positive B-cells from the animal can be collected, and phage libraries generated therefrom. In some embodiments, the phage express Fab fragments of candidate CD25 antibodies. The phage can undergo multiple rounds of screening (referred to herein as phage panning), for example against successively lower concentrations of a CD25 antigen, to select for those Fab fragments capable of binding CD25 with high affinities. The phage can be screened against CD25 antigen coated beads, or some other substrate, for example. In some embodiments, the screening is carried out a physiological pH (e.g. about pH 7.4). In other embodiments, the screening is carried out at a lower pH, for example, at a pH of about 6.5 to screen for Fab fragments capable of binding the CD25 antigen at a lower pH, for example, for use in a therapeutic context, e.g. for use in a hypoxic, acidic tumor microenvironment.

The CD25 antibodies generated herein may be tested for efficacy using a number of in vitro, in vivo, ex vivo, and/or cell-based assays.

In some embodiments, the CD25 antibodies herein can be assayed for, and further selected based on their ability to deplete regulatory T cells. In particular embodiments, the CD25 antibodies herein can be assayed for, and further selected based on their ability to deplete regulatory T cells in an acidic environment, e.g at a pH lower than physiological pH, e.g. at pH 7.3, 7.2, 7.1, 7.0, 6.9, 6.8, 6.7, 6.6, 6.5, 6.4, 6.3, 6.2, 6.1, or lower.

In some embodiments, the CD25 antibodies herein can be assayed for, and further selected based on a pSTAT5 in vitro assay, to assay for the signaling through the IL-2/IL-2 receptor pathway, the maintenance of which indicates that the antibody is not an IL-2 blocking antibody.

In some embodiments, the CD25 antibodies herein can be assayed for using biosensor screening to characterize molecular interactions.

In some embodiments, the CD25 antibodies herein can be assayed for competition for binding against other known CD25 antibodies, with known mechanisms.

In some embodiments, the CD25 antibodies herein can be assayed for epitope specificity.

In some embodiments, the CD25 antibodies herein can be assayed for their capacity to be a non IL-2 blocker, an IL-2 blocker, or a partial IL-2 blocker.

Therapeutic Uses

Provided herein are CD25 antibodies for therapeutic use, e.g. for use in proliferative diseases or disorders such as cancer or for use in autoimmune diseases.

Accordingly provided herein are methods of treating a cancer comprising administering to a subject in need thereof a therapeutically effective amount of a therapeutic CD25 antibody. In some embodiments, the cancer is a primary cancer. In some embodiments, the cancer is a metastatic cancer. In some embodiments, the cancer involves a solid tumor; in other embodiments, the cancer involves a liquid tumor, e.g. a blood based cancer. In exemplary embodiments, the CD25 antibody is a non IL-2 blocking antibody.

Accordingly provided herein are methods of treating an autoimmune-related disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a therapeutic CD25 antibody. In exemplary embodiments, the CD25 antibody is an IL-2 blocking antibody.

As used herein, a subject refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sport, or pet animals, such as dogs, horses, rabbits, cattle, pigs, hamsters, gerbils, mice, ferrets, rats, cats, and the like. Subjects may be male or female.

The administration of any of the therapeutic CD25 antibodies provided herein may be administered in combination with other known drugs/treatments (e.g. small molecule drugs, or biologics. The administration may be sequential or concurrent.

In vivo administration of the therapeutic CD25 antibodies described herein may be carried out intravenously, intratumorally, intracranially, intralesionally (e.g. intralesional injection, direct contact diffusion), intracavitary (intraperitoneal, intralpleural, intrauterine, intrarectal), intraperitoneally, intramuscularly, subcutaneously, topically, orally, transdermally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. In an exemplary embodiment, the route of administration is by intravenous injection.

A therapeutically effective amount of the therapeutic antibody will be administered. The appropriate dosage of the therapeutic antibody may be determined based on the severity of the cancer, the clinical condition of the subject, the subject's clinical history and response to the treatment, and the discretion of the attending physician

The dosage amounts of the CD25 antibodies provided herein may vary from about 1 ng/kg up to about 1000 mg/kg of a subject's body weight or more per day, depending upon the route of administration. For repeated administrations over several days or longer, depending on the severity of the cancer, the treatment may be sustained until a desired suppression of symptoms is achieved. Dosage regimens may be useful, depending on the pattern of pharmacokinetic decay that the physician wishes to achieve. For example, dosing an individual from one to twenty-one times a week is provided herein. In certain embodiments, dosing frequency is three times per day, twice per day, once per day, once every other day, once weekly, once every two weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, or once monthly, once every two months, once every three months, or longer. Progress of the therapy is may be monitored by conventional techniques and assays. The dosing regimen may vary over time independently of the dose used.

Diagnostic Uses

The CD25 antibodies provided herein may be used for diagnostic and detection purposes. Depending on the application, the CD25 antibody may be detected and quantified in vivo or in vitro.

The CD25 antibodies provided herein are amendable for use in a variety of immunoassays. These immunoassays include, but are not limited to enzyme-linked immunosorbent assay (ELISA), Western blot, radioimmunoassay (MA), flow cytometry, a radioimmunoassay, an immunofluorescence assay, spectrophotometry, radiography, electrophoresis, high performance liquid chromatography (HPLC), or thin layer chromatography (TLC).

The CD25 antibodies provided herein may be comprise a detectable label, for example detectable by spectroscopic, photochemical, biochemical, immunochemical, fluorescent, electrical, optical or chemical methods. Useful labels in the present disclosure include, but are not limited to fluorescent dyes, radiolabels, enzymes, colorimetric lables, avidin or biotin.

In some embodiments, the CD25 antibody is radiolabeled with an isotope, useful for imaging by nuclear medicine equipment (SPECT, PET, or scintigraphy).

Pharmaceutical Compositions

The disclosure provides compositions comprising therapeutic CD25 antibodies, In some embodiments the composition is sterile. The pharmaceutical compositions generally comprise an effective amount of the therapeutic antibody in a pharmaceutically acceptable excipient.

Kits and Articles of Manufacture

The disclosure also provides for kits comprising any of the CD25 antibodies described herein, e.g. for either therapeutic or diagnostic uses. In some embodiments, the kits further contain a component selected from any of secondary antibodies, reagents for immunohistochemistry analysis, pharmaceutically acceptable excipient and instruction manual and any combination thereof. In some embodiments, the kit comprises any one or more of the therapeutic compositions described herein, with one or more pharmaceutically acceptable excipients.

The present application also provides articles of manufacture comprising any one of the therapeutic or diagnostic compositions or kits described herein. Examples of an article of manufacture include vials (e.g. sealed vials).

The description provided herein sets forth numerous exemplary configurations, methods, parameters, and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure, but is instead provided as a description of exemplary embodiments.

The following examples are included for illustrative purposes and are not intend to limit the scope of the invention.

ENUMERATED EMBODIMENTS

Embodiment 1. A monoclonal CD25 antibody which binds to human CD25, and possesses at least one of the following characteristics:

a. the antibody does not disrupt the binding of the IL-2 ligand to the alpha chain of the IL-2 receptor (CD25), and binds to a different epitope than to which 7G7B6 binds;

b. the antibody does not disrupt the binding of the IL-2 ligand to the alpha chain of the IL-2 receptor (CD25), but does disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor;

c. the antibody disrupts the binding of the IL-2 ligand to the alpha (CD25), beta, and/or gamma chains of the IL-2 receptor, and binds to a different epitope than to which daclizumab or baciliximab bind;

d. the antibody exhibits a higher affinity of binding to CD25 at pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4;

e. the antibody comprises the amino acid sequence of any one of the variable heavy chains presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, and 5A or FIGS. 3A, 3B and 5 , humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto;

f. the antibody comprises the amino acid sequence of any one of the variable light chains presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, and 5B or FIGS. 4A, 4B and 6 , humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto;

g. the VH of the antibody comprises any one of the amino acid sequence of CDRH1, CDRH2, and CDRH3 as presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, 5A, and 6 or contained in the sequences presented in FIGS. 3A, 3B and 5 ;

h. the VL of the CD25 antibody comprises any one of the amino acid sequence of CDRL1, CDRL2, and CDRL3 as presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, 5B and 7, or contained in the sequences presented in FIGS. 4A, 4B and 6 ; and

i. the antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 of any one of the combinations presented in Table 6 and the amino acid sequence of CDRL1, CDRL2, and CDRL3 of any one of the combinations presented in Table 7.

Embodiment 2. The antibody of embodiment 1, wherein the antibody possesses at least two, at least three, at least four, at least five, or at least six of the characteristics provided therein.

Embodiment 3. The antibody of embodiment 1, wherein the antibody does not disrupt the binding of the IL-2 ligand to the alpha chain of the IL-2 receptor (CD25), and binds to a different epitope than to which 7G7B6 binds.

Embodiment 4. The antibody of embodiment 1, wherein the antibody does not disrupt the binding of the IL-2 ligand to the alpha chain of the IL-2 receptor (CD25), but does disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor.

Embodiment 5. The antibody of embodiment 1, wherein the antibody disrupts the binding of the IL-2 ligand to the IL-2 receptor, and binds to a different epitope than to which Daclizumab or Baciliximab bind.

Embodiment 6. The antibody of embodiment 1, wherein the antibody exhibits a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4.

Embodiment 7. The antibody of embodiment 6, wherein the antibody exhibits a higher affinity of binding to CD25 at a pH of about 6.5.

Embodiment 8. The antibody of any one of embodiments 1 to 7, wherein the antibody comprises the amino acid sequence of any one of the variable heavy chains presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, and 5A or FIGS. 3A, 3B and 5 , humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto.

Embodiment 9. The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the amino acid sequence of any one of the variable light chains presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, and 5B or FIGS. 4A, 4B and 6 , humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto.

Embodiment 10. The antibody of any one of embodiments 1 to 7, wherein the VH of the antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 as presented in Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, or 5A, or contained in the sequences presented in FIG. 3A, 3B or 5 .

Embodiment 11. The antibody of any one of embodiments 1 to 7 and embodiment 10, wherein the VL of the CD25 antibody comprises the amino acid sequence of CDRL1, CDRL2, and CDRL3 as presented in Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, or 5B, or contained in the sequences presented in FIG. 4A, 4B or 6 .

Embodiment 12. The antibody of any one of embodiments 1 to 10, wherein the CD25 antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 of any one of the combinations presented in Table 6.

Embodiment 13. The antibody of any one of embodiments 1 to 10, wherein the CD25 antibody comprises the amino acid sequence of CDRL1, CDRL2, and CDRL3 of any one of the combinations presented in Table 7.

Embodiment 14. The antibody of any one of embodiments 1 to 13, wherein the antibody is a human antibody.

Embodiment 15. The antibody of any one of embodiments 1 to 13, wherein the antibody is a humanized antibody.

Embodiment 16. The antibody of any one of embodiments 1 to 13, wherein the antibody is a chimeric antibody.

Embodiment 17. The antibody of embodiment 16, wherein the antibody comprises a mouse variable domain, and a human constant domain.

Embodiment 18. The antibody of any one of embodiments 1 to 15, wherein the antibody is an antibody fragment.

Embodiment 19. The antibody of any one of embodiments 1 to 18, wherein the antibody also binds cynomologous monkey CD25.

Embodiment 20. A pharmaceutical composition comprising any one of the antibodies of embodiments 1 to 19.

Embodiment 21. A nucleic acid sequence encoding any one of the antibodies of embodiments 1 to 19.

Embodiment 22. A vector comprising the nucleic acid sequence of embodiment 21.

Embodiment 23. A phage expressing any one of the antibodies of embodiments 1 to 19.

Embodiment 24. A method of treating a subject in need thereof comprising administering to the subject a therapeutically effective amount of any one of the antibodies of embodiments 1 to 19 or the pharmaceutical composition of embodiment 20.

Embodiment 25. A method of depleting the number of regulatory T cells in a subject comprising administering to the subject a therapeutically effective amount of any one of the antibodies of embodiments 1 to 19 or the pharmaceutical composition of embodiment 20.

Embodiment 26. The method of embodiment 24 or 25, wherein the subject suffers from cancer.

Embodiment 27. The method of embodiment 24 or 25, wherein the subject suffers from an autoimmune-related disease or disorder.

Embodiment 28. A method of depleting the number of regulatory T cells in a sample comprising peripheral blood mononuclear cells comprising contacting the sample with any one of the antibodies of embodiments 1 to 19.

Embodiment 29. A kit comprising any one of the antibodies of embodiments 1 to 19 or the pharmaceutical composition of embodiment 20.

EXAMPLES Example 1: Immunization with CD25

Full length CD25 conjugated to KLH was injected into five difference BalbC mice. All injections were done via the tail vein. The immunization protocol was as follows:

-   -   Day 0: Immunization 1     -   Day 14: Immunization 2     -   Day 28: Immunization 3     -   Day 35: Bleed

Splenocytes and Leukocytes from four of the five mice were used to generate four phage libraries. The phage libraries contained phage, expressing antigen binding (Fab) fragments. More specifically, a M13 phagemid library using materials from the immunized animals was constructed as follows. (i) Total RNA from leukocytes and splenocytes was extracted; (ii) VH and VL genes were amplified with specific primers; and (iii) VH and VL fragments were inserted into GenScript's M13 phagemid vector by two-step cloning. The library size >2×10{circumflex over ( )}8; the insert rate was >90%, and the in-frame rate was >80%. The library was a high diversity library, with at >95% of unique sequences.

Example 2: Phage Panning for CD25 Binding

3 rounds of phage panning of the Fab-containing phage libraries were carried out, using an ELISA-based assay. The phage were screened against beads coated with CD25. Each round was carried out with a decreasing concentration of CD25. Individual phage clones were expressed in E. coli TG1 cells (plated on LB/carbenicillin). Single colonies were cultured in 0.4 ml 2YT broth for 30 min at 37° C., and then infected with M13 K07 helper phage for 3 hours at 37° C. Then 50 μg/ml carbenicillin and 10 μg/ml Kanamycin were added to the culture which was then grown overnight at 25° C. The next day, phage was harvested from the cultures.

Positive clones were sequenced as follows. Positive hit clones were cultured overnight and plasmid DNA was prepared with a Qiagen plasmid miniprep kit. Purified plasmids were submitted to Genewiz and ELIM Biopharmaceuticals for sanger sequencing. The VH sequence was obtained with the sequencing primers (ACGCCTGCGAAGTCACCCAT (SEQ ID NO: 1497)) or (AGAAACACAAAGTCTACGCCTGCGAAGTCAC (SEQ ID NO: 1498)). The VL sequence was obtained with the sequencing primer (AGCGGATAACAATTTCACACAGGA (SEQ ID NO: 1499)), or CGGATAACAATTTCACACAG (SEQ ID NO: 1500).

FIGS. 3A, 3B, 4A, and 4B and Tables 2A, 2B, 3A, and 3B show VH and VL sequences of the Fabs selected after the second round of panning.

FIGS. 5 and 6 , and Tables 2C and 3C show VH and VL sequences of the Fabs selected after the third round of panning.

Tables 4A, 4B, 5A, and 5B show additional clones after similar panning protocols.

Further pH-based phage panning was carried out.

Example 3: Phage Panning for CD25 Binding at pH 6.5

Further phage panning was carried out to select for Fab candidates that bind CD25 at lower pH ranges, to select for binders that could bind, for example, in a hypoxic, acidic tumor microenvironment.

The four mouse HuCD25 immunized phage libraries (7807, 7808, 7809, 7810) were transformed by electroporation in TG1 and phage propagated with the addition of CM13 using standard Phage Display protocols (Barbas et al., 2001). TG1 cultures secreting phage were PEG precipitated with PEG/NaCl after incubation on ice for one hour.

The phage libraries (7807, 7808, 7809, 7810) were used for specific pH selections using standard protocols. To deplete antibodies that bind with high affinity at physiological pH, subtractive panning was first carried out by counter-selection of 3×10{circumflex over ( )}11 pfu phage (1000-fold representation of a 3×10{circumflex over ( )}8) at pH 7.4 by absorption for 1 hour on ELISA plates coated with 10 ug/ml full-length CD25 (400 nM) in PBST pH 7.4. Resulting phage supernatant was collected and pH was adjusted to pH 6.5 with PB ST. Subsequent phage panning selections were carried out at pH 6.5

Panning selections were pre-cleared with 25 microliters streptavidin dynabeads with no CD25 antigen after 1 hour incubation. Phage were then added to new pre-blocked Eppendorf LoBind tube. Biotinylated full-length CD25 antigen was added at 100 nM concentration for one hour. Samples were then incubated with 25 microliters streptavidin beads RT for one hour. Samples were pelleted and washed using magnet/magnetic beads 7-9 times with PBST. Tubes were changed twice to remove residual phage.

To elute phage, 800 microliters Glycine pH 2.2 were added to beads and incubated for no more than ten minutes. They were then neutralized with high pH Tris 9.0. Eluted phage were added to 1 ml TG1 freshly grown (0D600-0.5), and incubated for 20-30 minutes. Fractional log dilution series were plated on plates, and the remainder was transferred to 25 ml 2×YT (2×Yeast Tryptone Broth). These steps were repeated two additional times for a total of three panning rounds, followed by Phage ELISA and Octet screening of periplasmic extracts.

Sequencing

Positive hit clones were cultured overnight and plasmid DNA was prepared with a Qiagen plasmid miniprep kit. Purified plasmids were submitted to Genewiz and ELIM Biopharmaceuticals for sanger sequencing. The VH sequence was obtained with the sequencing primer (ACGCCTGCGAAGTCACCCAT (SEQ ID NO: 1497)) or (AGAAACACAAAGTCTACGCCTGCGAAGTCAC (SEQ ID NO: 1498)). The VL sequence was obtained with the sequencing primer (AGCGGATAACAATTTCACACAGGA (SEQ ID NO: 1499)) or (CGGATAACAATTTCACACAG (SEQ ID NO: 1500)). VH and VL V-D-J arrangements, nucleic acid alignments, and amino acid alignments were identified by IMGT High V-Quest.

Sequences for selected Fab clones D5, D11, D16, D17, D34, and D36 are presented in Tables 1A-1L.

Example 4: Phage ELISA Protocol and Biosensor/Octet Screening

ELISA/Extract Preparation

Phage ELISA, for assessing CD25 binding to Fab phage, and periplasmic extract preparation for Fab Octet screening were conducted essentially as described, with modifications noted (Schwimmer et al., 2013).

The CD25 antigen was diluted in PBS, pH 7.4. 50 microliters of antigen solution were made containing 1 ug of CD25 for each well of a 96-well plate to be coated. 50 microliters of antigen solution was added to the ELISA plate wells and incubate overnight at 4° C. Following the incubation, wells were washed twice with PBS, and wells were blocked by adding 200 microliters of 1×PBST 2.0% BSA and incubated for 2 hours at 25° C. Phage were diluted two-fold in 1×PBST 1.0% BSA, pH 6.5. 50 microliters were added per and incubated for 5 minutes at room temperature. The blocking solution was shaken out of the wells, and 50 ul of the dilute phage preparation was added to each well, and incubated for 1 hour at room temperature. The ELISA plate wells were washed 3-5 times with 200 microliters PBST pH 6.5. HRP-conjugated anti-M13 antibodies were diluted (Abcam, ab50370) 1:5000 with 1×PBST 1.0% BSA pH 6.5. 50 microliters of diluted secondary antibody conjugate was added to each well, and incubated for 1 hour at room temperature. ELISA plate wells were washed 3-5 times with 200 microliters PBST pH 6.5. The ECL Lumo substrate was prepared (e.g. Supersignal ELISA Pico Chemiluminescent Substrate) as described, into a 1:1 mixture. 50 microliters substrate solution was added to each well, incubated at room temperature for 5 to 60 minutes before reading.

Colonies were inoculated in 0.03-4 ml 2×YT 0.2% Glucose with 0.1 ml overnight culture (1 ml cultures in 96-well plate or 4 ml cultures in 14-ml falcon tubes). They were incubated at 250-700 rpm for 1.5-2 hours at 37° C. until the OD600˜0.5-1.0. Cultures were induced with 50-400 ul IPTG 0.025-0.1M. In some cases, the temperature was reduced to 30° C. with shaking at 250 rpm. They were then incubated overnight. Next day cultures were harvested by pelleting 3400 rcf for 10-15 minutes. The supernatant was discarded.

Cultures were resuspended with 50-75 ul PPB buffer (30 mM Tris-HCl, pH 8.0, 1 mM EDTA, 20% Sucrose) with 1× Halt Protease Inhibitor and incubated on a rocking platform for 15 minutes at room temperature or 4° C. for 10 min. Cultures were resuspended with 150-225 ul of cold ddH20 with 1× Halt Protease Inhibitor and incubated on a rocking platform for one hour at room temperature or 4° C. for 1-2 hours. The lysate suspension was spun at 15000 rcf for 10-15 min at 4C. Supernatant was collected and diluted.

Fab Expression and Purification Protocol

Single E. coli colonies were inoculated and grown in 50 2×YT 0.2% Glucose with 0.03-0.5 ml overnight culture in plates or 50 mL cultures. Cultures were incubated at 250-700 rpm at 37° C. for 1.5-hours. Cultures were induced with 50 ul of 25 mM-1M IPTG. The temperature was reduced to 30° C. and rpm to 150. Incubation was done overnight. 50 ml cultures or plates were harvested by pelleting 3400 rcf for 15 minutes. The supernatant was discarded. Cell pellets from 50 mL cultures were placed in a −80° C. freezer for 1 hour, while cultures grown in plates had 75 uL of PPB added with 1× Halt protease inhibitor, EDTA-free (Thermo Fisher Scientific) and vortexed. Plates were shaken at 4° C. for 10 minutes at 1000 rpm. The volume of 225 uL of cold water with 1× Halt protease inhibitor, EDTA-free (Thermo Fisher Scientific) was added to each well. Samples were mixed and shaken at 4° C. for 1-2 hours at max speed i.e. 1000 rpm. Plates were spun at 3500 rpm for 10 mins at 4° C. The supernatant (PPE) was transferred to fresh plates and stored at −20° C. Cell pellets from the 50 mL cultures were removed from the freezer and 5 ml PBS, 10 mM Imidazole was added with 2.5 mg/ml lysozyme and 1× Halt protease inhibitor, EDTA-free (Thermo Fisher Scientific). These were incubated at room temperature for 30 minutes once pellet had fully thawed/mixed. The lysate was centrifuged for 15 minutes at 3400 rcf. The supernatant was removed and pellet discarded. 500 ul Ni-NTA resin was added (pre-washed and pelleted) or a Ni-NTA spin column was used for Fab purification. Incubate with cleared lysate for 30 min-1 hr. This was spun at 1500 rcf. These were washed 5 times with 1 ml PBS, 10 mM Imidazole. Buffer was discarded after each spin. 1 ml PBS, 200 mM Imidazole were added and mixed, incubated for 30 minutes and spun at 1500 rcf for 15 minutes. The eluted protein was stored at 4° C. or 20° C. after determining protein concentration. Zeba columns were used for desalting/buffer exchange.

Octet/Biosensor Screening of Fabs

For Octet Koff rate screening in raw supernatants, 50 ul of lysate was used in 384-well Pall ForteBio Octet plates. Data was collected on an Octet RED 384 (MD ForteBio). Briefly, Human CD25 was coupled to AR2G tips (1 ug/ml). For data collection, baseline was assessed in PBST 1% BSA buffer at pH 6.5 for 60 seconds. Tips were then moved to 50 ul lysate pH6.5 adjusted and association measured for 300 seconds. Finally, tips were moved to PBST 1% BSA buffer at pH 6.5. Tips were then regenerated with 200 mM Tris-Glycine, pH 2.5 and neutralization with PBST, 1% BSA, pH 6.5. For data analysis, Double referencing was performed on Octet HT 11.0 software (no CD25 on tip as well as blank reference well), for reference subtraction.

Biosensor assays were carried out to determine whether selected Fabs would block IL-2 binding to CD25.

Octet/Biosensor Screening of Human IgG1 Antibodies

A subset of selected 40 Fabs were reformatted to contain a human IgG1 (referred to herein as human IgG1 antibodies), and data were collected these. The Fabs selected for reformatting are show in Tables 5A (heavy chains) and Table 5B (light chains). The Koff rates and affinity of the different reformatted IgG1 antibodies were evaluated on a FortéBio® Octet RED384™ bio-layer interferometry instrument. Purified antibodies were covalently immobilized on amine reactive biosensors (Fortebio® AR2G), and excess reactive esters were blocked with ethanolamine. Sensors were then dipped into running buffer as a baseline, transferred to wells containing 300 nM full-length CD25, and then transferred back into running buffer. Association of CD25 and subsequent dissociation was recorded in duplicate. Association of running buffer only (to control for sensor drift), and additional sensors with immobilized IgG from human ND serum (to control for non-specific IgG binding), were run as controls. The observed on and off rates were fit using a 1:1 binding fit model, and the equilibrium binding constant (KD) was calculated.

Epitope binning of reformatted human IgG1 antibodies were done using cross-competition assays performed in the classical sandwich format, which involves collecting a baseline, immobilizing the sample antibody onto the biosensor, capturing the antigen, and then incubating with a competitive analyte. The competitive analyte can bind the captured CD25 only if its binding epitope does not overlap with that of the immobilized antibody. Purified antibodies were covalently immobilized on amine reactive biosensors (Fortebio® AR2G), and excess reactive esters were blocked with ethanolamine. Sensors were dipped into running buffer as a baseline, followed by full-length CD25. Then the sensors were transferred to wells containing a competitive analyte (IL-2, 7G7B6, Basiliximab, Daclizumab) or running buffer as a reference. Sensors were regenerated when necessary by exposing them to 3 cycles of 0.1 M Glycine pH 2.0 for 10 seconds, followed by running buffer for 10 seconds.

Results

FIG. 7 depicts the identification of non IL-2 blockers and IL-2 blockers (Fabs), using a cross block assay at the molecular level. CD25 was coated on the biosensor tip, and brought into contact with the indicated Fab. IL2 was then added. An increase in signaling shows that the Fab and IL2 have different binding sites on CD25.

Table 8 shows that the Fab clones tested exhibited similar binding kinetics at physiological and acidic pH.

TABLE 8 pH Sample ID kdis (1/s) 6.5 D5 4.12E−03 7.4 D5 3.45E−03 6.5 D7 3.87E−03 7.4 D7 2.80E−03 6.5 D11 5.22E−03 7.4 D11 4.52E−03 6.5 D16 5.91E−03 7.4 D16 4.00E−03 6.5 D17 5.36E−03 7.4 D17 3.37E−03 6.5 D34 2.96E−03 7.4 D34 2.85E−03 6.5 D36 1.72E−03 7.4 D36 8.98E−04

FIG. 8 depicts phage express Fabs of the disclosure that compete with IL-2 non-blocking antibody, 7G7B6. The biosensor tip was coated with the antibody 7G7B6, and brought into contact first with CD25, and then with the indicated Fab or Basiliximab, a known IL2 blocking antibody. Clones D11, D34, and D36 do not bind when 7G7B6 is bound to CD25. Clones D5, D16, and D17 bind, but rapidly come off, indicating a possible cross-blocking function.

FIGS. 13A-13C shows kinetic analysis for Koff rates and affinity on the reformatted human IgG1 antibody clones (FIG. 13A). KD values of antibodies ranged from 4.4E-10 to 8.4 E-09 with Koff values from 6.4E-05 to 1.9E-03. Several antibodies had higher affinity (FIG. 13B) and Koff values (FIG. 13C) than commercially available antibodies 7G7B6, Daclizumab and Basilixumab (Kd values 2.6E-09, 4.5E-10, 4.7E-10, respectively and Koff rates of 2.3E-04, 1.1E-04, 1.9E-04, respectively). The clones BP003-T2P1D7. AH0580, AH05268, D36, D11, AH05259, BF003-T2P1D1, and D34 have better Kd values than 7G7B6 in this analysis; the clones D17, AH04526, AH04750, AH05285, AH05256, and AH04527 have better Kd values than Daclizumab and Basilixumab in this analysis (FIG. 13B). The clones AH05256, AH04527, AH04526, AH05251, AH05285, AH05259, D17, AH04750 have better Koff rates than 7G7B6 in this analysis (FIG. 13C).

FIGS. 14A-14D Epitope binning was carried out to evaluate the binding of the reformatted human IgG1 Fabs to epitopes overlapping commercially available anti-human CD25 antibodies 7G7B6, Daclizumab and Basilixumab, as well as with IL-2. The blocking profiles of the clones are: (FIG. 14A) blocked by 7G7B6, but not by IL-2, Daclizumab or Basiliximab; (FIG. 14B) blocked by IL-2, Daclizumab, Basiliximab, but not by 7G7B6; (FIG. 14C) blocked by 7G7B6 and Daclizumab, but not by Basilixumab; (FIG. 14D) blocked by IL-2, Daclizumab and Basilixumab. These blocking profiles indicate binding of the antibodies to different epitopes from different approach angles.

Additional epitope mapping of functional epitopes will be performed by Alanine Mutagensis. This method is used as an orthogonal method for binning antibodies as it operates on the functional epitope, rather than the structural epitope defined by competition assays. Various pairs of surface-accessible residues are selected for mutagenesis. Computational modeling is used to confirm that the alanine mutations selected for use in these assays do not impact global or local stability.

Example 5: Binding Assays

Cell Binding Assays for CD25 Specific Binding of Human IgG Antibodies

To validate antibody binding to CD25 on cells and for specificity, three cell lines SUDHL-1 and SUDHL-2 (human large diffuse histiocytic lymphoma cell lines, ATCC) and HEK IL-2 reporter cells (Invivogen) were used to test for CD25 binding. SUDHL-1 and HEK IL-2 reporter cell lines are CD25+, while SUDHL-2 are CD25− cells. For each cell line, 100,000 cells were plated in a 96 well round bottom plate in cell buffer (PBS+2% HI FBS) and centrifuged. Antibody concentrations from 1-10 ug/mL were used to test the binding of each antibody. Cell were resuspended in 100 uL of antibodies/well and incubated for 20 minutes on ice. After incubation, cells were centrifuged at 300×g for 5 minutes at room temperature, and resuspended and washed with ice cold cell buffer. Cells were then stained with an anti-human Fc secondary antibody conjugated to AF647 (Biolegend) and incubated on ice for 20 min in the dark. Cells were centrifuged, washed and resuspended in cold cell buffer with DAPI and analyzed using flow cytometry (Cytoflex, Becton Dickinson). DAPI+ cell were excluded from analysis. The mean fluorescence intensity was calculated using the median (FlowJo, TreeStar).

Recombinant CD25 Cynomolgus Monkey Binding of Human IgG1 Clones

To test for binding to recombinant cynomolgus monkey (cyno) CD25, microtiter plates were coated with 80 ul of 1 ug/ml Cyno CD25 in 50 mM sodium carbonate pH 9.6) at 4° C. overnight. The next day, remove the protein from the wells and block with 200 ul PBS/0.1% BSA/0.05% tween20. The plate was incubated for 1 hour at room temperature. Human IgG1 reformatted Fab clones (human IgG1 antibodies) starting 25 nM and 3 fold serially were diluted in PBT buffer and added to the plate for incubation at RT for 1 hour. The plate was then washed and then 1:2500 dilution of HRP conjugate anti-Fab antibody was added. The plate was washed 5-10 times with PBS/tween20 to remove non-specific binders. TMB perxidase substrate and peroxidase solution were added and incubated for the time needed to develop with 80 uL of ELISA stop solution added at the end. OD measurements were then taken at 450 nM using a plate reader (SpectraMax iD3 Plate Reader, Molecular Devices).

FIGS. 15A-15B shows validation and specific binding of all antibody clones (10 ug/mL) to both CD25+ cells lines, SUDHL-1 and HEK cells, and no binding on CD25− SUDHL-2 cell line. Additionally, the majority of antibodies bound similarly to controls, 7G7B6, Daclizumab, Basilixumab.

FIGS. 16A-16B show dose response curves of clones starting at 10 ug/mL with 5 fold serial dilutions binding on SUDHL-1 CD25+ cell line (FIG. 16A). A majority of clones bound in a dose dependent manner and had better EC50 values than commercially available 7G7B6 (FIG. 16B, Table 9), clone names referring to those presented in the above tables of the disclosure. Several Clones in Table 9 have better EC50 values than 7G7B6.

TABLE 9 Clone EC50 (ng/mL) 7G7B6 902.8 Daclizumab 190.7 Basilixumab 57.285 AH05256 71.48 AH04507 88.95 D17 95.7 AH04527 95.91 AH05247 97.73 AH04505 105.7 AH04750 107.2 AH04511 107.6 AH04523 108.2 AH05268 108.2 AH04502 108.9 AH04525 109.1 AH04522 109.6 AH05257 113.3 AH04518 114.4 AH04524 115.8 AH05259 120.7 AH04509 121.3 BP003-T2P1D7 124.8 BP003-T2P1E3 124.9 AH05251 132.2 AH04503 144.6 AH04501 158.9 AH04526 164.3 BP003-T2P1D10 165.4 AH05258 183.9 AH05274 227.9 AH05271 249.6 BP003-T2P1C4 294 AH05280 387 D5 602.9 AH05286 777.5 AH05249 896.9 D34 1098 D36 1491 AH04734 1906 D11 2120 AH05214 ~51090

FIG. 17 show dose response curves of several clones that bound to recombinant cyno CD25. Daclizumab and Basiliximab were used as positive controls.

Example 6: pSTAT5 Assay Using Primary Cells

pSTAT5 Assay for Screening Biological Activity of Fab Clones on Highly Purified Human Regulatory T Cells

The IL-2/JAK3/STAT-5 signaling pathway is involved in the survival and expansion of Tregs. This pathway initiates and maintains the expression of the transcription factor Foxp3, a factor that is essential for the suppressive activity of Tregs. When IL-2 binds to IL-2R, JAK proteins get activated; they are tyrosine kinases that are bound to the cytoplasmic regions of IL-2 receptors. This initiates trans-phosphorylation on specific tyrosine residues generating docking sites for STAT proteins to be recruited and phosphorylated. Dimerized and phosphorylated STATs are then translocated to the nucleus to bind specific DNA sequences, regulating the transcription of several target genes, such as Foxp3 and CD25 in Tregs.

In this example, the functionality of selected Fabs when bound to CD25 on primary human regulatory T cells was assessed. This assay allowed for determination which are IL-2 blockers, non-blockers and partial blockers, as well as potency, based on pSTAT5 levels. Controls used in the assay include a known IL-2 blocker (Daclizumab) and IL-2 non-blocker (7G7B6). First, fresh PBMC cells were isolated from leukocyte reduction system chambers (Stanford Blood Center). Equal volume of cell buffer (PBS+2% HI FBS) was added to each blood sample and added to a Ficoll Paque filled inside a 50 mL SepMate conical tube (Stem Cell Technologies) and followed standard protocol for PBMC isolation using SepMate tubes. To isolate human T regulatory cells from PBMCs, the EasySep Human CD4+CD127low CD25+ Regulatory T cell isolation kit (Stem Cell Technologies) and Regulatory Human CD4+CD25+ T cell kit (Dynabeads) were used. Respective isolation kit protocols were used for magnetic based isolation of cells. Treg isolation was confirmed by staining cells with anti-human CD4, CD25, CD127 antibodies and intracellular Foxp3 staining (BD Biosciences). For the pSTAT5 assay, 100,000 Tregs were plated in a 96 well round bottom plate and centrifuged. Antibody concentrations from 1-5 ug/mL were used. Tregs were resuspended in 50 uL of antibodies/well and incubated for 15 minutes in 37° C. incubator. Next, dilutions for IL-2 were prepared starting at 100 ng/mL concentration with 10 fold dilutions in cell media. IL-2 dilutions were added to the wells at 50 uL/well for 10 minutes in 37° C. incubator. After incubation, the plate was centrifuged at 300×g for 5 minutes at room temperature, and resuspended in 100 uL/well of room temperature fixation buffer (BD Biosciences), for 15 min at room temperature. Cells were spun down and resuspended in cold cell buffer (PBS+2% HI FBS). Cells were then resuspended in 100 uL/well of ice cold permeabilization buffer (BD Biosciences) and incubated on ice for 15 minutes. Cells were washed with cell buffer and resuspended in 50 uL of prepared pSTAT5 antibody for analysis using flow cytometry (Cytoflex, Becton Dickinson).

pSTAT5 Assay for Screening Biological Activity of Antibody Clones Using HEK IL-2 Reporter Cells

In this example, clones were tested using the HEK IL-2 reporter cell line (Invivogen). This cell line was generated by Invivogen to monitor the activation of the JAK-STAT pathway with the binding of IL-2. To obtain a fully active human IL-2 signaling pathway, the reporter cell line was created by stably transfecting HEK293 cells with human IL-2Rα, IL-2Rβ and IL-2Rγ genes, and JAK3 and STATS genes. This assay presents a high throughput method for evaluating IL-2 physiology and characterization of IL-2 blockers, non-blockers, partial blockers, with the addition of antibodies and competitors in the presence of IL-2, based on pSTAT5 levels. Controls used in the assay include a known IL-2 blocker (Daclizumab and Basiliximab) and IL-2 non-blocker (7G7B6). For a pSTAT5 assay, 100,000 cells were plated in a 96 well round bottom plate and centrifuged. Antibody concentrations from 1-5 ug/mL) were used. HEK cells were resuspended in 50 uL of antibodies/well and incubated for 15 minutes in 37° C. incubator. Next, dilutions for IL-2 were prepared starting at 10 ng/mL concentration with 10 fold dilutions in cell media. IL-2 dilutions were added to the wells at 50 uL/well for 10 minutes in 37° C. incubator. After incubation, the plate was centrifuged at 300×g for 5 minutes at room temperature, and resuspended in 100 uL/well of room temperature fixation buffer (BD Biosciences), for 15 min at room temperature. Cells were spun down and resuspended in cold cell buffer (PBS+2% HI FBS). Cells were then resuspended in 100 uL/well of ice cold permeabilization buffer (BD Biosciences) and incubated on ice for 15 minutes. Cells were washed with cell buffer and resuspended in 50 uL of prepared pSTAT5 antibody for analysis using flow cytometry (Cytoflex, Becton Dickinson). Percent pSTAT5+ cells were quantified based on the parental population and values were normalized to IL-2 at 10 ng/mL concentration.

Results

FIG. 9 shows that pSTAT5 signal is IL-2 dose dependent and is inhibited with Daclizumab (IL-2 blocker). pSTAT5 levels were correlated with doses of IL-2, with high IL-2 doses increasing pSTAT5 levels, while lower levels of IL-2 yielded lower levels of pSTAT5. In addition, when Daclizumab, an anti-human IL-2 antibody IL-2 blocker was added at fixed concentration of 2 ug/mL, it inhibited JAK/STATS signaling pathway, yielding less pSTAT5 levels.

FIG. 10 and FIG. 11 show testing of the D5 Fab in the pSTAT5 assay. The data in FIG. 10 show that the pSTAT5 assay was able to distinguish differences in D5 Fab activity at 1, 2 and 5 ug/mL compared to Daclizumab and IL-2 only. At the different concentrations of D5 there was a dose-dependent decrease in levels of pSTAT5, suggesting that D5 is partially blocking IL-2 binding to IL-2R, even at the lowest concentration of 1 ug/mL. The data is represented by raw MFI levels (mean fluorescence intensity) and by comparing pSTAT5 levels relative to maximum pSTAT5 level generated by the highest dose of IL-2 (100 ng/mL) (FIG. 11 ).

FIG. 12 shows preliminary Fab screen data from one donor. This assay from one donor shows differences in pSTAT5 levels between several Fab clones at 1, 2 and 5 ug/mL compared to the controls (IL-2 only, Daclizumab (Dac, an IL-2 blocker) and 7G7B6 (non IL-2 blocker). Some clones seem to be better IL-2 non-blockers than 7G7B6 while others are better IL-2 blockers than Daclizumab. Complete IL-2 non-blockers would be expected to have similar pSTAT5 levels as IL-2 and would not be expected to be concentration dependent. The data are represented by raw MFI levels (mean fluorescence intensity) and by comparing pSTAT5 levels relative to maximum pSTAT5 level generated by 7G7B6. In addition, the data can be used to observe differences in IC50 potency values of the Fab clones. (Table 10).

TABLE 10 IC50 IC50 IC50 (1 ug/mL) (2 ug/mL (5 ug/mL) Ab [ng/ml] [ng/ml] [ng/ml] 7G7B6 0.9629 0.9058 1.47 Dac 18.69 D34 2.558 2.355 2.275 D36 2.233 3.446 0.3782 D5 0.3032 0.4881 1.653 D17 0.2511 0.2173 0.2826 D11 0.4137 0.3032 0.5087 D16 0.43 4.77 40.33

Subsequent assays will include the Fab form of Daclizumab and 7G7B6 as well as testing the same Fab clones on multiple donors. In addition, the pSTAT5 assay will be performed at lower pH levels (pH 6.4-6.7) to recapitulate pH of the tumor microenvironment against clone activity at physiological pH.

FIGS. 18A-18B show functional characterization of reformatted human IgGlclones (at 5 ug/mL) as IL-2 blockers, non-blockers and partial blockers by measuring pSTAT5 in HEK IL-2 reporter cell lines starting at IL-2 concentration of 10 ng/ml with 10 fold serial dilutions. At IL-2 concentration of 0.1 ng/mL (closer to physiological levels), clones such as AH04503, AH04750 are better IL-2 blockers than either Daclizumab or Basilixumab, while clones AH05280 and AH02571 may be better IL-2 non-blockers than 7G7B6 at 5 ug/mL (A). Clones AH05251, AH05257 are examples of IL-2 partial blockers (FIG. 18A). IL-2 dose response curves clearly depict clones that are IL-2 non-blockers from those that are IL-2 blockers, with curves shifting to the left with 7G7B6 and curves shifting to the right with Daclizumab and Basilixumab, respectively (FIG. 18B).

Continued pSTAT5 studies may be done to test these antibody clones using primary Tregs and multiple donors.

Example 7: Antibody-Dependent Cell Cytotoxicity (ADCC)

Functional Cell Killing Assay ADCC and ADCP

One of the mechanisms for Treg depletion is through antibody-dependent cell cytotoxicity (ADCC). This is a cell-mediated immune defense mechanism that usually causes cell death, triggered by the recognition of immune/effector cells to antibodies bound to a specific antigen on a target cell. To elicit ADCC, antibodies with the human Fc subclass, IgG1, is commonly chosen for its effector functions with the ability to bind to the three Fc receptors: FcγRI (CD64), FCγRII (CD32), and FcγRIIIA (CD16), that are expressed on immune cells such as NK cells, monocytes and granulocytes. NK cells predominantly express FcγRIIIA and considered to be the main effector cell in ADCC

In this example, ADCC was quantified using a Lactate dehydrogenase (LDH) Cytotoxicity plate-based colorimetric assay (Thermo Fisher). In this assay, the release of LDH is proportional to the amount of cell killing. Lactate dehydrogenase (LDH) is a cytosolic enzyme, present in all cells, that is released when the plasma membrane is damaged. Extracellular LDH in the media is quantified by a coupled enzymatic reaction in which LDH catalyzes the conversion of lactate to pyruvate via NAD+ reduction to NADH. By addition of diaphorase, NADH is reduced to a tetrazolium salt (INT) to form a formazan product that can be measured at 490 nm. Controls for the assay include the use of Rituximab (anti-CD20 antibody) on human Raji lymphoma cell line and Daclizumab on SUDHL-1 cells (both antibodies are known to induce ADCC). Additional controls include: non-glycosylated human IgG1, as a negative control and non-fucosylated human IgG1, as a positive control. As a first initial screen, reformatted clones were tested in the ADCC assay at one concentration (10 ug/mL) using PBMCs from a single donor. Human PBMCs (ASTARTE Biologics) were thawed the day before and cultured overnight with X-VIVO 15 or 20 media (Lonza) at 37C in 5% CO2 incubator. On the day of experiment, PBMCs and SUDHL-1 target cells were counted and resuspended in X-VIVO 15 (Lonza, phenol red) serum free medium. Antibody dilutions were prepared starting with 10 ug/ml with 5 fold serial dilutions. Target cells were then plated in a 96 well 50 μL/well in a 96-well white flat bottom opaque plate (CORNING Ref #3917) and 10 μL/well antibody dilution was added to the target cells and incubated at 37° C. and 5% CO2 incubator for 30 min. After the incubation, PBMCs were added to the target cells (50 μL/well). For control target cells for spontaneous and max LDH release calculation, 50 μL/well of assay medium (X-VIVO15, phenol red free) was added. The co-incubation (ADCC induction) was done by incubating the plate for 4 h at 37° C. and 5% CO2 incubator 45 min before the co-incubation completed, 10% Triton X100 solution (in PBS) was added to the wells to calculate Max LDH release (10 μL/well, 11× dilution factor). After the incubation, 50 μL/well of the reaction substrate was plated in a 96-well plate (clear flat bottom) and then 50 μL/well of the supernatant of the assay plate was transferred to the reaction substrate. The plate was developed in the dark at RT for 30 min. After the incubation, 50 μL/well of stop solution was added and absorbance 490 nm and 680 nm was measured by using a plate reader (SpectraMax iD3 Plate Reader, Molecular Devices).

Additionally, function antibody-dependent cell phagocytosis (ADCP) assays will also be performed to test activity of macrophages to phagocytose Treg cells upon antibody binding. This may be an additional mechanism of action for Treg depletion. Fc receptor FCγRIIa (CD32b) on macrophages is thought to be the dominant inducer for ADCP. In this assay, primary Tregs will be used as target cells with human monocyte-derived macrophages as effector cells. PBMCs will be isolated from leukocyte reduction system chambers (Stanford Blood Center) for monocyte isolation using CD14 microbeads (Miltenyi Biotec) and for Tregs using Regulatory Human CD4+CD25+ T cell kit (Dynabeads) and Human Treg Cell Differentiation kit (R&D Systems). Monocytes will be cultured for 5-7 days with human serum or M-CSF in media. At days 5-7, macrophages will be cocultured with pre-labeled Tregs (labeled with a fixable viability dye (Invitrogen)) for 2-4 hours at 10 to 1 effector to target ratio with addition of anti-CD25 antibodies and controls, and fixed with fixation buffer (BD Bioscienes). Macrophages will be stained with CD14 to identify macrophages from labeled Tregs, and analyzed for the phagocytic population defined as CD14+ and Treg labeled+ population using flow cytometry. Anti-CD25 antibodies are expected to also induce ADCP.

Results

FIGS. 19A-19B show functional ADCC activity of all reformatted clones. In the first screen, clones bound to CD25+ cells, and ADCC was induced with cell killing ranging from 18.2% to 26.7% lysis (Raji cell killing is used as a reference; (FIG. 19A) To verify these findings, the assay was repeated with a dose response curve for select clones. The results show a range of ADCC activity from 2 to 6-fold over baseline lysis, with clones AH04511, AH05274, D11, D34, D36 eliciting the most potent ADCC and with greater potency than the 7G7B6 antibody, as measured by fold change over % background lysis.

Subsequent studies will include additional donors of PBMCs and NK cells as effectors for functional ADCC killing assays.

Example 8: Functional Characterization of CD25 Antibodies

Characterization, In Vitro

Subsequent in vitro characterizations will include T-cell activation and Treg suppression studies to evaluate the impact of CD25 antibodies on T-effector cell responses in the absence and presence of Treg cells. Readouts for activation will include intracellular granzyme B, proliferation and cytokine release (e.g. IL-2, IFNγ, TNF-α). Specifically, human primary conventional T cells (T cony cells) from healthy donors and donors with specific antigen responses (e.g. human cytomegalovirus or influenza flu antigens) will be labeled with a cell proliferation dye (e.g. ThermoFisher) and treated with varying concentrations of CD25 and control antibodies (1-10 ug/mL), followed by activation using CD3/CD28 beads and incubated with and without Tregs for incubation at 37° C., 5% CO2 for 48-72 hours. To evaluate T cell activation, supernatants will be collected for cytokine analysis and cells will be stained with fixable viability dye (e.g. Thermofisher) and with surface anti human T cell markers: CD3, CD4, CD8, CD45RA, CD25, followed by fixation and permeabilization for staining of intracellular Granzyme B and Foxp3. Cells will be analyzed using flow cytometry for Granzyme B positive and proliferating cells.

Characterization, In Vivo

In vivo activity of CD25 antibodies using a mouse xenograft tumor model. These experiments will help to distinguish differences in CD25 antibodies based on CD25+ tumor depletion via ADCC and/or ADCP. Candidate antibodies will be produced as mouse IgG2a isotype antibodies and used in immunodeficient RAG−/− knockout mice (with functional NK and APC cells, but no mature B or T lymphocytes). Animals will be subcutaneously engrafted with CD25+ human cell lines (e.g SUDHL-1, a CD25+ anaplastic large cell lymphoma). Various size tumors (palpable, 100-500 mm3) may be used to discern the differences between antibodies. Animals will be treated with different doses of CD25 antibodies (e.g. 1-10 mg/kg, 3× weekly or once daily) and monitored for changes in body weight and TGI.

Drug Efficacy and MOA Studies in Mouse Xenograft Tumor Models in Humanized Mice.

The more effective antibodies for tumor growth inhibition via Treg depletion and increased intratumoral Teff/Treg ratio with increased T effector cell activity will be tested in various human tumor models (e.g. liver, breast, melanoma, gastric, NSCLC and colon cancer) to establish efficacy and mechanism of action. Some studies may include using the triple negative breast cancer cell line MDA-MB-231, a gastric cell line, melanoma cell line A375 and liver cancer cell line Huh-7 as well as human PDX models that have been well characterized and have either shown correlations between infiltrated Tregs and tumor growth and/or have been treated with PD-1 antibody combinations in humanized mice engrafted with human PBMCs and/or CD34+ cells. In these models, tumors will be subcutaneously engrafted until tumors reach a range of sizes from palpable to 100-500 mm3, and treated with various doses of CD25 antibodies and dosing schedules (e.g. 1-10 mg/kg, 3× weekly or once daily). Animal health scoring, bodyweight, tumor growth as well as immunophenotyping of blood and tumors will be performed to characterize tumor and immune cell composition and tumor infilitrating cells, and cytokine secretion using flow cytometry, Meso Scale Discovery multiplex plates and histology.

Combination studies in mouse xenograft tumor models in humanized mice. Once the lead candidate and indication is established based on efficacy and MOA studies, we will perform combination studies using a wide range of agents to increase immunogenicity and activation of other pathways for immune activation (e.g. chemotherapy, checkpoint inhibitors, TLR agonists, vaccines). Combination experiments will be conducted in similar tumor models used in efficacy and MOA studies.

All patents, patent applications, publications, documents, web links, and articles cited herein are incorporated herein by reference in their entireties. 

1. A monoclonal CD25 antibody which binds to human CD25, and possesses at least one of the following characteristics: a. the antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 of any one of the combinations presented in SEQ ID NOS: 4, 6, 8, 19, 21, 23, 46, 48, 151-183, 224-258, 297-344, 482-492, 506-515, 531-557, 601-608, 611, 612, 614, 615, 617, 619, 691-697, 973, 977, 982, 984-987, 989-997, 1003, 1004, 1012-1016, 1020-1029, 1035, 1165, 1377-1379, 1395, 1416-1420, 1442-1445 and Table 6 and the amino acid sequence of CDRL1, CDRL2, and CDRL3 of any one of the combinations presented in SEQ ID NOS: 12, 13, 15, 27, 28, 30, 36, 42, 52, 54, 599, 600, 618, 833, 839, 924, 925, 927-930, 932-935, 944, 957, 966-972, 975, 976, 979-981, 983, 998-1002, 1036-1038, 1040, 1057-1063, 1081, 1092-1107, 1115, 1116, 1122, 1136, 1142, 1198-1202, 1204-1217, 1242-1244, 1246-1287, 1289-1296, 1298-1311, 1344-1346, 1360-1362, 1365, 1369-1376, 1380-1386, 1391, 1450, 1461-1466, 1475, 1476, 1495 and Table 7; b. the antibody does not disrupt the binding of the IL-2 ligand to the alpha chain of the IL-2 receptor (CD25), and binds to a different epitope than to which 7G7B6 binds; c. the antibody does not disrupt the binding of the IL-2 ligand to the alpha chain of the IL-2 receptor (CD25), but does disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor; d. the antibody disrupts the binding of the IL-2 ligand to the alpha (CD25), beta, and/or gamma chains of the IL-2 receptor, and binds to a different epitope than to which daclizumab or baciliximab bind; e. the antibody exhibits a higher affinity of binding to CD25 at pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4; f. the antibody comprises the amino acid sequence of any one of the variable heavy chain sequences presented in SEQ ID NOS: 2, 4, 6, 8, 17, 19, 21, 23, 32, 38, 44, 46, 48, 56, 60-107, 114, 157, 190, 195, 230, 235, 251, 265, 269, 398, 413, 421, 422, 424, 425, 431-460, 473, 601, 603-606, 608, 611, 615, 617, 619, 868, 869, 936-940, 942, 943, 945-952, 954, 955, 973, 977, 984, 986, 987, 992, 995, 997, 1003-1008, 1010-1015, 1017, 1018, 1020, 1021, 1023, 1025-1027, 1029-1035, 1074, 1075, 1118, 1119, 1123-1128, 1137-1139, 1165-1172, 1174-1179, 1181-1185, 1187, 1188, 1190-1197, 1218, 1220, 1222, 1223-1241, 1313-1318, 1321-1343, 1387-1389, 1395, 1416, 1417, 1419, 1420, 1442-1445, 1453-1455, 1448, 1474, 1496 and Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto; g. the antibody comprises the amino acid sequence of any one of the variable light chain sequences presented in SEQ ID NOS: 10, 12, 13, 15, 25, 27, 28, 30, 34, 36, 40, 50, 52, 54, 59, 599, 618, 700, 701, 703, 705, 707, 709, 711, 712, 713, 715, 717-720, 722, 724, 725, 727-732, 734-740, 742, 744, 745, 747, 749-752, 754-757, 759, 760, 762, 765-767, 769, 770, 773, 775-778, 780, 781, 783, 785, 787, 789, 791, 793, 794, 795, 797, 799, 801, 803, 804, 806, 807, 809-811, 813, 815, 816, 818, 821-825, 827-833, 835, 837, 838, 841, 842, 844, 846, 848, 849, 851, 853, 854, 857, 858-861, 864, 865, 870-880, 882, 884, 886, 888, 889, 890, 892, 894, 895, 897, 899, 900-903, 905-909, 912, 914, 915, 917-922, 926, 928, 930, 944, 958, 959, 961, 963, 966-968, 971, 974, 978, 1002, 1057, 1062, 1070-1072, 1076, 1085, 1088, 1091, 1097, 1103, 1105, 1106, 1109, 1110, 1112, 1117, 1132, 1151, 1154, 1157-1159, 1164, 1198, 1200-1202, 1206-1210, 1214-1216, 1246, 1248, 1253, 1255, 1258, 1265, 1271, 1272, 1281, 1283-1285, 1287, 1290, 1298, 1299, 1306, 1309, 1345, 1347-1350, 1352, 1353, 1355-1357, 1359, 1366, 1371, 1375, 1386, 1396-1402, 1404, 1408, 1413, 1414, 1423-1425, 1427, 1429, 1430, 1432, 1433, 1436, 1447, 1449, 1450, 1470, 1471, 1475-1478, 1481-1483, 1486-1491, 1495 and Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto; h. the VH of the antibody comprises any one of the amino acid sequence of CDRH1, CDRH2, and CDRH3 as presented in SEQ ID NOS: 4, 6, 8, 19, 21, 23, 46, 48, 114, 151-183, 190, 195, 224-258, 265, 269, 297-344, 398, 413, 421, 422, 424, 425, 431, 473, 482-492, 506-515, 531-557, 601-608, 611, 612, 614, 615, 617, 619, 691-697, 936-940, 942, 943, 945-952, 954, 955, 973, 977, 982, 984-987, 989-997, 1003-1008, 1010-1016, 1017, 1018, 1020-1029, 1025-1035, 1321-1326, 1336-1343, 1377-1379, 1074, 1075, 1118, 1119, 1123-1128, 1137-1139, 1165-1172, 1174-1179, 1181-1185, 1187, 1188, 1190-1197, 1218, 1220, 1223-1228, 1239-1241, 1313-1315, 1387-1389, 1395, 1416-1420, 1442-1445, 1448, 1453-1455, 1474, 1496 and Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, 5A, and 6; and i. the VL of the CD25 antibody comprises any one of the amino acid sequence of CDRL1, CDRL2, and CDRL3 as presented in SEQ ID NOS: 12, 13, 15, 27, 28, 30, 36, 42, 52, 54, 599, 600, 618, 700, 711, 713, 718-720, 729-732, 734, 738, 740, 744, 757, 760, 766, 770, 773, 793, 807, 816, 821, 828, 830-833, 837, 839, 854, 858, 865, 870-874, 889, 890, 894, 899, 900, 909, 915, 918, 924-930, 932-935, 944, 957-959, 961, 963, 966-972, 974-976, 978-981, 983, 998-1002, 1036-1038, 1040, 1057-1063, 1070-1072, 1076, 1081, 1085, 1088, 1091-1107, 1109, 1110, 1112, 1115-1117, 1122, 1132, 1136, 1142, 1151, 1154, 1157-1159, 1164, 1198-1202, 1204-1217, 1242-1244, 1246-1287, 1289-1296, 1298-1311, 1344-1350, 1352, 1353, 1355-1357, 1359, 1360-1362, 1365, 1366, 1369-1376, 1380-1386, 1391, 1396-1402, 1404, 1408, 1413, 1414, 1423-1425, 1427, 1429, 1430, 1432, 1433, 1436, 1447, 1449, 1450, 1461-1478, 1481-1483, 1486-1491, 1495 and Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, 5B and
 7. 2. The antibody of claim 1, wherein the antibody possesses at least two, at least three, at least four, at least five, or at least six of the characteristics provided therein.
 3. The antibody of claim 1, wherein the antibody does not disrupt the binding of the IL-2 ligand to the alpha chain of the IL-2 receptor (CD25), and binds to a different epitope than to which 7G7B6 binds.
 4. The antibody of claim 1, wherein the antibody does not disrupt the binding of the IL-2 ligand to the alpha chain of the IL-2 receptor (CD25), but does disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor.
 5. The antibody of claim 1, wherein the antibody disrupts the binding of the IL-2 ligand to the IL-2 receptor, and binds to a different epitope than to which Daclizumab or Baciliximab bind.
 6. The antibody of claim 1, wherein the antibody exhibits a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4.
 7. The antibody of claim 6, wherein the antibody exhibits a higher affinity of binding to CD25 at a pH of about 6.5.
 8. The antibody of claim 1, wherein the antibody comprises the amino acid sequence of any one of the variable heavy chain sequences presented in SEQ ID NOS: 2, 4, 6, 8, 17, 19, 21, 23, 32, 38, 44, 46, 48, 56, 60-107, 114, 157, 190, 195, 230, 235, 251, 265, 269, 398, 413, 421, 422, 424, 425, 431-460, 473, 601, 603-606, 608, 611, 615, 617, 619, 868, 869, 936-940, 942, 943, 945-952, 954, 955, 973, 977, 984, 986, 987, 992, 995, 997, 1003-1008, 1010-1015, 1017, 1018, 1020, 1021, 1023, 1025-1027, 1029-1035, 1074, 1075, 1118, 1119, 1123-1128, 1137-1139, 1165-1172, 1174-1179, 1181-1185, 1187, 1188, 1190-1197, 1218, 1220, 1222, 1223-1241, 1313-1318, 1321-1343, 1387-1389, 1395, 1416, 1417, 1419, 1420, 1442-1445, 1453-1455, 1448, 1474, 1496 and Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto.
 9. The antibody of claim 1, wherein the antibody comprises the amino acid sequence of any one of the variable light chain sequences presented in SEQ ID NOS: 10, 12, 13, 15, 25, 27, 28, 30, 34, 36, 40, 42, 50, 52, 54, 59, 599, 618, 700, 701, 703, 705, 707, 709, 711, 712, 713, 715, 717-720, 722, 724, 725, 727-732, 734-740, 742, 744, 745, 747, 749-752, 754-757, 759, 760, 762, 765-767, 769, 770, 773, 775-778, 780, 781, 783, 785, 787, 789, 791, 793, 794, 795, 797, 799, 801, 803, 804, 806, 807, 809-811, 813, 815, 816, 818, 821-825, 827-833, 835, 837, 838, 841, 842, 844, 846, 848, 849, 851, 853, 854, 857, 858-861, 864, 865, 870-880, 882, 884, 886, 888, 889, 890, 892, 894, 895, 897, 899, 900-903, 905-909, 912, 914, 915, 917-922, 926-928, 930, 944, 958, 959, 961, 963, 966-968, 971, 974, 978, 983, 1002, 1057, 1058, 1062, 1070-1072, 1076, 1085, 1088, 1091, 1097, 1103, 1105, 1106, 1109, 1110, 1112, 1117, 1132, 1142, 1151, 1154, 1157-1159, 1164, 1198, 1200-1202, 1206-1210, 1214-1216, 1243, 1246, 1248, 1249, 1252, 1253, 1255, 1258, 1260, 1265, 1271, 1272, 1277, 1281-1285, 1287, 1290, 1298, 1299, 1306, 1309, 1345, 1347-1350, 1352, 1353, 1355-1357, 1359, 1366, 1371, 1375, 1382, 1386, 1396-1402, 1404, 1408, 1413, 1414, 1423-1425, 1427, 1429, 1430, 1432, 1433, 1436, 1447, 1449, 1450, 1470, 1471, 1475-1478, 1481-1483, 1486-1491, 1495 and Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, and 5B, humanized versions thereof, or an amino acid sequence comprising at least a 80%, at least a 85%, at least a 90%, or at least a 95% sequence identity thereto.
 10. The antibody of claim 1, wherein the VH of the antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 as presented in SEQ ID NOS: 4, 6, 8, 19, 21, 23, 46, 48, 114, 151-183, 190, 195, 224-258, 265, 269, 297-344, 398, 413, 421, 422, 424, 425, 431, 473, 482-492, 506-515, 531-557, 601-608, 611, 612, 614, 615, 617, 619, 691-697, 936-940, 942, 943, 945-952, 954, 955, 973, 977, 982, 984-987, 989-997, 1003-1008, 1010-1018, 1020-1035, 1074, 1075, 1118, 1119, 1123-1128, 1137-1139, 1165-1172, 1174-1179, 1181-1185, 1187, 1188, 1190-1197, 1218, 1220, 1223-1228, 1239-1241, 1313-1315, 1321-1326, 1336-1343, 1377-1379, 1387-1389, 1395, 1416-1420, 1442-1445, 1448, 1453-1455, 1474, 1496 and Tables 1A, 1C, 1E, 1G, 1I, 1K, 2A, 2B, 2C, 4A, or 5A.
 11. The antibody of claim 1, wherein the VL of the CD25 antibody comprises the amino acid sequence of CDRL1, CDRL2, and CDRL3 as presented in SEQ ID NOS: 12, 13, 15, 27, 28, 30, 36, 42, 52, 54, 599, 600, 618, 700, 711, 713, 718-720, 729-732, 734, 738, 740, 744, 757, 760, 766, 770, 773, 793, 807, 816, 821, 828, 830-833, 837, 839, 854, 858, 865, 870-874, 889, 890, 894, 899, 900, 909, 915, 918, 924-930, 932-935, 944, 957-959, 961, 963, 966-972, 974-976, 978-981, 983, 998, 999-1002, 1036-1038, 1040, 1057-1063, 1070-1072, 1076, 1081, 1085, 1088, 1091-1107, 1109, 1110, 1112, 1115-1117, 1122, 1132, 1136, 1142, 1151, 1154, 1157-1159, 1164, 1198-1202, 1204-1217, 1242-1244, 1246-1287, 1289-1296, 1298-1310, 1344, 1345, 1347-1350, 1352, 1353, 1355-1357, 1359, 1362, 1365, 1366, 1370, 1371, 1373-1375, 1381, 1382, 1385, 1386, 1396-1402, 1404, 1408, 1413, 1414, 1423-1425, 1427, 1429, 1430, 1432, 1433, 1436, 1447, 1449, 1450, 1461, 1463-1478, 1481-1483, 1486-1491, 1495 and Tables 1B, 1D, 1F, 1H, 1J, 1L, 3A, 3B, 3C, 4B, or 5B.
 12. The antibody of claim 1, wherein the CD25 antibody comprises the amino acid sequence of CDRH1, CDRH2, and CDRH3 of any one of the combinations presented in SEQ ID NOS: 4, 6, 8, 19, 21, 23, 46, 48, 151-183, 224-258, 297-344, 482-492, 506-515, 531-557, 601-608, 611, 612, 614, 615, 617, 619, 691-697, 973, 977, 982, 984-987, 989-997, 1003, 1004, 1012-1016, 1020-1029, 1035, 1165, 1377-1379, 1395, 1416-1420, 1442-1445 and Table
 6. 13. The antibody of claim 1, wherein the CD25 antibody comprises the amino acid sequence of CDRL1, CDRL2, and CDRL3 of any one of the combinations presented in SEQ ID NOS: 12, 13, 15, 27, 28, 30, 36, 42, 52, 54, 599, 600, 618, 833, 839, 924, 925, 927-930, 932-935, 944, 957, 966-972, 975, 976, 979-981, 983, 998-1002, 1036-1038, 1040, 1057-1063, 1081, 1092-1107, 1115, 1116, 1122, 1136, 1142, 1198-1202, 1204-1217, 1242-1244, 1246-1287, 1289-1296, 1298-1311, 1344-1346, 1360-1362, 1365, 1369-1376, 1380-1386, 1391, 1450, 1461-1466, 1475, 1476, 1495 and Table
 7. 14. The antibody of claim 1, wherein the antibody is a human antibody.
 15. The antibody of claim 1, wherein the antibody is a humanized antibody.
 16. The antibody of claim 1, wherein the antibody is a chimeric antibody.
 17. The antibody of claim 16, wherein the antibody comprises a mouse variable domain, and a human constant domain.
 18. The antibody of claim 1, wherein the antibody is an antibody fragment.
 19. The antibody of claim 1, wherein the antibody also binds cynomologous monkey CD25.
 20. A pharmaceutical composition comprising the antibody of claim
 1. 21. A composition comprising a nucleic acid sequence encoding of the antibody of claim
 1. 22. A vector comprising the nucleic acid sequence of claim
 21. 23. A phage expressing any the antibody of claim
 1. 24. A method of treating a subject in need thereof comprising administering to the subject a therapeutically effective amount of the antibody of claim
 1. 25. A method of depleting the number of regulatory T cells in a subject comprising administering to the subject a therapeutically effective amount of the antibody of claim
 1. 26. The method of claim 24, wherein the subject suffers from cancer or an autoimmune-related disease or disorder.
 27. The method of claim 24, wherein the subject suffers from an autoimmune-related disease or disorder.
 28. A method of depleting the number of regulatory T cells in a sample comprising peripheral blood mononuclear cells comprising contacting the sample the antibody of claim
 1. 29. A kit comprising the antibody of claim
 1. 